Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15900474,flow rate,The perfusate is perfused at a flow rate of 5 microL min(-1).,Microdialysis sampling and high-performance liquid chromatography with chemiluminescence detection for in-vivo on-line determination and study of the pharmacokinetics of levodopa in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900474/),[μl] / [min],5,93,DB01174,Phenobarbital
,15900474,detection limit (3sigma),The response of the system is linearly related to the concentration of levodopa in the range 1 x 10(-8) to 1 x 10(-6) g mL(-1) (r2 = 0.9995) with a detection limit (3sigma) of 3 x 10(-9) g mL(-1) and sample throughput of 12 h(-1); RSD is 2.8% (n = 11).,Microdialysis sampling and high-performance liquid chromatography with chemiluminescence detection for in-vivo on-line determination and study of the pharmacokinetics of levodopa in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900474/),[g] / [ml],3 x 10(-9),94,DB01174,Phenobarbital
,15900474,sample throughput,The response of the system is linearly related to the concentration of levodopa in the range 1 x 10(-8) to 1 x 10(-6) g mL(-1) (r2 = 0.9995) with a detection limit (3sigma) of 3 x 10(-9) g mL(-1) and sample throughput of 12 h(-1); RSD is 2.8% (n = 11).,Microdialysis sampling and high-performance liquid chromatography with chemiluminescence detection for in-vivo on-line determination and study of the pharmacokinetics of levodopa in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900474/),1/[h],12,95,DB01174,Phenobarbital
,15900474,Cmax,"The method has been successfully used to study the pharmacokinetics of levodopa in vivo; the values of the pharmacokinetics parameters Cmax, AUC(0-t) and Tmax were 16.60, 20.92 ng mL(-1), and 90 min, respectively.",Microdialysis sampling and high-performance liquid chromatography with chemiluminescence detection for in-vivo on-line determination and study of the pharmacokinetics of levodopa in blood. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900474/),[ng] / [ml],16.60,96,DB01174,Phenobarbital
,15900474,AUC(0-t),"The method has been successfully used to study the pharmacokinetics of levodopa in vivo; the values of the pharmacokinetics parameters Cmax, AUC(0-t) and Tmax were 16.60, 20.92 ng mL(-1), and 90 min, respectively.",Microdialysis sampling and high-performance liquid chromatography with chemiluminescence detection for in-vivo on-line determination and study of the pharmacokinetics of levodopa in blood. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900474/),[ng] / [ml],20.92,97,DB01174,Phenobarbital
,15900474,Tmax,"The method has been successfully used to study the pharmacokinetics of levodopa in vivo; the values of the pharmacokinetics parameters Cmax, AUC(0-t) and Tmax were 16.60, 20.92 ng mL(-1), and 90 min, respectively.",Microdialysis sampling and high-performance liquid chromatography with chemiluminescence detection for in-vivo on-line determination and study of the pharmacokinetics of levodopa in blood. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900474/),min,90,98,DB01174,Phenobarbital
,15926192,total areas under the plasma concentration-time curve from time zero to time infinity (AUC),"After a 1 min intravenous administration of DA-8159 at a dose of 30 mg/kg to rats pretreated with dexamethasone (a main inducer of CYP3A1/2 in rats), the total areas under the plasma concentration-time curve from time zero to time infinity (AUC) values of DA-8159 (283 versus 349 microg min/ml) and DA-8164 (98.0 versus 79.8 microg min/ml) were significantly smaller and greater, respectively, than those in control rats.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],283,2102,DB01174,Phenobarbital
,15926192,total areas under the plasma concentration-time curve from time zero to time infinity (AUC),"After a 1 min intravenous administration of DA-8159 at a dose of 30 mg/kg to rats pretreated with dexamethasone (a main inducer of CYP3A1/2 in rats), the total areas under the plasma concentration-time curve from time zero to time infinity (AUC) values of DA-8159 (283 versus 349 microg min/ml) and DA-8164 (98.0 versus 79.8 microg min/ml) were significantly smaller and greater, respectively, than those in control rats.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],349,2103,DB01174,Phenobarbital
,15926192,total areas under the plasma concentration-time curve from time zero to time infinity (AUC),"After a 1 min intravenous administration of DA-8159 at a dose of 30 mg/kg to rats pretreated with dexamethasone (a main inducer of CYP3A1/2 in rats), the total areas under the plasma concentration-time curve from time zero to time infinity (AUC) values of DA-8159 (283 versus 349 microg min/ml) and DA-8164 (98.0 versus 79.8 microg min/ml) were significantly smaller and greater, respectively, than those in control rats.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],98.0,2104,DB01174,Phenobarbital
,15926192,total areas under the plasma concentration-time curve from time zero to time infinity (AUC),"After a 1 min intravenous administration of DA-8159 at a dose of 30 mg/kg to rats pretreated with dexamethasone (a main inducer of CYP3A1/2 in rats), the total areas under the plasma concentration-time curve from time zero to time infinity (AUC) values of DA-8159 (283 versus 349 microg min/ml) and DA-8164 (98.0 versus 79.8 microg min/ml) were significantly smaller and greater, respectively, than those in control rats.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],79.8,2105,DB01174,Phenobarbital
,15926192,AUC,"In rats pretreated with troleandomycin (a main inhibitor of CYP3A1/2 in rats), the AUC values of DA-8159 (435 versus 370 microg min/ml) and DA-8164 (34.8 versus 76.5 microg min/ml) were significantly greater and smaller, respectively.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],435,2106,DB01174,Phenobarbital
,15926192,AUC,"In rats pretreated with troleandomycin (a main inhibitor of CYP3A1/2 in rats), the AUC values of DA-8159 (435 versus 370 microg min/ml) and DA-8164 (34.8 versus 76.5 microg min/ml) were significantly greater and smaller, respectively.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],370,2107,DB01174,Phenobarbital
,15926192,AUC,"In rats pretreated with troleandomycin (a main inhibitor of CYP3A1/2 in rats), the AUC values of DA-8159 (435 versus 370 microg min/ml) and DA-8164 (34.8 versus 76.5 microg min/ml) were significantly greater and smaller, respectively.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],34.8,2108,DB01174,Phenobarbital
,15926192,AUC,"In rats pretreated with troleandomycin (a main inhibitor of CYP3A1/2 in rats), the AUC values of DA-8159 (435 versus 370 microg min/ml) and DA-8164 (34.8 versus 76.5 microg min/ml) were significantly greater and smaller, respectively.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],76.5,2109,DB01174,Phenobarbital
,6639842,oral clearance,"Rifampicin (600 mg/day) caused a large increase in propranolol's oral clearance (35.7 +/- 16.3 vs 96.1 +/- 26.9 ml min-1 kg-1, mean +/- s.d.), but neither the elimination half-life nor extent of plasma binding were affected.",Induction of propranolol metabolism by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639842/),[ml] / [kg·min],35.7,2502,DB01174,Phenobarbital
,6639842,oral clearance,"Rifampicin (600 mg/day) caused a large increase in propranolol's oral clearance (35.7 +/- 16.3 vs 96.1 +/- 26.9 ml min-1 kg-1, mean +/- s.d.), but neither the elimination half-life nor extent of plasma binding were affected.",Induction of propranolol metabolism by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639842/),[ml] / [kg·min],96.1,2503,DB01174,Phenobarbital
,12848774,terminal half-life,"After administration of a single 200 mg dose, retigabine was rapidly absorbed and eliminated with a mean terminal half-life of 6.7 h, a mean AUC of 3936 ng x ml(-1) x h and a mean apparent clearance of 0.76 l x h(-1) x kg(-1).",Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848774/),h,6.7,2517,DB01174,Phenobarbital
,12848774,AUC,"After administration of a single 200 mg dose, retigabine was rapidly absorbed and eliminated with a mean terminal half-life of 6.7 h, a mean AUC of 3936 ng x ml(-1) x h and a mean apparent clearance of 0.76 l x h(-1) x kg(-1).",Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848774/),[h·ng] / [ml],3936,2518,DB01174,Phenobarbital
,12848774,apparent clearance,"After administration of a single 200 mg dose, retigabine was rapidly absorbed and eliminated with a mean terminal half-life of 6.7 h, a mean AUC of 3936 ng x ml(-1) x h and a mean apparent clearance of 0.76 l x h(-1) x kg(-1).",Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848774/),[l] / [h·kg],0.76,2519,DB01174,Phenobarbital
,12848774,AUC,"After administration of phenobarbitone dosed to steady-state, the pharmacokinetics of retigabine at steady-state were similar (AUC of 4433 ng x ml(-1) x h and t1/2 of 8.5 h) to those of retigabine alone.",Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848774/),[h·ng] / [ml],4433,2520,DB01174,Phenobarbital
,12848774,t1/2,"After administration of phenobarbitone dosed to steady-state, the pharmacokinetics of retigabine at steady-state were similar (AUC of 4433 ng x ml(-1) x h and t1/2 of 8.5 h) to those of retigabine alone.",Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848774/),h,8.5,2521,DB01174,Phenobarbital
,12848774,AUC,The AUC of phenobarbitone was 298 mg x l(-1) x h when administered alone and 311 mg x ml(-1) x h after retigabine administration.,Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848774/),[h·mg] / [l],298,2522,DB01174,Phenobarbital
,12848774,AUC,The AUC of phenobarbitone was 298 mg x l(-1) x h when administered alone and 311 mg x ml(-1) x h after retigabine administration.,Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848774/),[h·mg] / [ml],311,2523,DB01174,Phenobarbital
,30086086,CD ratio,"In 10 patients using enzyme-inducing antiepileptic drugs (AEDs), the mean CD ratio increased by 53.5% [from 1389 to 2132 (ng/mL)/(mg/kg)] when they were CRP-positive.",Influence of Inflammation on the Pharmacokinetics of Perampanel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30086086/),[ml·ng] / [kg·mg],1389,3357,DB01174,Phenobarbital
,30086086,CD ratio,"In 10 patients using enzyme-inducing antiepileptic drugs (AEDs), the mean CD ratio increased by 53.5% [from 1389 to 2132 (ng/mL)/(mg/kg)] when they were CRP-positive.",Influence of Inflammation on the Pharmacokinetics of Perampanel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30086086/),[ml·ng] / [kg·mg],2132,3358,DB01174,Phenobarbital
,30086086,CD ratio,"In 13 patients without enzyme-inducing AEDs, the mean CD ratio increased by 100.8% [from 3826 ng/mL to 7683 (ng/mL)/(mg/kg)] when they were CRP-positive.",Influence of Inflammation on the Pharmacokinetics of Perampanel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30086086/),[ng] / [ml],3826,3359,DB01174,Phenobarbital
,30086086,CD ratio,"In 13 patients without enzyme-inducing AEDs, the mean CD ratio increased by 100.8% [from 3826 ng/mL to 7683 (ng/mL)/(mg/kg)] when they were CRP-positive.",Influence of Inflammation on the Pharmacokinetics of Perampanel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30086086/),[ml·ng] / [kg·mg],7683,3360,DB01174,Phenobarbital
,8500192,clearance,No significant differences of the elimination rates of TPH could be found between the times of TPH administration (clearance: 1.17 +/- 0.17 ml/kg/min at 07:00 h vs. 1.23 +/- 0.17 ml/kg/min at 19:00 hours).,Circadian time-dependent kinetics of theophylline and its modulation by phenobarbital pretreatment in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8500192/),[ml] / [kg·min],1.17,4085,DB01174,Phenobarbital
,8500192,clearance,No significant differences of the elimination rates of TPH could be found between the times of TPH administration (clearance: 1.17 +/- 0.17 ml/kg/min at 07:00 h vs. 1.23 +/- 0.17 ml/kg/min at 19:00 hours).,Circadian time-dependent kinetics of theophylline and its modulation by phenobarbital pretreatment in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8500192/),[ml] / [kg·min],1.23,4086,DB01174,Phenobarbital
,8500192,clearance,"The increase in clearance values was more expressed when TPH was injected at 07:00 h than at 19:00 h (2.48 +/- 0.67 vs. 2.06 +/- 0.41 ml/kg/min, p < 0.01).",Circadian time-dependent kinetics of theophylline and its modulation by phenobarbital pretreatment in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8500192/),[ml] / [kg·min],2.48,4087,DB01174,Phenobarbital
,8500192,clearance,"The increase in clearance values was more expressed when TPH was injected at 07:00 h than at 19:00 h (2.48 +/- 0.67 vs. 2.06 +/- 0.41 ml/kg/min, p < 0.01).",Circadian time-dependent kinetics of theophylline and its modulation by phenobarbital pretreatment in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8500192/),[ml] / [kg·min],2.06,4088,DB01174,Phenobarbital
,8376481,flow-rate,"The drugs and metabolites are eluted with a mobile phase containing potassium phosphate buffer-acetonitrile-methanol (110:50:30, v/v/v) at a flow-rate of 0.2 ml/min.","Simultaneous determination of carbamazepine, phenytoin, phenobarbital, primidone and their principal metabolites by high-performance liquid chromatography with photodiode-array detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376481/),[ml] / [min],0.2,6438,DB01174,Phenobarbital
,8376481,recovery rates,The recovery rates range from 95.12 to 104.42%.,"Simultaneous determination of carbamazepine, phenytoin, phenobarbital, primidone and their principal metabolites by high-performance liquid chromatography with photodiode-array detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376481/),%,95.12 to 104.42,6439,DB01174,Phenobarbital
,7108766,percentages of unbound,"After 3 weeks of phenobarbital therapy, the percentages of unbound propranolol fell from 15.2 +/- 1.2 (mean +/- S.E.) to 2.4 +/- 0.3 (P less than .001).",Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7108766/),,15.2,6835,DB01174,Phenobarbital
,7108766,percentages of unbound,"After 3 weeks of phenobarbital therapy, the percentages of unbound propranolol fell from 15.2 +/- 1.2 (mean +/- S.E.) to 2.4 +/- 0.3 (P less than .001).",Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7108766/),,2.4,6836,DB01174,Phenobarbital
,7108766,Km,"Using this model, the Km for phenobarbital-stimulated production of the binding protein was 1200 ng/ml, the turnover T1/2 of the protein was 3.4 days and the T1/2 for the lag phase was also 3.4 days.",Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7108766/),[ng] / [ml],1200,6837,DB01174,Phenobarbital
,7108766,turnover T1/2,"Using this model, the Km for phenobarbital-stimulated production of the binding protein was 1200 ng/ml, the turnover T1/2 of the protein was 3.4 days and the T1/2 for the lag phase was also 3.4 days.",Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7108766/),d,3.4,6838,DB01174,Phenobarbital
,7108766,T1/2,"Using this model, the Km for phenobarbital-stimulated production of the binding protein was 1200 ng/ml, the turnover T1/2 of the protein was 3.4 days and the T1/2 for the lag phase was also 3.4 days.",Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7108766/),d,3.4,6839,DB01174,Phenobarbital
,12387381,maximum serum bromide concentration,"In the prospective study, maximum serum bromide concentration was 1.1 +/- 0.2 mg/mL at 8 weeks.",Disposition and clinical use of bromide in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12387381/),[mg] / [ml],1.1,6840,DB01174,Phenobarbital
,12387381,disappearance half-life,Mean disappearance half-life was 1.6 +/- 0.2 weeks.,Disposition and clinical use of bromide in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12387381/),weeks,1.6,6841,DB01174,Phenobarbital
,495919,half-life (t0.5),Rats exposed to halothane (100 ppm) in a closed allglass-system eliminate halothane from the atmosphere of this system with a half-life (t0.5) of 0.99 h.,"[The influence of ethanol, dithiocarb, diethylmaleate and phenobarbital on the metabolic elimination of halothane in rats (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495919/),h,0.99,8118,DB01174,Phenobarbital
,495919,t0.5,In 24 h-fasted rats t0.5 was prolonged to 1.24 h.,"[The influence of ethanol, dithiocarb, diethylmaleate and phenobarbital on the metabolic elimination of halothane in rats (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495919/),h,1.24,8119,DB01174,Phenobarbital
,495919,t0.5,"On the other hand, ethanol (4.8 g/kg p.o.) applied 5 min before exposure to halothane markedly prolonged t0.5 to 3.79 h.","[The influence of ethanol, dithiocarb, diethylmaleate and phenobarbital on the metabolic elimination of halothane in rats (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495919/),h,3.79,8120,DB01174,Phenobarbital
,495919,t0.5,Pretreatment with phenobarbital (80 mg/kg i.p. for 4 days) shortened t0.5 significantly to 0.79 h.,"[The influence of ethanol, dithiocarb, diethylmaleate and phenobarbital on the metabolic elimination of halothane in rats (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495919/),h,0.79,8121,DB01174,Phenobarbital
,495919,t0.5,Inhibition of the mixed-function oxidase system by dithiocarb (100 mg/kg i.p.) or diethyl maleate (1 ml/kg i.p.) markedly prolonged t0.5 to 7.53 and 1.57 h. respectively.,"[The influence of ethanol, dithiocarb, diethylmaleate and phenobarbital on the metabolic elimination of halothane in rats (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495919/),h,7.53,8122,DB01174,Phenobarbital
,495919,t0.5,Inhibition of the mixed-function oxidase system by dithiocarb (100 mg/kg i.p.) or diethyl maleate (1 ml/kg i.p.) markedly prolonged t0.5 to 7.53 and 1.57 h. respectively.,"[The influence of ethanol, dithiocarb, diethylmaleate and phenobarbital on the metabolic elimination of halothane in rats (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495919/),h,1.57,8123,DB01174,Phenobarbital
,9101035,basic levels,The mean basic levels of bromide in plasma of rats receiving vehicle were 0.075 +/- 0.036 mmol/l (n = 27).,Chlorodibromomethane metabolism to bromide and carbon monoxide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9101035/),[mM] / [l],0.075,8297,DB01174,Phenobarbital
,627141,volume of distribution (Vd),The volume of distribution (Vd) of phenobarbital was 0.97 +/- .15 L/kg which was independent of the dose administered.,Phenobarbital pharmacokinetics in neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/627141/),[l] / [kg],0.97,8674,DB01174,Phenobarbital
,627141,t1/2,"Phenobarbital clearance calculated from average concentrations in patients maintained on phenobarbital for 1 to 4 wks was consistent, with a decrease in t1/2 from 115 hr after 1 wk to 67 hr after 4 wk of therapy.",Phenobarbital pharmacokinetics in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/627141/),h,115,8675,DB01174,Phenobarbital
,627141,t1/2,"Phenobarbital clearance calculated from average concentrations in patients maintained on phenobarbital for 1 to 4 wks was consistent, with a decrease in t1/2 from 115 hr after 1 wk to 67 hr after 4 wk of therapy.",Phenobarbital pharmacokinetics in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/627141/),h,67,8676,DB01174,Phenobarbital
,627141,t1/2,The elimination of phenobarbital decreased at an exponential rate with a t1/2 of 4.6 days.,Phenobarbital pharmacokinetics in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/627141/),d,4.6,8677,DB01174,Phenobarbital
,16615673,Plasma levels,"Plasma levels of citalopram were 1400 ng/ml, 583 ng/ml, 416 ng/ml, and 296 ng/ml, at one, six, 13, and 23 h post-ingestion, respectively.",Clinical course and toxicokinetic data following isolated citalopram overdose in an infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615673/),[ng] / [ml],1400,9368,DB01174,Phenobarbital
,16615673,Plasma levels,"Plasma levels of citalopram were 1400 ng/ml, 583 ng/ml, 416 ng/ml, and 296 ng/ml, at one, six, 13, and 23 h post-ingestion, respectively.",Clinical course and toxicokinetic data following isolated citalopram overdose in an infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615673/),[ng] / [ml],583,9369,DB01174,Phenobarbital
,16615673,Plasma levels,"Plasma levels of citalopram were 1400 ng/ml, 583 ng/ml, 416 ng/ml, and 296 ng/ml, at one, six, 13, and 23 h post-ingestion, respectively.",Clinical course and toxicokinetic data following isolated citalopram overdose in an infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615673/),[ng] / [ml],416,9370,DB01174,Phenobarbital
,16615673,Plasma levels,"Plasma levels of citalopram were 1400 ng/ml, 583 ng/ml, 416 ng/ml, and 296 ng/ml, at one, six, 13, and 23 h post-ingestion, respectively.",Clinical course and toxicokinetic data following isolated citalopram overdose in an infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615673/),[ng] / [ml],296,9371,DB01174,Phenobarbital
,16615673,elimination t1/2,The first level likely represents a predistributional level with subsequent levels giving an elimination t1/2 of 17.38 h.,Clinical course and toxicokinetic data following isolated citalopram overdose in an infant. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615673/),h,17.38,9372,DB01174,Phenobarbital
,16615673,t1/2,The elimination of the parent drug corresponds to an approximate t1/2 of 15-20 h in this single case.,Clinical course and toxicokinetic data following isolated citalopram overdose in an infant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615673/),h,15-20,9373,DB01174,Phenobarbital
above,12968992,plasma concentrations,All the children achieved plasma concentrations above 15 mg l(-1) by the end of the infusion.,Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968992/),[mg] / [l],15,13415,DB01174,Phenobarbital
,12968992,"area under curve [AUC (0, infinity)]","Mean (95% confidence interval or median and range for Cmax) pharmacokinetic parameters were: area under curve [AUC (0, infinity)]: 4259 (3169, 5448) mg l(-1).h, t(1/2): 82.9 (62, 103) h, CL: 5.8 (4.4, 7.3) ml kg(-1) h(-1), Vss: 0.8 (0.7, 0.9) l kg (-1), CSF: plasma phenobarbital concentration ratio: 0.7 (0.5, 0.8; n= 6) and Cmax: 19.9 (17.9-27.9) mg l(-1).",Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968992/),[h·mg] / [l],4259,13416,DB01174,Phenobarbital
,12968992,t(1/2),"Mean (95% confidence interval or median and range for Cmax) pharmacokinetic parameters were: area under curve [AUC (0, infinity)]: 4259 (3169, 5448) mg l(-1).h, t(1/2): 82.9 (62, 103) h, CL: 5.8 (4.4, 7.3) ml kg(-1) h(-1), Vss: 0.8 (0.7, 0.9) l kg (-1), CSF: plasma phenobarbital concentration ratio: 0.7 (0.5, 0.8; n= 6) and Cmax: 19.9 (17.9-27.9) mg l(-1).",Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968992/),h,82.9,13417,DB01174,Phenobarbital
,12968992,CL,"Mean (95% confidence interval or median and range for Cmax) pharmacokinetic parameters were: area under curve [AUC (0, infinity)]: 4259 (3169, 5448) mg l(-1).h, t(1/2): 82.9 (62, 103) h, CL: 5.8 (4.4, 7.3) ml kg(-1) h(-1), Vss: 0.8 (0.7, 0.9) l kg (-1), CSF: plasma phenobarbital concentration ratio: 0.7 (0.5, 0.8; n= 6) and Cmax: 19.9 (17.9-27.9) mg l(-1).",Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968992/),[ml] / [h·kg],5.8,13418,DB01174,Phenobarbital
,12968992,Vss,"Mean (95% confidence interval or median and range for Cmax) pharmacokinetic parameters were: area under curve [AUC (0, infinity)]: 4259 (3169, 5448) mg l(-1).h, t(1/2): 82.9 (62, 103) h, CL: 5.8 (4.4, 7.3) ml kg(-1) h(-1), Vss: 0.8 (0.7, 0.9) l kg (-1), CSF: plasma phenobarbital concentration ratio: 0.7 (0.5, 0.8; n= 6) and Cmax: 19.9 (17.9-27.9) mg l(-1).",Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968992/),-1·kg·l,0.8,13419,DB01174,Phenobarbital
,12968992,concentration ratio,"Mean (95% confidence interval or median and range for Cmax) pharmacokinetic parameters were: area under curve [AUC (0, infinity)]: 4259 (3169, 5448) mg l(-1).h, t(1/2): 82.9 (62, 103) h, CL: 5.8 (4.4, 7.3) ml kg(-1) h(-1), Vss: 0.8 (0.7, 0.9) l kg (-1), CSF: plasma phenobarbital concentration ratio: 0.7 (0.5, 0.8; n= 6) and Cmax: 19.9 (17.9-27.9) mg l(-1).",Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968992/),,0.7,13420,DB01174,Phenobarbital
,12968992,Cmax,"Mean (95% confidence interval or median and range for Cmax) pharmacokinetic parameters were: area under curve [AUC (0, infinity)]: 4259 (3169, 5448) mg l(-1).h, t(1/2): 82.9 (62, 103) h, CL: 5.8 (4.4, 7.3) ml kg(-1) h(-1), Vss: 0.8 (0.7, 0.9) l kg (-1), CSF: plasma phenobarbital concentration ratio: 0.7 (0.5, 0.8; n= 6) and Cmax: 19.9 (17.9-27.9) mg l(-1).",Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968992/),[mg] / [l],19.9,13421,DB01174,Phenobarbital
greater,12968992,maximum plasma concentrations,"Phenobarbital, given as an i.v. loading dose, 15 mg kg(-1), achieves maximum plasma concentrations of greater than 15 mg l(-1) with good clinical effect and no significant adverse events in children with severe falciparum malaria.",Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968992/),[mg] / [l],15,13422,DB01174,Phenobarbital
,28328763,C/D ratio,"The induration group showed significantly reduced C/D ratio compared with the noninduration group [median (range): 0.131 (0.114-0.334) versus 0.219 (0.180-0.322) d/L, P < 0.05).",Induration at Injection or Infusion Site May Reduce Bioavailability of Parenteral Phenobarbital Administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28328763/),[d] / [l],0.131,14117,DB01174,Phenobarbital
,28328763,C/D ratio,"The induration group showed significantly reduced C/D ratio compared with the noninduration group [median (range): 0.131 (0.114-0.334) versus 0.219 (0.180-0.322) d/L, P < 0.05).",Induration at Injection or Infusion Site May Reduce Bioavailability of Parenteral Phenobarbital Administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28328763/),[d] / [l],0.219,14118,DB01174,Phenobarbital
,7229122,elimination half-lives,"The elimination half-lives of primidone and phenobarbital of 6.2 and 83.5 hours, respectively, were within the ""normal range"" for patients on chronic therapy.",Acute phenytoin and primidone intoxication: a pharmacokinetic analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229122/),h,6.2,14472,DB01174,Phenobarbital
,7229122,elimination half-lives,"The elimination half-lives of primidone and phenobarbital of 6.2 and 83.5 hours, respectively, were within the ""normal range"" for patients on chronic therapy.",Acute phenytoin and primidone intoxication: a pharmacokinetic analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229122/),h,83.5,14473,DB01174,Phenobarbital
,6714282,maximal plasma phenobarbital concentrations,"Charcoal haemoperfusion was performed for 5-12 h in three patients with maximal plasma phenobarbital concentrations of 600, 946 and 1044 mumol/l (138, 217 and 240 micrograms/ml).",Pharmacokinetic evaluation of haemoperfusion in phenobarbital poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714282/),[μM] / [l],600,14869,DB01174,Phenobarbital
,6714282,maximal plasma phenobarbital concentrations,"Charcoal haemoperfusion was performed for 5-12 h in three patients with maximal plasma phenobarbital concentrations of 600, 946 and 1044 mumol/l (138, 217 and 240 micrograms/ml).",Pharmacokinetic evaluation of haemoperfusion in phenobarbital poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714282/),[μM] / [l],946,14870,DB01174,Phenobarbital
,6714282,maximal plasma phenobarbital concentrations,"Charcoal haemoperfusion was performed for 5-12 h in three patients with maximal plasma phenobarbital concentrations of 600, 946 and 1044 mumol/l (138, 217 and 240 micrograms/ml).",Pharmacokinetic evaluation of haemoperfusion in phenobarbital poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714282/),[μM] / [l],1044,14871,DB01174,Phenobarbital
,6714282,maximal plasma phenobarbital concentrations,"Charcoal haemoperfusion was performed for 5-12 h in three patients with maximal plasma phenobarbital concentrations of 600, 946 and 1044 mumol/l (138, 217 and 240 micrograms/ml).",Pharmacokinetic evaluation of haemoperfusion in phenobarbital poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714282/),[μg] / [ml],138,14872,DB01174,Phenobarbital
,6714282,maximal plasma phenobarbital concentrations,"Charcoal haemoperfusion was performed for 5-12 h in three patients with maximal plasma phenobarbital concentrations of 600, 946 and 1044 mumol/l (138, 217 and 240 micrograms/ml).",Pharmacokinetic evaluation of haemoperfusion in phenobarbital poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714282/),[μg] / [ml],217,14873,DB01174,Phenobarbital
,6714282,maximal plasma phenobarbital concentrations,"Charcoal haemoperfusion was performed for 5-12 h in three patients with maximal plasma phenobarbital concentrations of 600, 946 and 1044 mumol/l (138, 217 and 240 micrograms/ml).",Pharmacokinetic evaluation of haemoperfusion in phenobarbital poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714282/),[μg] / [ml],240,14874,DB01174,Phenobarbital
,6714282,half-lives,"During haemoperfusion with constant blood flow phenobarbital elimination followed first order kinetics with half-lives of 11.1, 10.0 and 7.2 h, respectively.",Pharmacokinetic evaluation of haemoperfusion in phenobarbital poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714282/),h,11.1,14875,DB01174,Phenobarbital
,6714282,half-lives,"During haemoperfusion with constant blood flow phenobarbital elimination followed first order kinetics with half-lives of 11.1, 10.0 and 7.2 h, respectively.",Pharmacokinetic evaluation of haemoperfusion in phenobarbital poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714282/),h,10.0,14876,DB01174,Phenobarbital
,6714282,half-lives,"During haemoperfusion with constant blood flow phenobarbital elimination followed first order kinetics with half-lives of 11.1, 10.0 and 7.2 h, respectively.",Pharmacokinetic evaluation of haemoperfusion in phenobarbital poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714282/),h,7.2,14877,DB01174,Phenobarbital
,6714282,half-lives,"After termination of the haemoperfusion there was no rebound effect in plasma phenobarbital concentration and the elimination was first order with half-lives of 51, 82 and 48 h, respectively.",Pharmacokinetic evaluation of haemoperfusion in phenobarbital poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714282/),h,51,14878,DB01174,Phenobarbital
,6714282,half-lives,"After termination of the haemoperfusion there was no rebound effect in plasma phenobarbital concentration and the elimination was first order with half-lives of 51, 82 and 48 h, respectively.",Pharmacokinetic evaluation of haemoperfusion in phenobarbital poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714282/),h,82,14879,DB01174,Phenobarbital
,6714282,half-lives,"After termination of the haemoperfusion there was no rebound effect in plasma phenobarbital concentration and the elimination was first order with half-lives of 51, 82 and 48 h, respectively.",Pharmacokinetic evaluation of haemoperfusion in phenobarbital poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714282/),h,48,14880,DB01174,Phenobarbital
,6714282,volume of distribution,In the same period 76-86% of the total body clearance of phenobarbital was due to the haemoperfusion column at a calculated volume of distribution of phenobarbital of 1.1-1.21/kg.,Pharmacokinetic evaluation of haemoperfusion in phenobarbital poisoning. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714282/),1/[kg],1.1-1.21,14881,DB01174,Phenobarbital
,8902429,Cmax,"The results showed that both mean Cmax and AUC of DTZ were lower (871.6 vs 79.8 ng/ml; 1171 vs 101.9 ng-h/ml), but the mean Cmax of the primary metabolites M1 and M(A) was higher after phenobarbital (M1 413.0 vs 648.9 ng/ml; M(A) 683.0 vs 814.8 ng/ml).",Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng] / [ml],871.6,15156,DB01174,Phenobarbital
,8902429,Cmax,"The results showed that both mean Cmax and AUC of DTZ were lower (871.6 vs 79.8 ng/ml; 1171 vs 101.9 ng-h/ml), but the mean Cmax of the primary metabolites M1 and M(A) was higher after phenobarbital (M1 413.0 vs 648.9 ng/ml; M(A) 683.0 vs 814.8 ng/ml).",Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng] / [ml],79.8,15157,DB01174,Phenobarbital
,8902429,Cmax,"The results showed that both mean Cmax and AUC of DTZ were lower (871.6 vs 79.8 ng/ml; 1171 vs 101.9 ng-h/ml), but the mean Cmax of the primary metabolites M1 and M(A) was higher after phenobarbital (M1 413.0 vs 648.9 ng/ml; M(A) 683.0 vs 814.8 ng/ml).",Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng-h] / [ml],1171,15158,DB01174,Phenobarbital
,8902429,AUC,"The results showed that both mean Cmax and AUC of DTZ were lower (871.6 vs 79.8 ng/ml; 1171 vs 101.9 ng-h/ml), but the mean Cmax of the primary metabolites M1 and M(A) was higher after phenobarbital (M1 413.0 vs 648.9 ng/ml; M(A) 683.0 vs 814.8 ng/ml).",Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng-h] / [ml],1171,15159,DB01174,Phenobarbital
,8902429,AUC,"The results showed that both mean Cmax and AUC of DTZ were lower (871.6 vs 79.8 ng/ml; 1171 vs 101.9 ng-h/ml), but the mean Cmax of the primary metabolites M1 and M(A) was higher after phenobarbital (M1 413.0 vs 648.9 ng/ml; M(A) 683.0 vs 814.8 ng/ml).",Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng-h] / [ml],101.9,15160,DB01174,Phenobarbital
,8902429,Cmax,"The results showed that both mean Cmax and AUC of DTZ were lower (871.6 vs 79.8 ng/ml; 1171 vs 101.9 ng-h/ml), but the mean Cmax of the primary metabolites M1 and M(A) was higher after phenobarbital (M1 413.0 vs 648.9 ng/ml; M(A) 683.0 vs 814.8 ng/ml).",Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng] / [ml],413.0,15161,DB01174,Phenobarbital
,8902429,Cmax,"The results showed that both mean Cmax and AUC of DTZ were lower (871.6 vs 79.8 ng/ml; 1171 vs 101.9 ng-h/ml), but the mean Cmax of the primary metabolites M1 and M(A) was higher after phenobarbital (M1 413.0 vs 648.9 ng/ml; M(A) 683.0 vs 814.8 ng/ml).",Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng] / [ml],648.9,15162,DB01174,Phenobarbital
,8902429,Cmax,"The results showed that both mean Cmax and AUC of DTZ were lower (871.6 vs 79.8 ng/ml; 1171 vs 101.9 ng-h/ml), but the mean Cmax of the primary metabolites M1 and M(A) was higher after phenobarbital (M1 413.0 vs 648.9 ng/ml; M(A) 683.0 vs 814.8 ng/ml).",Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng] / [ml],683.0,15163,DB01174,Phenobarbital
,8902429,Cmax,"The results showed that both mean Cmax and AUC of DTZ were lower (871.6 vs 79.8 ng/ml; 1171 vs 101.9 ng-h/ml), but the mean Cmax of the primary metabolites M1 and M(A) was higher after phenobarbital (M1 413.0 vs 648.9 ng/ml; M(A) 683.0 vs 814.8 ng/ml).",Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng] / [ml],814.8,15164,DB01174,Phenobarbital
,8902429,Cmax,The highest increase was seen in the mean Cmax and AUC of the secondary metabolite M2 (837.5 vs 2585.7 ng/ml; 3312.1 vs 13156.5 ng-h/ml).,Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng] / [ml],837.5,15165,DB01174,Phenobarbital
,8902429,Cmax,The highest increase was seen in the mean Cmax and AUC of the secondary metabolite M2 (837.5 vs 2585.7 ng/ml; 3312.1 vs 13156.5 ng-h/ml).,Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng] / [ml],2585.7,15166,DB01174,Phenobarbital
,8902429,AUC,The highest increase was seen in the mean Cmax and AUC of the secondary metabolite M2 (837.5 vs 2585.7 ng/ml; 3312.1 vs 13156.5 ng-h/ml).,Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng-h] / [ml],3312.1,15167,DB01174,Phenobarbital
,8902429,AUC,The highest increase was seen in the mean Cmax and AUC of the secondary metabolite M2 (837.5 vs 2585.7 ng/ml; 3312.1 vs 13156.5 ng-h/ml).,Effect of phenobarbital pretreatment on the pharmacokinetics and metabolism of diltiazem in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902429/),[ng-h] / [ml],13156.5,15168,DB01174,Phenobarbital
,8764817,elimination half-life (t1/2),"The median elimination half-life (t1/2) in patients receiving concomitant valproate (VPA) was 43.3 h; in patients receiving carbamazepine (CBZ) and/or phenobarbital (PB), it was 14.1 h; and in patients receiving both VPA and CBZ/ PB or other antiepileptic drugs (AEDs), it was 28.9 h.",Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8764817/),h,43.3,15735,DB01174,Phenobarbital
,8764817,elimination half-life (t1/2),"The median elimination half-life (t1/2) in patients receiving concomitant valproate (VPA) was 43.3 h; in patients receiving carbamazepine (CBZ) and/or phenobarbital (PB), it was 14.1 h; and in patients receiving both VPA and CBZ/ PB or other antiepileptic drugs (AEDs), it was 28.9 h.",Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8764817/),h,14.1,15736,DB01174,Phenobarbital
,8764817,elimination half-life (t1/2),"The median elimination half-life (t1/2) in patients receiving concomitant valproate (VPA) was 43.3 h; in patients receiving carbamazepine (CBZ) and/or phenobarbital (PB), it was 14.1 h; and in patients receiving both VPA and CBZ/ PB or other antiepileptic drugs (AEDs), it was 28.9 h.",Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8764817/),h,28.9,15737,DB01174,Phenobarbital
,16404803,Milk/maternal plasma concentration ratios,"Milk/maternal plasma concentration ratios close to 1 demonstrate extensive transfer to breast milk of many AEDs including ethosuximide, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate, and zonisamide.",Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast-feeding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404803/),,1,16688,DB01174,Phenobarbital
,9578008,time,"The time from initiation of high-dose barbiturate therapy to attainment of control of RSE was longer (123 min) than the time to attainment of seizure control in the group receiving propofol (2.6 min, p = 0.002).",Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578008/),min,123,18122,DB01174,Phenobarbital
,9578008,time to attainment of seizure control,"The time from initiation of high-dose barbiturate therapy to attainment of control of RSE was longer (123 min) than the time to attainment of seizure control in the group receiving propofol (2.6 min, p = 0.002).",Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578008/),min,2.6,18123,DB01174,Phenobarbital
,9578008,Plasma concentrations,Plasma concentrations of propofol associated with control of SE were 14 microM +/- 4 (2.5 microg/ml).,Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578008/),μM,14,18124,DB01174,Phenobarbital
,9578008,Plasma concentrations,Plasma concentrations of propofol associated with control of SE were 14 microM +/- 4 (2.5 microg/ml).,Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578008/),[μg] / [ml],2.5,18125,DB01174,Phenobarbital
,17433926,serum concentration,"The average (+/-SD) carbamazepine (CBZ) dose is 8.8 +/- 4.7 mg/kg/day, yielding a mean serum concentration of 6.3 +/- 2.2 mg/liter.",Pharmacokinetics of antiepileptic drugs in elderly nursing home residents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17433926/),[mg] / [l],6.3,18536,DB01174,Phenobarbital
,23855753,CL,"The population typical mean [per cent relative standard error (%RSE)] values for CL, apparent volume of distribution (Vd ) and bioavailability (F) were 0.0054 L/H/kg (7%), 0.64 L/kg (15%) and 48.9% (22%), respectively.","Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23855753/),[l] / [h·kg],0.0054,18879,DB01174,Phenobarbital
,23855753,apparent volume of distribution (Vd ),"The population typical mean [per cent relative standard error (%RSE)] values for CL, apparent volume of distribution (Vd ) and bioavailability (F) were 0.0054 L/H/kg (7%), 0.64 L/kg (15%) and 48.9% (22%), respectively.","Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23855753/),[l] / [kg],0.64,18880,DB01174,Phenobarbital
,23855753,bioavailability (F),"The population typical mean [per cent relative standard error (%RSE)] values for CL, apparent volume of distribution (Vd ) and bioavailability (F) were 0.0054 L/H/kg (7%), 0.64 L/kg (15%) and 48.9% (22%), respectively.","Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23855753/),%,48.9,18881,DB01174,Phenobarbital
,15246117,CL/F,"On average, elderly patients were found to exhibit slightly higher CL/F values compared with controls (14.6 +/- 4.7 ml h(-1) kg(-1) versus 13.1 +/- 4.2 ml h(-1) kg(-1), P < 0.05), the difference being probably related to the dose-dependent nature of phenytoin metabolism and the fact that elderly patients received lower dosages (4.4 +/- 1.1 mg kg(-1)day(-1) versus 5.3 +/- 1.1 mg kg(-1) day(-1), P < 0.001) and had lower serum phenytoin concentrations (14.1 +/- 5.7 microg ml(-1) versus 18.6 +/- 6.8 microg ml(-1), P < 0.0001).",Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15246117/),[ml] / [h·kg],14.6,19210,DB01174,Phenobarbital
,15246117,CL/F,"On average, elderly patients were found to exhibit slightly higher CL/F values compared with controls (14.6 +/- 4.7 ml h(-1) kg(-1) versus 13.1 +/- 4.2 ml h(-1) kg(-1), P < 0.05), the difference being probably related to the dose-dependent nature of phenytoin metabolism and the fact that elderly patients received lower dosages (4.4 +/- 1.1 mg kg(-1)day(-1) versus 5.3 +/- 1.1 mg kg(-1) day(-1), P < 0.001) and had lower serum phenytoin concentrations (14.1 +/- 5.7 microg ml(-1) versus 18.6 +/- 6.8 microg ml(-1), P < 0.0001).",Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15246117/),[ml] / [h·kg],13.1,19211,DB01174,Phenobarbital
,11526962,ED50,The ED50 value of AML against clonic seizures induced by PTZ was 5.4 mg/kg.,Amlodipine enhances the activity of antiepileptic drugs against pentylenetetrazole-induced seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11526962/),[mg] / [kg],5.4,20652,DB01174,Phenobarbital
,8641326,clearance,"Mean (95% confidence interval) phenobarbitone clearance values were 7.6 ml x h(-1) x kg(-1) (6.2, 9.0 ml x h(-1) x kg(-1) for the monotherapy group, 5.0 ml x h(-1) x hg(-1) (4.0, 6.0 ml x h(-1) x kg(-1)) in the presence of concomitant valproate and 6.8 ml x h(-1) x kg(-1) (5.6, 8.0 ml x h(-1) x kg(-1)) in the presence of concomitant carbamazepine or phenytoin.",Determination of phenobarbitone population clearance values for South African children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641326/),[ml] / [h·kg],7.6,21193,DB01174,Phenobarbital
,8641326,clearance,"Mean (95% confidence interval) phenobarbitone clearance values were 7.6 ml x h(-1) x kg(-1) (6.2, 9.0 ml x h(-1) x kg(-1) for the monotherapy group, 5.0 ml x h(-1) x hg(-1) (4.0, 6.0 ml x h(-1) x kg(-1)) in the presence of concomitant valproate and 6.8 ml x h(-1) x kg(-1) (5.6, 8.0 ml x h(-1) x kg(-1)) in the presence of concomitant carbamazepine or phenytoin.",Determination of phenobarbitone population clearance values for South African children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641326/),[ml] / [h·hg],5.0,21194,DB01174,Phenobarbital
,8641326,clearance,"Mean (95% confidence interval) phenobarbitone clearance values were 7.6 ml x h(-1) x kg(-1) (6.2, 9.0 ml x h(-1) x kg(-1) for the monotherapy group, 5.0 ml x h(-1) x hg(-1) (4.0, 6.0 ml x h(-1) x kg(-1)) in the presence of concomitant valproate and 6.8 ml x h(-1) x kg(-1) (5.6, 8.0 ml x h(-1) x kg(-1)) in the presence of concomitant carbamazepine or phenytoin.",Determination of phenobarbitone population clearance values for South African children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641326/),[ml] / [h·kg],6.8,21195,DB01174,Phenobarbital
,7850794,Vmax,"The mean (SD) Vmax and Km values were 1.47 (0.89) microM/min and 575 (347) microM, respectively.",Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850794/),[μM] / [min],1.47,22186,DB01174,Phenobarbital
,7850794,Km,"The mean (SD) Vmax and Km values were 1.47 (0.89) microM/min and 575 (347) microM, respectively.",Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850794/),μM,575,22187,DB01174,Phenobarbital
,7850794,initial,"The mean (SD) initial and final clearance rates were 51 (16) ml/min and 106 (48) ml/min, respectively.",Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850794/),[ml] / [min],51,22188,DB01174,Phenobarbital
,7850794,final clearance rates,"The mean (SD) initial and final clearance rates were 51 (16) ml/min and 106 (48) ml/min, respectively.",Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850794/),[ml] / [min],106,22189,DB01174,Phenobarbital
,7850794,renal clearance rate,The mean renal clearance rate was 17 ml/min in the first course and 16 ml/min in the second course.,Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850794/),[ml] / [min],17,22190,DB01174,Phenobarbital
,7850794,renal clearance rate,The mean renal clearance rate was 17 ml/min in the first course and 16 ml/min in the second course.,Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850794/),[ml] / [min],16,22191,DB01174,Phenobarbital
,10332532,peak concentration,A maintenance dose of 5 mg/kg/d provided a peak concentration of 19.7 micrograms/mL and trough concentration of 16.7 micrograms/mL after four doses.,Phenobarbital dosing and pharmacokinetics in a neonate receiving extracorporeal membrane oxygenation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10332532/),[μg] / [ml],19.7,23192,DB01174,Phenobarbital
,10332532,trough concentration,A maintenance dose of 5 mg/kg/d provided a peak concentration of 19.7 micrograms/mL and trough concentration of 16.7 micrograms/mL after four doses.,Phenobarbital dosing and pharmacokinetics in a neonate receiving extracorporeal membrane oxygenation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10332532/),[μg] / [ml],16.7,23193,DB01174,Phenobarbital
,10332532,volume of distribution,The calculated volume of distribution was 1.2 L/kg and the estimated elimination half-life was 92 hours.,Phenobarbital dosing and pharmacokinetics in a neonate receiving extracorporeal membrane oxygenation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10332532/),[l] / [kg],1.2,23194,DB01174,Phenobarbital
,10332532,elimination half-life,The calculated volume of distribution was 1.2 L/kg and the estimated elimination half-life was 92 hours.,Phenobarbital dosing and pharmacokinetics in a neonate receiving extracorporeal membrane oxygenation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10332532/),h,92,23195,DB01174,Phenobarbital
,7346748,peak time,"The mean peak time after phenobarbital sodium (0.92 hr) was significantly (p less than 0.01) shorter than that after phenobarbital acid (5.83 hr), whereas the mean peak levels (16.2 vs 13.8 microgram/ml) did not reach statistical difference (p less than 0.2) between both dosage forms.",Pharmacokinetics and relative bioavailability of intramuscular phenobarbital sodium or acid in infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7346748/),h,0.92,23584,DB01174,Phenobarbital
,7346748,peak time,"The mean peak time after phenobarbital sodium (0.92 hr) was significantly (p less than 0.01) shorter than that after phenobarbital acid (5.83 hr), whereas the mean peak levels (16.2 vs 13.8 microgram/ml) did not reach statistical difference (p less than 0.2) between both dosage forms.",Pharmacokinetics and relative bioavailability of intramuscular phenobarbital sodium or acid in infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7346748/),h,5.83,23585,DB01174,Phenobarbital
,7346748,peak levels,"The mean peak time after phenobarbital sodium (0.92 hr) was significantly (p less than 0.01) shorter than that after phenobarbital acid (5.83 hr), whereas the mean peak levels (16.2 vs 13.8 microgram/ml) did not reach statistical difference (p less than 0.2) between both dosage forms.",Pharmacokinetics and relative bioavailability of intramuscular phenobarbital sodium or acid in infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7346748/),[μg] / [ml],16.2,23586,DB01174,Phenobarbital
,7346748,peak levels,"The mean peak time after phenobarbital sodium (0.92 hr) was significantly (p less than 0.01) shorter than that after phenobarbital acid (5.83 hr), whereas the mean peak levels (16.2 vs 13.8 microgram/ml) did not reach statistical difference (p less than 0.2) between both dosage forms.",Pharmacokinetics and relative bioavailability of intramuscular phenobarbital sodium or acid in infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7346748/),[μg] / [ml],13.8,23587,DB01174,Phenobarbital
,7346748,t1/2,"The overall mean values of these variables were: t1/2, 64.0 hr, Vd/F, 0.667 1/kg, and C1/F, 0.136 m1/min/kg.",Pharmacokinetics and relative bioavailability of intramuscular phenobarbital sodium or acid in infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7346748/),h,64.0,23588,DB01174,Phenobarbital
,7346748,Vd/F,"The overall mean values of these variables were: t1/2, 64.0 hr, Vd/F, 0.667 1/kg, and C1/F, 0.136 m1/min/kg.",Pharmacokinetics and relative bioavailability of intramuscular phenobarbital sodium or acid in infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7346748/),[1] / [kg],0.667,23589,DB01174,Phenobarbital
,7346748,C1/F,"The overall mean values of these variables were: t1/2, 64.0 hr, Vd/F, 0.667 1/kg, and C1/F, 0.136 m1/min/kg.",Pharmacokinetics and relative bioavailability of intramuscular phenobarbital sodium or acid in infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7346748/),[m1] / [kg·min],0.136,23590,DB01174,Phenobarbital
,6704138,terminal (beta) half-life,Phenobarbitone pretreatment significantly (P less than 0.01) increased the plasma clearance of vitamin K1 and decreased the terminal (beta) half-life from 2.08 +/- 0.56 to 0.99 +/- 0.30 hr.,The effect of phenobarbitone pre-treatment on vitamin K1 disposition in the rat and rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6704138/),h,2.08,25704,DB01174,Phenobarbital
,6704138,terminal (beta) half-life,Phenobarbitone pretreatment significantly (P less than 0.01) increased the plasma clearance of vitamin K1 and decreased the terminal (beta) half-life from 2.08 +/- 0.56 to 0.99 +/- 0.30 hr.,The effect of phenobarbitone pre-treatment on vitamin K1 disposition in the rat and rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6704138/),h,0.99,25705,DB01174,Phenobarbital
,590316,elimination half-life,"The distribution volumes within the individual age groups and the rate constants k12 and k21 showed no significant differences, but the elimination half-life was significantly longer in neonates (118.6+/-16.1h) than in babies (62.9+/-5.2h) or infants (68.5+/-3.2h).",Pharmacokinetics of phenobarbital in childhood. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/590316/),h,118.6,27549,DB01174,Phenobarbital
,590316,elimination half-life,"The distribution volumes within the individual age groups and the rate constants k12 and k21 showed no significant differences, but the elimination half-life was significantly longer in neonates (118.6+/-16.1h) than in babies (62.9+/-5.2h) or infants (68.5+/-3.2h).",Pharmacokinetics of phenobarbital in childhood. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/590316/),h,62.9,27550,DB01174,Phenobarbital
,590316,elimination half-life,"The distribution volumes within the individual age groups and the rate constants k12 and k21 showed no significant differences, but the elimination half-life was significantly longer in neonates (118.6+/-16.1h) than in babies (62.9+/-5.2h) or infants (68.5+/-3.2h).",Pharmacokinetics of phenobarbital in childhood. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/590316/),h,68.5,27551,DB01174,Phenobarbital
,3806416,distribution volumes,"A mean (S.E.M.) of 0.73 (0.07) of R-fenoprofen was inverted to S-fenoprofen and the distribution volumes for bound plus unbound R-fenoprofen and S-fenoprofen were 50.3 (4.5) and 98.5 (5.9) ml/kg, respectively.",Enantioselective disposition of 2-arylpropionic acid nonsteroidal anti-inflammatory drugs. Fenoprofen disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806416/),[ml] / [kg],50.3,28874,DB01174,Phenobarbital
,3806416,distribution volumes,"A mean (S.E.M.) of 0.73 (0.07) of R-fenoprofen was inverted to S-fenoprofen and the distribution volumes for bound plus unbound R-fenoprofen and S-fenoprofen were 50.3 (4.5) and 98.5 (5.9) ml/kg, respectively.",Enantioselective disposition of 2-arylpropionic acid nonsteroidal anti-inflammatory drugs. Fenoprofen disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806416/),[ml] / [kg],98.5,28875,DB01174,Phenobarbital
,3806416,area,"The mean (S.E.M.) predicted area, 2.1 (0.2) mg X min/ml/kg, was within 94% of the observed area 2.2 (0.2) mg X min/ml/kg.",Enantioselective disposition of 2-arylpropionic acid nonsteroidal anti-inflammatory drugs. Fenoprofen disposition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806416/),[mg·min] / [kg·ml],2.1,28876,DB01174,Phenobarbital
,3806416,area,"The mean (S.E.M.) predicted area, 2.1 (0.2) mg X min/ml/kg, was within 94% of the observed area 2.2 (0.2) mg X min/ml/kg.",Enantioselective disposition of 2-arylpropionic acid nonsteroidal anti-inflammatory drugs. Fenoprofen disposition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806416/),[mg·min] / [kg·ml],2.2,28877,DB01174,Phenobarbital
,2384074,"apparent terminal half-life (t1/2, beta)","Analysis of plasma and whole brain homogenates of mice indicated that AHR-11748 has an apparent terminal half-life (t1/2, beta) of 1.0 h.","Pharmacodynamics and pharmacokinetics of AHR-11748, a new antiepileptic agent, in rodents. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384074/),h,1.0,29349,DB01174,Phenobarbital
,2384074,brain:plasma ratio,The brain:plasma ratio of AHR-11748 was 3.4:1 from 0.5 h to 6 h.,"Pharmacodynamics and pharmacokinetics of AHR-11748, a new antiepileptic agent, in rodents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384074/),,3.4,29350,DB01174,Phenobarbital
,2384074,brain:plasma ratio,The brain:plasma ratio of AHR-11748 was 3.4:1 from 0.5 h to 6 h.,"Pharmacodynamics and pharmacokinetics of AHR-11748, a new antiepileptic agent, in rodents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384074/),h,0.,29351,DB01174,Phenobarbital
,2384074,brain:plasma ratio,The brain:plasma ratio of AHR-11748 was 3.4:1 from 0.5 h to 6 h.,"Pharmacodynamics and pharmacokinetics of AHR-11748, a new antiepileptic agent, in rodents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384074/),h,6,29352,DB01174,Phenobarbital
,346286,peak serum concentration,"With a single 600mg dose, peak serum concentration of the order of 10microgram/ml generally occur 2 hours after administration.",Clinical pharmacokinetics of rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/346286/),[μg] / [ml],10,29442,DB01174,Phenobarbital
,346286,half-life,The half-life of rifampicin for this dose level is of the order of 2.5 hours.,Clinical pharmacokinetics of rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/346286/),h,2.5,29443,DB01174,Phenobarbital
,8832915,nonrenal clearance,"The nonrenal clearance of furosemide (2.20 versus 3.53 ml/min/kg) increased significantly, and the 24 h-urinary excretion of furosemide (both the amount and percentages of iv dose) decreased significantly in the YH-439 treated rats when compared with those in the control rats.","Effect of a hepatoprotective agent, YH-439, on the pharmacokinetics of furosemide and azosemide in rats. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832915/),[ml] / [kg·min],2.20,30378,DB01174,Phenobarbital
,8832915,nonrenal clearance,"The nonrenal clearance of furosemide (2.20 versus 3.53 ml/min/kg) increased significantly, and the 24 h-urinary excretion of furosemide (both the amount and percentages of iv dose) decreased significantly in the YH-439 treated rats when compared with those in the control rats.","Effect of a hepatoprotective agent, YH-439, on the pharmacokinetics of furosemide and azosemide in rats. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832915/),[ml] / [kg·min],3.53,30379,DB01174,Phenobarbital
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],302.7,31407,DB01174,Phenobarbital
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],383.2,31408,DB01174,Phenobarbital
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],378.9,31409,DB01174,Phenobarbital
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],214.0,31410,DB01174,Phenobarbital
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],1179.1,31411,DB01174,Phenobarbital
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],1687.0,31412,DB01174,Phenobarbital
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],2209.5,31413,DB01174,Phenobarbital
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],381.7,31414,DB01174,Phenobarbital
,3665340,Bioavailability,Bioavailability of prednisolone after the oral administration of prednisone and methylprednisolone ranged from 86% to 104% during anticonvulsant therapy.,Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),%,86,31415,DB01174,Phenobarbital
,3665340,Bioavailability,Bioavailability of prednisolone after the oral administration of prednisone and methylprednisolone ranged from 86% to 104% during anticonvulsant therapy.,Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),%,104,31416,DB01174,Phenobarbital
,9545146,Residual variability,Residual variability was 1.8 mg/L.,Population pharmacokinetics of carbamazepine in adults with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545146/),[mg] / [l],1.8,31609,DB01174,Phenobarbital
,6649682,blood clearance,Treatment with PB increased antipyrine blood clearance from 11.1 to 59.1 ml/min per kg.,Influence of allylisopropylacetamide and phenobarbital treatment on in vivo antipyrine metabolite formation in rats. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6649682/),[ml] / [kg·min],11,31662,DB01174,Phenobarbital
,6649682,blood clearance,Treatment with PB increased antipyrine blood clearance from 11.1 to 59.1 ml/min per kg.,Influence of allylisopropylacetamide and phenobarbital treatment on in vivo antipyrine metabolite formation in rats. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6649682/),[ml] / [kg·min],59,31663,DB01174,Phenobarbital
,6649682,clearance,Treatment with AIA resulted in a reduction of antipyrine clearance to 5.6 ml/min per kg.,Influence of allylisopropylacetamide and phenobarbital treatment on in vivo antipyrine metabolite formation in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6649682/),[ml] / [kg·min],5.6,31664,DB01174,Phenobarbital
,6649682,Blood clearance,Blood clearance of antipyrine was reduced from 59.1 to 12.3 ml/min per kg.,Influence of allylisopropylacetamide and phenobarbital treatment on in vivo antipyrine metabolite formation in rats. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6649682/),[ml] / [kg·min],59.1,31665,DB01174,Phenobarbital
,6649682,Blood clearance,Blood clearance of antipyrine was reduced from 59.1 to 12.3 ml/min per kg.,Influence of allylisopropylacetamide and phenobarbital treatment on in vivo antipyrine metabolite formation in rats. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6649682/),[ml] / [kg·min],12.3,31666,DB01174,Phenobarbital
,10997154,t1/2,Dietary protein or fat restriction induced significantly greater changes: t1/2 (hours) was lower in groups 2 (mean +/- SD; 25.9 +/- 6.10 hours) and 3 (24.0 +/- 4.70) than in group 1 (32.9 +/- 5.20).,Effects of diet on pharmacokinetics of phenobarbital in healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997154/),h,25.9,32604,DB01174,Phenobarbital
,10997154,t1/2,Dietary protein or fat restriction induced significantly greater changes: t1/2 (hours) was lower in groups 2 (mean +/- SD; 25.9 +/- 6.10 hours) and 3 (24.0 +/- 4.70) than in group 1 (32.9 +/- 5.20).,Effects of diet on pharmacokinetics of phenobarbital in healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997154/),h,24.0,32605,DB01174,Phenobarbital
,10997154,t1/2,Dietary protein or fat restriction induced significantly greater changes: t1/2 (hours) was lower in groups 2 (mean +/- SD; 25.9 +/- 6.10 hours) and 3 (24.0 +/- 4.70) than in group 1 (32.9 +/- 5.20).,Effects of diet on pharmacokinetics of phenobarbital in healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997154/),h,32.9,32606,DB01174,Phenobarbital
,10997154,clearance rate,Phenobarbital clearance rate (ml/kg/min) was significantly higher in group 3 (0.22 +/- 0.05 ml/kg/min) than in groups 1 (0.17 +/- 0.03) or 2 (0.18 +/- 0.03).,Effects of diet on pharmacokinetics of phenobarbital in healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997154/),[ml] / [kg·min],0.22,32607,DB01174,Phenobarbital
,10997154,clearance rate,Phenobarbital clearance rate (ml/kg/min) was significantly higher in group 3 (0.22 +/- 0.05 ml/kg/min) than in groups 1 (0.17 +/- 0.03) or 2 (0.18 +/- 0.03).,Effects of diet on pharmacokinetics of phenobarbital in healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997154/),[ml] / [kg·min],0.17,32608,DB01174,Phenobarbital
,10997154,clearance rate,Phenobarbital clearance rate (ml/kg/min) was significantly higher in group 3 (0.22 +/- 0.05 ml/kg/min) than in groups 1 (0.17 +/- 0.03) or 2 (0.18 +/- 0.03).,Effects of diet on pharmacokinetics of phenobarbital in healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997154/),[ml] / [kg·min],0.18,32609,DB01174,Phenobarbital
,10997154,serum,Induction of serum alkaline phosphatase activity (U/L) was greater in groups 2 (192.4 +/- 47.5 U/L) and 3 (202.0 +/- 98.2) than in group 1 (125.0 +/- 47.5).,Effects of diet on pharmacokinetics of phenobarbital in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997154/),[u] / [l],192.4,32610,DB01174,Phenobarbital
,10997154,serum,Induction of serum alkaline phosphatase activity (U/L) was greater in groups 2 (192.4 +/- 47.5 U/L) and 3 (202.0 +/- 98.2) than in group 1 (125.0 +/- 47.5).,Effects of diet on pharmacokinetics of phenobarbital in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997154/),,202.0,32611,DB01174,Phenobarbital
,10997154,serum,Induction of serum alkaline phosphatase activity (U/L) was greater in groups 2 (192.4 +/- 47.5 U/L) and 3 (202.0 +/- 98.2) than in group 1 (125.0 +/- 47.5).,Effects of diet on pharmacokinetics of phenobarbital in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997154/),[u] / [l],125.0,32612,DB01174,Phenobarbital
,31256150,effectiveness,Anticonvulsant effectiveness was 65.5% for phenobarbital and 37.1% for add-on midazolam.,"Phenobarbital, Midazolam Pharmacokinetics, Effectiveness, and Drug-Drug Interaction in Asphyxiated Neonates Undergoing Therapeutic Hypothermia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31256150/),%,65.5,34584,DB01174,Phenobarbital
,31256150,effectiveness,Anticonvulsant effectiveness was 65.5% for phenobarbital and 37.1% for add-on midazolam.,"Phenobarbital, Midazolam Pharmacokinetics, Effectiveness, and Drug-Drug Interaction in Asphyxiated Neonates Undergoing Therapeutic Hypothermia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31256150/),%,37.1,34585,DB01174,Phenobarbital
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,105.15,35400,DB01174,Phenobarbital
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,84.76,35401,DB01174,Phenobarbital
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,94.45,35402,DB01174,Phenobarbital
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,96.52,35403,DB01174,Phenobarbital
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,98.62,35404,DB01174,Phenobarbital
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,95.08,35405,DB01174,Phenobarbital
,3631715,half-lives,"Comparing prephenobarbital (control) digoxin half-lives of 42.4 +/- 8.8 hours and postphenobarbital digoxin half-lives of 18.0 +/- 2.2 hours, the half-life was significantly (P less than 0.05) decreased after phenobarbital administration.",Pharmacokinetics and interactions of digoxin with phenobarbital in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631715/),h,42.4,36449,DB01174,Phenobarbital
,3631715,half-lives,"Comparing prephenobarbital (control) digoxin half-lives of 42.4 +/- 8.8 hours and postphenobarbital digoxin half-lives of 18.0 +/- 2.2 hours, the half-life was significantly (P less than 0.05) decreased after phenobarbital administration.",Pharmacokinetics and interactions of digoxin with phenobarbital in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631715/),h,18.0,36450,DB01174,Phenobarbital
,3631715,half-lives,Mean (+/- SD) half-lives of digoxin were 29.0 +/- 7.2 hours before phenobarbital treatment (control) and were 34.8 +/- 7.2 hours after phenobarbital treatment.,Pharmacokinetics and interactions of digoxin with phenobarbital in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631715/),h,29.0,36451,DB01174,Phenobarbital
,3631715,half-lives,Mean (+/- SD) half-lives of digoxin were 29.0 +/- 7.2 hours before phenobarbital treatment (control) and were 34.8 +/- 7.2 hours after phenobarbital treatment.,Pharmacokinetics and interactions of digoxin with phenobarbital in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631715/),h,34.8,36452,DB01174,Phenobarbital
,2237913,oral availability,"The oral availability of unchanged nicotine, derived by comparison of the respective areas under the concentration vs time curves (AUC), was 89%, indicating low hepatic extraction ratios of about 10%.",Increased hepatic nicotine elimination after phenobarbital induction in the conscious rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2237913/),%,89,36559,DB01174,Phenobarbital
,2237913,hepatic extraction ratios,"The oral availability of unchanged nicotine, derived by comparison of the respective areas under the concentration vs time curves (AUC), was 89%, indicating low hepatic extraction ratios of about 10%.",Increased hepatic nicotine elimination after phenobarbital induction in the conscious rat. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2237913/),%,10,36560,DB01174,Phenobarbital
,2237913,oral availability,The oral availability of unchanged nicotine in plasma dropped to 1.4% of the corresponding values obtained from PB-treated rats receiving nicotine iv.,Increased hepatic nicotine elimination after phenobarbital induction in the conscious rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2237913/),%,1.4,36561,DB01174,Phenobarbital
,7471611,half-life (t 1/2),"PRM elimination was slower (p less than 0.05) after the initial dose in MT patients (half-life (t 1/2) = 15.2 hr, apparent clearance = 35 ml/hr/kg) than in CT patients (t 1/2 = 8.3 hr, clearance = 51 ml/hr/kg).",Primidone kinetics: effects of concurrent drugs and duration of therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7471611/),h,15.2,36747,DB01174,Phenobarbital
,7471611,apparent clearance,"PRM elimination was slower (p less than 0.05) after the initial dose in MT patients (half-life (t 1/2) = 15.2 hr, apparent clearance = 35 ml/hr/kg) than in CT patients (t 1/2 = 8.3 hr, clearance = 51 ml/hr/kg).",Primidone kinetics: effects of concurrent drugs and duration of therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7471611/),[ml] / [h·kg],35,36748,DB01174,Phenobarbital
,7471611,t 1/2,"PRM elimination was slower (p less than 0.05) after the initial dose in MT patients (half-life (t 1/2) = 15.2 hr, apparent clearance = 35 ml/hr/kg) than in CT patients (t 1/2 = 8.3 hr, clearance = 51 ml/hr/kg).",Primidone kinetics: effects of concurrent drugs and duration of therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7471611/),h,8.3,36749,DB01174,Phenobarbital
,7471611,clearance,"PRM elimination was slower (p less than 0.05) after the initial dose in MT patients (half-life (t 1/2) = 15.2 hr, apparent clearance = 35 ml/hr/kg) than in CT patients (t 1/2 = 8.3 hr, clearance = 51 ml/hr/kg).",Primidone kinetics: effects of concurrent drugs and duration of therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7471611/),[ml] / [h·kg],51,36750,DB01174,Phenobarbital
,7471611,apparent clearance,In four CT patients in whom other antiepileptics were withdrawn there was a decrease in apparent clearance (61.4 to 29.9 ml/hr/kg) no rates in the range of MT patients.,Primidone kinetics: effects of concurrent drugs and duration of therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7471611/),[ml] / [h·kg],61.4 to 29.9,36751,DB01174,Phenobarbital
>,12959634,bioavailability,The bioavailability of the oral formulation of oxcarbazepine is high (>95%).,Clinical pharmacokinetics of oxcarbazepine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),%,95,36869,DB01174,Phenobarbital
,12959634,plasma protein binding,The plasma protein binding of MHD is about 40%.,Clinical pharmacokinetics of oxcarbazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),%,40,36870,DB01174,Phenobarbital
,12959634,Elimination half-lives,Elimination half-lives in healthy volunteers are 1-5 hours for oxcarbazepine and 7-20 hours for MHD.,Clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),h,1-5,36871,DB01174,Phenobarbital
,12959634,Elimination half-lives,Elimination half-lives in healthy volunteers are 1-5 hours for oxcarbazepine and 7-20 hours for MHD.,Clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),h,7-20,36872,DB01174,Phenobarbital
,3659250,half-life,The mean maximum rate of fall in plasma phenobarbitone concentrations corresponded to a half-life of only 6.2 +/- 2.5 h (normally three to five days); 62 to 93 per cent of the absorbed dose was eliminated within 24 h and the mean total body clearance of the drug during and for up to 12 h after administration of charcoal was 84 +/- 34 ml/min.,Treatment of phenobarbitone poisoning with repeated oral administration of activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3659250/),h,6.2,36903,DB01174,Phenobarbital
,3659250,total body clearance,The mean maximum rate of fall in plasma phenobarbitone concentrations corresponded to a half-life of only 6.2 +/- 2.5 h (normally three to five days); 62 to 93 per cent of the absorbed dose was eliminated within 24 h and the mean total body clearance of the drug during and for up to 12 h after administration of charcoal was 84 +/- 34 ml/min.,Treatment of phenobarbitone poisoning with repeated oral administration of activated charcoal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3659250/),[ml] / [min],84,36904,DB01174,Phenobarbital
,28940525,volume of distribution,"In the whole study population (N = 36), phenobarbital volume of distribution, clearance and half-life median (interquartile range) values were 0.49 (0.38-0.59) L/kg, 0.0045 (0.0034-0.0055) L/h/kg and 75.1 (60.2-103.3) hours, respectively.",Estimation of initial phenobarbital dosing in term neonates with moderate-to-severe hypoxic ischaemic encephalopathy following perinatal asphyxia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28940525/),[l] / [kg],0.49,37197,DB01174,Phenobarbital
,28940525,clearance,"In the whole study population (N = 36), phenobarbital volume of distribution, clearance and half-life median (interquartile range) values were 0.49 (0.38-0.59) L/kg, 0.0045 (0.0034-0.0055) L/h/kg and 75.1 (60.2-103.3) hours, respectively.",Estimation of initial phenobarbital dosing in term neonates with moderate-to-severe hypoxic ischaemic encephalopathy following perinatal asphyxia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28940525/),[l] / [h·kg],0.0045,37198,DB01174,Phenobarbital
,28940525,half-life,"In the whole study population (N = 36), phenobarbital volume of distribution, clearance and half-life median (interquartile range) values were 0.49 (0.38-0.59) L/kg, 0.0045 (0.0034-0.0055) L/h/kg and 75.1 (60.2-103.3) hours, respectively.",Estimation of initial phenobarbital dosing in term neonates with moderate-to-severe hypoxic ischaemic encephalopathy following perinatal asphyxia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28940525/),h,75.1,37199,DB01174,Phenobarbital
,24049884,half-lives,The observed PHB half-lives were between 37.3 and 74.6 hours with a mean of 53.0 +/- 15 hours.,Pharmacokinetics of phenobarbital in dogs after multiple oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049884/),h,37.3 and 74.6,37216,DB01174,Phenobarbital
,24049884,half-lives,The observed PHB half-lives were between 37.3 and 74.6 hours with a mean of 53.0 +/- 15 hours.,Pharmacokinetics of phenobarbital in dogs after multiple oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049884/),h,53.0,37217,DB01174,Phenobarbital
,24049884,volume of distribution (Vd/F),"The calculated volume of distribution (Vd/F) was 743.6 +/- 69.8 ml/kg, and the total body clearance (ClT/F) was 0.173 +/- 0.053 ml/min/ kg.",Pharmacokinetics of phenobarbital in dogs after multiple oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049884/),[ml] / [kg],743.6,37218,DB01174,Phenobarbital
,24049884,total body clearance (ClT/F),"The calculated volume of distribution (Vd/F) was 743.6 +/- 69.8 ml/kg, and the total body clearance (ClT/F) was 0.173 +/- 0.053 ml/min/ kg.",Pharmacokinetics of phenobarbital in dogs after multiple oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049884/),[ml] / [·kg·min],0.173,37219,DB01174,Phenobarbital
,24049884,absorption half-life,The absorption half-life was 1.27 +/- 0.21 hours.,Pharmacokinetics of phenobarbital in dogs after multiple oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049884/),h,1.27,37220,DB01174,Phenobarbital
,24049884,serum concentrations,"From average values, predicted maintenance doses of 1.8 mg/kg of body weight 3 times a day or 5.5 mg/kg once daily would be required to achieve average serum concentrations of 20 microg/ml.",Pharmacokinetics of phenobarbital in dogs after multiple oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049884/),[μg] / [ml],20,37221,DB01174,Phenobarbital
,3097715,Terminal half-lives,Terminal half-lives were 4.3 +/- 1.5 h in the patients and 4.3 +/- 1.8 h in the controls.,Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3097715/),h,4.3,37445,DB01174,Phenobarbital
,3097715,Terminal half-lives,Terminal half-lives were 4.3 +/- 1.5 h in the patients and 4.3 +/- 1.8 h in the controls.,Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3097715/),h,4.3,37446,DB01174,Phenobarbital
,3097715,Clearance,"Clearance and volume of distribution calculated after IV dosing in the patients were 124 +/- 11 ml h-1 kg-1 and 0.73 +/- 0.28 l/kg, respectively.",Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3097715/),[ml] / [h·kg],124,37447,DB01174,Phenobarbital
,3097715,volume of distribution,"Clearance and volume of distribution calculated after IV dosing in the patients were 124 +/- 11 ml h-1 kg-1 and 0.73 +/- 0.28 l/kg, respectively.",Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3097715/),[l] / [kg],0.73,37448,DB01174,Phenobarbital
,3097715,absolute oral availability,The absolute oral availability was 85 +/- 14%.,Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3097715/),%,85,37449,DB01174,Phenobarbital
,9533107,AUC0-8 h,The AUC0-8 h of M1 (47.1 versus 7.85 micrograms min mL-1) and M2 (20.7 versus 44.3 micrograms min mL-1) decreased significantly in the PBT group compared to those in the PBC group.,"Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],47.1,38103,DB01174,Phenobarbital
,9533107,AUC0-8 h,The AUC0-8 h of M1 (47.1 versus 7.85 micrograms min mL-1) and M2 (20.7 versus 44.3 micrograms min mL-1) decreased significantly in the PBT group compared to those in the PBC group.,"Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],7.85,38104,DB01174,Phenobarbital
,9533107,AUC0-8 h,The AUC0-8 h of M1 (47.1 versus 7.85 micrograms min mL-1) and M2 (20.7 versus 44.3 micrograms min mL-1) decreased significantly in the PBT group compared to those in the PBC group.,"Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],20.7,38105,DB01174,Phenobarbital
,9533107,AUC0-8 h,The AUC0-8 h of M1 (47.1 versus 7.85 micrograms min mL-1) and M2 (20.7 versus 44.3 micrograms min mL-1) decreased significantly in the PBT group compared to those in the PBC group.,"Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],44.3,38106,DB01174,Phenobarbital
,9533107,M1,"However, the corresponding value of only M1 (74.6 versus 89.9 micrograms min mL-1) decreased significantly in the MCT group.","Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],74.6,38107,DB01174,Phenobarbital
,9533107,M1,"However, the corresponding value of only M1 (74.6 versus 89.9 micrograms min mL-1) decreased significantly in the MCT group.","Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],89.9,38108,DB01174,Phenobarbital
,9533107,AUC0-8 h,The AUC0-8 h of both M1 (126 versus 78.5 micrograms min mL-1) and M2 (69.2 versus 44.3 micrograms min mL-1) increased significantly in the SKT group compared to the SKC group.,"Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],126,38109,DB01174,Phenobarbital
,9533107,AUC0-8 h,The AUC0-8 h of both M1 (126 versus 78.5 micrograms min mL-1) and M2 (69.2 versus 44.3 micrograms min mL-1) increased significantly in the SKT group compared to the SKC group.,"Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],78.5,38110,DB01174,Phenobarbital
,9533107,AUC0-8 h,The AUC0-8 h of both M1 (126 versus 78.5 micrograms min mL-1) and M2 (69.2 versus 44.3 micrograms min mL-1) increased significantly in the SKT group compared to the SKC group.,"Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],69.2,38111,DB01174,Phenobarbital
,9533107,AUC0-8 h,The AUC0-8 h of both M1 (126 versus 78.5 micrograms min mL-1) and M2 (69.2 versus 44.3 micrograms min mL-1) increased significantly in the SKT group compared to the SKC group.,"Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],44.3,38112,DB01174,Phenobarbital
,10716065,Tmax,"After administration, by intraperitoneal injection (50, 100 or 200 mg/kg), primidone rapidly appeared in both serum (Tmax mean range 1.5-2.5 h) and CSF (Tmax mean range 2.0-3.5 h), suggesting ready penetration of the blood-brain-barrier.","Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10716065/),h,1.5-2.5,38273,DB01174,Phenobarbital
,10716065,Tmax,"After administration, by intraperitoneal injection (50, 100 or 200 mg/kg), primidone rapidly appeared in both serum (Tmax mean range 1.5-2.5 h) and CSF (Tmax mean range 2.0-3.5 h), suggesting ready penetration of the blood-brain-barrier.","Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10716065/),h,2.0-3.5,38274,DB01174,Phenobarbital
,10716065,free fraction (free/total concentration ratio),"The mean free fraction (free/total concentration ratio) for primidone, phenylethylmalonamide and phenobarbital was 0.86, 0.97 and 0.88, respectively, and, as their respective mean CSF/serum ratio values were 0.73, 1.06 and 0.65, it would suggest that equilibration between the blood and CSF compartments is rapid.","Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10716065/),,0.86,38275,DB01174,Phenobarbital
,10716065,free fraction (free/total concentration ratio),"The mean free fraction (free/total concentration ratio) for primidone, phenylethylmalonamide and phenobarbital was 0.86, 0.97 and 0.88, respectively, and, as their respective mean CSF/serum ratio values were 0.73, 1.06 and 0.65, it would suggest that equilibration between the blood and CSF compartments is rapid.","Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10716065/),,0.97,38276,DB01174,Phenobarbital
,10716065,free fraction (free/total concentration ratio),"The mean free fraction (free/total concentration ratio) for primidone, phenylethylmalonamide and phenobarbital was 0.86, 0.97 and 0.88, respectively, and, as their respective mean CSF/serum ratio values were 0.73, 1.06 and 0.65, it would suggest that equilibration between the blood and CSF compartments is rapid.","Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10716065/),,0.88,38277,DB01174,Phenobarbital
,10716065,CSF/serum ratio,"The mean free fraction (free/total concentration ratio) for primidone, phenylethylmalonamide and phenobarbital was 0.86, 0.97 and 0.88, respectively, and, as their respective mean CSF/serum ratio values were 0.73, 1.06 and 0.65, it would suggest that equilibration between the blood and CSF compartments is rapid.","Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10716065/),,0.73,38278,DB01174,Phenobarbital
,10716065,CSF/serum ratio,"The mean free fraction (free/total concentration ratio) for primidone, phenylethylmalonamide and phenobarbital was 0.86, 0.97 and 0.88, respectively, and, as their respective mean CSF/serum ratio values were 0.73, 1.06 and 0.65, it would suggest that equilibration between the blood and CSF compartments is rapid.","Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10716065/),,1.06,38279,DB01174,Phenobarbital
,10716065,CSF/serum ratio,"The mean free fraction (free/total concentration ratio) for primidone, phenylethylmalonamide and phenobarbital was 0.86, 0.97 and 0.88, respectively, and, as their respective mean CSF/serum ratio values were 0.73, 1.06 and 0.65, it would suggest that equilibration between the blood and CSF compartments is rapid.","Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10716065/),,0.65,38280,DB01174,Phenobarbital
,3437492,terminal half-life,"Based on the combined evaluation of i.v. and oral results, phenobarbital displayed two-compartment pharmacokinetics in the horse with a terminal half-life of 19.0 +/- 4.4 (mean +/- SD) h.",A pharmacokinetic study of phenobarbital in mature horses after oral dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3437492/),h,19.0,39168,DB01174,Phenobarbital
,3437492,steady-state volume of distribution (Vdss/F),"The steady-state volume of distribution (Vdss/F) and the total body clearance (Clt/F) of phenobarbital were 0.753 +/- 0.115 l/kg and 27.9 +/- 9.2 ml/h/kg, respectively.",A pharmacokinetic study of phenobarbital in mature horses after oral dosing. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3437492/),[l] / [kg],0.753,39169,DB01174,Phenobarbital
,3437492,total body clearance (Clt/F),"The steady-state volume of distribution (Vdss/F) and the total body clearance (Clt/F) of phenobarbital were 0.753 +/- 0.115 l/kg and 27.9 +/- 9.2 ml/h/kg, respectively.",A pharmacokinetic study of phenobarbital in mature horses after oral dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3437492/),[ml] / [h·kg],27.9,39170,DB01174,Phenobarbital
,3437492,extent of oral absorption,The average extent of oral absorption was 101% with a range of 76 to 124% among the six horses.,A pharmacokinetic study of phenobarbital in mature horses after oral dosing. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3437492/),%,101,39171,DB01174,Phenobarbital
,3437492,mean residence time (MRT),The mean residence time (MRT) was 36.9 +/- 4.1 h and the mean residence time for oral absorption (MRTabs) was 11.3 h.,A pharmacokinetic study of phenobarbital in mature horses after oral dosing. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3437492/),h,36.9,39172,DB01174,Phenobarbital
,3437492,mean residence time for oral absorption (MRTabs),The mean residence time (MRT) was 36.9 +/- 4.1 h and the mean residence time for oral absorption (MRTabs) was 11.3 h.,A pharmacokinetic study of phenobarbital in mature horses after oral dosing. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3437492/),h,11.3,39173,DB01174,Phenobarbital
less,2613393,metabolic ratio (MR),"In PM on rifampicin, the debrisoquine metabolic ratio (MR) was significantly reduced, even reaching a value less than 12.6 in 2 subjects but on phenobarbital and cimetidine, the MR was not significantly modified.","Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2613393/),,12,39596,DB01174,Phenobarbital
,1233212,half-lives,"Plasma concentrations, which were analysed by mass fragmentography, reached a maximum 1-7 hours after dosing, and then declined monoexponentially with half-lives ranging from 24 to 46 hours.",Distribution and elimination kinetics of carbamazepine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233212/),h,24 to 46,40645,DB01174,Phenobarbital
,1233212,apparent distribution volume,The apparent distribution volume ranged from 0.79 to 1.40 1/kg.,Distribution and elimination kinetics of carbamazepine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233212/),[1] / [kg],0.79 to 1.40,40646,DB01174,Phenobarbital
,7128675,half-lives,"After IV PB distributive half-lives were 75 to 126 h, steady state volume of distribution (Vss) was 0.54 +/- 0.03 l/kg, and clearance (CL) was 3.8 +/- 0.77 ml/h/kg.",Kinetics of phenobarbital in normal subjects and epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),h,75 to 126,41767,DB01174,Phenobarbital
,7128675,steady state volume of distribution (Vss),"After IV PB distributive half-lives were 75 to 126 h, steady state volume of distribution (Vss) was 0.54 +/- 0.03 l/kg, and clearance (CL) was 3.8 +/- 0.77 ml/h/kg.",Kinetics of phenobarbital in normal subjects and epileptic patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),[l] / [kg],0.54,41768,DB01174,Phenobarbital
,7128675,clearance (CL),"After IV PB distributive half-lives were 75 to 126 h, steady state volume of distribution (Vss) was 0.54 +/- 0.03 l/kg, and clearance (CL) was 3.8 +/- 0.77 ml/h/kg.",Kinetics of phenobarbital in normal subjects and epileptic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),[ml] / [h·kg],3.8,41769,DB01174,Phenobarbital
,7128675,Absolute bioavailability,Absolute bioavailability of IM PB was 101 +/- 11%.,Kinetics of phenobarbital in normal subjects and epileptic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),%,101,41770,DB01174,Phenobarbital
,7128675,disposition half-lives,"Epileptic patients exhibited similar PB kinetics: disposition half-lives were 77 to 128 h, Vss 0.61 +/- 0.05 l/kg, and Cl 3.9 +/- 0.76 ml/h/kg.",Kinetics of phenobarbital in normal subjects and epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),h,77 to 128,41771,DB01174,Phenobarbital
,7128675,Vss,"Epileptic patients exhibited similar PB kinetics: disposition half-lives were 77 to 128 h, Vss 0.61 +/- 0.05 l/kg, and Cl 3.9 +/- 0.76 ml/h/kg.",Kinetics of phenobarbital in normal subjects and epileptic patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),[l] / [kg],0.61,41772,DB01174,Phenobarbital
,7128675,Cl,"Epileptic patients exhibited similar PB kinetics: disposition half-lives were 77 to 128 h, Vss 0.61 +/- 0.05 l/kg, and Cl 3.9 +/- 0.76 ml/h/kg.",Kinetics of phenobarbital in normal subjects and epileptic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128675/),[ml] / [h·kg],3.9,41773,DB01174,Phenobarbital
,17564310,area under the plasma concentration-time curve from time zero to time infinity,"After intravenous administration of 2-AP at a dose of 50 mg/kg to rats with U-ARF, the area under the plasma concentration-time curve from time zero to time infinity of 2-AP was significantly smaller (1030 versus 1360 microg min/ml) due to significantly faster CL of 2-AP (48.4 versus 36.8 ml/min/kg).","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of 2-(allylthio) pyrazine, a chemoprotective agent, in rats: the role of CYP3A23 induction. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564310/),[min·μg] / [ml],1030,42103,DB01174,Phenobarbital
,17564310,area under the plasma concentration-time curve from time zero to time infinity,"After intravenous administration of 2-AP at a dose of 50 mg/kg to rats with U-ARF, the area under the plasma concentration-time curve from time zero to time infinity of 2-AP was significantly smaller (1030 versus 1360 microg min/ml) due to significantly faster CL of 2-AP (48.4 versus 36.8 ml/min/kg).","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of 2-(allylthio) pyrazine, a chemoprotective agent, in rats: the role of CYP3A23 induction. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564310/),[min·μg] / [ml],1360,42104,DB01174,Phenobarbital
,17564310,CL,"After intravenous administration of 2-AP at a dose of 50 mg/kg to rats with U-ARF, the area under the plasma concentration-time curve from time zero to time infinity of 2-AP was significantly smaller (1030 versus 1360 microg min/ml) due to significantly faster CL of 2-AP (48.4 versus 36.8 ml/min/kg).","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of 2-(allylthio) pyrazine, a chemoprotective agent, in rats: the role of CYP3A23 induction. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564310/),[ml] / [kg·min],48.4,42105,DB01174,Phenobarbital
,17564310,CL,"After intravenous administration of 2-AP at a dose of 50 mg/kg to rats with U-ARF, the area under the plasma concentration-time curve from time zero to time infinity of 2-AP was significantly smaller (1030 versus 1360 microg min/ml) due to significantly faster CL of 2-AP (48.4 versus 36.8 ml/min/kg).","Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of 2-(allylthio) pyrazine, a chemoprotective agent, in rats: the role of CYP3A23 induction. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564310/),[ml] / [kg·min],36.8,42106,DB01174,Phenobarbital
,19943867,maximum total dosage,Nine patients received 20 mg/kg; the maximum total dosage administered was 80 mg/kg with a concentration of 283 micromol/L.,Rescue therapy with high-dose oral phenobarbitone loading for refractory status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19943867/),[mg] / [kg],80,43527,DB01174,Phenobarbital
,19943867,volume of distribution,"The typical population value of the volume of distribution was 1.2 (95% confidence interval (CI): 0.8-1.6) L/kg with interindividual variability (as coefficient of variation) of 53% (95% CI, 9-74%).",Rescue therapy with high-dose oral phenobarbitone loading for refractory status epilepticus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19943867/),[l] / [kg],1.2,43528,DB01174,Phenobarbital
,15083216,volume of distribution (Vd),"The mean +/- SD TH-PKP were volume of distribution (Vd) = 0.77 +/- 0.25 L/kg; elimination rate constant (Ke) = 0.027 +/- 0.011 h(-1); CL = 0.019 +/- 0.006 L/h/kg, t0.5 = 30.7 +/- 12.1.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),[l] / [kg],0.77,43855,DB01174,Phenobarbital
,15083216,elimination rate constant (Ke),"The mean +/- SD TH-PKP were volume of distribution (Vd) = 0.77 +/- 0.25 L/kg; elimination rate constant (Ke) = 0.027 +/- 0.011 h(-1); CL = 0.019 +/- 0.006 L/h/kg, t0.5 = 30.7 +/- 12.1.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),1/[h],0.027,43856,DB01174,Phenobarbital
,15083216,CL,"The mean +/- SD TH-PKP were volume of distribution (Vd) = 0.77 +/- 0.25 L/kg; elimination rate constant (Ke) = 0.027 +/- 0.011 h(-1); CL = 0.019 +/- 0.006 L/h/kg, t0.5 = 30.7 +/- 12.1.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),[l] / [h·kg],0.019,43857,DB01174,Phenobarbital
,15083216,t0.5,"The mean +/- SD TH-PKP were volume of distribution (Vd) = 0.77 +/- 0.25 L/kg; elimination rate constant (Ke) = 0.027 +/- 0.011 h(-1); CL = 0.019 +/- 0.006 L/h/kg, t0.5 = 30.7 +/- 12.1.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),,30.7,43858,DB01174,Phenobarbital
,15083216,Css level,"In view of the results and practical considerations, initial dosage regimen to attain a TH Css level within the therapeutic range (6-12 ug/ml) was suggested: LD 6-7 mg/kg, MD 1.5 - 2.0 mg/kg/12 hours.",Pharmacokinetics of theophylline in preterm neonates during the first month of life. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083216/),[ug] / [ml],6-12,43859,DB01174,Phenobarbital
,1981715,mean residence time,"Following iv doses of 12, 25, and 100 mg/kg, the parent drug was rapidly eliminated from plasma (mean residence time, 6.3 min; systemic clearance, 64 ml/min/kg).","Pharmacokinetics of the anti-AIDS drug 2',3'-dideoxyinosine in the rat. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981715/),min,6.3,43964,DB01174,Phenobarbital
,1981715,systemic clearance,"Following iv doses of 12, 25, and 100 mg/kg, the parent drug was rapidly eliminated from plasma (mean residence time, 6.3 min; systemic clearance, 64 ml/min/kg).","Pharmacokinetics of the anti-AIDS drug 2',3'-dideoxyinosine in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981715/),[ml] / [kg·min],64,43965,DB01174,Phenobarbital
,1981715,terminal elimination half-life,The mean terminal elimination half-life was 28 min and the volume of distribution at steady state was 0.39 liter/kg.,"Pharmacokinetics of the anti-AIDS drug 2',3'-dideoxyinosine in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981715/),min,28,43966,DB01174,Phenobarbital
,1981715,volume of distribution at steady state,The mean terminal elimination half-life was 28 min and the volume of distribution at steady state was 0.39 liter/kg.,"Pharmacokinetics of the anti-AIDS drug 2',3'-dideoxyinosine in the rat. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981715/),[l] / [kg],0.39,43967,DB01174,Phenobarbital
less,1981715,t1/2,"Solution stability data suggested that ddlno was unstable at gastric pH (pH 1, t1/2 less than 30 sec).","Pharmacokinetics of the anti-AIDS drug 2',3'-dideoxyinosine in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981715/),s,30,43968,DB01174,Phenobarbital
,1981715,tissue-to-plasma ratios of radioactivity,"Following iv infusion of [3H]ddlno to steady state conditions, the highest tissue-to-plasma ratios of radioactivity were found in the kidney (2.2), liver (1.7), and spleen (1.5).","Pharmacokinetics of the anti-AIDS drug 2',3'-dideoxyinosine in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981715/),,2.2,43969,DB01174,Phenobarbital
,1981715,tissue-to-plasma ratios of radioactivity,"Following iv infusion of [3H]ddlno to steady state conditions, the highest tissue-to-plasma ratios of radioactivity were found in the kidney (2.2), liver (1.7), and spleen (1.5).","Pharmacokinetics of the anti-AIDS drug 2',3'-dideoxyinosine in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981715/),,1.7,43970,DB01174,Phenobarbital
,1981715,tissue-to-plasma ratios of radioactivity,"Following iv infusion of [3H]ddlno to steady state conditions, the highest tissue-to-plasma ratios of radioactivity were found in the kidney (2.2), liver (1.7), and spleen (1.5).","Pharmacokinetics of the anti-AIDS drug 2',3'-dideoxyinosine in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981715/),,1.5,43971,DB01174,Phenobarbital
,12959317,AUC,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),[h·μg] / [ml],2.9,44201,DB01174,Phenobarbital
,12959317,AUC,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),[h·μg] / [ml],5.1,44202,DB01174,Phenobarbital
,12959317,AUC,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),[h·μg] / [ml],89,44203,DB01174,Phenobarbital
,12959317,AUC,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),[h·μg] / [ml],119,44204,DB01174,Phenobarbital
,12959317,half-lives,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),h,17,44205,DB01174,Phenobarbital
,12959317,half-lives,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),h,20,44206,DB01174,Phenobarbital
,15005415,percentage of recovery,The percentage of recovery was 98.63 +/- 2.47.,Rapid and simple high-performance liquid chromatographic determination of felbamate in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005415/),,98.63,44903,DB01174,Phenobarbital
,18503564,elimination half-life,"During repeated dosing, steady state is reached within 2 days, consistent with its elimination half-life of 6-10 h.",Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18503564/),h,6-10,45117,DB01174,Phenobarbital
,7460192,bioavailability,"The IP bioavailability of DEMIS (1.07 mmol/kg) was 100%, but that of MIS (1 mmol/kg) was 80%, suggesting some first-pass metabolism.",Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460192/),%,100,46101,DB01174,Phenobarbital
,7460192,bioavailability,"The IP bioavailability of DEMIS (1.07 mmol/kg) was 100%, but that of MIS (1 mmol/kg) was 80%, suggesting some first-pass metabolism.",Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460192/),%,80,46102,DB01174,Phenobarbital
,3709336,apparent half-life,The mean apparent half-life of phenobarbital estimated in 11 infants was 175.5 +/- 45.6 h.,Pharmacokinetic basis for antenatal dosing of phenobarbital for the prevention of neonatal intracerebral hemorrhage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709336/),h,175.5,46851,DB01174,Phenobarbital
,2130290,Plasma peaks,"Plasma peaks after the 50- and 100-mg dose were, respectively, 3.38 +/- 1.29 and 4.09 +/- 1.24 micrograms/ml.","Quantitative EEG effects and drug plasma concentration of phenobarbital, 50 and 100 mg single-dose oral administration to healthy volunteers: evidence of early CNS bioavailability. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130290/),[μg] / [ml],3.38,48507,DB01174,Phenobarbital
,2130290,Plasma peaks,"Plasma peaks after the 50- and 100-mg dose were, respectively, 3.38 +/- 1.29 and 4.09 +/- 1.24 micrograms/ml.","Quantitative EEG effects and drug plasma concentration of phenobarbital, 50 and 100 mg single-dose oral administration to healthy volunteers: evidence of early CNS bioavailability. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130290/),[μg] / [ml],4.09,48508,DB01174,Phenobarbital
,18341442,maximum serum levetiracetam concentration,"Median maximum serum levetiracetam concentration was 25.5 microg/mL, median minimum serum levetiracetam concentration was 8.3 microg/mL, and median elimination half-life was 2.9 hours.",Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18341442/),[μg] / [ml],25.5,48959,DB01174,Phenobarbital
,18341442,minimum serum levetiracetam concentration,"Median maximum serum levetiracetam concentration was 25.5 microg/mL, median minimum serum levetiracetam concentration was 8.3 microg/mL, and median elimination half-life was 2.9 hours.",Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18341442/),[μg] / [ml],8.3,48960,DB01174,Phenobarbital
,18341442,elimination half-life,"Median maximum serum levetiracetam concentration was 25.5 microg/mL, median minimum serum levetiracetam concentration was 8.3 microg/mL, and median elimination half-life was 2.9 hours.",Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18341442/),h,2.9,48961,DB01174,Phenobarbital
,12823575,CL/F,"Compared with corresponding controls, mean CBZ CL/F values were 23% and 24% lower, respectively, in the groups of elderly patients receiving monotherapy (57.1 +/- 20.6 vs. 74.6 +/- 28.3 ml/h/kg; p < 0.0001) and PB comedication (74.7 +/- 25.5 vs. 98.7 +/- 34.9 ml/h/kg; p < 0.01).",Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12823575/),[ml] / [h·kg],57.1,51545,DB01174,Phenobarbital
,12823575,CL/F,"Compared with corresponding controls, mean CBZ CL/F values were 23% and 24% lower, respectively, in the groups of elderly patients receiving monotherapy (57.1 +/- 20.6 vs. 74.6 +/- 28.3 ml/h/kg; p < 0.0001) and PB comedication (74.7 +/- 25.5 vs. 98.7 +/- 34.9 ml/h/kg; p < 0.01).",Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12823575/),[ml] / [h·kg],74.6,51546,DB01174,Phenobarbital
,12823575,CL/F,"Compared with corresponding controls, mean CBZ CL/F values were 23% and 24% lower, respectively, in the groups of elderly patients receiving monotherapy (57.1 +/- 20.6 vs. 74.6 +/- 28.3 ml/h/kg; p < 0.0001) and PB comedication (74.7 +/- 25.5 vs. 98.7 +/- 34.9 ml/h/kg; p < 0.01).",Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12823575/),[ml] / [h·kg],74.7,51547,DB01174,Phenobarbital
,12823575,CL/F,"Compared with corresponding controls, mean CBZ CL/F values were 23% and 24% lower, respectively, in the groups of elderly patients receiving monotherapy (57.1 +/- 20.6 vs. 74.6 +/- 28.3 ml/h/kg; p < 0.0001) and PB comedication (74.7 +/- 25.5 vs. 98.7 +/- 34.9 ml/h/kg; p < 0.01).",Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12823575/),[ml] / [h·kg],98.7,51548,DB01174,Phenobarbital
,6403891,accumulation half-life,"N-desmethylmethsuximide was the principal substance detected in plasma and had the following pharmacokinetic values: accumulation half-life, 49.7 hours; time to steady state, 10.4 days; elimination half-life, 72.2 hours; therapeutic range of plasma concentration, 10 to 30 mg per liter.","Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6403891/),h,49.7,52153,DB01174,Phenobarbital
,6403891,time to steady state,"N-desmethylmethsuximide was the principal substance detected in plasma and had the following pharmacokinetic values: accumulation half-life, 49.7 hours; time to steady state, 10.4 days; elimination half-life, 72.2 hours; therapeutic range of plasma concentration, 10 to 30 mg per liter.","Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6403891/),d,10.4,52154,DB01174,Phenobarbital
,6403891,elimination half-life,"N-desmethylmethsuximide was the principal substance detected in plasma and had the following pharmacokinetic values: accumulation half-life, 49.7 hours; time to steady state, 10.4 days; elimination half-life, 72.2 hours; therapeutic range of plasma concentration, 10 to 30 mg per liter.","Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6403891/),h,72.2,52155,DB01174,Phenobarbital
,29927880,serum concentrations,"Mean serum concentrations of 17.5 ± 7.8 mg/L were at a median 4.2 hours (interquartile range, 2.5-7.8 hr) after a dose.",Fosphenytoin Population Pharmacokinetics in the Acutely Ill Pediatric Population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29927880/),[mg] / [l],17.5,52777,DB01174,Phenobarbital
,3988389,half-life (t1/2),A prolongation in antipyrine half-life (t1/2) was observed in 108 patients with liver disease (24.59 +/- 1.72 h) as compared to 12 controls (11.63 +/- 0.86 h).,Impairment of drug elimination in patients with liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988389/),h,24.59,53228,DB01174,Phenobarbital
,3988389,half-life (t1/2),A prolongation in antipyrine half-life (t1/2) was observed in 108 patients with liver disease (24.59 +/- 1.72 h) as compared to 12 controls (11.63 +/- 0.86 h).,Impairment of drug elimination in patients with liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988389/),h,11.63,53229,DB01174,Phenobarbital
,22171585,CL/F,"Eslicarbazepine CL/F was affected by bodyweight, dose of carbamazepine (D(CAR)) and co-administration of barbiturates or phenytoin (AED(PB)), as predicted by the equation CL/F = (2.36 + 0.00149 • D(CAR) + 1.41 • AED(PB)) • (weight/70)0.75, which means that CL/F is 2.36 L/h for a subject with a bodyweight of 70 kg and without concomitant carbamazepine and barbiturates/phenytoin.","Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22171585/),[l] / [h],2.36,53544,DB01174,Phenobarbital
,627139,saliva/plasma ratio,The saliva/plasma ratio for CBZ concentration was 0.26 +/- 0.01 (SD).,"Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/627139/),,0.26,53852,DB01174,Phenobarbital
,627139,binding,"Since CBZ binding to plasma proteins is in the order of 76%, saliva CBZ concentration seems to reflect the unbound fraction of the drug in plasma.","Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/627139/),%,76,53853,DB01174,Phenobarbital
,8613932,Cl(f),"In phenobarbital-induced rats receiving a nontoxic dose of APAP (100 mg/kg i.v.), a single dose of caffeine (100 mg/kg i.p.) co-administered with APAP increased the Cl(f) of NAPQI formation from 0.58 +/- 0.47 to 2.08 +/- 1.1 1 ml/min/kg (P = .01).",Effects of caffeine and theophylline on acetaminophen pharmacokinetics: P450 inhibition and activation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8613932/),[1·ml] / [kg·min],0.58,54661,DB01174,Phenobarbital
,8613932,Cl(f),"In phenobarbital-induced rats receiving a nontoxic dose of APAP (100 mg/kg i.v.), a single dose of caffeine (100 mg/kg i.p.) co-administered with APAP increased the Cl(f) of NAPQI formation from 0.58 +/- 0.47 to 2.08 +/- 1.1 1 ml/min/kg (P = .01).",Effects of caffeine and theophylline on acetaminophen pharmacokinetics: P450 inhibition and activation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8613932/),[1·ml] / [kg·min],2.08,54662,DB01174,Phenobarbital
,15355124,oral clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],22-36,55128,DB01174,Phenobarbital
,15355124,renal clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],10-20,55129,DB01174,Phenobarbital
,15355124,half-life,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),h,19-25,55130,DB01174,Phenobarbital
,15355124,absolute bioavailability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55131,DB01174,Phenobarbital
,15355124,oral availability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55132,DB01174,Phenobarbital
,4205524,total hepatic blood flow,Phenobarbital significantly increased total hepatic blood flow from 179+/-15 to 239+/-27 ml/min.,Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4205524/),[ml] / [min],179,56651,DB01174,Phenobarbital
,4205524,total hepatic blood flow,Phenobarbital significantly increased total hepatic blood flow from 179+/-15 to 239+/-27 ml/min.,Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4205524/),[ml] / [min],239,56652,DB01174,Phenobarbital
,12405865,bioavailability,Methadone has a mean bioavailability of around 75% (range 36-100%).,Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),%,75,57243,DB01174,Phenobarbital
,12405865,free fraction,"Its mean free fraction is around 13%, with a 4-fold interindividual variation.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),%,13,57244,DB01174,Phenobarbital
,12405865,volume of distribution,Its volume of distribution is about 4 L/kg (range 2-13 L/kg).,Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[l] / [kg],4,57245,DB01174,Phenobarbital
,12405865,Total body clearance,"Total body clearance is about 0.095 L/min, with wide interindividual variation (range 0.02-2 L/min).",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[l] / [min],0.095,57246,DB01174,Phenobarbital
,12405865,elimination half-life,"Plasma concentrations of methadone decrease in a biexponential manner, with a mean value of around 22 hours (range 5-130 hours) for elimination half-life.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),h,22,57247,DB01174,Phenobarbital
,12405865,elimination half-life,"Plasma concentrations of methadone decrease in a biexponential manner, with a mean value of around 22 hours (range 5-130 hours) for elimination half-life.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),h,5,57248,DB01174,Phenobarbital
,12405865,trough plasma concentrations,"In the case of non-response trough plasma concentrations of 400 microg/L for (R,S)-methadone or 250 microg/L for (R)-methadone might be used as target values.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[μg] / [l],400,57249,DB01174,Phenobarbital
,12405865,trough plasma concentrations,"In the case of non-response trough plasma concentrations of 400 microg/L for (R,S)-methadone or 250 microg/L for (R)-methadone might be used as target values.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[μg] / [l],250,57250,DB01174,Phenobarbital
,7891306,recovery rates,The recovery rates were 96.8-101.8%.,Simultaneous determination of primidone and its active metabolites in rat plasma by high-performance liquid chromatography using a solid-phase extraction technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891306/),%,96.8-101.8,57836,DB01174,Phenobarbital
,7891306,Tmax,"The Tmax values for PRM, PEMA, and PB were 1.4, 5.7, and 6.6 h, respectively, and the Cmax values were 18.2, 8.1, and 9.6 micrograms/mL, respectively.",Simultaneous determination of primidone and its active metabolites in rat plasma by high-performance liquid chromatography using a solid-phase extraction technique. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891306/),h,1.4,57837,DB01174,Phenobarbital
,7891306,Tmax,"The Tmax values for PRM, PEMA, and PB were 1.4, 5.7, and 6.6 h, respectively, and the Cmax values were 18.2, 8.1, and 9.6 micrograms/mL, respectively.",Simultaneous determination of primidone and its active metabolites in rat plasma by high-performance liquid chromatography using a solid-phase extraction technique. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891306/),h,5.7,57838,DB01174,Phenobarbital
,7891306,Tmax,"The Tmax values for PRM, PEMA, and PB were 1.4, 5.7, and 6.6 h, respectively, and the Cmax values were 18.2, 8.1, and 9.6 micrograms/mL, respectively.",Simultaneous determination of primidone and its active metabolites in rat plasma by high-performance liquid chromatography using a solid-phase extraction technique. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891306/),h,6.6,57839,DB01174,Phenobarbital
,7891306,Cmax,"The Tmax values for PRM, PEMA, and PB were 1.4, 5.7, and 6.6 h, respectively, and the Cmax values were 18.2, 8.1, and 9.6 micrograms/mL, respectively.",Simultaneous determination of primidone and its active metabolites in rat plasma by high-performance liquid chromatography using a solid-phase extraction technique. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891306/),[μg] / [ml],18.2,57840,DB01174,Phenobarbital
,7891306,Cmax,"The Tmax values for PRM, PEMA, and PB were 1.4, 5.7, and 6.6 h, respectively, and the Cmax values were 18.2, 8.1, and 9.6 micrograms/mL, respectively.",Simultaneous determination of primidone and its active metabolites in rat plasma by high-performance liquid chromatography using a solid-phase extraction technique. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891306/),[μg] / [ml],8.1,57841,DB01174,Phenobarbital
,7891306,Cmax,"The Tmax values for PRM, PEMA, and PB were 1.4, 5.7, and 6.6 h, respectively, and the Cmax values were 18.2, 8.1, and 9.6 micrograms/mL, respectively.",Simultaneous determination of primidone and its active metabolites in rat plasma by high-performance liquid chromatography using a solid-phase extraction technique. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891306/),[μg] / [ml],9.6,57842,DB01174,Phenobarbital
,3432160,clearance,The enzyme inducers increased the theophylline clearance from 0.157 l/kg/h in control to 0.232 l/kg/h after chrysene and 0.266 l/kg/h after phenobarbital pretreatment.,Effect of phenobarbital and chrysene on theophylline elimination determined by noncompartmental analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3432160/),[l] / [h·kg],0.157,58414,DB01174,Phenobarbital
,3432160,clearance,The enzyme inducers increased the theophylline clearance from 0.157 l/kg/h in control to 0.232 l/kg/h after chrysene and 0.266 l/kg/h after phenobarbital pretreatment.,Effect of phenobarbital and chrysene on theophylline elimination determined by noncompartmental analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3432160/),[l] / [h·kg],0.232,58415,DB01174,Phenobarbital
,3432160,clearance,The enzyme inducers increased the theophylline clearance from 0.157 l/kg/h in control to 0.232 l/kg/h after chrysene and 0.266 l/kg/h after phenobarbital pretreatment.,Effect of phenobarbital and chrysene on theophylline elimination determined by noncompartmental analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3432160/),[l] / [h·kg],0.266,58416,DB01174,Phenobarbital
,2782717,total body clearance (Clt/F),"After single administration of 5.5 mg/kg of body weight or 15 mg/kg, the total body clearance (Clt/F) was 5.58 +/- 1.89 ml/h/kg and 7.28 +/- 1.07 ml/h/kg, respectively.",Pharmacokinetics of phenobarbital in dogs given multiple doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782717/),[ml] / [h·kg],5.58,58901,DB01174,Phenobarbital
,2782717,total body clearance (Clt/F),"After single administration of 5.5 mg/kg of body weight or 15 mg/kg, the total body clearance (Clt/F) was 5.58 +/- 1.89 ml/h/kg and 7.28 +/- 1.07 ml/h/kg, respectively.",Pharmacokinetics of phenobarbital in dogs given multiple doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782717/),[ml] / [h·kg],7.28,58902,DB01174,Phenobarbital
,2782717,half-lives (t1/2),The half-lives (t1/2) for the 2 groups were 88.7 +/- 19.6 hours for the 5.5-mg/kg dose and 99.6 +/- 22.6 hours for the 15-mg/kg dose.,Pharmacokinetics of phenobarbital in dogs given multiple doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782717/),h,88.7,58903,DB01174,Phenobarbital
,2782717,half-lives (t1/2),The half-lives (t1/2) for the 2 groups were 88.7 +/- 19.6 hours for the 5.5-mg/kg dose and 99.6 +/- 22.6 hours for the 15-mg/kg dose.,Pharmacokinetics of phenobarbital in dogs given multiple doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782717/),h,99.6,58904,DB01174,Phenobarbital
,2782717,Clt/F,"The Clt/F and t1/2 were 10.2 +/- 1.7 ml/h/kg and 47.3 +/- 10.7 hours for the group given the low dose and 15.6 +/- 2.5 ml/h/kg and 31.1 +/- 4.4 hours for the group given the high dose, respectively.",Pharmacokinetics of phenobarbital in dogs given multiple doses. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782717/),[ml] / [h·kg],10.2,58905,DB01174,Phenobarbital
,2782717,Clt/F,"The Clt/F and t1/2 were 10.2 +/- 1.7 ml/h/kg and 47.3 +/- 10.7 hours for the group given the low dose and 15.6 +/- 2.5 ml/h/kg and 31.1 +/- 4.4 hours for the group given the high dose, respectively.",Pharmacokinetics of phenobarbital in dogs given multiple doses. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782717/),[ml] / [h·kg],15.6,58906,DB01174,Phenobarbital
,2782717,t1/2,"The Clt/F and t1/2 were 10.2 +/- 1.7 ml/h/kg and 47.3 +/- 10.7 hours for the group given the low dose and 15.6 +/- 2.5 ml/h/kg and 31.1 +/- 4.4 hours for the group given the high dose, respectively.",Pharmacokinetics of phenobarbital in dogs given multiple doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782717/),h,47.3,58907,DB01174,Phenobarbital
,2782717,t1/2,"The Clt/F and t1/2 were 10.2 +/- 1.7 ml/h/kg and 47.3 +/- 10.7 hours for the group given the low dose and 15.6 +/- 2.5 ml/h/kg and 31.1 +/- 4.4 hours for the group given the high dose, respectively.",Pharmacokinetics of phenobarbital in dogs given multiple doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782717/),h,31.1,58908,DB01174,Phenobarbital
,8226400,renal clearance,"The mean renal clearance for rats pre-treated with MS, Pb and NS was 0.61 +/- 0.07.",Effect of morphine or phenobarbital on teicoplanin elimination pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226400/),,0.61,59238,DB01174,Phenobarbital
,8226400,non-renal clearance,"mL/min/kg, 0.60 +/- 0.13 mL/min/kg, and 0.46 +/- 0.02 mL/min/kg, respectively; the mean non-renal clearance was 0.33 +/- 0.18 mL/min/kg, 0.17 +/- 0.15 mL/min/kg, and 0.08 +/- 0.03 mL/min/kg, respectively.",Effect of morphine or phenobarbital on teicoplanin elimination pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226400/),[ml] / [kg·min],0.33,59239,DB01174,Phenobarbital
,8226400,non-renal clearance,"mL/min/kg, 0.60 +/- 0.13 mL/min/kg, and 0.46 +/- 0.02 mL/min/kg, respectively; the mean non-renal clearance was 0.33 +/- 0.18 mL/min/kg, 0.17 +/- 0.15 mL/min/kg, and 0.08 +/- 0.03 mL/min/kg, respectively.",Effect of morphine or phenobarbital on teicoplanin elimination pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226400/),[ml] / [kg·min],0.17,59240,DB01174,Phenobarbital
,8226400,non-renal clearance,"mL/min/kg, 0.60 +/- 0.13 mL/min/kg, and 0.46 +/- 0.02 mL/min/kg, respectively; the mean non-renal clearance was 0.33 +/- 0.18 mL/min/kg, 0.17 +/- 0.15 mL/min/kg, and 0.08 +/- 0.03 mL/min/kg, respectively.",Effect of morphine or phenobarbital on teicoplanin elimination pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226400/),[ml] / [kg·min],0.08,59241,DB01174,Phenobarbital
,8226400,half-life,"The mean half-life for MS-, Pb-, and NS pre-treated groups was 8.1 +/- 3.1 h, 5.9 +/- 3.3 h, and 34.6 +/- 20.7 h, respectively.",Effect of morphine or phenobarbital on teicoplanin elimination pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226400/),h,8.1,59242,DB01174,Phenobarbital
,8226400,half-life,"The mean half-life for MS-, Pb-, and NS pre-treated groups was 8.1 +/- 3.1 h, 5.9 +/- 3.3 h, and 34.6 +/- 20.7 h, respectively.",Effect of morphine or phenobarbital on teicoplanin elimination pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226400/),h,5.9,59243,DB01174,Phenobarbital
,8226400,half-life,"The mean half-life for MS-, Pb-, and NS pre-treated groups was 8.1 +/- 3.1 h, 5.9 +/- 3.3 h, and 34.6 +/- 20.7 h, respectively.",Effect of morphine or phenobarbital on teicoplanin elimination pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8226400/),h,34.6,59244,DB01174,Phenobarbital
,2763578,area under the curve,Pharmacokinetic parameters following intramuscular versus rectal administration were the following: area under the curve 5916 vs. 5253 mumol.h/L; half-life 112 vs.,Relative bioavailability of rectally administered phenobarbital sodium parenteral solution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2763578/),[h·μM] / [l],5916,59507,DB01174,Phenobarbital
,2763578,area under the curve,Pharmacokinetic parameters following intramuscular versus rectal administration were the following: area under the curve 5916 vs. 5253 mumol.h/L; half-life 112 vs.,Relative bioavailability of rectally administered phenobarbital sodium parenteral solution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2763578/),[h·μM] / [l],5253,59508,DB01174,Phenobarbital
,2763578,half-life,Pharmacokinetic parameters following intramuscular versus rectal administration were the following: area under the curve 5916 vs. 5253 mumol.h/L; half-life 112 vs.,Relative bioavailability of rectally administered phenobarbital sodium parenteral solution. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2763578/),,112,59509,DB01174,Phenobarbital
,2763578,time to maximum concentration,113 h; time to maximum concentration 2.1 vs.,Relative bioavailability of rectally administered phenobarbital sodium parenteral solution. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2763578/),,2.1,59510,DB01174,Phenobarbital
,2763578,maximum serum concentration,4.4 h; and maximum serum concentration 36.2 vs.,Relative bioavailability of rectally administered phenobarbital sodium parenteral solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2763578/),,36.2,59511,DB01174,Phenobarbital
,2763578,relative bioavailability,Mean relative bioavailability for rectal phenobarbital was 90 percent.,Relative bioavailability of rectally administered phenobarbital sodium parenteral solution. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2763578/),%,90,59512,DB01174,Phenobarbital
,14639056,CL/F,"In particular, CL/F values in children aged less than 10 years (112 +/- 82 mL/kg/h, mean +/- SD, n = 14) were almost three times as high as those observed in patients aged >15 to 30 years (42 +/- 16 mL/kg/h, n = 17), whereas the CL/F value in children aged 10 to 15 years (66 +/- 22 mL/kg/h, n = 11) was intermediate between those found in the two other age groups.","Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639056/),[ml] / [h·kg],112,60607,DB01174,Phenobarbital
,14639056,CL/F,"In particular, CL/F values in children aged less than 10 years (112 +/- 82 mL/kg/h, mean +/- SD, n = 14) were almost three times as high as those observed in patients aged >15 to 30 years (42 +/- 16 mL/kg/h, n = 17), whereas the CL/F value in children aged 10 to 15 years (66 +/- 22 mL/kg/h, n = 11) was intermediate between those found in the two other age groups.","Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639056/),[ml] / [h·kg],42,60608,DB01174,Phenobarbital
,14639056,CL/F,"In particular, CL/F values in children aged less than 10 years (112 +/- 82 mL/kg/h, mean +/- SD, n = 14) were almost three times as high as those observed in patients aged >15 to 30 years (42 +/- 16 mL/kg/h, n = 17), whereas the CL/F value in children aged 10 to 15 years (66 +/- 22 mL/kg/h, n = 11) was intermediate between those found in the two other age groups.","Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639056/),[ml] / [h·kg],66,60609,DB01174,Phenobarbital
,30696292,CLB,The levels of CLB and N-desmethylclobazam (NCLB) in plasma were initially 8.3 and 14.8 mg/L.,Clinical consequences related to a defective elimination of clobazam caused by homozygous mutated CYP2C19 allele. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30696292/),[mg] / [l],8.3,61515,DB01174,Phenobarbital
,30696292,half-life elimination,The half-life elimination of CLB is 18 h that of NCLB is between 40 and 50 h.,Clinical consequences related to a defective elimination of clobazam caused by homozygous mutated CYP2C19 allele. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30696292/),,18,61516,DB01174,Phenobarbital
,30696292,half-life elimination,The half-life elimination of CLB is 18 h that of NCLB is between 40 and 50 h.,Clinical consequences related to a defective elimination of clobazam caused by homozygous mutated CYP2C19 allele. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30696292/),h,40 and 50,61517,DB01174,Phenobarbital
,12576167,concentration at 1h (C(1h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],2.1,63306,DB01174,Phenobarbital
,12576167,concentration at 12h (C(12h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],0.8,63307,DB01174,Phenobarbital
,12576167,area under the curve from 0 to 12h (AUC(0-12h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],17.1,63308,DB01174,Phenobarbital
,12576167,half-life (t(1/2)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),h,8.1,63309,DB01174,Phenobarbital
,12576167,apparent oral clearance (CL/F),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),1/[mlmin],0.97,63310,DB01174,Phenobarbital
,6681550,half-life,Declining serum levels from postnatal days 8 to 13 on a constant dose of 9 mg per kilogram per day suggested that the rate of phenytoin metabolism was gradually increasing; rapid elimination was documented on day 18 by a half-life measurement of 8.8 hours from three samples.,High intravenous phenytoin dosage requirement in a newborn infant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6681550/),h,8.8,64285,DB01174,Phenobarbital
,1777369,peak steady-state plasma phenobarbitone concentration,5. The revised estimate of peak steady-state plasma phenobarbitone concentration utilising the 96 h post-single dose concentration (356 ng ml-1) was least biased (mean prediction error +/- 95% CI = 10.6 +/- 19.8 ng ml-1) and most precise (root mean square error +/- 95% CI = 28.3 +/- 19.0 ng ml-1).,The prediction of steady-state plasma phenobarbitone concentrations (following low-dose phenobarbitone) to refine its use as an indicator of compliance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777369/),[ng] / [ml],356,65361,DB01174,Phenobarbital
,1777369,peak steady-state plasma phenobarbitone concentration,5. The revised estimate of peak steady-state plasma phenobarbitone concentration utilising the 96 h post-single dose concentration (356 ng ml-1) was least biased (mean prediction error +/- 95% CI = 10.6 +/- 19.8 ng ml-1) and most precise (root mean square error +/- 95% CI = 28.3 +/- 19.0 ng ml-1).,The prediction of steady-state plasma phenobarbitone concentrations (following low-dose phenobarbitone) to refine its use as an indicator of compliance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777369/),[ng] / [ml],10.6,65362,DB01174,Phenobarbital
,1777369,peak steady-state plasma phenobarbitone concentration,5. The revised estimate of peak steady-state plasma phenobarbitone concentration utilising the 96 h post-single dose concentration (356 ng ml-1) was least biased (mean prediction error +/- 95% CI = 10.6 +/- 19.8 ng ml-1) and most precise (root mean square error +/- 95% CI = 28.3 +/- 19.0 ng ml-1).,The prediction of steady-state plasma phenobarbitone concentrations (following low-dose phenobarbitone) to refine its use as an indicator of compliance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777369/),[ng] / [ml],28.3,65363,DB01174,Phenobarbital
,15730534,CL/F,PB CL/F values were significantly lower in elderly patients than in controls (3.2 +/- 0.8 vs. 4.1 +/- 1.2 ml/h/kg; p < 0.0001).,Phenobarbital pharmacokinetics in old age: a case-matched evaluation based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730534/),[ml] / [h·kg],3.2,65549,DB01174,Phenobarbital
,15730534,CL/F,PB CL/F values were significantly lower in elderly patients than in controls (3.2 +/- 0.8 vs. 4.1 +/- 1.2 ml/h/kg; p < 0.0001).,Phenobarbital pharmacokinetics in old age: a case-matched evaluation based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15730534/),[ml] / [h·kg],4.1,65550,DB01174,Phenobarbital
,15927909,serum concentrations,"On day 4 of therapy, serum concentrations of voriconazole were 3.27 microg/ml immediately after infusion and 0.33 microg/ml 6 hours after infusion.",Intravenous voriconazole therapy in a preterm infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15927909/),[μg] / [ml],3.27,66043,DB01174,Phenobarbital
,15927909,serum concentrations,"On day 4 of therapy, serum concentrations of voriconazole were 3.27 microg/ml immediately after infusion and 0.33 microg/ml 6 hours after infusion.",Intravenous voriconazole therapy in a preterm infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15927909/),,0.33,66044,DB01174,Phenobarbital
,15927909,serum concentrations,"After the infant's dosage was increased to 6 mg/kg every 8 hours, serum concentrations were 5.33 microg/ml 30 minutes after infusion and 2.67 microg/ml 6 hours after infusion.",Intravenous voriconazole therapy in a preterm infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15927909/),[μg] / [ml],5.33,66045,DB01174,Phenobarbital
,15927909,serum concentrations,"After the infant's dosage was increased to 6 mg/kg every 8 hours, serum concentrations were 5.33 microg/ml 30 minutes after infusion and 2.67 microg/ml 6 hours after infusion.",Intravenous voriconazole therapy in a preterm infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15927909/),[μg] / [ml],2.67,66046,DB01174,Phenobarbital
,6360176,T50,"Average T50 amounted to 29 min in controls, was reduced to 20 min after enzyme induction by phenobarbital or 3-methylcholanthrene, and prolonged to 45, 46 and 66 min after bile duct ligation, portacaval shunt and a single dose of ethanol, respectively.",In vivo hydroxylation of 3H-acetanilide--evaluation of a new radiospirometric method in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6360176/),min,29,69545,DB01174,Phenobarbital
,6360176,T50,"Average T50 amounted to 29 min in controls, was reduced to 20 min after enzyme induction by phenobarbital or 3-methylcholanthrene, and prolonged to 45, 46 and 66 min after bile duct ligation, portacaval shunt and a single dose of ethanol, respectively.",In vivo hydroxylation of 3H-acetanilide--evaluation of a new radiospirometric method in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6360176/),min,20,69546,DB01174,Phenobarbital
,6360176,T50,"Average T50 amounted to 29 min in controls, was reduced to 20 min after enzyme induction by phenobarbital or 3-methylcholanthrene, and prolonged to 45, 46 and 66 min after bile duct ligation, portacaval shunt and a single dose of ethanol, respectively.",In vivo hydroxylation of 3H-acetanilide--evaluation of a new radiospirometric method in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6360176/),min,45,69547,DB01174,Phenobarbital
,6360176,T50,"Average T50 amounted to 29 min in controls, was reduced to 20 min after enzyme induction by phenobarbital or 3-methylcholanthrene, and prolonged to 45, 46 and 66 min after bile duct ligation, portacaval shunt and a single dose of ethanol, respectively.",In vivo hydroxylation of 3H-acetanilide--evaluation of a new radiospirometric method in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6360176/),min,46,69548,DB01174,Phenobarbital
,6360176,T50,"Average T50 amounted to 29 min in controls, was reduced to 20 min after enzyme induction by phenobarbital or 3-methylcholanthrene, and prolonged to 45, 46 and 66 min after bile duct ligation, portacaval shunt and a single dose of ethanol, respectively.",In vivo hydroxylation of 3H-acetanilide--evaluation of a new radiospirometric method in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6360176/),min,66,69549,DB01174,Phenobarbital
,6479136,peak phenobarbital serum concentration,The mean (+/- sd) peak phenobarbital serum concentration was 18.6 +/- 2.1 micrograms/ml at 1 h after initiation of infusion with a mean (+/- se) half-life of 12.8 +/- 2.1 h.,Preliminary study on the pharmacokinetics of phenobarbital in the neonatal foal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6479136/),[μg] / [ml],18.6,70705,DB01174,Phenobarbital
,6479136,half-life,The mean (+/- sd) peak phenobarbital serum concentration was 18.6 +/- 2.1 micrograms/ml at 1 h after initiation of infusion with a mean (+/- se) half-life of 12.8 +/- 2.1 h.,Preliminary study on the pharmacokinetics of phenobarbital in the neonatal foal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6479136/),h,12.8,70706,DB01174,Phenobarbital
,6479136,volume of distribution,The mean (+/- se) volume of distribution was 0.86 +/- 0.026 litres/kg bwt and mean (+/- se) total body clearance was 0.0564 +/- 0.0065 litres/kg bwt/h.,Preliminary study on the pharmacokinetics of phenobarbital in the neonatal foal. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6479136/),[l] / [bwt·kg],0.86,70707,DB01174,Phenobarbital
,6479136,total body clearance,The mean (+/- se) volume of distribution was 0.86 +/- 0.026 litres/kg bwt and mean (+/- se) total body clearance was 0.0564 +/- 0.0065 litres/kg bwt/h.,Preliminary study on the pharmacokinetics of phenobarbital in the neonatal foal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6479136/),[l] / [bwt·h·kg],0.0564,70708,DB01174,Phenobarbital
,6479136,steady state serum phenobarbital concentrations,"With this regimen, average steady state serum phenobarbital concentrations should range between approximately 11.6 and 53 micrograms/ml.",Preliminary study on the pharmacokinetics of phenobarbital in the neonatal foal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6479136/),[μg] / [ml],11.6 and 53,70709,DB01174,Phenobarbital
,26751267,total C/D ratio,"The interindividual pharmacokinetic variability was extensive, as illustrated by a 100-fold variability in serum concentration compared with dose (total C/D ratio 0.03-3.29 µmol·L·mg).",Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and Comedication on Pharmacokinetic Variability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26751267/),l·mg·μM,0.03-3.29,70769,DB01174,Phenobarbital
,7420295,detection limit,The detection limit of the method was 0.1 micrograms/ml for both compounds.,Simultaneous analysis of phenobarbital and p-hydroxyphenobarbital in biological fluids by GLC-chemical-ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420295/),[μg] / [ml],0.1,74287,DB01174,Phenobarbital
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.52,74496,DB01174,Phenobarbital
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.17,74497,DB01174,Phenobarbital
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.803,74498,DB01174,Phenobarbital
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.636,74499,DB01174,Phenobarbital
,22495532,clearance (CL),LEV clearance (CL) increased from a mean of 0.7 ml/min/kg (SD 0.27 ml/min/kg) on day 1 to 1.33 ml/min/kg (SD 0.35 ml/min/kg) by day 7.,A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495532/),[ml] / [kg·min],0.7,76048,DB01174,Phenobarbital
,22495532,clearance (CL),LEV clearance (CL) increased from a mean of 0.7 ml/min/kg (SD 0.27 ml/min/kg) on day 1 to 1.33 ml/min/kg (SD 0.35 ml/min/kg) by day 7.,A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495532/),[ml] / [kg·min],1.33,76049,DB01174,Phenobarbital
,22495532,half-life,Mean half-life was 18.5 h (SD 7.1 h) on day 1 of the study and decreased to 9.1 h (SD 2.0 h) by day 7.,A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495532/),h,18.5,76050,DB01174,Phenobarbital
,22495532,half-life,Mean half-life was 18.5 h (SD 7.1 h) on day 1 of the study and decreased to 9.1 h (SD 2.0 h) by day 7.,A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495532/),h,9.1,76051,DB01174,Phenobarbital
,22495532,volume of distribution,The mean volume of distribution was 1.01 l/kg (SD 0.13 l/kg).,A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495532/),[l] / [kg],1.01,76052,DB01174,Phenobarbital
,30027304,CLPB,Median CLPB (range) in short-surviving cancer patients [0.076 (0.057‒0.114) L/kg/day] was significantly (p < 0.05) lower than that in non-cancer patients [0.105 (0.060‒0.226) L/kg/day] and in long-surviving cancer patients [0.100 (0.082‒0.149) L/kg/day].,Reduced Clearance of Phenobarbital in Advanced Cancer Patients near the End of Life. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30027304/),[l] / [d·kg],0.076,76279,DB01174,Phenobarbital
,30027304,CLPB,Median CLPB (range) in short-surviving cancer patients [0.076 (0.057‒0.114) L/kg/day] was significantly (p < 0.05) lower than that in non-cancer patients [0.105 (0.060‒0.226) L/kg/day] and in long-surviving cancer patients [0.100 (0.082‒0.149) L/kg/day].,Reduced Clearance of Phenobarbital in Advanced Cancer Patients near the End of Life. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30027304/),[l] / [d·kg],0.105,76280,DB01174,Phenobarbital
,30027304,CLPB,Median CLPB (range) in short-surviving cancer patients [0.076 (0.057‒0.114) L/kg/day] was significantly (p < 0.05) lower than that in non-cancer patients [0.105 (0.060‒0.226) L/kg/day] and in long-surviving cancer patients [0.100 (0.082‒0.149) L/kg/day].,Reduced Clearance of Phenobarbital in Advanced Cancer Patients near the End of Life. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30027304/),[l] / [d·kg],0.100,76281,DB01174,Phenobarbital
,6710514,maximum velocity of metabolism,"In naive rats, the maximum velocity of metabolism was 10.0 mg/kg/hr, and Km was of the order of 0.2 mg/liter.","Inhalation pharmacokinetics: evaluating systemic extraction, total in vivo metabolism, and the time course of enzyme induction for inhaled styrene in rats based on arterial blood:inhaled air concentration ratios. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6710514/),[mg] / [h·kg],10.0,77324,DB01174,Phenobarbital
,6710514,Km,"In naive rats, the maximum velocity of metabolism was 10.0 mg/kg/hr, and Km was of the order of 0.2 mg/liter.","Inhalation pharmacokinetics: evaluating systemic extraction, total in vivo metabolism, and the time course of enzyme induction for inhaled styrene in rats based on arterial blood:inhaled air concentration ratios. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6710514/),[mg] / [l],0.2,77325,DB01174,Phenobarbital
,6710514,lag,"At 400 ppm, induction began after a lag of 15.5 hr, had a half-life of 3.5 hr, and reached 2.7 times the Vmax in naive rats.","Inhalation pharmacokinetics: evaluating systemic extraction, total in vivo metabolism, and the time course of enzyme induction for inhaled styrene in rats based on arterial blood:inhaled air concentration ratios. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6710514/),h,15.5,77326,DB01174,Phenobarbital
,6710514,half-life,"At 400 ppm, induction began after a lag of 15.5 hr, had a half-life of 3.5 hr, and reached 2.7 times the Vmax in naive rats.","Inhalation pharmacokinetics: evaluating systemic extraction, total in vivo metabolism, and the time course of enzyme induction for inhaled styrene in rats based on arterial blood:inhaled air concentration ratios. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6710514/),h,3.5,77327,DB01174,Phenobarbital
,6710514,half-life,"At 600 ppm, it began after 10.6 hr, proceeded with a half-life of 2.2 hr, and increased Vmax by 3.4 times.","Inhalation pharmacokinetics: evaluating systemic extraction, total in vivo metabolism, and the time course of enzyme induction for inhaled styrene in rats based on arterial blood:inhaled air concentration ratios. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6710514/),h,2.2,77328,DB01174,Phenobarbital
,9127813,Cmax,"In PB-treated rats, pharmacokinetic parameters (Cmax, AUC0-12) of PB between 0 and 12 hr after a single oral administration were significantly decreased during lactation.",Influence of lactation on plasma phenobarbital concentrations in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9127813/),h,0 and 12,77643,DB01174,Phenobarbital
,543743,half-life,"Primidone was rapidly absorbed, so that maximal serum concentrations were reached after 2 hr, the concentration fell then with a half-life averaging 5 hr in Beagles and 10 hr in Mongrels.",Pharmacokinetics of primidone and its active metabolites in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/543743/),h,5,79797,DB01174,Phenobarbital
,543743,half-life,"Primidone was rapidly absorbed, so that maximal serum concentrations were reached after 2 hr, the concentration fell then with a half-life averaging 5 hr in Beagles and 10 hr in Mongrels.",Pharmacokinetics of primidone and its active metabolites in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/543743/),h,10,79798,DB01174,Phenobarbital
,543743,ka,"PEMA appeared in plasma with a ka of 0.003--0.005 min-1, reached maximal concentrations after about 6.5 hr in Beagles and 12 hr in Mongrels.",Pharmacokinetics of primidone and its active metabolites in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/543743/),1/[min],0.003,79799,DB01174,Phenobarbital
,543743,elimination half-life,The elimination half-life averaged 7.5 hr in Beagles and 14 hr in Mongrels.,Pharmacokinetics of primidone and its active metabolites in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/543743/),h,7.5,79800,DB01174,Phenobarbital
,543743,elimination half-life,The elimination half-life averaged 7.5 hr in Beagles and 14 hr in Mongrels.,Pharmacokinetics of primidone and its active metabolites in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/543743/),h,14,79801,DB01174,Phenobarbital
,543743,elimination half-life,Phenobarbital had an elimination half-life of 32 +/- 4.8 hr in Beagles and of 70 +/- 16 hr in Mongrels.,Pharmacokinetics of primidone and its active metabolites in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/543743/),h,32,79802,DB01174,Phenobarbital
,543743,elimination half-life,Phenobarbital had an elimination half-life of 32 +/- 4.8 hr in Beagles and of 70 +/- 16 hr in Mongrels.,Pharmacokinetics of primidone and its active metabolites in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/543743/),h,70,79803,DB01174,Phenobarbital
,543743,steady-state concentrations,"During continued treatment with daily doses of 30--50 mg/kg primidone, steady-state concentrations of about 15 micrograms/ml (65 nmole/ml) were reached after 6--8 days, the PEMA concentrations showed rather pronounced fluctuations around average values of 8--10 micrograms/ml (39--49 nmole/ml), whereas the concentrations of primidone mainly remained below 5 micrograms/ml (23 nmole/ml).",Pharmacokinetics of primidone and its active metabolites in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/543743/),[μg] / [ml],15,79804,DB01174,Phenobarbital
,543743,steady-state concentrations,"During continued treatment with daily doses of 30--50 mg/kg primidone, steady-state concentrations of about 15 micrograms/ml (65 nmole/ml) were reached after 6--8 days, the PEMA concentrations showed rather pronounced fluctuations around average values of 8--10 micrograms/ml (39--49 nmole/ml), whereas the concentrations of primidone mainly remained below 5 micrograms/ml (23 nmole/ml).",Pharmacokinetics of primidone and its active metabolites in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/543743/),[nmole] / [ml],65,79805,DB01174,Phenobarbital
,8119045,bioavailability,The bioavailability of the oral formulation is about 98%.,Lamotrigine clinical pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),%,98,80086,DB01174,Phenobarbital
,8119045,plasma protein binding,The degree of plasma protein binding is 56%.,Lamotrigine clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),%,56,80087,DB01174,Phenobarbital
,8119045,half-lives,Mean half-lives of lamotrigine in healthy volunteers (single and multiple doses) as well as in epileptic patients receiving lamotrigine monotherapy range from 22.8 to 37.4 hours.,Lamotrigine clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),h,22.8 to 37.4,80088,DB01174,Phenobarbital
,8119045,half-life,"Enzyme-inducing antiepileptic drugs such as phenytoin, phenobarbital (phenobarbitone) or carbamazepine reduce the half-life of lamotrigine (to mean values of 13.5 to 15 hours), whereas valproic acid increases the half-life of the drug (to mean values of 48.3 to 59 hours).",Lamotrigine clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),h,13.5 to 15,80089,DB01174,Phenobarbital
,8119045,half-life,"Enzyme-inducing antiepileptic drugs such as phenytoin, phenobarbital (phenobarbitone) or carbamazepine reduce the half-life of lamotrigine (to mean values of 13.5 to 15 hours), whereas valproic acid increases the half-life of the drug (to mean values of 48.3 to 59 hours).",Lamotrigine clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),h,48.3 to 59,80090,DB01174,Phenobarbital
,8120112,peak height,Linear relationships between the amount of drug and peak height were confirmed at 1-20 micrograms/ml in serum for carbamazepine and 5-40 micrograms/ml in serum for phenytoin and phenobarbital.,Simple and accurate high-performance liquid chromatographic method for the measurement of three antiepileptics in therapeutic drug monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8120112/),,1,80668,DB01174,Phenobarbital
,8120112,peak height,Linear relationships between the amount of drug and peak height were confirmed at 1-20 micrograms/ml in serum for carbamazepine and 5-40 micrograms/ml in serum for phenytoin and phenobarbital.,Simple and accurate high-performance liquid chromatographic method for the measurement of three antiepileptics in therapeutic drug monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8120112/),,5-40,80669,DB01174,Phenobarbital
,1287181,elimination half-life,The elimination half-life of PRM was decreased from 19.4 +/- 2.2 (mean +/- S.E.) to 10.2 +/- 5.1 h (p < 0.05) and the total body clearance was increased from 24.6 +/- 3.1 to 45.1 +/- 5.1 ml/h/kg (p < 0.01) in the presence of PHT.,"Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287181/),h,19.4,80682,DB01174,Phenobarbital
,1287181,elimination half-life,The elimination half-life of PRM was decreased from 19.4 +/- 2.2 (mean +/- S.E.) to 10.2 +/- 5.1 h (p < 0.05) and the total body clearance was increased from 24.6 +/- 3.1 to 45.1 +/- 5.1 ml/h/kg (p < 0.01) in the presence of PHT.,"Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287181/),h,10.2,80683,DB01174,Phenobarbital
,1287181,total body clearance,The elimination half-life of PRM was decreased from 19.4 +/- 2.2 (mean +/- S.E.) to 10.2 +/- 5.1 h (p < 0.05) and the total body clearance was increased from 24.6 +/- 3.1 to 45.1 +/- 5.1 ml/h/kg (p < 0.01) in the presence of PHT.,"Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287181/),[ml] / [h·kg],24.6,80684,DB01174,Phenobarbital
,1287181,total body clearance,The elimination half-life of PRM was decreased from 19.4 +/- 2.2 (mean +/- S.E.) to 10.2 +/- 5.1 h (p < 0.05) and the total body clearance was increased from 24.6 +/- 3.1 to 45.1 +/- 5.1 ml/h/kg (p < 0.01) in the presence of PHT.,"Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287181/),[ml] / [h·kg],45.1,80685,DB01174,Phenobarbital
,1287181,peak concentrations,About a 6-fold increase in the peak concentrations of both the metabolites were observed (PB 8.2 mumol/l; PEMA 11.0 mumol/l).,"Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287181/),[μM] / [l],8.2,80686,DB01174,Phenobarbital
,1287181,peak concentrations,About a 6-fold increase in the peak concentrations of both the metabolites were observed (PB 8.2 mumol/l; PEMA 11.0 mumol/l).,"Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287181/),[μM] / [l],11.0,80687,DB01174,Phenobarbital
,9832379,ED50,"Valproate, at its ED50 of 280 mg/kg against maximal electroshock, produced motor impairment.","LY 300164, a novel antagonist of AMPA/kainate receptors, potentiates the anticonvulsive activity of antiepileptic drugs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832379/),[mg] / [kg],280,81809,DB01174,Phenobarbital
,9811432,peak plasma concentrations,"Mean peak plasma concentrations after i.v. administration were 5963 and 5565 ng/mL, before and after phenobarbital treatment, respectively.",Chronic phenobarbital therapy reduces plasma benzodiazepine concentrations after intravenous and rectal administration of diazepam in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811432/),[ng] / [ml],5963,81953,DB01174,Phenobarbital
,9811432,peak plasma concentrations,"Mean peak plasma concentrations after i.v. administration were 5963 and 5565 ng/mL, before and after phenobarbital treatment, respectively.",Chronic phenobarbital therapy reduces plasma benzodiazepine concentrations after intravenous and rectal administration of diazepam in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811432/),[ng] / [ml],5565,81954,DB01174,Phenobarbital
,9811432,peak concentrations,"After p.r. administration, mean peak concentrations were 629 ng/mL and 274 ng/mL and were reached within 30 min before and after phenobarbital treatment, respectively.",Chronic phenobarbital therapy reduces plasma benzodiazepine concentrations after intravenous and rectal administration of diazepam in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811432/),[ng] / [ml],629,81955,DB01174,Phenobarbital
,9811432,peak concentrations,"After p.r. administration, mean peak concentrations were 629 ng/mL and 274 ng/mL and were reached within 30 min before and after phenobarbital treatment, respectively.",Chronic phenobarbital therapy reduces plasma benzodiazepine concentrations after intravenous and rectal administration of diazepam in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811432/),[ng] / [ml],274,81956,DB01174,Phenobarbital
,9811432,time to attainment of target concentration,The target concentration for potential seizure control (i.e. 150 ng/mL) was attained in five dogs in the post phenobarbital p.r. group with a median time to attainment of target concentration of 8 min.,Chronic phenobarbital therapy reduces plasma benzodiazepine concentrations after intravenous and rectal administration of diazepam in the dog. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811432/),min,8,81957,DB01174,Phenobarbital
,25220641,Ka,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),1/[h],0.83,82170,DB01174,Phenobarbital
,25220641,Vd,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[l] / [kg],0.67,82171,DB01174,Phenobarbital
,25220641,CL,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[l] / [h·kg],0.035,82172,DB01174,Phenobarbital
,25220641,MP,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[mg] / [l],0.01,82173,DB01174,Phenobarbital
,25220641,MAE,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[mg] / [l],0.46,82174,DB01174,Phenobarbital
,25220641,MSE,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),,0.39,82175,DB01174,Phenobarbital
,1524295,elimination half-life,"Mean kinetic variables after single and repeated orally administered doses (42 days) were: elimination half-life = 24.2 +/- 4.7 and 11.2 +/- 2.3 hours, volume of distribution = 0.960 +/- 0.060 and 0.914 +/- 0.119 L/kg, and clearance = 28.2 +/- 5.1 and 57.3 +/- 9.6 ml/h/kg, respectively.",Pharmacokinetics of phenobarbital in horses after single and repeated oral administration of the drug. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524295/),h,24.2,82266,DB01174,Phenobarbital
,1524295,elimination half-life,"Mean kinetic variables after single and repeated orally administered doses (42 days) were: elimination half-life = 24.2 +/- 4.7 and 11.2 +/- 2.3 hours, volume of distribution = 0.960 +/- 0.060 and 0.914 +/- 0.119 L/kg, and clearance = 28.2 +/- 5.1 and 57.3 +/- 9.6 ml/h/kg, respectively.",Pharmacokinetics of phenobarbital in horses after single and repeated oral administration of the drug. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524295/),h,11.2,82267,DB01174,Phenobarbital
,1524295,volume of distribution,"Mean kinetic variables after single and repeated orally administered doses (42 days) were: elimination half-life = 24.2 +/- 4.7 and 11.2 +/- 2.3 hours, volume of distribution = 0.960 +/- 0.060 and 0.914 +/- 0.119 L/kg, and clearance = 28.2 +/- 5.1 and 57.3 +/- 9.6 ml/h/kg, respectively.",Pharmacokinetics of phenobarbital in horses after single and repeated oral administration of the drug. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524295/),[l] / [kg],0.960,82268,DB01174,Phenobarbital
,1524295,volume of distribution,"Mean kinetic variables after single and repeated orally administered doses (42 days) were: elimination half-life = 24.2 +/- 4.7 and 11.2 +/- 2.3 hours, volume of distribution = 0.960 +/- 0.060 and 0.914 +/- 0.119 L/kg, and clearance = 28.2 +/- 5.1 and 57.3 +/- 9.6 ml/h/kg, respectively.",Pharmacokinetics of phenobarbital in horses after single and repeated oral administration of the drug. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524295/),[l] / [kg],0.914,82269,DB01174,Phenobarbital
,1524295,clearance,"Mean kinetic variables after single and repeated orally administered doses (42 days) were: elimination half-life = 24.2 +/- 4.7 and 11.2 +/- 2.3 hours, volume of distribution = 0.960 +/- 0.060 and 0.914 +/- 0.119 L/kg, and clearance = 28.2 +/- 5.1 and 57.3 +/- 9.6 ml/h/kg, respectively.",Pharmacokinetics of phenobarbital in horses after single and repeated oral administration of the drug. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524295/),[ml] / [h·kg],28.2,82270,DB01174,Phenobarbital
,1524295,clearance,"Mean kinetic variables after single and repeated orally administered doses (42 days) were: elimination half-life = 24.2 +/- 4.7 and 11.2 +/- 2.3 hours, volume of distribution = 0.960 +/- 0.060 and 0.914 +/- 0.119 L/kg, and clearance = 28.2 +/- 5.1 and 57.3 +/- 9.6 ml/h/kg, respectively.",Pharmacokinetics of phenobarbital in horses after single and repeated oral administration of the drug. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524295/),[ml] / [h·kg],57.3,82271,DB01174,Phenobarbital
,1302767,CL,"Predicted PF CL for a patient with median covariates values was similar in both BE/MLR and NONMEM analysis (4.02 and 3.92 L/hr, respectively).",Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1302767/),[l] / [h],4.02,82274,DB01174,Phenobarbital
,1302767,CL,"Predicted PF CL for a patient with median covariates values was similar in both BE/MLR and NONMEM analysis (4.02 and 3.92 L/hr, respectively).",Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1302767/),[l] / [h],3.92,82275,DB01174,Phenobarbital
,6134816,elimination half-lives,"In control rats (n = 8) elimination half-lives and intrinsic clearance values ranged between 13 to 28 min and 96 to 435 ml/min X kg for hexobarbital and between 8 to 21 min and 84 to 371 ml/min X kg for heptabarbital, respectively.",Pharmacokinetics of simultaneously administered hexobarbital and heptabarbital in rats: an alternative approach to metabolic correlation studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6134816/),min,13 to 28,82642,DB01174,Phenobarbital
,6134816,intrinsic clearance,"In control rats (n = 8) elimination half-lives and intrinsic clearance values ranged between 13 to 28 min and 96 to 435 ml/min X kg for hexobarbital and between 8 to 21 min and 84 to 371 ml/min X kg for heptabarbital, respectively.",Pharmacokinetics of simultaneously administered hexobarbital and heptabarbital in rats: an alternative approach to metabolic correlation studies. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6134816/),[ml] / [kg·min],96 to 435,82643,DB01174,Phenobarbital
,756009,elimination rate constant,"In the single dose studies, mean values of elimination rate constant (0.0155h) and clearance (1.85L/h) for untreated subjects were different from those for the pretreated subjects (0.0375h and 5.10L/h), while the apparent volumes of distribution did not differ significantly between the two groups (120.3L vs 140.8L).",Preliminary observations on the pharmacokinetics of methylphenobarbitone. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/756009/),h,0.0155,82829,DB01174,Phenobarbital
,756009,elimination rate constant,"In the single dose studies, mean values of elimination rate constant (0.0155h) and clearance (1.85L/h) for untreated subjects were different from those for the pretreated subjects (0.0375h and 5.10L/h), while the apparent volumes of distribution did not differ significantly between the two groups (120.3L vs 140.8L).",Preliminary observations on the pharmacokinetics of methylphenobarbitone. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/756009/),h,0.0375,82830,DB01174,Phenobarbital
,756009,clearance,"In the single dose studies, mean values of elimination rate constant (0.0155h) and clearance (1.85L/h) for untreated subjects were different from those for the pretreated subjects (0.0375h and 5.10L/h), while the apparent volumes of distribution did not differ significantly between the two groups (120.3L vs 140.8L).",Preliminary observations on the pharmacokinetics of methylphenobarbitone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/756009/),[l] / [h],1.85,82831,DB01174,Phenobarbital
,756009,clearance,"In the single dose studies, mean values of elimination rate constant (0.0155h) and clearance (1.85L/h) for untreated subjects were different from those for the pretreated subjects (0.0375h and 5.10L/h), while the apparent volumes of distribution did not differ significantly between the two groups (120.3L vs 140.8L).",Preliminary observations on the pharmacokinetics of methylphenobarbitone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/756009/),h,0.0375,82832,DB01174,Phenobarbital
,756009,clearance,"In the single dose studies, mean values of elimination rate constant (0.0155h) and clearance (1.85L/h) for untreated subjects were different from those for the pretreated subjects (0.0375h and 5.10L/h), while the apparent volumes of distribution did not differ significantly between the two groups (120.3L vs 140.8L).",Preliminary observations on the pharmacokinetics of methylphenobarbitone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/756009/),[l] / [h],5.10,82833,DB01174,Phenobarbital
,756009,apparent volumes of distribution,"In the single dose studies, mean values of elimination rate constant (0.0155h) and clearance (1.85L/h) for untreated subjects were different from those for the pretreated subjects (0.0375h and 5.10L/h), while the apparent volumes of distribution did not differ significantly between the two groups (120.3L vs 140.8L).",Preliminary observations on the pharmacokinetics of methylphenobarbitone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/756009/),l,120.3,82834,DB01174,Phenobarbital
,756009,apparent volumes of distribution,"In the single dose studies, mean values of elimination rate constant (0.0155h) and clearance (1.85L/h) for untreated subjects were different from those for the pretreated subjects (0.0375h and 5.10L/h), while the apparent volumes of distribution did not differ significantly between the two groups (120.3L vs 140.8L).",Preliminary observations on the pharmacokinetics of methylphenobarbitone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/756009/),l,140.8,82835,DB01174,Phenobarbital
,8799524,half-lives,"2. Compared with controls, epileptic patients showed markedly shorter ethosuximide half-lives (29.0 +/- 7.8 vs 53.7 +/- 14.3 h, means +/- s.d., P < 0.001) and higher apparent oral clearance (CL/F) values (15.3 +/- 3.8 vs 9.2 +/- 1.9 ml kg-1 h-1, P < 0.001).",Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799524/),h,29.0,85129,DB01174,Phenobarbital
,8799524,half-lives,"2. Compared with controls, epileptic patients showed markedly shorter ethosuximide half-lives (29.0 +/- 7.8 vs 53.7 +/- 14.3 h, means +/- s.d., P < 0.001) and higher apparent oral clearance (CL/F) values (15.3 +/- 3.8 vs 9.2 +/- 1.9 ml kg-1 h-1, P < 0.001).",Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799524/),h,53.7,85130,DB01174,Phenobarbital
,8799524,apparent oral clearance (CL/F),"2. Compared with controls, epileptic patients showed markedly shorter ethosuximide half-lives (29.0 +/- 7.8 vs 53.7 +/- 14.3 h, means +/- s.d., P < 0.001) and higher apparent oral clearance (CL/F) values (15.3 +/- 3.8 vs 9.2 +/- 1.9 ml kg-1 h-1, P < 0.001).",Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799524/),[ml] / [h·kg],15.3,85131,DB01174,Phenobarbital
,8799524,apparent oral clearance (CL/F),"2. Compared with controls, epileptic patients showed markedly shorter ethosuximide half-lives (29.0 +/- 7.8 vs 53.7 +/- 14.3 h, means +/- s.d., P < 0.001) and higher apparent oral clearance (CL/F) values (15.3 +/- 3.8 vs 9.2 +/- 1.9 ml kg-1 h-1, P < 0.001).",Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799524/),[ml] / [h·kg],9.2,85132,DB01174,Phenobarbital
,8799524,apparent volume of distribution (V/F),"The apparent volume of distribution (V/F) of ethosuximide was slightly lower in the patients than in controls (0.6 +/- 0.1 vs 0.7 +/- 0.1 l kg-1, P < 0.05).",Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799524/),[l] / [kg],0.6,85133,DB01174,Phenobarbital
,8799524,apparent volume of distribution (V/F),"The apparent volume of distribution (V/F) of ethosuximide was slightly lower in the patients than in controls (0.6 +/- 0.1 vs 0.7 +/- 0.1 l kg-1, P < 0.05).",Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799524/),[l] / [kg],0.7,85134,DB01174,Phenobarbital
,422308,maximum concentrations,"5. Absorption was generally delayed by about half an hour, the maximum concentrations ranging from 3.14 to 10 microgram.",Pharmacokinetics of carbamazepine in the neonate and in the child. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/422308/),μg,3.14 to 10,86079,DB01174,Phenobarbital
,422308,half-life for absorption,The mean half-life for absorption was 1.42 +/- 0.34 hr.,Pharmacokinetics of carbamazepine in the neonate and in the child. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/422308/),h,1.42,86080,DB01174,Phenobarbital
,422308,half-life for elimination,The mean half-life for elimination was 8.76 +/- 0.85 hr.,Pharmacokinetics of carbamazepine in the neonate and in the child. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/422308/),h,8.76,86081,DB01174,Phenobarbital
,3909980,elimination half life,Results show important variability between patients: the elimination half life was 2.70 +/- 0.78 hr.; Tmax time to reach Cmax was 2.10 +/- 1.08 hr.; Maximal concentration (Cmax) was 474 +/- 153 ng/ml.,[Pharmacokinetics of prednisone after oral administration in children with renal grafts. Changes induced by phenobarbital and renal insufficiency]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909980/),h,2.70,86144,DB01174,Phenobarbital
,3909980,Tmax time to reach Cmax,Results show important variability between patients: the elimination half life was 2.70 +/- 0.78 hr.; Tmax time to reach Cmax was 2.10 +/- 1.08 hr.; Maximal concentration (Cmax) was 474 +/- 153 ng/ml.,[Pharmacokinetics of prednisone after oral administration in children with renal grafts. Changes induced by phenobarbital and renal insufficiency]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909980/),h,2.10,86145,DB01174,Phenobarbital
,3909980,Maximal concentration (Cmax),Results show important variability between patients: the elimination half life was 2.70 +/- 0.78 hr.; Tmax time to reach Cmax was 2.10 +/- 1.08 hr.; Maximal concentration (Cmax) was 474 +/- 153 ng/ml.,[Pharmacokinetics of prednisone after oral administration in children with renal grafts. Changes induced by phenobarbital and renal insufficiency]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909980/),[ng] / [ml],474,86146,DB01174,Phenobarbital
,3909980,urinary excretion,"With respect to the dose of steroid administered, the urinary excretion of corticosteroids: 17-hydroxycorticosteroids was 12.9 +/- 7.4% and that of unchanged prednisolone 2.8 +/- 3.1%.",[Pharmacokinetics of prednisone after oral administration in children with renal grafts. Changes induced by phenobarbital and renal insufficiency]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909980/),%,12.9,86147,DB01174,Phenobarbital
,3909980,urinary excretion,"With respect to the dose of steroid administered, the urinary excretion of corticosteroids: 17-hydroxycorticosteroids was 12.9 +/- 7.4% and that of unchanged prednisolone 2.8 +/- 3.1%.",[Pharmacokinetics of prednisone after oral administration in children with renal grafts. Changes induced by phenobarbital and renal insufficiency]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909980/),%,2.8,86148,DB01174,Phenobarbital
,26658225,t1/2,The t1/2 for CYP3A4 mRNA was 26 hours and that for the functional protein was 49 hours.,Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26658225/),h,26,88520,DB01174,Phenobarbital
,26658225,t1/2,The t1/2 for CYP3A4 mRNA was 26 hours and that for the functional protein was 49 hours.,Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26658225/),h,49,88521,DB01174,Phenobarbital
,26658225,t1/2,"The t1/2 of CYP2B6 was 38 hours (mRNA) and 68 hours (activity), which is longer than CYP3A4 and shows the differential turnover of these two proteins.",Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26658225/),h,38,88522,DB01174,Phenobarbital
,26658225,t1/2,"The t1/2 of CYP2B6 was 38 hours (mRNA) and 68 hours (activity), which is longer than CYP3A4 and shows the differential turnover of these two proteins.",Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26658225/),h,68,88523,DB01174,Phenobarbital
,32960986,peak,"We developed a population PK model using nonlinear mixed-effects modeling, performed simulations using the final PK parameters, and determined optimal dosing based on attainment of peak and trough concentrations between 20 and 40 mg/L.",Population Pharmacokinetics of Phenobarbital in Neonates and Infants on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32960986/),[mg] / [l],20 and 40,90571,DB01174,Phenobarbital
,32960986,trough concentrations,"We developed a population PK model using nonlinear mixed-effects modeling, performed simulations using the final PK parameters, and determined optimal dosing based on attainment of peak and trough concentrations between 20 and 40 mg/L.",Population Pharmacokinetics of Phenobarbital in Neonates and Infants on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32960986/),[mg] / [l],20 and 40,90572,DB01174,Phenobarbital
,32960986,clearance,"Typical clearance and volume of distribution for a 3.4-kg infant were 0.038 L/h and 3.83 L, respectively.",Population Pharmacokinetics of Phenobarbital in Neonates and Infants on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32960986/),[l] / [h],0.038,90573,DB01174,Phenobarbital
,32960986,volume of distribution,"Typical clearance and volume of distribution for a 3.4-kg infant were 0.038 L/h and 3.83 L, respectively.",Population Pharmacokinetics of Phenobarbital in Neonates and Infants on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32960986/),l,3.83,90574,DB01174,Phenobarbital
,7377892,elimination half-life,Plasma concentrations declined with an elimination half-life of 1.5 hr.,Pharmacokinetics of carbamazepine in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7377892/),h,1.5,92213,DB01174,Phenobarbital
,7377892,half-life,"The concentrations of the epoxide remained high as long as plasma concentrations of carbamazepine were above 2--4 nmole/ml, then they fell with an average half-life of 2.2 hr.",Pharmacokinetics of carbamazepine in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7377892/),h,2.2,92214,DB01174,Phenobarbital
,7377892,Binding,4. Binding to serum proteins was about 70% for carbamazepine and 40% for the epoxide in dog serum; slightly higher values were found for human serum.,Pharmacokinetics of carbamazepine in the dog. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7377892/),%,70,92215,DB01174,Phenobarbital
,7377892,Binding,4. Binding to serum proteins was about 70% for carbamazepine and 40% for the epoxide in dog serum; slightly higher values were found for human serum.,Pharmacokinetics of carbamazepine in the dog. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7377892/),%,40,92216,DB01174,Phenobarbital
,11908134,half-life,The half-life is 9 to 21 hours.,[Griseofulvin]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11908134/),h,9 to 21,97230,DB01174,Phenobarbital
,11908134,Clinical response rates,Clinical response rates have been reported between 80 and 90 p. 100 in controlled studies.,[Griseofulvin]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11908134/),100·p,80 and 90,97231,DB01174,Phenobarbital
,3758147,plasma half-lives,"The plasma half-lives in these ""phenobarbital pretreated neonates' were of the same order of magnitude as those reported in adults (20-43 h).",Clonazepam pharmacokinetics and therapeutic efficacy in neonatal seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3758147/),h,20-43,97508,DB01174,Phenobarbital
,89025,peak serum level,"Bleomycin (1 mg/kg, ip) reached a peak serum level of 0.7-1.0 microgram/ml in 54 +/- 4 min (mean +/- SE) and was eliminated with a t 1/2 of 32 +/- 1 min.","Disposition of the pulmonary toxin, bleomycin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/89025/),[μg] / [ml],0.7-1.0,98552,DB01174,Phenobarbital
,89025,t 1/2,"Bleomycin (1 mg/kg, ip) reached a peak serum level of 0.7-1.0 microgram/ml in 54 +/- 4 min (mean +/- SE) and was eliminated with a t 1/2 of 32 +/- 1 min.","Disposition of the pulmonary toxin, bleomycin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/89025/),min,32,98553,DB01174,Phenobarbital
,89025,apparent volume of distribution,The apparent volume of distribution in rats was 184 +/- 11 ml/kg.,"Disposition of the pulmonary toxin, bleomycin. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/89025/),[ml] / [kg],184,98554,DB01174,Phenobarbital
,2038745,systemic clearance (Cls),"The mean systemic clearance (Cls) for AC in the adults and pups was 16.1 and 13.7 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],16.1,99215,DB01174,Phenobarbital
,2038745,systemic clearance (Cls),"The mean systemic clearance (Cls) for AC in the adults and pups was 16.1 and 13.7 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],13.7,99216,DB01174,Phenobarbital
,2038745,half-lives,"The mean half-lives of AC (t1/2) were 25.5 and 33.3 min in the adult and pup groups, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,25.5,99217,DB01174,Phenobarbital
,2038745,half-lives,"The mean half-lives of AC (t1/2) were 25.5 and 33.3 min in the adult and pup groups, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,33.3,99218,DB01174,Phenobarbital
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,97.5,99219,DB01174,Phenobarbital
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,95.1,99220,DB01174,Phenobarbital
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,347.6,99221,DB01174,Phenobarbital
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],5.34,99222,DB01174,Phenobarbital
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],6.30,99223,DB01174,Phenobarbital
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],1.91,99224,DB01174,Phenobarbital
,2038745,t1/2,The time course of SA was prolonged in the suckling pups (t1/2 of 633 min in the pups vs 78.7 min in the adult).,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,633,99225,DB01174,Phenobarbital
,2038745,t1/2,The time course of SA was prolonged in the suckling pups (t1/2 of 633 min in the pups vs 78.7 min in the adult).,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,78.7,99226,DB01174,Phenobarbital
,2038745,Cls,"The mean Cls values in the adults and the pups were 1.05 and 0.27 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],1.05,99227,DB01174,Phenobarbital
,2038745,Cls,"The mean Cls values in the adults and the pups were 1.05 and 0.27 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],0.27,99228,DB01174,Phenobarbital
,2038745,systemic clearance of unbound drug (Clu),The mean systemic clearance of unbound drug (Clu) for SA was 11.2 ml/min/kg in the adults and 0.92 ml/min/kg in the pups.,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],11.2,99229,DB01174,Phenobarbital
,2038745,systemic clearance of unbound drug (Clu),The mean systemic clearance of unbound drug (Clu) for SA was 11.2 ml/min/kg in the adults and 0.92 ml/min/kg in the pups.,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],0.92,99230,DB01174,Phenobarbital
,2038745,free fraction,"The serum protein binding of AC and AN was limited, whereas the mean free fraction for SA was 9.7% in adult serum and 32.5% in pup serum.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),%,9.7,99231,DB01174,Phenobarbital
,2038745,free fraction,"The serum protein binding of AC and AN was limited, whereas the mean free fraction for SA was 9.7% in adult serum and 32.5% in pup serum.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),%,32.5,99232,DB01174,Phenobarbital
,7196518,apparent distribution volume,"The mean apparent distribution volume, half-life, and apparent total body clearance were 0.81 liter per kilogram, 103.4 hours, and 6.4 ml per hour per kilogram, respectively.",Phenobarbital maintenance dose requirements in treating neonatal seizures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7196518/),[l] / [kg],0.81,99458,DB01174,Phenobarbital
,7196518,half-life,"The mean apparent distribution volume, half-life, and apparent total body clearance were 0.81 liter per kilogram, 103.4 hours, and 6.4 ml per hour per kilogram, respectively.",Phenobarbital maintenance dose requirements in treating neonatal seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7196518/),h,103.4,99459,DB01174,Phenobarbital
,7196518,apparent total body clearance,"The mean apparent distribution volume, half-life, and apparent total body clearance were 0.81 liter per kilogram, 103.4 hours, and 6.4 ml per hour per kilogram, respectively.",Phenobarbital maintenance dose requirements in treating neonatal seizures. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7196518/),[ml] / [h·kg],6.4,99460,DB01174,Phenobarbital
,10604819,metabolite-to-parent drug ratio,"The metabolite-to-parent drug ratio shifted from a median value of 2.8 in group A to 13 in group B, and up to 29 in patients receiving polytherapy with FBM (p < 0.001).",Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604819/),,2.8,99721,DB01174,Phenobarbital
,10604819,metabolite-to-parent drug ratio,"The metabolite-to-parent drug ratio shifted from a median value of 2.8 in group A to 13 in group B, and up to 29 in patients receiving polytherapy with FBM (p < 0.001).",Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604819/),,13,99722,DB01174,Phenobarbital
,10604819,metabolite-to-parent drug ratio,"The metabolite-to-parent drug ratio shifted from a median value of 2.8 in group A to 13 in group B, and up to 29 in patients receiving polytherapy with FBM (p < 0.001).",Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604819/),,29,99723,DB01174,Phenobarbital
less,6662841,peak serum levels,Forty-one per cent of subjects had potentially toxic serum levels; subtherapeutic peak serum levels (less than 15 mg/l) were recorded in 39/90 babies.,The pharmacokinetics of chloramphenicol in the neonate and young infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662841/),[mg] / [l],15,102092,DB01174,Phenobarbital
,23254984,maturation half-life,The clearance of phenobarbital was linearly related to body weight and matured with increasing age with a maturation half-life of 22.1 days.,Population pharmacokinetics of phenobarbital in infants with neonatal encephalopathy treated with therapeutic hypothermia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23254984/),d,22.1,102784,DB01174,Phenobarbital
,15811,hepatic clearance,The mean hepatic clearance of carbamazepine was 0.28 ml per min per g of liver corresponding to a mean extraction ratio of 0.16 and a mean intrinsic clearance of 0.33 ml per min g of liver.,"Disposition of carbamazepine and its 10,11-epoxide metabolite in the isolated perfused rat liver. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811/),[ml] / [g·min],0.28,103576,DB01174,Phenobarbital
,15811,extraction ratio,The mean hepatic clearance of carbamazepine was 0.28 ml per min per g of liver corresponding to a mean extraction ratio of 0.16 and a mean intrinsic clearance of 0.33 ml per min g of liver.,"Disposition of carbamazepine and its 10,11-epoxide metabolite in the isolated perfused rat liver. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811/),,0.16,103577,DB01174,Phenobarbital
,15811,intrinsic clearance,The mean hepatic clearance of carbamazepine was 0.28 ml per min per g of liver corresponding to a mean extraction ratio of 0.16 and a mean intrinsic clearance of 0.33 ml per min g of liver.,"Disposition of carbamazepine and its 10,11-epoxide metabolite in the isolated perfused rat liver. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811/),[ml] / [g·min],0.33,103578,DB01174,Phenobarbital
,15811,extraction ratio,"In phenobarbital-pretreated rats, there was an approximately 40% increase in the hepatic clearance due to a concomitant increase in the mean extraction ratio from 0.16 to 0.26.","Disposition of carbamazepine and its 10,11-epoxide metabolite in the isolated perfused rat liver. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811/),,0.16,103579,DB01174,Phenobarbital
,15811,extraction ratio,"In phenobarbital-pretreated rats, there was an approximately 40% increase in the hepatic clearance due to a concomitant increase in the mean extraction ratio from 0.16 to 0.26.","Disposition of carbamazepine and its 10,11-epoxide metabolite in the isolated perfused rat liver. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811/),,0.26,103580,DB01174,Phenobarbital
,15811,extraction ratio,The mean extraction ratio of the epoxide in this situation was only 0.016 and it was unaffected by prior treatment of the rats with phenobarbital.,"Disposition of carbamazepine and its 10,11-epoxide metabolite in the isolated perfused rat liver. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811/),,0.016,103581,DB01174,Phenobarbital
,3427136,elimination half-life,In 7 pregnant hypertensive patients the elimination half-life of propranolol was enhanced to 6.1 +/- 1.2 h in comparison to 4.4 +/- 0.4 in 9 nonpregnant females.,The influence of phenobarbital on the pharmacokinetics of propranolol in pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427136/),h,6.1,104682,DB01174,Phenobarbital
,3427136,elimination half-life,In 7 pregnant hypertensive patients the elimination half-life of propranolol was enhanced to 6.1 +/- 1.2 h in comparison to 4.4 +/- 0.4 in 9 nonpregnant females.,The influence of phenobarbital on the pharmacokinetics of propranolol in pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427136/),h,4.4,104683,DB01174,Phenobarbital
,3427136,half-life,"In 8 out of 11 pregnant hypertensive patients in the 29th week of gestation treated with 90 mg phenobarbital daily for at least 7 days before starting propranolol therapy, the half-life of propranolol was 3.1 +/- 0.4 h only.",The influence of phenobarbital on the pharmacokinetics of propranolol in pregnancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427136/),h,3.1,104684,DB01174,Phenobarbital
,797496,half-life,It has a relatively long half-life (in adults 2 to 3 days; in children shorter).,Clinical pharmacokinetics of anticonvulsants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/797496/),d,2 to 3,104851,DB01174,Phenobarbital
,1941559,nonrenal clearance,The nonrenal clearance (4.58 versus 6.18 mL/min/kg) increased significantly in PB-treated rats.,Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and pharmacodynamics of furosemide in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941559/),[ml] / [kg·min],4.58,104862,DB01174,Phenobarbital
,1941559,nonrenal clearance,The nonrenal clearance (4.58 versus 6.18 mL/min/kg) increased significantly in PB-treated rats.,Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and pharmacodynamics of furosemide in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941559/),[ml] / [kg·min],6.18,104863,DB01174,Phenobarbital
,1941559,urinary excretion,"The 8-h urine output per 100 g of body weight increased significantly in PB-treated rats; however, the 8-h urinary excretion of furosemide per 100 g of body weight (797 versus 635 micrograms) decreased significantly in PB-treated rats.",Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and pharmacodynamics of furosemide in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941559/),μg,797,104864,DB01174,Phenobarbital
,1941559,urinary excretion,"The 8-h urine output per 100 g of body weight increased significantly in PB-treated rats; however, the 8-h urinary excretion of furosemide per 100 g of body weight (797 versus 635 micrograms) decreased significantly in PB-treated rats.",Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and pharmacodynamics of furosemide in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941559/),μg,635,104865,DB01174,Phenobarbital
,7084140,oral bioavailability,The oral bioavailability estimated on the basis of the recovery of unchanged drug in the urine of normal subjects was at least 80%.,Pharmacokinetics of phenylethylmalonamide (PEMA) in normal subjects and in patients treated with antiepileptic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7084140/),%,80,105229,DB01174,Phenobarbital
,7084140,Half-life,Half-life values ranged from 17 to 25 h in normal subjects and from 10 to 23 h in the patients.,Pharmacokinetics of phenylethylmalonamide (PEMA) in normal subjects and in patients treated with antiepileptic drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7084140/),h,17 to 25,105230,DB01174,Phenobarbital
,7084140,Half-life,Half-life values ranged from 17 to 25 h in normal subjects and from 10 to 23 h in the patients.,Pharmacokinetics of phenylethylmalonamide (PEMA) in normal subjects and in patients treated with antiepileptic drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7084140/),h,10 to 23,105231,DB01174,Phenobarbital
,529017,half-life,"Its half-life after single doses is 54 hr (range 31--90), and its total body clearance (100% nonrenal) is 2.6 liters/hr (range 1.73--3.59).","Pharmacokinetics of phenylethylacetylurea (pheneturide), an old antiepileptic drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/529017/),h,54,105413,DB01174,Phenobarbital
,529017,total body clearance (100% nonrenal),"Its half-life after single doses is 54 hr (range 31--90), and its total body clearance (100% nonrenal) is 2.6 liters/hr (range 1.73--3.59).","Pharmacokinetics of phenylethylacetylurea (pheneturide), an old antiepileptic drug. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/529017/),[l] / [h],2.6,105414,DB01174,Phenobarbital
,529017,half-life,"After repetitive administration, half-life is 40 hr (but clearance remains unchanged because of a lower volume of distribution).","Pharmacokinetics of phenylethylacetylurea (pheneturide), an old antiepileptic drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/529017/),h,40,105415,DB01174,Phenobarbital
,2287006,steady-state trough serum level,"An average steady-state trough serum level of phenobarbitone of 52,96 +/- 8.40 mmol l-1 was achieved after 3 weeks of daily dosing.",The pharmacokinetics of phenobarbitone in fasting and non-fasting dogs. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287006/),[mM] / [l],"52,96",106793,DB01174,Phenobarbital
,2287006,elimination half-lives,The mean elimination half-lives for Day 1 and Day 22 were 46.3 +/- 11.3 h and 29.3 +/- 4.6 h respectively.,The pharmacokinetics of phenobarbitone in fasting and non-fasting dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287006/),h,46.3,106794,DB01174,Phenobarbital
,2287006,elimination half-lives,The mean elimination half-lives for Day 1 and Day 22 were 46.3 +/- 11.3 h and 29.3 +/- 4.6 h respectively.,The pharmacokinetics of phenobarbitone in fasting and non-fasting dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287006/),h,29.3,106795,DB01174,Phenobarbital
,2287006,area under the curve,"The area under the curve for Day 22 was 1,656.17 +/- 186.45 mumol h-1 l-1 and for Day 24 was 1,493.06 +/- 205.4 mumol h-1 l-1.",The pharmacokinetics of phenobarbitone in fasting and non-fasting dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287006/),[μM] / [h·l],"1,656.17",106796,DB01174,Phenobarbital
,2287006,area under the curve,"The area under the curve for Day 22 was 1,656.17 +/- 186.45 mumol h-1 l-1 and for Day 24 was 1,493.06 +/- 205.4 mumol h-1 l-1.",The pharmacokinetics of phenobarbitone in fasting and non-fasting dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287006/),[μM] / [h·l],"1,493.06",106797,DB01174,Phenobarbital
,2287006,clearance,The mean clearance value for Day 22 was 0.0133 +/- 0.0016 l h-1 kg-1.,The pharmacokinetics of phenobarbitone in fasting and non-fasting dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287006/),[l] / [h·kg],0.0133,106798,DB01174,Phenobarbital
,2287006,serum concentration,It was concluded that a dose of 5 mg kg-1 would achieve an average serum concentration of 64.59 mumol l-1 in adult dogs.,The pharmacokinetics of phenobarbitone in fasting and non-fasting dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287006/),[μM] / [l],64.59,106799,DB01174,Phenobarbital
,2242706,terminal half-life,"The terminal half-life of thiopental averaged 9 h, the total plasma clearance 0.20 l/h/kg, and the steady-state volume of distribution 3.6 l/h/kg.",Thiopental efficacy in phenobarbital-resistant neonatal seizures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2242706/),h,9,107849,DB01174,Phenobarbital
,2242706,total plasma clearance,"The terminal half-life of thiopental averaged 9 h, the total plasma clearance 0.20 l/h/kg, and the steady-state volume of distribution 3.6 l/h/kg.",Thiopental efficacy in phenobarbital-resistant neonatal seizures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2242706/),[l] / [h·kg],0.20,107850,DB01174,Phenobarbital
,2242706,steady-state volume of distribution,"The terminal half-life of thiopental averaged 9 h, the total plasma clearance 0.20 l/h/kg, and the steady-state volume of distribution 3.6 l/h/kg.",Thiopental efficacy in phenobarbital-resistant neonatal seizures. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2242706/),[l] / [h·kg],3.6,107851,DB01174,Phenobarbital
,4000780,apparent volume of distribution,"The mean serum concentration of phenobarbital two hours after loading was 30.0 +/- 3.2 micrograms/mL, the apparent volume of distribution was 0.97 +/- 0.18 L/kg, total clearance was 0.08 +/- 0.03 mL/min/kg, and mean serum half-life was 148 +/- 55 hours.",Safety of a higher loading dose of phenobarbital in the term newborn. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4000780/),[l] / [kg],0.97,108231,DB01174,Phenobarbital
,4000780,total clearance,"The mean serum concentration of phenobarbital two hours after loading was 30.0 +/- 3.2 micrograms/mL, the apparent volume of distribution was 0.97 +/- 0.18 L/kg, total clearance was 0.08 +/- 0.03 mL/min/kg, and mean serum half-life was 148 +/- 55 hours.",Safety of a higher loading dose of phenobarbital in the term newborn. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4000780/),[ml] / [kg·min],0.08,108232,DB01174,Phenobarbital
,4000780,serum half-life,"The mean serum concentration of phenobarbital two hours after loading was 30.0 +/- 3.2 micrograms/mL, the apparent volume of distribution was 0.97 +/- 0.18 L/kg, total clearance was 0.08 +/- 0.03 mL/min/kg, and mean serum half-life was 148 +/- 55 hours.",Safety of a higher loading dose of phenobarbital in the term newborn. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4000780/),h,148,108233,DB01174,Phenobarbital
,30826570,TID20,The experimentally determined TID20 value for TP427 was 11.71 mg/kg.,"New derivative of 1,2,4-triazole-3-thione (TP427) potentiates the anticonvulsant action of valproate, but not that of carbamazepine, phenytoin or phenobarbital in the mouse tonic-clonic seizure model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30826570/),[mg] / [kg],11.71,109717,DB01174,Phenobarbital
,624773,elimination half-life,"Serum levels were similar from both dosage routes, with peak levels occurring at 1-3 hours after dosing and then declining slowly with an elimination half-life of about 90 hours.",Bioavailability of oral and intramuscular phenobarbital. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/624773/),h,90,110019,DB01174,Phenobarbital
,624773,overall efficiency,The overall efficiency of phenobarbital absorption from intramuscular doses was approximately 80 per cent of that from equivalent oral doses.,Bioavailability of oral and intramuscular phenobarbital. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/624773/),%,80,110020,DB01174,Phenobarbital
,32154280,Bioavailability,Bioavailability of phenobarbital was 24.9%.,Pharmacokinetics of Intravenous and Oral Phenobarbital Sodium in Healthy Goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154280/),%,24.9,111440,DB01174,Phenobarbital
,32154280,half-life,Mean ± SD for half-life was similar between the oral (3.80 ± 0.826 h) and intravenous (4.0 ± 0.619 h) routes.,Pharmacokinetics of Intravenous and Oral Phenobarbital Sodium in Healthy Goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154280/),h,3.80,111441,DB01174,Phenobarbital
,32154280,half-life,Mean ± SD for half-life was similar between the oral (3.80 ± 0.826 h) and intravenous (4.0 ± 0.619 h) routes.,Pharmacokinetics of Intravenous and Oral Phenobarbital Sodium in Healthy Goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154280/),h,4.0,111442,DB01174,Phenobarbital
,32154280,Time to observed maximum concentration (Tmax),"Time to observed maximum concentration (Tmax), and maximum plasma concentration (Cmax) for the oral administration were 1.75 ± 0.46 h and 4,478.7 ± 962.4 ng/mL, respectively.",Pharmacokinetics of Intravenous and Oral Phenobarbital Sodium in Healthy Goats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154280/),h,1.75,111443,DB01174,Phenobarbital
,32154280,maximum plasma concentration (Cmax),"Time to observed maximum concentration (Tmax), and maximum plasma concentration (Cmax) for the oral administration were 1.75 ± 0.46 h and 4,478.7 ± 962.4 ng/mL, respectively.",Pharmacokinetics of Intravenous and Oral Phenobarbital Sodium in Healthy Goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154280/),[ng] / [ml],"4,478.7",111444,DB01174,Phenobarbital
,32154280,Clearance,Clearance was 152.5 ± 102.7 ml/h/kg.,Pharmacokinetics of Intravenous and Oral Phenobarbital Sodium in Healthy Goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154280/),[ml] / [h·kg],152.5,111445,DB01174,Phenobarbital
,32154280,Area under the curve from zero to infinity (AUC0→∞),"Area under the curve from zero to infinity (AUC0→∞) was 155,813 ± 218,448 and 38,763 ± 9,832 h*ng/mL for the intravenous and oral administration routes, respectively.",Pharmacokinetics of Intravenous and Oral Phenobarbital Sodium in Healthy Goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154280/),[h·ng] / [ml],"155,813",111446,DB01174,Phenobarbital
,32154280,Area under the curve from zero to infinity (AUC0→∞),"Area under the curve from zero to infinity (AUC0→∞) was 155,813 ± 218,448 and 38,763 ± 9,832 h*ng/mL for the intravenous and oral administration routes, respectively.",Pharmacokinetics of Intravenous and Oral Phenobarbital Sodium in Healthy Goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154280/),[h·ng] / [ml],"38,763",111447,DB01174,Phenobarbital
,19160725,clearance,The population mean values of phenobarbitone clearance obtained were 0.250 litres/day/kg for children on phenobarbitone only and 0.208 litres/day/ kg for those on concomitant CBZ or PTO.,Determination of phenobarbitone population clearance values for physically and mentally handicapped Chinese children with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19160725/),[l] / [d·kg],0.250,111732,DB01174,Phenobarbital
,19160725,clearance,The population mean values of phenobarbitone clearance obtained were 0.250 litres/day/kg for children on phenobarbitone only and 0.208 litres/day/ kg for those on concomitant CBZ or PTO.,Determination of phenobarbitone population clearance values for physically and mentally handicapped Chinese children with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19160725/),[l] / [·d·kg],0.208,111733,DB01174,Phenobarbital
,469023,urinary excretion,"Five-day urinary excretion of phenobarbital and p-hydroxyphenobarbital accounted for 16 and 21 per cent, respectively, of the initial dose.",Pharmacokinetics of phenobarbital following single and repeated doses. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/469023/),%,16,113581,DB01174,Phenobarbital
,469023,urinary excretion,"Five-day urinary excretion of phenobarbital and p-hydroxyphenobarbital accounted for 16 and 21 per cent, respectively, of the initial dose.",Pharmacokinetics of phenobarbital following single and repeated doses. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/469023/),%,21,113582,DB01174,Phenobarbital
,10082193,ED50,The ED50 value of ethosuximide was significantly increased from 108 to 158 mg/kg.,N(G)-nitro-L-arginine impairs the anticonvulsive action of ethosuximide against pentylenetetrazol. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10082193/),[mg] / [kg],108,114767,DB01174,Phenobarbital
,10082193,ED50,The ED50 value of ethosuximide was significantly increased from 108 to 158 mg/kg.,N(G)-nitro-L-arginine impairs the anticonvulsive action of ethosuximide against pentylenetetrazol. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10082193/),[mg] / [kg],158,114768,DB01174,Phenobarbital
up to,6143468,time to the steady-state,"Due to the long half-life of phenobarbital its plasma concentrations change slowly, and time to the steady-state may be up to 30 days, if no loading dose is given.",Pharmacokinetics of antiepileptic drugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143468/),d,30,115019,DB01174,Phenobarbital
,6143468,half-lives,"Diazepam, clonazepam and nitrazepam are largely bound to plasma proteins and extensively metabolized with the half-lives of 20 to 60 hours.",Pharmacokinetics of antiepileptic drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143468/),h,20 to 60,115020,DB01174,Phenobarbital
,3940216,peak blood concentrations,"With IV administration a dose of 50 mg/kg gave peak blood concentrations of 100 micrograms/ml in mice, while 25 mg/kg gave peak plasma concentrations of 27 micrograms/ml in dogs.",CB 1954 revisited. I. Disposition kinetics and metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),[μg] / [ml],100,115688,DB01174,Phenobarbital
,3940216,peak plasma concentrations,"With IV administration a dose of 50 mg/kg gave peak blood concentrations of 100 micrograms/ml in mice, while 25 mg/kg gave peak plasma concentrations of 27 micrograms/ml in dogs.",CB 1954 revisited. I. Disposition kinetics and metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),[μg] / [ml],27,115689,DB01174,Phenobarbital
,3940216,bioavailabilities,"Peak concentrations were 3 to 5-fold lower for the IP route in mice and the oral route in dogs, and the bioavailabilities were 85% and 40%, respectively.",CB 1954 revisited. I. Disposition kinetics and metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),%,85,115690,DB01174,Phenobarbital
,3940216,bioavailabilities,"Peak concentrations were 3 to 5-fold lower for the IP route in mice and the oral route in dogs, and the bioavailabilities were 85% and 40%, respectively.",CB 1954 revisited. I. Disposition kinetics and metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),%,40,115691,DB01174,Phenobarbital
,3940216,Elimination t1/2,Elimination t1/2 values were 1.4-2 h in mice and 2.5-4 h in dogs and were independent of route of administration.,CB 1954 revisited. I. Disposition kinetics and metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),h,1.4-2,115692,DB01174,Phenobarbital
,3940216,Elimination t1/2,Elimination t1/2 values were 1.4-2 h in mice and 2.5-4 h in dogs and were independent of route of administration.,CB 1954 revisited. I. Disposition kinetics and metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),h,2.5-4,115693,DB01174,Phenobarbital
,3940216,Plasma protein binding,Plasma protein binding was 57% but tissue penetration in mice was generally good.,CB 1954 revisited. I. Disposition kinetics and metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),%,57,115694,DB01174,Phenobarbital
,3940216,Tu,"Tumour: plasma ratios were 50%-90%, while brain: plasma ratios were lower, at 37%-50%.",CB 1954 revisited. I. Disposition kinetics and metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),,50,115695,DB01174,Phenobarbital
,3940216,total recovery,"The parent drug and several metabolites were identified and quantified in mouse urine, the total recovery being 24%-29%, of which 16%-25% was parent drug.",CB 1954 revisited. I. Disposition kinetics and metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),%,24,115696,DB01174,Phenobarbital
,3940216,total recovery,"The parent drug and several metabolites were identified and quantified in mouse urine, the total recovery being 24%-29%, of which 16%-25% was parent drug.",CB 1954 revisited. I. Disposition kinetics and metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),%,16,115697,DB01174,Phenobarbital
,22536830,peak,"The final model shows that for commonly used dosing regimens, the population mean PG peak and trough concentrations range between 33-144 and 28-218 mg l(-1) (peak) and 19-109 and 6-112 mg l(-1) (trough) for paracetamol and phenobarbital formulations, respectively, depending on birth weight and age of the neonates.",Developmental pharmacokinetics of propylene glycol in preterm and term neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22536830/),[mg] / [l],33-144,115936,DB01174,Phenobarbital
,22536830,trough concentrations,"The final model shows that for commonly used dosing regimens, the population mean PG peak and trough concentrations range between 33-144 and 28-218 mg l(-1) (peak) and 19-109 and 6-112 mg l(-1) (trough) for paracetamol and phenobarbital formulations, respectively, depending on birth weight and age of the neonates.",Developmental pharmacokinetics of propylene glycol in preterm and term neonates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22536830/),[mg] / [l],28,115937,DB01174,Phenobarbital
,22536830,peak,"The final model shows that for commonly used dosing regimens, the population mean PG peak and trough concentrations range between 33-144 and 28-218 mg l(-1) (peak) and 19-109 and 6-112 mg l(-1) (trough) for paracetamol and phenobarbital formulations, respectively, depending on birth weight and age of the neonates.",Developmental pharmacokinetics of propylene glycol in preterm and term neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22536830/),[mg] / [l],28,115938,DB01174,Phenobarbital
,22536830,trough,"The final model shows that for commonly used dosing regimens, the population mean PG peak and trough concentrations range between 33-144 and 28-218 mg l(-1) (peak) and 19-109 and 6-112 mg l(-1) (trough) for paracetamol and phenobarbital formulations, respectively, depending on birth weight and age of the neonates.",Developmental pharmacokinetics of propylene glycol in preterm and term neonates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22536830/),[mg] / [l],19-109,115939,DB01174,Phenobarbital
,22536830,trough,"The final model shows that for commonly used dosing regimens, the population mean PG peak and trough concentrations range between 33-144 and 28-218 mg l(-1) (peak) and 19-109 and 6-112 mg l(-1) (trough) for paracetamol and phenobarbital formulations, respectively, depending on birth weight and age of the neonates.",Developmental pharmacokinetics of propylene glycol in preterm and term neonates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22536830/),[mg] / [l],6-112,115940,DB01174,Phenobarbital
,1712992,Vmaxc,Dietary exposures resulted in increased Vmaxc value for BrCCl3 metabolism as compared to control (3.55 +/- 0.14 mg/hr/kg) for PB (8.52 +/- 0.28 mg/hr/kg) and M (5.06 +/- 0.19 mg/hr/kg) but not for CD (3.92 +/- 0.19 mg/hr/kg).,"PB-PK derived metabolic constants, hepatotoxicity, and lethality of BrCCl3 in rats pretreated with chlordecone, phenobarbital, or mirex. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712992/),[mg] / [h·kg],3.55,116498,DB01174,Phenobarbital
,1712992,Vmaxc,Dietary exposures resulted in increased Vmaxc value for BrCCl3 metabolism as compared to control (3.55 +/- 0.14 mg/hr/kg) for PB (8.52 +/- 0.28 mg/hr/kg) and M (5.06 +/- 0.19 mg/hr/kg) but not for CD (3.92 +/- 0.19 mg/hr/kg).,"PB-PK derived metabolic constants, hepatotoxicity, and lethality of BrCCl3 in rats pretreated with chlordecone, phenobarbital, or mirex. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712992/),[mg] / [h·kg],8.52,116499,DB01174,Phenobarbital
,1712992,Vmaxc,Dietary exposures resulted in increased Vmaxc value for BrCCl3 metabolism as compared to control (3.55 +/- 0.14 mg/hr/kg) for PB (8.52 +/- 0.28 mg/hr/kg) and M (5.06 +/- 0.19 mg/hr/kg) but not for CD (3.92 +/- 0.19 mg/hr/kg).,"PB-PK derived metabolic constants, hepatotoxicity, and lethality of BrCCl3 in rats pretreated with chlordecone, phenobarbital, or mirex. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712992/),[mg] / [h·kg],5.06,116500,DB01174,Phenobarbital
,1712992,Vmaxc,Dietary exposures resulted in increased Vmaxc value for BrCCl3 metabolism as compared to control (3.55 +/- 0.14 mg/hr/kg) for PB (8.52 +/- 0.28 mg/hr/kg) and M (5.06 +/- 0.19 mg/hr/kg) but not for CD (3.92 +/- 0.19 mg/hr/kg).,"PB-PK derived metabolic constants, hepatotoxicity, and lethality of BrCCl3 in rats pretreated with chlordecone, phenobarbital, or mirex. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712992/),[mg] / [h·kg],3.92,116501,DB01174,Phenobarbital
,1712992,Kfc,"Kfc, the first-order rate constant for BrCCl3 metabolism, was decreased after PB (12.9 +/- 0.5 hr-1/kg) and increased after M (17.6 +/- 0.5 hr-1/kg), but unchanged after CD (15.5 +/- 0.6 hr-1/kg) exposure as compared to control (15.0 +/- 0.3 hr-1/kg).","PB-PK derived metabolic constants, hepatotoxicity, and lethality of BrCCl3 in rats pretreated with chlordecone, phenobarbital, or mirex. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712992/),1/[h·kg],12.9,116502,DB01174,Phenobarbital
,1712992,Kfc,"Kfc, the first-order rate constant for BrCCl3 metabolism, was decreased after PB (12.9 +/- 0.5 hr-1/kg) and increased after M (17.6 +/- 0.5 hr-1/kg), but unchanged after CD (15.5 +/- 0.6 hr-1/kg) exposure as compared to control (15.0 +/- 0.3 hr-1/kg).","PB-PK derived metabolic constants, hepatotoxicity, and lethality of BrCCl3 in rats pretreated with chlordecone, phenobarbital, or mirex. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712992/),1/[h·kg],17.6,116503,DB01174,Phenobarbital
,1712992,Kfc,"Kfc, the first-order rate constant for BrCCl3 metabolism, was decreased after PB (12.9 +/- 0.5 hr-1/kg) and increased after M (17.6 +/- 0.5 hr-1/kg), but unchanged after CD (15.5 +/- 0.6 hr-1/kg) exposure as compared to control (15.0 +/- 0.3 hr-1/kg).","PB-PK derived metabolic constants, hepatotoxicity, and lethality of BrCCl3 in rats pretreated with chlordecone, phenobarbital, or mirex. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712992/),1/[h·kg],15.5,116504,DB01174,Phenobarbital
,1712992,Kfc,"Kfc, the first-order rate constant for BrCCl3 metabolism, was decreased after PB (12.9 +/- 0.5 hr-1/kg) and increased after M (17.6 +/- 0.5 hr-1/kg), but unchanged after CD (15.5 +/- 0.6 hr-1/kg) exposure as compared to control (15.0 +/- 0.3 hr-1/kg).","PB-PK derived metabolic constants, hepatotoxicity, and lethality of BrCCl3 in rats pretreated with chlordecone, phenobarbital, or mirex. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712992/),1/[h·kg],15.0,116505,DB01174,Phenobarbital
,23891703,Volume of distribution,Volume of distribution of TPM was estimated at 0.575 l/kg.,Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891703/),[l] / [kg],0.575,116785,DB01174,Phenobarbital
,23891703,CL/F,"Mean TPM CL/F during CBZ co-therapy was 2.46 l/h, which is higher for 60.8% than in patients not co-treated with CBZ.",Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891703/),[l] / [h],2.46,116786,DB01174,Phenobarbital
,2565213,terminal plasma half-life,"The extensive hydroxylation of (R)-MPB resulted in rapid elimination of this enantiomer, with a terminal plasma half-life of 7.52 +/- 1.70 (SD) hr.",Stereoselective metabolism and pharmacokinetics of racemic methylphenobarbital in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565213/),h,7.52,118210,DB01174,Phenobarbital
,2565213,t1/2,"The (S)-MPB, the only recognized metabolites of which were (S)-4-hydroxy-MPB and phenobarbital (PB), was eliminated very slowly [t1/2, 69.78 +/- 14.77 (SD) hr].",Stereoselective metabolism and pharmacokinetics of racemic methylphenobarbital in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565213/),h,69.78,118211,DB01174,Phenobarbital
,2565213,oral clearance,The oral clearance of (R)-MPB (0.470 +/- 0.184 (SD) liters/hr/kg) was much higher than that of (S)-MPB [0.017 +/- 0.001 (SD) liters/hr/kg].,Stereoselective metabolism and pharmacokinetics of racemic methylphenobarbital in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565213/),[l] / [h·kg],0.470,118212,DB01174,Phenobarbital
,2565213,oral clearance,The oral clearance of (R)-MPB (0.470 +/- 0.184 (SD) liters/hr/kg) was much higher than that of (S)-MPB [0.017 +/- 0.001 (SD) liters/hr/kg].,Stereoselective metabolism and pharmacokinetics of racemic methylphenobarbital in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565213/),[l] / [h·kg],0.017,118213,DB01174,Phenobarbital
,17085857,effective dose (ED50),"Moreover, CAF at doses of and 92.4 mg/kg attenuated the protective action of ETS against PTZ-induced seizures, by increasing its median effective dose (ED50) from 127.7 to 182.3 (p<0.05), and 198.3 mg/kg (p<0.01), respectively.","Acute exposure to caffeine decreases the anticonvulsant action of ethosuximide, but not that of clonazepam, phenobarbital and valproate against pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085857/),[mg] / [kg],127.7,122128,DB01174,Phenobarbital
,17085857,effective dose (ED50),"Moreover, CAF at doses of and 92.4 mg/kg attenuated the protective action of ETS against PTZ-induced seizures, by increasing its median effective dose (ED50) from 127.7 to 182.3 (p<0.05), and 198.3 mg/kg (p<0.01), respectively.","Acute exposure to caffeine decreases the anticonvulsant action of ethosuximide, but not that of clonazepam, phenobarbital and valproate against pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085857/),[mg] / [kg],182.3,122129,DB01174,Phenobarbital
,17085857,effective dose (ED50),"Moreover, CAF at doses of and 92.4 mg/kg attenuated the protective action of ETS against PTZ-induced seizures, by increasing its median effective dose (ED50) from 127.7 to 182.3 (p<0.05), and 198.3 mg/kg (p<0.01), respectively.","Acute exposure to caffeine decreases the anticonvulsant action of ethosuximide, but not that of clonazepam, phenobarbital and valproate against pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085857/),[mg] / [kg],198.3,122130,DB01174,Phenobarbital
,33171342,concentration,"In 206 patients, the seizure reduction from baseline was > 50 % and the median perampanel concentration was 351 ng/mL (interquartile range, 191-603 ng/mL).","Pharmacokinetics, tolerability, and clinical effectiveness of perampanel in Japanese patients with epilepsy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33171342/),,35,122290,DB01174,Phenobarbital
,6122294,total clearance rate,"The means of the total clearance rate (0.255 L/h), the relative clearance rate (4.0 ml/h/kg of body weight), the elimination half-life (95 h), the elimination rate constant (0.0071/h), and the apparent volume of distribution (35.49 L) were within the ranges observed in nonpregnant subjects.",Phenobarbital pharmacokinetics and salivary and serum concentrations in pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122294/),[l] / [h],0.255,124557,DB01174,Phenobarbital
,6122294,relative clearance rate,"The means of the total clearance rate (0.255 L/h), the relative clearance rate (4.0 ml/h/kg of body weight), the elimination half-life (95 h), the elimination rate constant (0.0071/h), and the apparent volume of distribution (35.49 L) were within the ranges observed in nonpregnant subjects.",Phenobarbital pharmacokinetics and salivary and serum concentrations in pregnancy. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122294/),[ml] / [h·kg],4.0,124558,DB01174,Phenobarbital
,6122294,elimination half-life,"The means of the total clearance rate (0.255 L/h), the relative clearance rate (4.0 ml/h/kg of body weight), the elimination half-life (95 h), the elimination rate constant (0.0071/h), and the apparent volume of distribution (35.49 L) were within the ranges observed in nonpregnant subjects.",Phenobarbital pharmacokinetics and salivary and serum concentrations in pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122294/),h,95,124559,DB01174,Phenobarbital
,6122294,elimination rate constant,"The means of the total clearance rate (0.255 L/h), the relative clearance rate (4.0 ml/h/kg of body weight), the elimination half-life (95 h), the elimination rate constant (0.0071/h), and the apparent volume of distribution (35.49 L) were within the ranges observed in nonpregnant subjects.",Phenobarbital pharmacokinetics and salivary and serum concentrations in pregnancy. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122294/),1/[h],0.0071,124560,DB01174,Phenobarbital
,6122294,apparent volume of distribution,"The means of the total clearance rate (0.255 L/h), the relative clearance rate (4.0 ml/h/kg of body weight), the elimination half-life (95 h), the elimination rate constant (0.0071/h), and the apparent volume of distribution (35.49 L) were within the ranges observed in nonpregnant subjects.",Phenobarbital pharmacokinetics and salivary and serum concentrations in pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122294/),l,35.49,124561,DB01174,Phenobarbital
,18611447,elimination half-life (t(1/2)),The results revealed fluctuations exceeding those expected from its elimination half-life (t(1/2)) of 22h as reported in the literature.,Diurnal lamotrigine plasma level fluctuations: clinical significance and indication of shorter half-life with chronic administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611447/),h,22,124928,DB01174,Phenobarbital
,18611447,C(min)/C(max) ratios,Patients on twice-daily regimens without pharmacokinetic interactions exhibited C(min)/C(max) ratios between 0.62 and 0.69.,Diurnal lamotrigine plasma level fluctuations: clinical significance and indication of shorter half-life with chronic administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611447/),,0.62,124929,DB01174,Phenobarbital
,18611447,C(min)/C(max) ratios,Patients on twice-daily regimens without pharmacokinetic interactions exhibited C(min)/C(max) ratios between 0.62 and 0.69.,Diurnal lamotrigine plasma level fluctuations: clinical significance and indication of shorter half-life with chronic administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611447/),,0.,124930,DB01174,Phenobarbital
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],16 to 28,126871,DB01174,Phenobarbital
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],7.4 to 14,126872,DB01174,Phenobarbital
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],18 to 26,126873,DB01174,Phenobarbital
,3622413,ED50,"Aminophylline decreased anticonvulsant activity of PB, PHT, CBZ, and VPA, increasing the respective ED50 values from 16 to 28 mg/kg, 7.4 to 14 mg/kg, 18 to 26 mg/kg, and 260 to 335 mg/kg.",Effect of aminophylline and enprofylline on the protective efficacy of common antiepileptic drugs against electroconvulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622413/),[mg] / [kg],260 to 335,126874,DB01174,Phenobarbital
,7194086,relative bioavailabilities,The estimated relative bioavailabilities of the single substances in the suppository formulation vary between 120% for propyphenazone and 83% for phenobarbital in comparison to the tablets.,"[A comparative pharmacokinetic study for tablet and suppository formulations of a combination product of caffeine, ethaverine, propyphenazone, paracetamol and phenobarbital (author's transl)]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194086/),%,120,127131,DB01174,Phenobarbital
,7194086,relative bioavailabilities,The estimated relative bioavailabilities of the single substances in the suppository formulation vary between 120% for propyphenazone and 83% for phenobarbital in comparison to the tablets.,"[A comparative pharmacokinetic study for tablet and suppository formulations of a combination product of caffeine, ethaverine, propyphenazone, paracetamol and phenobarbital (author's transl)]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194086/),%,83,127132,DB01174,Phenobarbital
,10762607,half-life,"The half-life of rGSTA1/A2 mRNA in control animals was 3.6 h, whereas it was 10.2 h in phenobarbital-treated animals.",Differential lobular induction in rat liver of glutathione S-transferase A1/A2 by phenobarbital. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10762607/),h,3.6,128366,DB01174,Phenobarbital
,10762607,half-life,"The half-life of rGSTA1/A2 mRNA in control animals was 3.6 h, whereas it was 10.2 h in phenobarbital-treated animals.",Differential lobular induction in rat liver of glutathione S-transferase A1/A2 by phenobarbital. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10762607/),h,10.2,128367,DB01174,Phenobarbital
,12021623,area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],6.1,128709,DB01174,Phenobarbital
,12021623,area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],2.1,128710,DB01174,Phenobarbital
,12021623,area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],3.1,128711,DB01174,Phenobarbital
,12021623,area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],2.4,128712,DB01174,Phenobarbital
,12021623,maximum plasma concentration (C(max)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.8,128713,DB01174,Phenobarbital
,12021623,maximum plasma concentration (C(max)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.3,128714,DB01174,Phenobarbital
,12021623,maximum plasma concentration (C(max)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.4,128715,DB01174,Phenobarbital
,12021623,half-life (t1/2),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),h,8.0,128716,DB01174,Phenobarbital
,12021623,half-life (t1/2),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),h,3.8,128717,DB01174,Phenobarbital
,12021623,half-life (t1/2),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),h,4.1,128718,DB01174,Phenobarbital
,12021623,half-life (t1/2),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),h,4.9,128719,DB01174,Phenobarbital
,12021623,AUC(0-12),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],1.8,128720,DB01174,Phenobarbital
,12021623,AUC(0-12),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],0.4,128721,DB01174,Phenobarbital
,12021623,AUC(0-12),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],0.6,128722,DB01174,Phenobarbital
,12021623,AUC(0-12),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],0.5,128723,DB01174,Phenobarbital
,12021623,C(max),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.2,128724,DB01174,Phenobarbital
,12021623,C(max),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.06,128725,DB01174,Phenobarbital
,12021623,C(max),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.1,128726,DB01174,Phenobarbital
,12021623,t(1/2)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),,4.3,128727,DB01174,Phenobarbital
,12021623,t(1/2)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),,1.9,128728,DB01174,Phenobarbital
,12021623,t(1/2)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),,2.2,128729,DB01174,Phenobarbital
,16940857,half-life,"The median decreases in the NVP half-life were 18.8, 19.0, and 16.9 hours, respectively.",Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940857/),h,19.0,129028,DB01174,Phenobarbital
,16940857,half-life,"The median decreases in the NVP half-life were 18.8, 19.0, and 16.9 hours, respectively.",Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940857/),h,16.9,129029,DB01174,Phenobarbital
,3225771,peak plasma concentrations,The peak plasma concentrations ranged from 7.2 micrograms/mL with the 15-mg/d dose to 82 micrograms/mL with the 400-mg/d dose.,Autoinduction of phenobarbital elimination in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3225771/),[μg] / [ml],7.2,130138,DB01174,Phenobarbital
,3225771,peak plasma concentrations,The peak plasma concentrations ranged from 7.2 micrograms/mL with the 15-mg/d dose to 82 micrograms/mL with the 400-mg/d dose.,Autoinduction of phenobarbital elimination in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3225771/),[μg] / [ml],82,130139,DB01174,Phenobarbital
,3225771,elimination rate constant,The major determinant of this increased clearance was an increase in the elimination rate constant of phenobarbital from 0.18 h-1 at the 15-mg/d dose to 0.36 h-1 at the 400-mg/d dose.,Autoinduction of phenobarbital elimination in the dog. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3225771/),1/[h],0.18,130140,DB01174,Phenobarbital
,3225771,elimination rate constant,The major determinant of this increased clearance was an increase in the elimination rate constant of phenobarbital from 0.18 h-1 at the 15-mg/d dose to 0.36 h-1 at the 400-mg/d dose.,Autoinduction of phenobarbital elimination in the dog. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3225771/),1/[h],0.36,130141,DB01174,Phenobarbital
,10632085,biological half-life,"The pretreatment resulted in an increase in biological half-life (5.8 +/- 1.5 vs 3.7 +/- 0.93 h control group, P < 0.05) and area under plasma concentration-time curve (19.6 +/- 1.7 vs 14.65 +/- 1.68 mg h L(-1) control group, P < 0.05).","Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632085/),h,5.8,132028,DB01174,Phenobarbital
,10632085,biological half-life,"The pretreatment resulted in an increase in biological half-life (5.8 +/- 1.5 vs 3.7 +/- 0.93 h control group, P < 0.05) and area under plasma concentration-time curve (19.6 +/- 1.7 vs 14.65 +/- 1.68 mg h L(-1) control group, P < 0.05).","Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632085/),h,3.7,132029,DB01174,Phenobarbital
,10632085,area under plasma concentration-time curve,"The pretreatment resulted in an increase in biological half-life (5.8 +/- 1.5 vs 3.7 +/- 0.93 h control group, P < 0.05) and area under plasma concentration-time curve (19.6 +/- 1.7 vs 14.65 +/- 1.68 mg h L(-1) control group, P < 0.05).","Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632085/),[h·mg] / [l],19.6,132030,DB01174,Phenobarbital
,10632085,area under plasma concentration-time curve,"The pretreatment resulted in an increase in biological half-life (5.8 +/- 1.5 vs 3.7 +/- 0.93 h control group, P < 0.05) and area under plasma concentration-time curve (19.6 +/- 1.7 vs 14.65 +/- 1.68 mg h L(-1) control group, P < 0.05).","Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632085/),[h·mg] / [l],14.65,132031,DB01174,Phenobarbital
,3917507,Ki,Piperine caused noncompetitive inhibition of hepatic microsomal AHH from the untreated and 3-methylcholanthrene-treated rats with a Ki of 30 microM which was close to the apparent Km of AHH observed in the controls.,Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3917507/),μM,30,133221,DB01174,Phenobarbital
,3917507,apparent Km,"Similarly, the kinetics of inhibition of ethylmorphine-N-demethylase from control rat liver microsomes exhibited noncompetitive inhibition with an apparent Km of 0.8 mM and Ki of 35 microM.",Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3917507/),mM,0.8,133222,DB01174,Phenobarbital
,3917507,Ki,"Similarly, the kinetics of inhibition of ethylmorphine-N-demethylase from control rat liver microsomes exhibited noncompetitive inhibition with an apparent Km of 0.8 mM and Ki of 35 microM.",Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3917507/),μM,35,133223,DB01174,Phenobarbital
,1880318,clearance,"Theophylline clearance decreased an average of 19% in patients randomized to receive MTX, from 48.0 +/- 2.0 ml/hr/kg to 38.9 +/- 3.6 ml/hr/kg (p less than 0.05).",Effect of low-dose methotrexate on the disposition of glucocorticoids and theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880318/),[ml] / [h·kg],48.0,134416,DB01174,Phenobarbital
,1880318,clearance,"Theophylline clearance decreased an average of 19% in patients randomized to receive MTX, from 48.0 +/- 2.0 ml/hr/kg to 38.9 +/- 3.6 ml/hr/kg (p less than 0.05).",Effect of low-dose methotrexate on the disposition of glucocorticoids and theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880318/),[ml] / [h·kg],38.9,134417,DB01174,Phenobarbital
,12640710,Vm,The children's phenytoin population pharmacokinetic parameters Vm and Km were 9.8 mg.,[Population pharmacokinetics of phenytoin in pediatric patients]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12640710/),mg,9.8,134513,DB01174,Phenobarbital
,29210977,CL/F,"The mean (±SD) of LEV CL/F in group A (n = 180), B (n = 92), and C (n = 58) was 4.41 ± 2.06 L/h, 7.23 ± 3.72 L/h, and 4.87 ± 1.65 L/h, respectively.",Influence of Comedication on Levetiracetam Pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[l] / [h],4.41,134944,DB01174,Phenobarbital
,29210977,CL/F,"The mean (±SD) of LEV CL/F in group A (n = 180), B (n = 92), and C (n = 58) was 4.41 ± 2.06 L/h, 7.23 ± 3.72 L/h, and 4.87 ± 1.65 L/h, respectively.",Influence of Comedication on Levetiracetam Pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[l] / [h],7.23,134945,DB01174,Phenobarbital
,29210977,CL/F,"The mean (±SD) of LEV CL/F in group A (n = 180), B (n = 92), and C (n = 58) was 4.41 ± 2.06 L/h, 7.23 ± 3.72 L/h, and 4.87 ± 1.65 L/h, respectively.",Influence of Comedication on Levetiracetam Pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[l] / [h],4.87,134946,DB01174,Phenobarbital
,29210977,C0,LEV C0 values were significantly lower in the EIAEDs group than in the monotherapy group (17.30 ± 7.77 versus 20.08 ± 9.69 mcg/mL; P = 0.038) or indeed the NEIAEDs group (17.30 ± 7.77 versus 20.49 ± 9.46 mcg/mL; P = 0.027).,Influence of Comedication on Levetiracetam Pharmacokinetics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[mcg] / [ml],17.30,134947,DB01174,Phenobarbital
,29210977,C0,LEV C0 values were significantly lower in the EIAEDs group than in the monotherapy group (17.30 ± 7.77 versus 20.08 ± 9.69 mcg/mL; P = 0.038) or indeed the NEIAEDs group (17.30 ± 7.77 versus 20.49 ± 9.46 mcg/mL; P = 0.027).,Influence of Comedication on Levetiracetam Pharmacokinetics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[mcg] / [ml],20.08,134948,DB01174,Phenobarbital
,29210977,C0,LEV C0 values were significantly lower in the EIAEDs group than in the monotherapy group (17.30 ± 7.77 versus 20.08 ± 9.69 mcg/mL; P = 0.038) or indeed the NEIAEDs group (17.30 ± 7.77 versus 20.49 ± 9.46 mcg/mL; P = 0.027).,Influence of Comedication on Levetiracetam Pharmacokinetics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[mcg] / [ml],20.49,134949,DB01174,Phenobarbital
,17922078,Km,"SYUIQ-5 metabolism in rat liver microsomes followed Michaelis-Menten kinetics, with Km and Vmax values of 12.3 microM and 2.01 nmol/min/mg protein, respectively.","Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922078/),μM,12.3,134955,DB01174,Phenobarbital
,17922078,Vmax,"SYUIQ-5 metabolism in rat liver microsomes followed Michaelis-Menten kinetics, with Km and Vmax values of 12.3 microM and 2.01 nmol/min/mg protein, respectively.","Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922078/),[nM] / [mg·min],2.01,134956,DB01174,Phenobarbital
,26865186,half-life,"The half-life of retigabine in plasma was 2.5 h, with appreciable concentrations reached in the brain within 1 h of administration.",Profile of retigabine-induced neuronal apoptosis in the developing rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26865186/),h,2.5,135025,DB01174,Phenobarbital
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.045-0.070,137436,DB01174,Phenobarbital
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.028,137437,DB01174,Phenobarbital
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.014,137438,DB01174,Phenobarbital
,21351809,absolute bioavailability,"Rufinamide is well absorbed when taken with food, with an absolute bioavailability between 70% and 85%.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),%,70,138159,DB01174,Phenobarbital
,21351809,absolute bioavailability,"Rufinamide is well absorbed when taken with food, with an absolute bioavailability between 70% and 85%.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),%,85,138160,DB01174,Phenobarbital
,21351809,elimination half-life,"The elimination half-life of the drug is around 6-10 hours, with a time to maximum plasma concentration (C(max)) of approximately 4-6 hours.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),h,6-10,138161,DB01174,Phenobarbital
,21351809,time to maximum plasma concentration (C(max)),"The elimination half-life of the drug is around 6-10 hours, with a time to maximum plasma concentration (C(max)) of approximately 4-6 hours.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),h,4-6,138162,DB01174,Phenobarbital
,21351809,C(max),"The C(max) at a dosage of 10 mg/kg/day and 30 mg/kg/day is 4.01 μg/mL and 8.68 μg/mL, respectively, and the area under the plasma concentration-time curve from time 0 to 12 hours was 37.8 ± 47 μg · h/mL and 89.3 ± 58 μg · h/mL, respectively.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),[μg] / [ml],4.01,138163,DB01174,Phenobarbital
,21351809,C(max),"The C(max) at a dosage of 10 mg/kg/day and 30 mg/kg/day is 4.01 μg/mL and 8.68 μg/mL, respectively, and the area under the plasma concentration-time curve from time 0 to 12 hours was 37.8 ± 47 μg · h/mL and 89.3 ± 58 μg · h/mL, respectively.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),[μg] / [ml],8.68,138164,DB01174,Phenobarbital
,21351809,area under the plasma concentration-time curve from time 0 to 12 hours,"The C(max) at a dosage of 10 mg/kg/day and 30 mg/kg/day is 4.01 μg/mL and 8.68 μg/mL, respectively, and the area under the plasma concentration-time curve from time 0 to 12 hours was 37.8 ± 47 μg · h/mL and 89.3 ± 58 μg · h/mL, respectively.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),[h·μg] / [ml],37.8,138165,DB01174,Phenobarbital
,21351809,area under the plasma concentration-time curve from time 0 to 12 hours,"The C(max) at a dosage of 10 mg/kg/day and 30 mg/kg/day is 4.01 μg/mL and 8.68 μg/mL, respectively, and the area under the plasma concentration-time curve from time 0 to 12 hours was 37.8 ± 47 μg · h/mL and 89.3 ± 58 μg · h/mL, respectively.",Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),[h·μg] / [ml],89.3,138166,DB01174,Phenobarbital
,21351809,volume of distribution,The volume of distribution in children is similar to that in adults (0.8-1.2 L/kg) and the drug binds rather poorly to plasma protein (26.2-34.8%).,Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351809/),[l] / [kg],0.8-1.2,138167,DB01174,Phenobarbital
,8991789,half-lives,The harmonic mean half-lives of 3.8 to 4.9 h were remarkably constant across dosages and shorter than those of historical control subjects not taking enzyme-inducing AEDs suggesting that epilepsy patients not taking enzyme-inducing AEDs may require lower tiagabine.,Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991789/),h,3.8 to 4.9,138431,DB01174,Phenobarbital
,18694901,length of treatment,The mean length of treatment for those in the neonatal-opium-solution group was 32 compared with 22 days for the buprenorphine group.,Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18694901/),,32,139468,DB01174,Phenobarbital
,18694901,length of treatment,The mean length of treatment for those in the neonatal-opium-solution group was 32 compared with 22 days for the buprenorphine group.,Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18694901/),,22,139469,DB01174,Phenobarbital
,18694901,length of stay,The mean length of stay for the neonatal-opium-solution group was 38 days compared with 27 days for those in the buprenorphine group.,Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18694901/),d,38,139470,DB01174,Phenobarbital
,18694901,length of stay,The mean length of stay for the neonatal-opium-solution group was 38 days compared with 27 days for those in the buprenorphine group.,Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18694901/),d,27,139471,DB01174,Phenobarbital
,6653406,rate,"Results indicate that Pb was cleared at a mean rate of 433 ml/h during the exchange periods examined, with a mean overall elimination constant of 0.20 h-1.",The effects of exchange transfusion on the pharmacokinetics of phenobarbital. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653406/),[ml] / [h],433,143363,DB01174,Phenobarbital
,6653406,overall elimination constant,"Results indicate that Pb was cleared at a mean rate of 433 ml/h during the exchange periods examined, with a mean overall elimination constant of 0.20 h-1.",The effects of exchange transfusion on the pharmacokinetics of phenobarbital. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653406/),1/[h],0.20,143364,DB01174,Phenobarbital
,6653406,exchange time,A mean of 22.3 mg of Pb was calculated to be removed over an average exchange time of 2.2 hours.,The effects of exchange transfusion on the pharmacokinetics of phenobarbital. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653406/),h,2.2,143365,DB01174,Phenobarbital
,2777046,elimination half-life,"The elimination half-life of secretin was not affected by cirrhosis, averaging 5 +/- 2 min in both groups.",Effect of secretin on bile formation in rats with cirrhosis of the liver: structure-function relationship. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2777046/),min,5,143643,DB01174,Phenobarbital
,34114632,AUC0-12,"Range 1 demonstrated AUC0-12 167.0 ± 45.6 h*μg/mL, Cmax 19.19 ± 4.12 μg/mL and Ctrough 9.99 ± 3.86 µg/mL.",The Pharmacokinetics of Crushed Levetiracetam Tablets Administered to Neonates. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114632/),[h·μg] / [ml],167.0,143683,DB01174,Phenobarbital
,34114632,Cmax,"Range 1 demonstrated AUC0-12 167.0 ± 45.6 h*μg/mL, Cmax 19.19 ± 4.12 μg/mL and Ctrough 9.99 ± 3.86 µg/mL.",The Pharmacokinetics of Crushed Levetiracetam Tablets Administered to Neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114632/),[μg] / [ml],19.19,143684,DB01174,Phenobarbital
,34114632,Ctrough,"Range 1 demonstrated AUC0-12 167.0 ± 45.6 h*μg/mL, Cmax 19.19 ± 4.12 μg/mL and Ctrough 9.99 ± 3.86 µg/mL.",The Pharmacokinetics of Crushed Levetiracetam Tablets Administered to Neonates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114632/),[μg] / [ml],9.99,143685,DB01174,Phenobarbital
,34114632,AUC0-12,"Range 2, AUC0-12 316.5 ± 108.4 h*μg/mL, Cmax 35.12 ± 10.54 µg/mL and Ctrough 19.25 ± 8.48 µg/mL.",The Pharmacokinetics of Crushed Levetiracetam Tablets Administered to Neonates. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114632/),[h·μg] / [ml],316.5,143686,DB01174,Phenobarbital
,34114632,Cmax,"Range 2, AUC0-12 316.5 ± 108.4 h*μg/mL, Cmax 35.12 ± 10.54 µg/mL and Ctrough 19.25 ± 8.48 µg/mL.",The Pharmacokinetics of Crushed Levetiracetam Tablets Administered to Neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114632/),[μg] / [ml],35.12,143687,DB01174,Phenobarbital
,34114632,Ctrough,"Range 2, AUC0-12 316.5 ± 108.4 h*μg/mL, Cmax 35.12 ± 10.54 µg/mL and Ctrough 19.25 ± 8.48 µg/mL.",The Pharmacokinetics of Crushed Levetiracetam Tablets Administered to Neonates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114632/),[μg] / [ml],19.25,143688,DB01174,Phenobarbital
,34114632,AUC0-12,"Range 3, AUC0-12 290.9 (range 176.14-405.59) h*μg/mL, Cmax 36.11 (range 27.58-44.64) µg/mL and Ctrough 13.03 (2.98-23.07) µg/mL.",The Pharmacokinetics of Crushed Levetiracetam Tablets Administered to Neonates. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114632/),[h·μg] / [ml],290.9,143689,DB01174,Phenobarbital
,34114632,Cmax,"Range 3, AUC0-12 290.9 (range 176.14-405.59) h*μg/mL, Cmax 36.11 (range 27.58-44.64) µg/mL and Ctrough 13.03 (2.98-23.07) µg/mL.",The Pharmacokinetics of Crushed Levetiracetam Tablets Administered to Neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114632/),[μg] / [ml],36.11,143690,DB01174,Phenobarbital
,34114632,Ctrough,"Range 3, AUC0-12 290.9 (range 176.14-405.59) h*μg/mL, Cmax 36.11 (range 27.58-44.64) µg/mL and Ctrough 13.03 (2.98-23.07) µg/mL.",The Pharmacokinetics of Crushed Levetiracetam Tablets Administered to Neonates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114632/),[μg] / [ml],13.03,143691,DB01174,Phenobarbital
,7639079,Vm,"The Vm and Km of phenytoin in a 60 kg adult out-patient, without combination with other drugs (phenobarbital, clonazepam or diazepam) were estimated to be 439 mg.d-1 and 6.21 micrograms.",[NONMEM approach for estimating population pharmacokinetic parameters of phenytoin in Chinese epileptics]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639079/),[mg] / [d],439,144566,DB01174,Phenobarbital
,7639079,Km,"The Vm and Km of phenytoin in a 60 kg adult out-patient, without combination with other drugs (phenobarbital, clonazepam or diazepam) were estimated to be 439 mg.d-1 and 6.21 micrograms.",[NONMEM approach for estimating population pharmacokinetic parameters of phenytoin in Chinese epileptics]. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639079/),μg,6.21,144567,DB01174,Phenobarbital
,7639079,Vm,"The Vm of patients treated with phenytoin combined with phenobarbital, clonazepam or diazepam will increase 8.4 mg.",[NONMEM approach for estimating population pharmacokinetic parameters of phenytoin in Chinese epileptics]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639079/),mg,8.4,144568,DB01174,Phenobarbital
,3126410,volume of distribution (V),"VPA pharmacokinetic measurements were as follows: for total VPA, volume of distribution (V) = 0.40 l/kg (range, 0.36 to 0.47 l/kg), serum clearance (Cl) = 14.4 ml/h/kg (5.5 to 18.2 ml/h/kg), half-life (T1/2) = 26.4 hours (8.6 to 48.5); for unbound VPA, V = 2.02 l/kg (1.14 to 2.44 l/kg), Cl = 108.9 ml/h/kg (42.0 to 252.0 ml/h/kg).","Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3126410/),[l] / [kg],0.40,145872,DB01174,Phenobarbital
,3126410,serum clearance (Cl),"VPA pharmacokinetic measurements were as follows: for total VPA, volume of distribution (V) = 0.40 l/kg (range, 0.36 to 0.47 l/kg), serum clearance (Cl) = 14.4 ml/h/kg (5.5 to 18.2 ml/h/kg), half-life (T1/2) = 26.4 hours (8.6 to 48.5); for unbound VPA, V = 2.02 l/kg (1.14 to 2.44 l/kg), Cl = 108.9 ml/h/kg (42.0 to 252.0 ml/h/kg).","Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3126410/),[ml] / [h·kg],14.4,145873,DB01174,Phenobarbital
,3126410,half-life (T1/2),"VPA pharmacokinetic measurements were as follows: for total VPA, volume of distribution (V) = 0.40 l/kg (range, 0.36 to 0.47 l/kg), serum clearance (Cl) = 14.4 ml/h/kg (5.5 to 18.2 ml/h/kg), half-life (T1/2) = 26.4 hours (8.6 to 48.5); for unbound VPA, V = 2.02 l/kg (1.14 to 2.44 l/kg), Cl = 108.9 ml/h/kg (42.0 to 252.0 ml/h/kg).","Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3126410/),h,26.4,145874,DB01174,Phenobarbital
,3126410,V,"VPA pharmacokinetic measurements were as follows: for total VPA, volume of distribution (V) = 0.40 l/kg (range, 0.36 to 0.47 l/kg), serum clearance (Cl) = 14.4 ml/h/kg (5.5 to 18.2 ml/h/kg), half-life (T1/2) = 26.4 hours (8.6 to 48.5); for unbound VPA, V = 2.02 l/kg (1.14 to 2.44 l/kg), Cl = 108.9 ml/h/kg (42.0 to 252.0 ml/h/kg).","Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3126410/),[l] / [kg],2.02,145875,DB01174,Phenobarbital
,3126410,Cl,"VPA pharmacokinetic measurements were as follows: for total VPA, volume of distribution (V) = 0.40 l/kg (range, 0.36 to 0.47 l/kg), serum clearance (Cl) = 14.4 ml/h/kg (5.5 to 18.2 ml/h/kg), half-life (T1/2) = 26.4 hours (8.6 to 48.5); for unbound VPA, V = 2.02 l/kg (1.14 to 2.44 l/kg), Cl = 108.9 ml/h/kg (42.0 to 252.0 ml/h/kg).","Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3126410/),[ml] / [h·kg],108.9,145876,DB01174,Phenobarbital
,3126410,T1/2,T1/2 = 17.6 hours (6.7 to 34.2).,"Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3126410/),h,17.6,145877,DB01174,Phenobarbital
,3126410,free fraction,"VPA free fraction ranged from 11.3 to 31.6% (mean, 19.2%).","Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3126410/),%,19.2,145878,DB01174,Phenobarbital
,32714422,C max,"Pharmacokinetic parameters for rats administered carbamazepine with Cellgevity® vis-a-vis carbamazepine with normal saline were as follows: C max; 20 μmol/L vs 11 μmol/L, AUC0⟶24; 347 μmol h/L vs 170 μmol h/L, K e; 0.28 h-1 vs 0.41 h-1, and t 1/2; 2.3 h vs 1.7 h, respectively.",Effect of Cellgevity® Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity and Pharmacokinetic Parameters of Carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32714422/),[μM] / [l],20,146255,DB01174,Phenobarbital
,32714422,C max,"Pharmacokinetic parameters for rats administered carbamazepine with Cellgevity® vis-a-vis carbamazepine with normal saline were as follows: C max; 20 μmol/L vs 11 μmol/L, AUC0⟶24; 347 μmol h/L vs 170 μmol h/L, K e; 0.28 h-1 vs 0.41 h-1, and t 1/2; 2.3 h vs 1.7 h, respectively.",Effect of Cellgevity® Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity and Pharmacokinetic Parameters of Carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32714422/),[μM] / [l],11,146256,DB01174,Phenobarbital
,32714422,AUC0⟶24,"Pharmacokinetic parameters for rats administered carbamazepine with Cellgevity® vis-a-vis carbamazepine with normal saline were as follows: C max; 20 μmol/L vs 11 μmol/L, AUC0⟶24; 347 μmol h/L vs 170 μmol h/L, K e; 0.28 h-1 vs 0.41 h-1, and t 1/2; 2.3 h vs 1.7 h, respectively.",Effect of Cellgevity® Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity and Pharmacokinetic Parameters of Carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32714422/),[h·μM] / [l],347,146257,DB01174,Phenobarbital
,32714422,AUC0⟶24,"Pharmacokinetic parameters for rats administered carbamazepine with Cellgevity® vis-a-vis carbamazepine with normal saline were as follows: C max; 20 μmol/L vs 11 μmol/L, AUC0⟶24; 347 μmol h/L vs 170 μmol h/L, K e; 0.28 h-1 vs 0.41 h-1, and t 1/2; 2.3 h vs 1.7 h, respectively.",Effect of Cellgevity® Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity and Pharmacokinetic Parameters of Carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32714422/),[h·μM] / [l],170,146258,DB01174,Phenobarbital
,32714422,K e,"Pharmacokinetic parameters for rats administered carbamazepine with Cellgevity® vis-a-vis carbamazepine with normal saline were as follows: C max; 20 μmol/L vs 11 μmol/L, AUC0⟶24; 347 μmol h/L vs 170 μmol h/L, K e; 0.28 h-1 vs 0.41 h-1, and t 1/2; 2.3 h vs 1.7 h, respectively.",Effect of Cellgevity® Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity and Pharmacokinetic Parameters of Carbamazepine. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32714422/),1/[h],0.28,146259,DB01174,Phenobarbital
,32714422,K e,"Pharmacokinetic parameters for rats administered carbamazepine with Cellgevity® vis-a-vis carbamazepine with normal saline were as follows: C max; 20 μmol/L vs 11 μmol/L, AUC0⟶24; 347 μmol h/L vs 170 μmol h/L, K e; 0.28 h-1 vs 0.41 h-1, and t 1/2; 2.3 h vs 1.7 h, respectively.",Effect of Cellgevity® Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity and Pharmacokinetic Parameters of Carbamazepine. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32714422/),1/[h],0.41,146260,DB01174,Phenobarbital
,32714422,t 1/2,"Pharmacokinetic parameters for rats administered carbamazepine with Cellgevity® vis-a-vis carbamazepine with normal saline were as follows: C max; 20 μmol/L vs 11 μmol/L, AUC0⟶24; 347 μmol h/L vs 170 μmol h/L, K e; 0.28 h-1 vs 0.41 h-1, and t 1/2; 2.3 h vs 1.7 h, respectively.",Effect of Cellgevity® Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity and Pharmacokinetic Parameters of Carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32714422/),h,2.3,146261,DB01174,Phenobarbital
,32714422,t 1/2,"Pharmacokinetic parameters for rats administered carbamazepine with Cellgevity® vis-a-vis carbamazepine with normal saline were as follows: C max; 20 μmol/L vs 11 μmol/L, AUC0⟶24; 347 μmol h/L vs 170 μmol h/L, K e; 0.28 h-1 vs 0.41 h-1, and t 1/2; 2.3 h vs 1.7 h, respectively.",Effect of Cellgevity® Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity and Pharmacokinetic Parameters of Carbamazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32714422/),h,1.7,146262,DB01174,Phenobarbital
,1686651,half-life,Higher doses of the levo enantiomer prolonged aminopyrine half-life to 78 (1 mg/kg) and 162 min. (10 mg/kg).,Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,78,146690,DB01174,Phenobarbital
,1686651,half-life,Higher doses of the levo enantiomer prolonged aminopyrine half-life to 78 (1 mg/kg) and 162 min. (10 mg/kg).,Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,162,146691,DB01174,Phenobarbital
,1686651,sleeping time,"The hexobarbital sleeping time was prolonged by the dose of 1 mg/kg of the levo enantiomer (128 min. versus 20 min. in controls), while the dose of 0.1 mg/kg had no effect (23 versus 20 min.).",Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,128,146692,DB01174,Phenobarbital
,1686651,sleeping time,"The hexobarbital sleeping time was prolonged by the dose of 1 mg/kg of the levo enantiomer (128 min. versus 20 min. in controls), while the dose of 0.1 mg/kg had no effect (23 versus 20 min.).",Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,20,146693,DB01174,Phenobarbital
,1686651,sleeping time,"The hexobarbital sleeping time was prolonged by the dose of 1 mg/kg of the levo enantiomer (128 min. versus 20 min. in controls), while the dose of 0.1 mg/kg had no effect (23 versus 20 min.).",Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,23,146694,DB01174,Phenobarbital
,8453849,log metabolic ratio,"In 110 healthy white adults, the log metabolic ratio ranged from 1.28 to 2.05 (mean +/- SD, 1.68 +/- 0.155).",Measurement of in vivo microsomal epoxide hydrolase activity in white subjects. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453849/),,1.28 to 2.05,147593,DB01174,Phenobarbital
,8453849,log metabolic ratio,"In 110 healthy white adults, the log metabolic ratio ranged from 1.28 to 2.05 (mean +/- SD, 1.68 +/- 0.155).",Measurement of in vivo microsomal epoxide hydrolase activity in white subjects. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453849/),,1.68,147594,DB01174,Phenobarbital
,6541487,total blood clearance,"In control rats, the total blood clearance of lorcainide was 30 ml/kg/min and the bioavailability was 14%.",Effect of enzyme induction on the disposition of lorcainide in rats following intravenous and oral administration. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6541487/),[ml] / [kg·min],30,149209,DB01174,Phenobarbital
,6541487,bioavailability,"In control rats, the total blood clearance of lorcainide was 30 ml/kg/min and the bioavailability was 14%.",Effect of enzyme induction on the disposition of lorcainide in rats following intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6541487/),%,14,149210,DB01174,Phenobarbital
,1184723,MCR,"The MCR, half-life, and volume of distribution were, respectively, 383 +/- 72 (SD) liters/day, 165 +/- 49 minutes, and 61 +/- 12 liters for MP, and 234 +/- 37, 160 +/- 19, and 41 +/- 6 for MPHS.","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),[l] / [d],383,149337,DB01174,Phenobarbital
,1184723,volume of distribution,"The MCR, half-life, and volume of distribution were, respectively, 383 +/- 72 (SD) liters/day, 165 +/- 49 minutes, and 61 +/- 12 liters for MP, and 234 +/- 37, 160 +/- 19, and 41 +/- 6 for MPHS.","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),l,61,149338,DB01174,Phenobarbital
,1184723,MCR,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,424,149339,DB01174,Phenobarbital
,1184723,MCR,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,977,149340,DB01174,Phenobarbital
,1184723,half-life,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,149,149341,DB01174,Phenobarbital
,1184723,half-life,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,69,149342,DB01174,Phenobarbital
,6185649,plasma half-life,"The mean plasma half-life of valproate, using a one-compartment model, was 10.9 +/- 1.3 h (mean +/- SD).",Plasma concentrations of valproate during maintenance therapy in epileptic children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6185649/),h,10.9,149798,DB01174,Phenobarbital
,8038465,trough concentrations,Phenobarbital dosage was subsequently reduced to 150 mg/d; this resulted in phenobarbital trough concentrations of 60 micrograms/mL.,Potential pharmacokinetic interaction between felbamate and phenobarbital. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8038465/),[μg] / [ml],60,152050,DB01174,Phenobarbital
,30238679,CMAX,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[μg] / [ml],13.38,152549,DB01174,Phenobarbital
,30238679,CMAX,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[μg] / [ml],33.01,152550,DB01174,Phenobarbital
,30238679,CMAX,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[μg] / [ml],34.13,152551,DB01174,Phenobarbital
,30238679,AUC,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[h·μg] / [ml],134.86,152552,DB01174,Phenobarbital
,30238679,AUC,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[h·μg] / [ml],352.95,152553,DB01174,Phenobarbital
,30238679,AUC,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[h·μg] / [ml],452.76,152554,DB01174,Phenobarbital
,30238679,CL/F,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[l] / [h·kg],0.17,152555,DB01174,Phenobarbital
,30238679,CL/F,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[l] / [h·kg],0.08,152556,DB01174,Phenobarbital
,30238679,CL/F,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[l] / [h·kg],0.07,152557,DB01174,Phenobarbital
,30238679,half,The half-life that defined the terminal slope of the plasma concentration versus time curve (~5 hours) was similar to values previously reported for healthy dogs.,"Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),h,5,152558,DB01174,Phenobarbital
,17099560,bioavailability,Its mean bioavailability is around 75%.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),%,75,153478,DB01174,Phenobarbital
,17099560,volume of distribution,Its volume of distribution is of around 4 L/kg.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),[l] / [kg],4,153479,DB01174,Phenobarbital
,17099560,half-life elimination,The value of half-life elimination is of around 22 hours.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),h,22,153480,DB01174,Phenobarbital
,17099560,bioavibility,"Thus, bioavibility ranges from 36 to 100%.",[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),%,36 to 100,153481,DB01174,Phenobarbital
,17099560,plasmatic target,The methadone plasmatic target value of 400 microg/ml can be recommended for therapeutic drug monitoring.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),[μg] / [ml],400,153482,DB01174,Phenobarbital
,2327624,excretion,"In 10 group-B dogs given 3H-digitoxin (groups 1B, 2B, and 4B), the excretion of total radioactivity in urine and bile was 15 to 20 and 7% of the dose, respectively in the first 24 hours.",Influence of induced cholestasis on pharmacokinetics of digoxin and digitoxin in dogs. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327624/),%,15 to 20,153682,DB01174,Phenobarbital
,2327624,excretion,"In 10 group-B dogs given 3H-digitoxin (groups 1B, 2B, and 4B), the excretion of total radioactivity in urine and bile was 15 to 20 and 7% of the dose, respectively in the first 24 hours.",Influence of induced cholestasis on pharmacokinetics of digoxin and digitoxin in dogs. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327624/),%,7,153683,DB01174,Phenobarbital
,28506869,Clearance (CL),"Clearance (CL) and volume (Vd) for a child with a birthweight of 2.6kg at PNA day 4.5 was 0.0091L/h (9%) and 2.38L (5%), respectively.",Model-based clinical dose optimization for phenobarbital in neonates: An illustration of the importance of data sharing and external validation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28506869/),[l] / [h],0.0091,156210,DB01174,Phenobarbital
,28506869,volume (Vd),"Clearance (CL) and volume (Vd) for a child with a birthweight of 2.6kg at PNA day 4.5 was 0.0091L/h (9%) and 2.38L (5%), respectively.",Model-based clinical dose optimization for phenobarbital in neonates: An illustration of the importance of data sharing and external validation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28506869/),l,2.38,156211,DB01174,Phenobarbital
,8227234,half-life,"The half-life of the drug was estimated to be (mean +/- SD) 114.2 +/- 43.0 h, 73.19 +/- 24.17 h and 41.23 +/- 13.95 h in patients 1-10, 11-30 and 31-70 days old, respectively.",Dosage programming of phenobarbital in neonatal seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227234/),h,114.2,156332,DB01174,Phenobarbital
,8227234,half-life,"The half-life of the drug was estimated to be (mean +/- SD) 114.2 +/- 43.0 h, 73.19 +/- 24.17 h and 41.23 +/- 13.95 h in patients 1-10, 11-30 and 31-70 days old, respectively.",Dosage programming of phenobarbital in neonatal seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227234/),h,73.19,156333,DB01174,Phenobarbital
,8227234,half-life,"The half-life of the drug was estimated to be (mean +/- SD) 114.2 +/- 43.0 h, 73.19 +/- 24.17 h and 41.23 +/- 13.95 h in patients 1-10, 11-30 and 31-70 days old, respectively.",Dosage programming of phenobarbital in neonatal seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227234/),h,41.23,156334,DB01174,Phenobarbital
,11198504,volume of distribution,"The volume of distribution and the serum clearance of valproate were approximately 0.245 L/kg and 25 mL/h/kg, respectively.",Intravenous valproate dosing in neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11198504/),[l] / [kg],0.245,157020,DB01174,Phenobarbital
,11198504,serum clearance,"The volume of distribution and the serum clearance of valproate were approximately 0.245 L/kg and 25 mL/h/kg, respectively.",Intravenous valproate dosing in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11198504/),[ml] / [h·kg],25,157021,DB01174,Phenobarbital
,2306662,distribution half-life,"Following intravenous administration, the drug was rapidly distributed (distribution half-life = 0.046 +/- 0.007 h) with a large apparent volume of distribution (931 +/- 44.8 mL/kg).",Pharmacokinetics of phenobarbital in the cat following intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2306662/),h,0.046,157075,DB01174,Phenobarbital
,2306662,apparent volume of distribution,"Following intravenous administration, the drug was rapidly distributed (distribution half-life = 0.046 +/- 0.007 h) with a large apparent volume of distribution (931 +/- 44.8 mL/kg).",Pharmacokinetics of phenobarbital in the cat following intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2306662/),[ml] / [kg],931,157076,DB01174,Phenobarbital
,2306662,elimination half-life,Subsequent elimination of phenobarbital from the body was slow (elimination half-life = 58.8 +/- 4.21 h).,Pharmacokinetics of phenobarbital in the cat following intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2306662/),h,58.8,157077,DB01174,Phenobarbital
,2306662,absorption half-life,"After oral administration, the initial rapid absorption phase (absorption half-life = 0.382 +/- 0.099 h) was followed by a plateau in the serum concentration (13.5 +/- 0.148 micrograms/mL) for approximately 10 h.",Pharmacokinetics of phenobarbital in the cat following intravenous and oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2306662/),h,0.382,157078,DB01174,Phenobarbital
,2306662,half-life of the terminal elimination phase,The half-life of the terminal elimination phase (76.1 +/- 6.96 h) was not significantly different from the half-life determined for the intravenous route.,Pharmacokinetics of phenobarbital in the cat following intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2306662/),h,76.1,157079,DB01174,Phenobarbital
,2306662,Bioavailability,Bioavailability of the oral drug was high (F = 1.20 +/- 0.120).,Pharmacokinetics of phenobarbital in the cat following intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2306662/),,1.20,157080,DB01174,Phenobarbital
,2306662,F,Bioavailability of the oral drug was high (F = 1.20 +/- 0.120).,Pharmacokinetics of phenobarbital in the cat following intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2306662/),,1.20,157081,DB01174,Phenobarbital
,2867146,Vdss,In the control rats the Vdss of imipramine was large at 19.9 litre kg-1.,Effect of phenobarbitone on the distribution and elimination of imipramine in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867146/),[l] / [kg],19.9,157550,DB01174,Phenobarbital
less,2867146,urinary excretion ratios,"The urinary excretion ratios of imipramine and desipramine, to the dose of imipramine over 8 h, were less than 1.5% in both groups.",Effect of phenobarbitone on the distribution and elimination of imipramine in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867146/),%,1.5,157551,DB01174,Phenobarbital
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],12.1,157653,DB01174,Phenobarbital
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],8,157654,DB01174,Phenobarbital
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],18,157655,DB01174,Phenobarbital
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],11,157656,DB01174,Phenobarbital
,10208286,ED50s,"No potentiation was observed in the case of valproate and diphenylhydantoin (their ED50s were changed from 253 to 249 and from 10.3 to 9.7 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],253,157657,DB01174,Phenobarbital
,10208286,ED50s,"No potentiation was observed in the case of valproate and diphenylhydantoin (their ED50s were changed from 253 to 249 and from 10.3 to 9.7 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],249,157658,DB01174,Phenobarbital
,10208286,ED50s,"No potentiation was observed in the case of valproate and diphenylhydantoin (their ED50s were changed from 253 to 249 and from 10.3 to 9.7 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],10,157659,DB01174,Phenobarbital
,29788839,Vd,"The mean (SD) Vd and CL values in neonates were 0.46 (0.24) L/kg and 8.0 (4.5) mL/h/kg, respectively.",Phenobarbital pharmacokinetics in neonates and infants during extracorporeal membrane oxygenation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29788839/),[l] / [kg],0.46,158422,DB01174,Phenobarbital
,29788839,CL,"The mean (SD) Vd and CL values in neonates were 0.46 (0.24) L/kg and 8.0 (4.5) mL/h/kg, respectively.",Phenobarbital pharmacokinetics in neonates and infants during extracorporeal membrane oxygenation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29788839/),[ml] / [h·kg],8.0,158423,DB01174,Phenobarbital
,6374250,half-life,"Pharmacokinetic analysis showed that the half-life of prednisolone was shorter in the anticonvulsant group compared to the controls, based on both total (2.3 +/- 0.4 vs. 3.4 +/- 0.2 hr (SD), P less than 0.01) and unbound (1.7 +/- 0.3 vs. 2.4 +/- 0.2 hr, P less than 0.01) concentrations.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),h,2.3,160807,DB01174,Phenobarbital
,6374250,half-life,"Pharmacokinetic analysis showed that the half-life of prednisolone was shorter in the anticonvulsant group compared to the controls, based on both total (2.3 +/- 0.4 vs. 3.4 +/- 0.2 hr (SD), P less than 0.01) and unbound (1.7 +/- 0.3 vs. 2.4 +/- 0.2 hr, P less than 0.01) concentrations.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),h,3.4,160808,DB01174,Phenobarbital
,6374250,unbound,"Pharmacokinetic analysis showed that the half-life of prednisolone was shorter in the anticonvulsant group compared to the controls, based on both total (2.3 +/- 0.4 vs. 3.4 +/- 0.2 hr (SD), P less than 0.01) and unbound (1.7 +/- 0.3 vs. 2.4 +/- 0.2 hr, P less than 0.01) concentrations.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),h,1.7,160809,DB01174,Phenobarbital
,6374250,unbound,"Pharmacokinetic analysis showed that the half-life of prednisolone was shorter in the anticonvulsant group compared to the controls, based on both total (2.3 +/- 0.4 vs. 3.4 +/- 0.2 hr (SD), P less than 0.01) and unbound (1.7 +/- 0.3 vs. 2.4 +/- 0.2 hr, P less than 0.01) concentrations.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),h,2.4,160810,DB01174,Phenobarbital
,6374250,Total drug clearance,Total drug clearance was 10.4 +/- 2.8 liters/hr (0.171 +/- 0.087 liters/hr X kg) in the anticonvulsant group versus 7.2 +/- 1.2 liters/hr (0.100 +/- 0.014 liters/hr X kg) in the controls (P less than 0.05).,Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h],10.4,160811,DB01174,Phenobarbital
,6374250,Total drug clearance,Total drug clearance was 10.4 +/- 2.8 liters/hr (0.171 +/- 0.087 liters/hr X kg) in the anticonvulsant group versus 7.2 +/- 1.2 liters/hr (0.100 +/- 0.014 liters/hr X kg) in the controls (P less than 0.05).,Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h·kg],0.171,160812,DB01174,Phenobarbital
,6374250,Total drug clearance,Total drug clearance was 10.4 +/- 2.8 liters/hr (0.171 +/- 0.087 liters/hr X kg) in the anticonvulsant group versus 7.2 +/- 1.2 liters/hr (0.100 +/- 0.014 liters/hr X kg) in the controls (P less than 0.05).,Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h],7.2,160813,DB01174,Phenobarbital
,6374250,Total drug clearance,Total drug clearance was 10.4 +/- 2.8 liters/hr (0.171 +/- 0.087 liters/hr X kg) in the anticonvulsant group versus 7.2 +/- 1.2 liters/hr (0.100 +/- 0.014 liters/hr X kg) in the controls (P less than 0.05).,Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h·kg],0.100,160814,DB01174,Phenobarbital
,6374250,Unbound prednisolone clearance,"Unbound prednisolone clearance was 57.2 +/- 12.1 versus 46.4 +/- 8.7 liters/hr (P greater than 0.05) and for weight-corrected estimates 0.886 +/- 0.224 liters/hr X kg versus 0.644 +/- 0.115 liters/hr X kg (P less than 0.05) in the two groups, respectively.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h],57.2,160815,DB01174,Phenobarbital
,6374250,Unbound prednisolone clearance,"Unbound prednisolone clearance was 57.2 +/- 12.1 versus 46.4 +/- 8.7 liters/hr (P greater than 0.05) and for weight-corrected estimates 0.886 +/- 0.224 liters/hr X kg versus 0.644 +/- 0.115 liters/hr X kg (P less than 0.05) in the two groups, respectively.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h],46.4,160816,DB01174,Phenobarbital
,6374250,Unbound prednisolone clearance,"Unbound prednisolone clearance was 57.2 +/- 12.1 versus 46.4 +/- 8.7 liters/hr (P greater than 0.05) and for weight-corrected estimates 0.886 +/- 0.224 liters/hr X kg versus 0.644 +/- 0.115 liters/hr X kg (P less than 0.05) in the two groups, respectively.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h·kg],0.886,160817,DB01174,Phenobarbital
,6374250,Unbound prednisolone clearance,"Unbound prednisolone clearance was 57.2 +/- 12.1 versus 46.4 +/- 8.7 liters/hr (P greater than 0.05) and for weight-corrected estimates 0.886 +/- 0.224 liters/hr X kg versus 0.644 +/- 0.115 liters/hr X kg (P less than 0.05) in the two groups, respectively.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h·kg],0.644,160818,DB01174,Phenobarbital
,833762,Metabolic clearance,Metabolic clearance was found to decrease from 1.74+/-0.11 ml/min in animals which received furosemide alone to 1.06+/-0.10 ml/min in animals which received both furosemide and probenecid.,Metabolic clearance of furosemide in the rat. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/833762/),[ml] / [min],1.74,161846,DB01174,Phenobarbital
,833762,Metabolic clearance,Metabolic clearance was found to decrease from 1.74+/-0.11 ml/min in animals which received furosemide alone to 1.06+/-0.10 ml/min in animals which received both furosemide and probenecid.,Metabolic clearance of furosemide in the rat. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/833762/),[ml] / [min],1.06,161847,DB01174,Phenobarbital
,760753,oral bioavailability,"3 The oral bioavailability (mean +/- s.e. mean) was significantly lower in the epileptic patients than in the normal subjects (0.77 +/- 0.03 and 0.89 +/- 0.02 respectively, P less than 0.01), whereas the urinary excretion total (free+conjugated) paracetamol was almost identical in the two groups.",Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/760753/),,0.77,162430,DB01174,Phenobarbital
,760753,oral bioavailability,"3 The oral bioavailability (mean +/- s.e. mean) was significantly lower in the epileptic patients than in the normal subjects (0.77 +/- 0.03 and 0.89 +/- 0.02 respectively, P less than 0.01), whereas the urinary excretion total (free+conjugated) paracetamol was almost identical in the two groups.",Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/760753/),,0.89,162431,DB01174,Phenobarbital
,3208791,peak plasma concentrations,"In dogs, the chronic administration of 400 mg/d of phenobarbital produced peak plasma concentrations of 78 micrograms/ml which so markedly induced the metabolism of antipyrine that the conventional schemes by which antipyrine kinetics assess induction were rendered invalid.",The effect of induction with phenobarbital on the kinetics and bioavailability of antipyrine in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208791/),[μg] / [ml],78,163947,DB01174,Phenobarbital
,3208791,bioavailability,The bioavailability of antipyrine was only 20% due to first-pass metabolism.,The effect of induction with phenobarbital on the kinetics and bioavailability of antipyrine in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208791/),%,20,163948,DB01174,Phenobarbital
,3208791,clearance,"Induction raised the observed antipyrine clearance to 31 ml/min/kg, a value approaching hepatic blood flow.",The effect of induction with phenobarbital on the kinetics and bioavailability of antipyrine in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208791/),[ml] / [kg·min],31,163949,DB01174,Phenobarbital
,3208791,induction factor,"Acknowledging that antipyrine is nonideal, one can calculate a correct induction factor of 13.6.",The effect of induction with phenobarbital on the kinetics and bioavailability of antipyrine in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208791/),,13.6,163950,DB01174,Phenobarbital
,11180194,area under plasma concentration-time curve from time zero to time infinity (AUC),"After 1-min intravenous administration of 2-AP, 50 mg/kg, to rats pretreated with SKF 525-A (a non-specific CYP inhibitor in rats), the plasma concentrations were significantly higher, and the area under plasma concentration-time curve from time zero to time infinity (AUC) was significantly greater (1365 compared with 1034 microg min/mL) as a result of significantly slower total body clearance (Cl) (36.6 compared with 48.3 mL/min/kg) than those in control rats, indicating that 2-AP was metabolized by CYP isozymes.","Effects of enzyme inducers and inhibitor on the pharmacokinetics of intravenous 2-(allylthio)pyrazine, a new chemoprotective agent, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180194/),[min·μg] / [ml],1365,165074,DB01174,Phenobarbital
,11180194,area under plasma concentration-time curve from time zero to time infinity (AUC),"After 1-min intravenous administration of 2-AP, 50 mg/kg, to rats pretreated with SKF 525-A (a non-specific CYP inhibitor in rats), the plasma concentrations were significantly higher, and the area under plasma concentration-time curve from time zero to time infinity (AUC) was significantly greater (1365 compared with 1034 microg min/mL) as a result of significantly slower total body clearance (Cl) (36.6 compared with 48.3 mL/min/kg) than those in control rats, indicating that 2-AP was metabolized by CYP isozymes.","Effects of enzyme inducers and inhibitor on the pharmacokinetics of intravenous 2-(allylthio)pyrazine, a new chemoprotective agent, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180194/),[min·μg] / [ml],1034,165075,DB01174,Phenobarbital
,11180194,total body clearance (Cl),"After 1-min intravenous administration of 2-AP, 50 mg/kg, to rats pretreated with SKF 525-A (a non-specific CYP inhibitor in rats), the plasma concentrations were significantly higher, and the area under plasma concentration-time curve from time zero to time infinity (AUC) was significantly greater (1365 compared with 1034 microg min/mL) as a result of significantly slower total body clearance (Cl) (36.6 compared with 48.3 mL/min/kg) than those in control rats, indicating that 2-AP was metabolized by CYP isozymes.","Effects of enzyme inducers and inhibitor on the pharmacokinetics of intravenous 2-(allylthio)pyrazine, a new chemoprotective agent, in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180194/),[ml] / [kg·min],36.6,165076,DB01174,Phenobarbital
,11180194,total body clearance (Cl),"After 1-min intravenous administration of 2-AP, 50 mg/kg, to rats pretreated with SKF 525-A (a non-specific CYP inhibitor in rats), the plasma concentrations were significantly higher, and the area under plasma concentration-time curve from time zero to time infinity (AUC) was significantly greater (1365 compared with 1034 microg min/mL) as a result of significantly slower total body clearance (Cl) (36.6 compared with 48.3 mL/min/kg) than those in control rats, indicating that 2-AP was metabolized by CYP isozymes.","Effects of enzyme inducers and inhibitor on the pharmacokinetics of intravenous 2-(allylthio)pyrazine, a new chemoprotective agent, in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180194/),[ml] / [kg·min],48.3,165077,DB01174,Phenobarbital
,6519155,elimination half-life,"The elimination half-life and the apparent clearance of unchanged PRM in the patients were 18.0 +/- 3.1 h and 42 +/- 14 ml X h-1 X kg-1, respectively (mean +/- SD) and did not differ significantly from the values in the controls (half-life 17.0 +/- 2.4 h; clearance 35 +/- 8 ml X h-1 X kg-1).",Single-dose kinetics of primidone in acute viral hepatitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519155/),h,18.0,165188,DB01174,Phenobarbital
,6519155,apparent clearance,"The elimination half-life and the apparent clearance of unchanged PRM in the patients were 18.0 +/- 3.1 h and 42 +/- 14 ml X h-1 X kg-1, respectively (mean +/- SD) and did not differ significantly from the values in the controls (half-life 17.0 +/- 2.4 h; clearance 35 +/- 8 ml X h-1 X kg-1).",Single-dose kinetics of primidone in acute viral hepatitis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519155/),[ml] / [h·kg],42,165189,DB01174,Phenobarbital
,6519155,half-life,"The elimination half-life and the apparent clearance of unchanged PRM in the patients were 18.0 +/- 3.1 h and 42 +/- 14 ml X h-1 X kg-1, respectively (mean +/- SD) and did not differ significantly from the values in the controls (half-life 17.0 +/- 2.4 h; clearance 35 +/- 8 ml X h-1 X kg-1).",Single-dose kinetics of primidone in acute viral hepatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519155/),h,17.0,165190,DB01174,Phenobarbital
,6519155,clearance,"The elimination half-life and the apparent clearance of unchanged PRM in the patients were 18.0 +/- 3.1 h and 42 +/- 14 ml X h-1 X kg-1, respectively (mean +/- SD) and did not differ significantly from the values in the controls (half-life 17.0 +/- 2.4 h; clearance 35 +/- 8 ml X h-1 X kg-1).",Single-dose kinetics of primidone in acute viral hepatitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519155/),[ml] / [h·kg],35,165191,DB01174,Phenobarbital
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,6.3,165985,DB01174,Phenobarbital
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,7.2,165986,DB01174,Phenobarbital
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,7.5,165987,DB01174,Phenobarbital
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,7.6,165988,DB01174,Phenobarbital
,8911883,Cmax,"During the single dose study, the mean plasma concentrations of idebenone and its main metabolites and mean pharmacokinetic parameters were comparable to published results (Cmax = 452.2 ng.ml-1, tmax = 2.3 h, AUC = 26 micrograms.",Plasma concentrations and pharmacokinetics of idebenone and its metabolites following single and repeated doses in young patients with mitochondrial encephalomyopathy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911883/),[ng] / [ml],452.2,166901,DB01174,Phenobarbital
,8911883,tmax,"During the single dose study, the mean plasma concentrations of idebenone and its main metabolites and mean pharmacokinetic parameters were comparable to published results (Cmax = 452.2 ng.ml-1, tmax = 2.3 h, AUC = 26 micrograms.",Plasma concentrations and pharmacokinetics of idebenone and its metabolites following single and repeated doses in young patients with mitochondrial encephalomyopathy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911883/),h,2.3,166902,DB01174,Phenobarbital
,8911883,AUC,"During the single dose study, the mean plasma concentrations of idebenone and its main metabolites and mean pharmacokinetic parameters were comparable to published results (Cmax = 452.2 ng.ml-1, tmax = 2.3 h, AUC = 26 micrograms.",Plasma concentrations and pharmacokinetics of idebenone and its metabolites following single and repeated doses in young patients with mitochondrial encephalomyopathy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911883/),μg,26,166903,DB01174,Phenobarbital
,8911883,t1/2 beta,"ml-1.h, t1/2 beta = 16.5 h).",Plasma concentrations and pharmacokinetics of idebenone and its metabolites following single and repeated doses in young patients with mitochondrial encephalomyopathy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911883/),h,16.5,166904,DB01174,Phenobarbital
,8911883,residual plasma concentrations,"During the repeated doses study, no significant difference was found between mean residual plasma concentrations of idebenone on Day 2 (47 ng.ml-1) and Day 5 (70.6 ng.ml-1), and mean t1/2 beta of idebenone after the single and after repeated dose studies, i.e., there was no evidence of accumulation.",Plasma concentrations and pharmacokinetics of idebenone and its metabolites following single and repeated doses in young patients with mitochondrial encephalomyopathy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911883/),[ng] / [ml],47,166905,DB01174,Phenobarbital
,8911883,residual plasma concentrations,"During the repeated doses study, no significant difference was found between mean residual plasma concentrations of idebenone on Day 2 (47 ng.ml-1) and Day 5 (70.6 ng.ml-1), and mean t1/2 beta of idebenone after the single and after repeated dose studies, i.e., there was no evidence of accumulation.",Plasma concentrations and pharmacokinetics of idebenone and its metabolites following single and repeated doses in young patients with mitochondrial encephalomyopathy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911883/),[ng] / [ml],70.6,166906,DB01174,Phenobarbital
,6848749,bioavailability,Phenobarbital decreased the bioavailability of propranolol from 7.7 to 3.5%.,"Interactions of phenobarbital with propranolol in the dog. 2. Bioavailability, metabolism and pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6848749/),%,7.7,170232,DB01174,Phenobarbital
,6848749,bioavailability,Phenobarbital decreased the bioavailability of propranolol from 7.7 to 3.5%.,"Interactions of phenobarbital with propranolol in the dog. 2. Bioavailability, metabolism and pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6848749/),%,3.5,170233,DB01174,Phenobarbital
,4055163,ED50,"The analgesic effect of paracetamol, studied in the Randall-Selitto test in rats, was not changed by methionine: ED50 was 94.6 mg/kg without methionine and 94.1 mg/kg with it.","Methionine in paracetamol tablets, a tool to reduce paracetamol toxicity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4055163/),[mg] / [kg],94.6,171961,DB01174,Phenobarbital
,4055163,ED50,"The analgesic effect of paracetamol, studied in the Randall-Selitto test in rats, was not changed by methionine: ED50 was 94.6 mg/kg without methionine and 94.1 mg/kg with it.","Methionine in paracetamol tablets, a tool to reduce paracetamol toxicity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4055163/),[mg] / [kg],94.1,171962,DB01174,Phenobarbital
,786678,biological half lives,Elimination of the drug appeared to follow a monophasic exponential course; biological half lives were 8 to 15 hours.,Pharmacokinetics of di-n-propylacetate in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/786678/),h,8 to 15,172938,DB01174,Phenobarbital
,786678,relative distribution volumes,The drug appeared to have a relatively restricted distribution: calculated relative distribution volumes ranged from 0.15 to 0.40 1/kg.,Pharmacokinetics of di-n-propylacetate in epileptic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/786678/),[1] / [kg],0.15 to 0.40,172939,DB01174,Phenobarbital
,22023343,Vd/F,"The final pharmacokinetic parameters were CL/F (mL/h) = (5.95.TBW (kg) +1.41.PNA (weeks)) Conc (serum phenobarbital concentration >50 μg/mL)(-0.221),Vd/F(L) =1.01.",Population pharmacokinetics of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants: an update. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22023343/),l,1.01,172940,DB01174,Phenobarbital
,7107978,Dialysis clearance,"Dialysis clearance calculated by the instantaneous dialyzate method averaged 97.7 ml/min, which is considerably greater than the metabolic clearance of 30 ml/min for the drug.",Pharmacokinetics of primidone elimination by uremic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7107978/),[ml] / [min],97.7,173249,DB01174,Phenobarbital
,7107978,metabolic clearance,"Dialysis clearance calculated by the instantaneous dialyzate method averaged 97.7 ml/min, which is considerably greater than the metabolic clearance of 30 ml/min for the drug.",Pharmacokinetics of primidone elimination by uremic patients. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7107978/),[ml] / [min],30,173250,DB01174,Phenobarbital
,7107978,extraction efficiency,The extraction efficiency of the hollow-fiber dialyzers averaged 40.2 pr cent for plasma samples.,Pharmacokinetics of primidone elimination by uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7107978/),cent·pr,40.2,173251,DB01174,Phenobarbital
,7107978,half-life,"The half-life was 5.1 hours in our patients during hemodialysis, a nearly two-thirds reduction of the 13.9-hour half-life calculated in uremic patients.",Pharmacokinetics of primidone elimination by uremic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7107978/),h,5.1,173252,DB01174,Phenobarbital
,7107978,half-life,"The half-life was 5.1 hours in our patients during hemodialysis, a nearly two-thirds reduction of the 13.9-hour half-life calculated in uremic patients.",Pharmacokinetics of primidone elimination by uremic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7107978/),h,13.9,173253,DB01174,Phenobarbital
,7107978,half,"The half-life was 5.1 hours in our patients during hemodialysis, a nearly two-thirds reduction of the 13.9-hour half-life calculated in uremic patients.",Pharmacokinetics of primidone elimination by uremic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7107978/),h,13.9,173254,DB01174,Phenobarbital
,1732431,systemic clearance,"The mean systemic clearance (range) for the six anticonvulsant-treated patients studied during 22 courses of therapy was 32 mL/min/m2 (range, 21 to 54 mL/min/m2), significantly higher (P less than .001) than the mean value of 13 mL/min/m2 (range, 7 to 17 mL/min/m2) for the control patients studied during 26 courses of therapy.",Increased teniposide clearance with concomitant anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732431/),[ml] / [m2·min],32,175387,DB01174,Phenobarbital
,1732431,systemic clearance,"The mean systemic clearance (range) for the six anticonvulsant-treated patients studied during 22 courses of therapy was 32 mL/min/m2 (range, 21 to 54 mL/min/m2), significantly higher (P less than .001) than the mean value of 13 mL/min/m2 (range, 7 to 17 mL/min/m2) for the control patients studied during 26 courses of therapy.",Increased teniposide clearance with concomitant anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732431/),[ml] / [m2·min],13,175388,DB01174,Phenobarbital
,1541306,peak concentration,"Phenobarbitone was rapidly absorbed, reaching a mean (range) peak concentration of 34.2 [29.3-42.6] mumol.l-1 in a median (range) of 4 (2.5-12) h.",Absorption of intramuscular phenobarbitone in children with severe falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1541306/),[μM] / [l],34.2,175424,DB01174,Phenobarbital
,6139756,half-life,"After the i.v. administration of either salt, phenobarbital plasma levels declined monoexponentially with a half-life of 7.5 h; the volume of distribution was 0.78 l/kg.",Pharmacokinetics of phenobarbital and propylhexedrine after administration of barbexaclone in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6139756/),h,7.5,176321,DB01174,Phenobarbital
,6139756,volume of distribution,"After the i.v. administration of either salt, phenobarbital plasma levels declined monoexponentially with a half-life of 7.5 h; the volume of distribution was 0.78 l/kg.",Pharmacokinetics of phenobarbital and propylhexedrine after administration of barbexaclone in the mouse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6139756/),[l] / [kg],0.78,176322,DB01174,Phenobarbital
,6139756,t0.5 alpha,"After i.v. application of barbexaclone the following pharmacokinetic parameters for propylhexedrine were determined: t0.5 alpha 0.31 h, t0.5 beta 2.5 h, Vd beta 19.3 l/kg; bioavailability (AUC oral/AUC i.v.) 0.37.",Pharmacokinetics of phenobarbital and propylhexedrine after administration of barbexaclone in the mouse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6139756/),h,0.31,176323,DB01174,Phenobarbital
,6139756,t0.5 beta,"After i.v. application of barbexaclone the following pharmacokinetic parameters for propylhexedrine were determined: t0.5 alpha 0.31 h, t0.5 beta 2.5 h, Vd beta 19.3 l/kg; bioavailability (AUC oral/AUC i.v.) 0.37.",Pharmacokinetics of phenobarbital and propylhexedrine after administration of barbexaclone in the mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6139756/),h,2.5,176324,DB01174,Phenobarbital
,6139756,Vd beta,"After i.v. application of barbexaclone the following pharmacokinetic parameters for propylhexedrine were determined: t0.5 alpha 0.31 h, t0.5 beta 2.5 h, Vd beta 19.3 l/kg; bioavailability (AUC oral/AUC i.v.) 0.37.",Pharmacokinetics of phenobarbital and propylhexedrine after administration of barbexaclone in the mouse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6139756/),[l] / [kg],19.3,176325,DB01174,Phenobarbital
,6139756,bioavailability (AUC oral/AUC,"After i.v. application of barbexaclone the following pharmacokinetic parameters for propylhexedrine were determined: t0.5 alpha 0.31 h, t0.5 beta 2.5 h, Vd beta 19.3 l/kg; bioavailability (AUC oral/AUC i.v.) 0.37.",Pharmacokinetics of phenobarbital and propylhexedrine after administration of barbexaclone in the mouse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6139756/),,0.37,176326,DB01174,Phenobarbital
,7050705,serum half-life,"A pharmacokinetic analysis showed that the charcoal decreased the serum half-life of phenobarbital form 110 +/- 8 to 45 +/- 6 hours (S.E.M.) (P less than 0.01), increased the total body clearance of phenobarbital from 4.4 +/- 0.2 to 12.0 +/- 1.6 ml per kilogram per hour (P less than 0.01), and increased the nonrenal clearance from 52 to 80 per cent of the total body clearance.",Acceleration of the body clearance of phenobarbital by oral activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7050705/),h,110,177073,DB01174,Phenobarbital
,7050705,serum half-life,"A pharmacokinetic analysis showed that the charcoal decreased the serum half-life of phenobarbital form 110 +/- 8 to 45 +/- 6 hours (S.E.M.) (P less than 0.01), increased the total body clearance of phenobarbital from 4.4 +/- 0.2 to 12.0 +/- 1.6 ml per kilogram per hour (P less than 0.01), and increased the nonrenal clearance from 52 to 80 per cent of the total body clearance.",Acceleration of the body clearance of phenobarbital by oral activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7050705/),h,45,177074,DB01174,Phenobarbital
,7050705,total body clearance,"A pharmacokinetic analysis showed that the charcoal decreased the serum half-life of phenobarbital form 110 +/- 8 to 45 +/- 6 hours (S.E.M.) (P less than 0.01), increased the total body clearance of phenobarbital from 4.4 +/- 0.2 to 12.0 +/- 1.6 ml per kilogram per hour (P less than 0.01), and increased the nonrenal clearance from 52 to 80 per cent of the total body clearance.",Acceleration of the body clearance of phenobarbital by oral activated charcoal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7050705/),[ml] / [h·kg],4.4,177075,DB01174,Phenobarbital
,7050705,total body clearance,"A pharmacokinetic analysis showed that the charcoal decreased the serum half-life of phenobarbital form 110 +/- 8 to 45 +/- 6 hours (S.E.M.) (P less than 0.01), increased the total body clearance of phenobarbital from 4.4 +/- 0.2 to 12.0 +/- 1.6 ml per kilogram per hour (P less than 0.01), and increased the nonrenal clearance from 52 to 80 per cent of the total body clearance.",Acceleration of the body clearance of phenobarbital by oral activated charcoal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7050705/),[ml] / [h·kg],12.0,177076,DB01174,Phenobarbital
,7050705,nonrenal clearance,"A pharmacokinetic analysis showed that the charcoal decreased the serum half-life of phenobarbital form 110 +/- 8 to 45 +/- 6 hours (S.E.M.) (P less than 0.01), increased the total body clearance of phenobarbital from 4.4 +/- 0.2 to 12.0 +/- 1.6 ml per kilogram per hour (P less than 0.01), and increased the nonrenal clearance from 52 to 80 per cent of the total body clearance.",Acceleration of the body clearance of phenobarbital by oral activated charcoal. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7050705/),%,52,177077,DB01174,Phenobarbital
,7050705,nonrenal clearance,"A pharmacokinetic analysis showed that the charcoal decreased the serum half-life of phenobarbital form 110 +/- 8 to 45 +/- 6 hours (S.E.M.) (P less than 0.01), increased the total body clearance of phenobarbital from 4.4 +/- 0.2 to 12.0 +/- 1.6 ml per kilogram per hour (P less than 0.01), and increased the nonrenal clearance from 52 to 80 per cent of the total body clearance.",Acceleration of the body clearance of phenobarbital by oral activated charcoal. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7050705/),%,80,177078,DB01174,Phenobarbital
,32639476,clearance,"In a one-compartment model, clearance and volume of distribution for a typical neonate off extracorporeal membrane oxygenation and with a median birth body weight (3.21 kg) at median postnatal age (2 d) were 0.0096 L/hr (relative SE = 11%)) and 2.72 L (16%), respectively.",Rapid Increase in Clearance of Phenobarbital in Neonates on Extracorporeal Membrane Oxygenation: A Pilot Retrospective Population Pharmacokinetic Analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32639476/),[l] / [h],0.0096,177242,DB01174,Phenobarbital
,32639476,volume of distribution,"In a one-compartment model, clearance and volume of distribution for a typical neonate off extracorporeal membrane oxygenation and with a median birth body weight (3.21 kg) at median postnatal age (2 d) were 0.0096 L/hr (relative SE = 11%)) and 2.72 L (16%), respectively.",Rapid Increase in Clearance of Phenobarbital in Neonates on Extracorporeal Membrane Oxygenation: A Pilot Retrospective Population Pharmacokinetic Analysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32639476/),l,2.72,177243,DB01174,Phenobarbital
,1868813,plasma levels,"""Active"" plasma levels ranged from approximately 300 ng/ml in the MES threshold test to approximately 1,300 ng/ml in the MES test.","Ralitoline: a reevaluation of anticonvulsant profile and determination of ""active"" plasma concentrations in comparison with prototype antiepileptic drugs in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868813/),[ng] / [ml],300,177484,DB01174,Phenobarbital
,1868813,plasma levels,"""Active"" plasma levels ranged from approximately 300 ng/ml in the MES threshold test to approximately 1,300 ng/ml in the MES test.","Ralitoline: a reevaluation of anticonvulsant profile and determination of ""active"" plasma concentrations in comparison with prototype antiepileptic drugs in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868813/),[ng] / [ml],"1,300",177485,DB01174,Phenobarbital
,6840172,peak level (Cmax,"After fasting, the peak level (Cmax = 29.1 +/- 3.2 ng/ml; mean +/- SEM) was reached at 1.3 +/- 0.1 h (Tmax).","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ng] / [ml],29.1,178034,DB01174,Phenobarbital
,6840172,Tmax,"After fasting, the peak level (Cmax = 29.1 +/- 3.2 ng/ml; mean +/- SEM) was reached at 1.3 +/- 0.1 h (Tmax).","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),h,1.3,178035,DB01174,Phenobarbital
,6840172,total area under the serum concentration-time curve (AUC0-infinity),"The total area under the serum concentration-time curve (AUC0-infinity) was 154.4 +/- 33.8 ng x h/ml, total clearance (Cltot) 751.5 +/- 90.6 ml/min, renal clearance (Clren) 97.2 +/- 10.1 ml/min, elimination half-life (t1/2) 2.9 +/- 0.3 h and 24-h recovery in urine (X0u-24) 11.1 +/- 1.4% of the dose.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[h·ng] / [ml],154.4,178036,DB01174,Phenobarbital
,6840172,total clearance (Cltot),"The total area under the serum concentration-time curve (AUC0-infinity) was 154.4 +/- 33.8 ng x h/ml, total clearance (Cltot) 751.5 +/- 90.6 ml/min, renal clearance (Clren) 97.2 +/- 10.1 ml/min, elimination half-life (t1/2) 2.9 +/- 0.3 h and 24-h recovery in urine (X0u-24) 11.1 +/- 1.4% of the dose.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ml] / [min],751.5,178037,DB01174,Phenobarbital
,6840172,renal clearance (Clren),"The total area under the serum concentration-time curve (AUC0-infinity) was 154.4 +/- 33.8 ng x h/ml, total clearance (Cltot) 751.5 +/- 90.6 ml/min, renal clearance (Clren) 97.2 +/- 10.1 ml/min, elimination half-life (t1/2) 2.9 +/- 0.3 h and 24-h recovery in urine (X0u-24) 11.1 +/- 1.4% of the dose.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ml] / [min],97.2,178038,DB01174,Phenobarbital
,6840172,elimination half-life (t1/2),"The total area under the serum concentration-time curve (AUC0-infinity) was 154.4 +/- 33.8 ng x h/ml, total clearance (Cltot) 751.5 +/- 90.6 ml/min, renal clearance (Clren) 97.2 +/- 10.1 ml/min, elimination half-life (t1/2) 2.9 +/- 0.3 h and 24-h recovery in urine (X0u-24) 11.1 +/- 1.4% of the dose.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),h,2.9,178039,DB01174,Phenobarbital
,6840172,Cmax,"Dihydralazine enhanced Cmax (38.2 +/- 4.6 ng/ml) only when compared to phenobarbitone treatment, and did not affect any other parameters.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ng] / [ml],38.2,178040,DB01174,Phenobarbital
,6840172,Cmax,"Phenobarbitone pretreatment somewhat lowered Cmax (25.5 +/- 3.9 ng/ml), AUC0-infinity (117.5 +/- 22.1; p less than 0.05 vs food) and X0u-24 (8.7 +/- 1.2%), evidently by increasing Cltot (957.5 +/- 116.9 ml/min; p less than 0.05 vs food), but it did not affect Clren.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ng] / [ml],25.5,178041,DB01174,Phenobarbital
,6840172,AUC0-infinity,"Phenobarbitone pretreatment somewhat lowered Cmax (25.5 +/- 3.9 ng/ml), AUC0-infinity (117.5 +/- 22.1; p less than 0.05 vs food) and X0u-24 (8.7 +/- 1.2%), evidently by increasing Cltot (957.5 +/- 116.9 ml/min; p less than 0.05 vs food), but it did not affect Clren.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),,117.5,178042,DB01174,Phenobarbital
,6840172,Cltot,"Phenobarbitone pretreatment somewhat lowered Cmax (25.5 +/- 3.9 ng/ml), AUC0-infinity (117.5 +/- 22.1; p less than 0.05 vs food) and X0u-24 (8.7 +/- 1.2%), evidently by increasing Cltot (957.5 +/- 116.9 ml/min; p less than 0.05 vs food), but it did not affect Clren.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ml] / [min],957.5,178043,DB01174,Phenobarbital
,3440098,Cp 21st day,The disposition of orally administered disopyramide was studied in a population of smokers (n = 6) and non-smokers (n = 8) before and during phenobarbitone treatment (100 mg daily for 21 days; Cp 21st day = 13.9 +/- 2.0 micrograms ml-1).,Disopyramide pharmacokinetics and metabolism: effect of inducers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),[μg] / [ml],13.9,180959,DB01174,Phenobarbital
,3440098,half-lives,"2. Smokers and non-smokers exhibited similar half-lives (6.48 +/- 1.49 vs 6.66 +/- 1.02 h), apparent total body clearances (0.100 +/- 0.020 vs 0.117 +/- 0.034 l h-1 kg-1), mean renal clearances (0.043 +/- 0.0093 vs 0.057 +/- 0.013 l h-1 kg-1) and apparent intrinsic metabolic clearances (0.057 +/- 0.015 vs 0.060 +/- 0.024 l h-1 kg-1) before phenobarbitone treatment.",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),h,6.48,180960,DB01174,Phenobarbital
,3440098,half-lives,"2. Smokers and non-smokers exhibited similar half-lives (6.48 +/- 1.49 vs 6.66 +/- 1.02 h), apparent total body clearances (0.100 +/- 0.020 vs 0.117 +/- 0.034 l h-1 kg-1), mean renal clearances (0.043 +/- 0.0093 vs 0.057 +/- 0.013 l h-1 kg-1) and apparent intrinsic metabolic clearances (0.057 +/- 0.015 vs 0.060 +/- 0.024 l h-1 kg-1) before phenobarbitone treatment.",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),h,6.66,180961,DB01174,Phenobarbital
,3440098,apparent total body clearances,"2. Smokers and non-smokers exhibited similar half-lives (6.48 +/- 1.49 vs 6.66 +/- 1.02 h), apparent total body clearances (0.100 +/- 0.020 vs 0.117 +/- 0.034 l h-1 kg-1), mean renal clearances (0.043 +/- 0.0093 vs 0.057 +/- 0.013 l h-1 kg-1) and apparent intrinsic metabolic clearances (0.057 +/- 0.015 vs 0.060 +/- 0.024 l h-1 kg-1) before phenobarbitone treatment.",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),[l] / [h·kg],0.100,180962,DB01174,Phenobarbital
,3440098,apparent total body clearances,"2. Smokers and non-smokers exhibited similar half-lives (6.48 +/- 1.49 vs 6.66 +/- 1.02 h), apparent total body clearances (0.100 +/- 0.020 vs 0.117 +/- 0.034 l h-1 kg-1), mean renal clearances (0.043 +/- 0.0093 vs 0.057 +/- 0.013 l h-1 kg-1) and apparent intrinsic metabolic clearances (0.057 +/- 0.015 vs 0.060 +/- 0.024 l h-1 kg-1) before phenobarbitone treatment.",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),[l] / [h·kg],0.117,180963,DB01174,Phenobarbital
,3440098,renal clearances,"2. Smokers and non-smokers exhibited similar half-lives (6.48 +/- 1.49 vs 6.66 +/- 1.02 h), apparent total body clearances (0.100 +/- 0.020 vs 0.117 +/- 0.034 l h-1 kg-1), mean renal clearances (0.043 +/- 0.0093 vs 0.057 +/- 0.013 l h-1 kg-1) and apparent intrinsic metabolic clearances (0.057 +/- 0.015 vs 0.060 +/- 0.024 l h-1 kg-1) before phenobarbitone treatment.",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),[l] / [h·kg],0.043,180964,DB01174,Phenobarbital
,3440098,renal clearances,"2. Smokers and non-smokers exhibited similar half-lives (6.48 +/- 1.49 vs 6.66 +/- 1.02 h), apparent total body clearances (0.100 +/- 0.020 vs 0.117 +/- 0.034 l h-1 kg-1), mean renal clearances (0.043 +/- 0.0093 vs 0.057 +/- 0.013 l h-1 kg-1) and apparent intrinsic metabolic clearances (0.057 +/- 0.015 vs 0.060 +/- 0.024 l h-1 kg-1) before phenobarbitone treatment.",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),[l] / [h·kg],0.057,180965,DB01174,Phenobarbital
,3440098,apparent intrinsic metabolic clearances,"2. Smokers and non-smokers exhibited similar half-lives (6.48 +/- 1.49 vs 6.66 +/- 1.02 h), apparent total body clearances (0.100 +/- 0.020 vs 0.117 +/- 0.034 l h-1 kg-1), mean renal clearances (0.043 +/- 0.0093 vs 0.057 +/- 0.013 l h-1 kg-1) and apparent intrinsic metabolic clearances (0.057 +/- 0.015 vs 0.060 +/- 0.024 l h-1 kg-1) before phenobarbitone treatment.",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),[l] / [h·kg],0.057,180966,DB01174,Phenobarbital
,3440098,apparent intrinsic metabolic clearances,"2. Smokers and non-smokers exhibited similar half-lives (6.48 +/- 1.49 vs 6.66 +/- 1.02 h), apparent total body clearances (0.100 +/- 0.020 vs 0.117 +/- 0.034 l h-1 kg-1), mean renal clearances (0.043 +/- 0.0093 vs 0.057 +/- 0.013 l h-1 kg-1) and apparent intrinsic metabolic clearances (0.057 +/- 0.015 vs 0.060 +/- 0.024 l h-1 kg-1) before phenobarbitone treatment.",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),[l] / [h·kg],0.060,180967,DB01174,Phenobarbital
,3440098,AUC,"4. Phenobarbitone treatment of non-smokers resulted in an increase in the AUC of the active metabolite N-despropyl disopyramide (MND), but not significantly (3.8 +/- 1.6 vs 4.1 +/- 2.3 micrograms ml-1 h).",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),[h·μg] / [ml],3.8,180968,DB01174,Phenobarbital
,3440098,AUC,"4. Phenobarbitone treatment of non-smokers resulted in an increase in the AUC of the active metabolite N-despropyl disopyramide (MND), but not significantly (3.8 +/- 1.6 vs 4.1 +/- 2.3 micrograms ml-1 h).",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),[h·μg] / [ml],4.1,180969,DB01174,Phenobarbital
,3440098,percent,"5. The percent of administered dose recovered in urine as disopyramide in non-smokers was significantly decreased upon phenobarbitone treatment (43 +/- 6% vs 25 +/- 5%), whereas the percent of dose recovered as MND increased significantly in this group (25 +/- 6% vs 31 +/- 5%).",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),%,43,180970,DB01174,Phenobarbital
,3440098,percent,"5. The percent of administered dose recovered in urine as disopyramide in non-smokers was significantly decreased upon phenobarbitone treatment (43 +/- 6% vs 25 +/- 5%), whereas the percent of dose recovered as MND increased significantly in this group (25 +/- 6% vs 31 +/- 5%).",Disopyramide pharmacokinetics and metabolism: effect of inducers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440098/),%,25,180971,DB01174,Phenobarbital
,11174078,flow rate,"The livers were perfused in a single-pass way at a flow rate of 15 ml/min using a perfusate which consisted of Krebs-Henseleit buffer containing glucose, taurocholate, bovine albumin and erythrocytes.",No effect of phenobarbital pretreatment of rats on methotrexate pharmacokinetics in the isolated liver perfused in a single-pass way. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11174078/),[ml] / [min],15,181550,DB01174,Phenobarbital
,11174078,steady-state biliary clearance,"During the perfusion with 50 micromol/l MTX, the steady-state biliary clearance (1.26 +/- 0.24 ml/min) in 7 nonpretreated rats accounted for a major proportion of the hepatic clearance (1.30 +/- 0.33 ml/min), metabolism of MTX to 7- OHMTX was minor (partial metabolic clearance = 0.041 +/- 0.023 ml/min).",No effect of phenobarbital pretreatment of rats on methotrexate pharmacokinetics in the isolated liver perfused in a single-pass way. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11174078/),[ml] / [min],1.26,181551,DB01174,Phenobarbital
,11174078,hepatic clearance,"During the perfusion with 50 micromol/l MTX, the steady-state biliary clearance (1.26 +/- 0.24 ml/min) in 7 nonpretreated rats accounted for a major proportion of the hepatic clearance (1.30 +/- 0.33 ml/min), metabolism of MTX to 7- OHMTX was minor (partial metabolic clearance = 0.041 +/- 0.023 ml/min).",No effect of phenobarbital pretreatment of rats on methotrexate pharmacokinetics in the isolated liver perfused in a single-pass way. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11174078/),[ml] / [min],1.30,181552,DB01174,Phenobarbital
,11174078,partial metabolic clearance,"During the perfusion with 50 micromol/l MTX, the steady-state biliary clearance (1.26 +/- 0.24 ml/min) in 7 nonpretreated rats accounted for a major proportion of the hepatic clearance (1.30 +/- 0.33 ml/min), metabolism of MTX to 7- OHMTX was minor (partial metabolic clearance = 0.041 +/- 0.023 ml/min).",No effect of phenobarbital pretreatment of rats on methotrexate pharmacokinetics in the isolated liver perfused in a single-pass way. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11174078/),[ml] / [min],0.041,181553,DB01174,Phenobarbital
,6866129,elimination half life,"In the brain the elimination half life of THN was calculated to be 1.8 h, the elimination half life of the radioactivity in the blood 6.24 h, and the accumulation half life in the urine 9.24 h.",Pharmacokinetics of tetrahydronorharmane (tetrahydro-beta-carboline) in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6866129/),h,1.8,183108,DB01174,Phenobarbital
,6866129,elimination half life,"In the brain the elimination half life of THN was calculated to be 1.8 h, the elimination half life of the radioactivity in the blood 6.24 h, and the accumulation half life in the urine 9.24 h.",Pharmacokinetics of tetrahydronorharmane (tetrahydro-beta-carboline) in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6866129/),h,6.24,183109,DB01174,Phenobarbital
,6866129,accumulation half life,"In the brain the elimination half life of THN was calculated to be 1.8 h, the elimination half life of the radioactivity in the blood 6.24 h, and the accumulation half life in the urine 9.24 h.",Pharmacokinetics of tetrahydronorharmane (tetrahydro-beta-carboline) in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6866129/),h,9.24,183110,DB01174,Phenobarbital
,3266736,elimination half-life,The elimination half-life of the untreated control group (n = 27) was 4.62 h.,Effects of drugs on aminophylline elimination in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,4.62,184893,DB01174,Phenobarbital
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.09,184894,DB01174,Phenobarbital
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.47,184895,DB01174,Phenobarbital
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.19,184896,DB01174,Phenobarbital
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2,184897,DB01174,Phenobarbital
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.85,184898,DB01174,Phenobarbital
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.74,184899,DB01174,Phenobarbital
,8689950,Half-life,"Half-life, clearance, and volume of distribution were respectively, 1.6 hr, 160 ml/hr/kg, and 405 ml/kg for O6-benzylguanine, and 1.2 hr, 312 ml/hr/kg, and 507 ml/kg for O6-benzyl-8-oxoguanine.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),h,1.6,185521,DB01174,Phenobarbital
,8689950,clearance,"Half-life, clearance, and volume of distribution were respectively, 1.6 hr, 160 ml/hr/kg, and 405 ml/kg for O6-benzylguanine, and 1.2 hr, 312 ml/hr/kg, and 507 ml/kg for O6-benzyl-8-oxoguanine.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),[ml] / [h·kg],160,185522,DB01174,Phenobarbital
,8689950,clearance,"Half-life, clearance, and volume of distribution were respectively, 1.6 hr, 160 ml/hr/kg, and 405 ml/kg for O6-benzylguanine, and 1.2 hr, 312 ml/hr/kg, and 507 ml/kg for O6-benzyl-8-oxoguanine.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),h,1.2,185523,DB01174,Phenobarbital
,8689950,clearance,"Half-life, clearance, and volume of distribution were respectively, 1.6 hr, 160 ml/hr/kg, and 405 ml/kg for O6-benzylguanine, and 1.2 hr, 312 ml/hr/kg, and 507 ml/kg for O6-benzyl-8-oxoguanine.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),[ml] / [h·kg],312,185524,DB01174,Phenobarbital
,8689950,volume of distribution,"Half-life, clearance, and volume of distribution were respectively, 1.6 hr, 160 ml/hr/kg, and 405 ml/kg for O6-benzylguanine, and 1.2 hr, 312 ml/hr/kg, and 507 ml/kg for O6-benzyl-8-oxoguanine.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),[ml] / [kg],405,185525,DB01174,Phenobarbital
,8689950,volume of distribution,"Half-life, clearance, and volume of distribution were respectively, 1.6 hr, 160 ml/hr/kg, and 405 ml/kg for O6-benzylguanine, and 1.2 hr, 312 ml/hr/kg, and 507 ml/kg for O6-benzyl-8-oxoguanine.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),[ml] / [kg],507,185526,DB01174,Phenobarbital
,8689950,Renal,"Renal excretion accounted for 8 and 62% of the administered O6-benzylguanine and O6-benzyl-8-oxoguanine, respectively.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),,8,185527,DB01174,Phenobarbital
,8689950,Renal,"Renal excretion accounted for 8 and 62% of the administered O6-benzylguanine and O6-benzyl-8-oxoguanine, respectively.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),,62,185528,DB01174,Phenobarbital
,8689950,KM,"Kinetic constants, KM and Vmax were estimated as 19.6 microM and 0.02 nmol/min/mg protein and 13.4 microM and 0.96 nmol/min/mg protein, for uninduced and induced rat liver microsomes, respectively.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),μM,19.6,185529,DB01174,Phenobarbital
,8689950,KM,"Kinetic constants, KM and Vmax were estimated as 19.6 microM and 0.02 nmol/min/mg protein and 13.4 microM and 0.96 nmol/min/mg protein, for uninduced and induced rat liver microsomes, respectively.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),[nM] / [mg·min],0.02,185530,DB01174,Phenobarbital
,8689950,KM,"Kinetic constants, KM and Vmax were estimated as 19.6 microM and 0.02 nmol/min/mg protein and 13.4 microM and 0.96 nmol/min/mg protein, for uninduced and induced rat liver microsomes, respectively.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),μM,13.4,185531,DB01174,Phenobarbital
,8689950,Vmax,"Kinetic constants, KM and Vmax were estimated as 19.6 microM and 0.02 nmol/min/mg protein and 13.4 microM and 0.96 nmol/min/mg protein, for uninduced and induced rat liver microsomes, respectively.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),[nM] / [mg·min],0.02,185532,DB01174,Phenobarbital
,8689950,Vmax,"Kinetic constants, KM and Vmax were estimated as 19.6 microM and 0.02 nmol/min/mg protein and 13.4 microM and 0.96 nmol/min/mg protein, for uninduced and induced rat liver microsomes, respectively.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),[nM] / [mg·min],0.96,185533,DB01174,Phenobarbital
,9029743,clearance,"The clearance and volume of distribution of felbamate were 41.1 ml/h/kg and 908 ml/kg, respectively.",Population pharmacokinetics of felbamate in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029743/),[ml] / [h·kg],41.1,185907,DB01174,Phenobarbital
,9029743,volume of distribution,"The clearance and volume of distribution of felbamate were 41.1 ml/h/kg and 908 ml/kg, respectively.",Population pharmacokinetics of felbamate in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029743/),[ml] / [kg],908,185908,DB01174,Phenobarbital
,12504914,electroconvulsive threshold,"(2S,2R)-4-Methylglutamic acid (SYM 2081), a potent selective agonist of GluR5 and GluR6 kainate receptor subtypes, applied at the dose of 15.5 mg/kg, equal to its CD(16) value (i.e., a dose required to induce convulsions in 16% of mice), significantly decreased the electroconvulsive threshold from 7.0 to 5.8 mA.",Low-affinity kainate receptor-mediated events reduce the protective activity of phenobarbital and diphenylhydantoin against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504914/),m,7.0,186820,DB01174,Phenobarbital
,12504914,electroconvulsive threshold,"(2S,2R)-4-Methylglutamic acid (SYM 2081), a potent selective agonist of GluR5 and GluR6 kainate receptor subtypes, applied at the dose of 15.5 mg/kg, equal to its CD(16) value (i.e., a dose required to induce convulsions in 16% of mice), significantly decreased the electroconvulsive threshold from 7.0 to 5.8 mA.",Low-affinity kainate receptor-mediated events reduce the protective activity of phenobarbital and diphenylhydantoin against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504914/),m,5,186821,DB01174,Phenobarbital
,12504914,ED(50),"The respective ED(50) values were increased from 18.5 to 23.8 mg/kg for phenobarbital, and from 11.7 to 14.7 mg/kg for diphenylhydantoin.",Low-affinity kainate receptor-mediated events reduce the protective activity of phenobarbital and diphenylhydantoin against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504914/),[mg] / [kg],18.5 to 23.8,186822,DB01174,Phenobarbital
,12504914,ED(50),"The respective ED(50) values were increased from 18.5 to 23.8 mg/kg for phenobarbital, and from 11.7 to 14.7 mg/kg for diphenylhydantoin.",Low-affinity kainate receptor-mediated events reduce the protective activity of phenobarbital and diphenylhydantoin against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504914/),[mg] / [kg],11.7 to 14.7,186823,DB01174,Phenobarbital
,9686882,flow-rate,The flow-rate is 1.0 ml/min and 25 microl are injected and detected at 215 nm.,"Method for the determination of 5,5-diphenylbarbituric acid and its separation from 1,3-dimethoxymethyl-5,5-diphenylbarbituric acid in plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9686882/),[ml] / [min],1.0,187553,DB01174,Phenobarbital
,8666331,rate constant,Acute administration of phenobarbital to the liver (1.12 mg) decreased the rate constant for canalicular egress of V-G (0.0489 +/- 0.0266 vs. 0.164 +/- 0.075 min(-1)).,Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666331/),1/[min],0.0489,188744,DB01174,Phenobarbital
,8666331,rate constant,Acute administration of phenobarbital to the liver (1.12 mg) decreased the rate constant for canalicular egress of V-G (0.0489 +/- 0.0266 vs. 0.164 +/- 0.075 min(-1)).,Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666331/),1/[min],0.164,188745,DB01174,Phenobarbital
,8666331,biliary excretion,"In vivo pretreatment with phenobarbital (75 mg/kg/d x 5 d) before liver isolation decreased the biliary excretion of both VPA (1.06E-04 +/- 0.27E-04 vs. 2.76E-04 +/- 0.45E-04 min(-1)) and V-G (5.63E- 03 +/- 1.98E-03 vs. 1.74E-02 +/- 0.5E-02 min(-1)), and increased the apparent volume of distribution of VPA (84.6 +/- 2.2 vs. 72.3 +/- 2.1 mL).",Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666331/),1/[min],1.06,188746,DB01174,Phenobarbital
,8666331,biliary excretion,"In vivo pretreatment with phenobarbital (75 mg/kg/d x 5 d) before liver isolation decreased the biliary excretion of both VPA (1.06E-04 +/- 0.27E-04 vs. 2.76E-04 +/- 0.45E-04 min(-1)) and V-G (5.63E- 03 +/- 1.98E-03 vs. 1.74E-02 +/- 0.5E-02 min(-1)), and increased the apparent volume of distribution of VPA (84.6 +/- 2.2 vs. 72.3 +/- 2.1 mL).",Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666331/),1/[min],2.76E-04,188747,DB01174,Phenobarbital
,8666331,V-G,"In vivo pretreatment with phenobarbital (75 mg/kg/d x 5 d) before liver isolation decreased the biliary excretion of both VPA (1.06E-04 +/- 0.27E-04 vs. 2.76E-04 +/- 0.45E-04 min(-1)) and V-G (5.63E- 03 +/- 1.98E-03 vs. 1.74E-02 +/- 0.5E-02 min(-1)), and increased the apparent volume of distribution of VPA (84.6 +/- 2.2 vs. 72.3 +/- 2.1 mL).",Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666331/),1/[min],5.63,188748,DB01174,Phenobarbital
,8666331,V-G,"In vivo pretreatment with phenobarbital (75 mg/kg/d x 5 d) before liver isolation decreased the biliary excretion of both VPA (1.06E-04 +/- 0.27E-04 vs. 2.76E-04 +/- 0.45E-04 min(-1)) and V-G (5.63E- 03 +/- 1.98E-03 vs. 1.74E-02 +/- 0.5E-02 min(-1)), and increased the apparent volume of distribution of VPA (84.6 +/- 2.2 vs. 72.3 +/- 2.1 mL).",Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666331/),1/[min],1.74E-02,188749,DB01174,Phenobarbital
,8666331,apparent volume of distribution,"In vivo pretreatment with phenobarbital (75 mg/kg/d x 5 d) before liver isolation decreased the biliary excretion of both VPA (1.06E-04 +/- 0.27E-04 vs. 2.76E-04 +/- 0.45E-04 min(-1)) and V-G (5.63E- 03 +/- 1.98E-03 vs. 1.74E-02 +/- 0.5E-02 min(-1)), and increased the apparent volume of distribution of VPA (84.6 +/- 2.2 vs. 72.3 +/- 2.1 mL).",Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666331/),ml,84.6,188750,DB01174,Phenobarbital
,8666331,apparent volume of distribution,"In vivo pretreatment with phenobarbital (75 mg/kg/d x 5 d) before liver isolation decreased the biliary excretion of both VPA (1.06E-04 +/- 0.27E-04 vs. 2.76E-04 +/- 0.45E-04 min(-1)) and V-G (5.63E- 03 +/- 1.98E-03 vs. 1.74E-02 +/- 0.5E-02 min(-1)), and increased the apparent volume of distribution of VPA (84.6 +/- 2.2 vs. 72.3 +/- 2.1 mL).",Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666331/),ml,72.3,188751,DB01174,Phenobarbital
,33078242,clearance,"The estimated phenobarbital clearance and volume of distribution ranged from 0.0034 to 0.0104 L/h/kg and 0.37 to 1.21 L/kg, respectively, with body weight, age, and concomitant antiepileptic drugs being the three most frequently identified predictors of clearance.",Pharmacokinetic variability of phenobarbital: a systematic review of population pharmacokinetic analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33078242/),[l] / [h·kg],0.0034 to 0.0104,188752,DB01174,Phenobarbital
,33078242,volume of distribution,"The estimated phenobarbital clearance and volume of distribution ranged from 0.0034 to 0.0104 L/h/kg and 0.37 to 1.21 L/kg, respectively, with body weight, age, and concomitant antiepileptic drugs being the three most frequently identified predictors of clearance.",Pharmacokinetic variability of phenobarbital: a systematic review of population pharmacokinetic analysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33078242/),[l] / [kg],0.37 to 1.21,188753,DB01174,Phenobarbital
,8368611,maximal nordiazepam concentrations,"After a single oral dose of clorazepate, maximal nordiazepam concentrations ranged from 569.6 to 1,387.9 ng/ml (mean, 880.2 +/- 248.9 ng/ml) and were detected 16.8 to 131.4 minutes (mean, 85.2 +/- 36 minutes) after dosing.",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[ng] / [ml],"569.6 to 1,387.9",189693,DB01174,Phenobarbital
,8368611,maximal nordiazepam concentrations,"After a single oral dose of clorazepate, maximal nordiazepam concentrations ranged from 569.6 to 1,387.9 ng/ml (mean, 880.2 +/- 248.9 ng/ml) and were detected 16.8 to 131.4 minutes (mean, 85.2 +/- 36 minutes) after dosing.",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[ng] / [ml],880.2,189694,DB01174,Phenobarbital
,8368611,maximal nordiazepam concentrations,"After administration of phenobarbital for 44 consecutive days, maximal nordiazepam concentrations were significantly (P < 0.01) lower, ranging from 209.6 to 698.5 ng/ml (mean, 399.3 +/- 155.6 ng/ml) at 68.4 to 145.8 minutes (mean, 93 +/- 25.8 minutes) after dosing.",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[ng] / [ml],209.6 to 698.5,189695,DB01174,Phenobarbital
,8368611,maximal nordiazepam concentrations,"After administration of phenobarbital for 44 consecutive days, maximal nordiazepam concentrations were significantly (P < 0.01) lower, ranging from 209.6 to 698.5 ng/ml (mean, 399.3 +/- 155.6 ng/ml) at 68.4 to 145.8 minutes (mean, 93 +/- 25.8 minutes) after dosing.",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[ng] / [ml],39,189696,DB01174,Phenobarbital
,8368611,area under the curve (AUC),"Mean area under the curve (AUC) on day 1 (mean, 3.37 +/- 0.598 ng.min/ml) was significantly (P < 0.001) greater than AUC on day 44 (1.66 +/- 0.308 ng.min/ml).",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[min·ng] / [ml],3.37,189697,DB01174,Phenobarbital
,8368611,AUC,"Mean area under the curve (AUC) on day 1 (mean, 3.37 +/- 0.598 ng.min/ml) was significantly (P < 0.001) greater than AUC on day 44 (1.66 +/- 0.308 ng.min/ml).",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[min·ng] / [ml],1.66,189698,DB01174,Phenobarbital
,8368611,Oral clearance,"Oral clearance was significantly (P < 0.01) greater on day 44 (12.44 +/- 2.55 ml/min/kg), compared with that on day 1 (6.16 +/- 1.35 ml/min/kg).",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[ml] / [kg·min],12.44,189699,DB01174,Phenobarbital
,8368611,Oral clearance,"Oral clearance was significantly (P < 0.01) greater on day 44 (12.44 +/- 2.55 ml/min/kg), compared with that on day 1 (6.16 +/- 1.35 ml/min/kg).",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[ml] / [kg·min],6.16,189700,DB01174,Phenobarbital
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,2.6,189846,DB01174,Phenobarbital
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,15.8,189847,DB01174,Phenobarbital
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,22.3,189848,DB01174,Phenobarbital
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,16.3,189849,DB01174,Phenobarbital
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,3.2,189850,DB01174,Phenobarbital
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,0.8,189851,DB01174,Phenobarbital
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,7.5,189852,DB01174,Phenobarbital
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,7.7,189853,DB01174,Phenobarbital
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,16.0,189854,DB01174,Phenobarbital
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,1.5,189855,DB01174,Phenobarbital
,10369622,Apparent volume of distribution (Vd),Apparent volume of distribution (Vd) following a 20 mg/kg loading dose was 0.29 L/kg.,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[l] / [kg],0.29,190062,DB01174,Phenobarbital
,10369622,steady-state total concentrations,Maintenance infusions of 4-6 mg/kg/h produced steady-state total concentrations of 66 mg/L and 92.4 mg/L (unbound concentration 44.6 mg/L).,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],66,190063,DB01174,Phenobarbital
,10369622,steady-state total concentrations,Maintenance infusions of 4-6 mg/kg/h produced steady-state total concentrations of 66 mg/L and 92.4 mg/L (unbound concentration 44.6 mg/L).,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],92.4,190064,DB01174,Phenobarbital
,10369622,unbound concentration,Maintenance infusions of 4-6 mg/kg/h produced steady-state total concentrations of 66 mg/L and 92.4 mg/L (unbound concentration 44.6 mg/L).,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],44.6,190065,DB01174,Phenobarbital
,10369622,Clearance,Clearance ranged from 63-66 mL/h/kg.,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[ml] / [h·kg],63-66,190066,DB01174,Phenobarbital
,10369622,Total,"Total and unbound steady-state VPA concentrations were 32.9 mg/L and 21.2 mg/L, respectively.",Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],32.9,190067,DB01174,Phenobarbital
,10369622,unbound steady-state VPA concentrations,"Total and unbound steady-state VPA concentrations were 32.9 mg/L and 21.2 mg/L, respectively.",Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],21.2,190068,DB01174,Phenobarbital
,10369622,Unbound fractions,Unbound fractions (48.3% and 66%) were significantly higher than normal.,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),%,48.3,190069,DB01174,Phenobarbital
,10369622,Unbound fractions,Unbound fractions (48.3% and 66%) were significantly higher than normal.,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),%,66,190070,DB01174,Phenobarbital
,16771232,retention times,"Clindamycin was separated from the internal standard (phenobarbital) on a Luna C18 column (250 x 4.6 mm, 5 mm particle size: Phenomenex, USA), with retention times of 5.6 and 14.2 minutes, respectively.",An alternative high-performance liquid chromatographic method for determination of clindamycin in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16771232/),min,5.6,190607,DB01174,Phenobarbital
,16771232,retention times,"Clindamycin was separated from the internal standard (phenobarbital) on a Luna C18 column (250 x 4.6 mm, 5 mm particle size: Phenomenex, USA), with retention times of 5.6 and 14.2 minutes, respectively.",An alternative high-performance liquid chromatographic method for determination of clindamycin in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16771232/),min,14.2,190608,DB01174,Phenobarbital
,16771232,flow rate,"The mobile phase consisted of a solution of 0.02 M disodiumhydrogenphosphate (pH 2.8) and acetonitrile (76:24 v/v), running through the column at a flow rate of 1.0 ml/min.",An alternative high-performance liquid chromatographic method for determination of clindamycin in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16771232/),[ml] / [min],1.0,190609,DB01174,Phenobarbital
,16771232,Limit of quantification,Limit of quantification was accepted as 0.07 microg using 1 ml plasma sample.,An alternative high-performance liquid chromatographic method for determination of clindamycin in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16771232/),μg,0.07,190610,DB01174,Phenobarbital
greater,16771232,recovery,The mean recovery for clindamycin and the internal standard were greater than 95%.,An alternative high-performance liquid chromatographic method for determination of clindamycin in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16771232/),%,95,190611,DB01174,Phenobarbital
less,3456242,elimination half-life,"When mitozolomide was administered i.p. to mice, drug disposition appeared to fit a simple, one-compartment kinetic model with an elimination half-life of less than 1 h.",Plasma and tissue disposition of mitozolomide in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3456242/),h,1,191502,DB01174,Phenobarbital
,6985719,half-life,The drug was absorbed and excreted rapidly; the mean half-life was 9.6 hours.,Sodium valproate: pharmacokinetics and effectivensss in treating intractable seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6985719/),h,9.6,191690,DB01174,Phenobarbital
,1680651,rapid phase t1/2,The two-compartment maternal pharmacokinetics demonstrated a rapid phase t1/2 of 11 min and a slower phase t 1/2 of 137 min.,Pharmacokinetics and pharmacodynamics of nifedipine in pregnant sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680651/),min,11,192172,DB01174,Phenobarbital
,1680651,slower phase t 1/2,The two-compartment maternal pharmacokinetics demonstrated a rapid phase t1/2 of 11 min and a slower phase t 1/2 of 137 min.,Pharmacokinetics and pharmacodynamics of nifedipine in pregnant sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680651/),min,137,192173,DB01174,Phenobarbital
,1680651,t 1/2,The drug reached the fetus via a first-order process with a t 1/2 of 22 min.,Pharmacokinetics and pharmacodynamics of nifedipine in pregnant sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680651/),min,22,192174,DB01174,Phenobarbital
,328018,half-life,After withdrawal of DPA the half-life was about 14 h in adult patients.,Preliminary observations on valproic acid kinetics in patients with epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/328018/),h,14,192230,DB01174,Phenobarbital
,3592381,distribution-phase half-life,Biexponential decrease in serum phenobarbital concentrations was observed with a distribution-phase half-life of 0.101 +/- 0.086 hour (mean +/- SD) and a terminal-phase elimination half-life of 18.3 +/- 3.65 hours.,Pharmacokinetics of phenobarbital in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592381/),h,0.101,192278,DB01174,Phenobarbital
,3592381,terminal-phase elimination half-life,Biexponential decrease in serum phenobarbital concentrations was observed with a distribution-phase half-life of 0.101 +/- 0.086 hour (mean +/- SD) and a terminal-phase elimination half-life of 18.3 +/- 3.65 hours.,Pharmacokinetics of phenobarbital in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592381/),h,18.3,192279,DB01174,Phenobarbital
,3592381,volume of distribution at steady state,The volume of distribution at steady state was 0.803 +/- 0.070 L/kg.,Pharmacokinetics of phenobarbital in the horse. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592381/),[l] / [kg],0.803,192280,DB01174,Phenobarbital
,3592381,Total body clearance,Total body clearance of phenobarbital was 30.8 +/- 6.2 ml/h/kg.,Pharmacokinetics of phenobarbital in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592381/),[ml] / [h·kg],30.8,192281,DB01174,Phenobarbital
,3592381,peaks,"Seemingly, 6.65 mg of phenobarbital/kg as a 20-minute infusion given every 12 hours would provide approximate peaks of 29 micrograms/ml and troughs of 15 micrograms/ml.",Pharmacokinetics of phenobarbital in the horse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592381/),[μg] / [ml],29,192282,DB01174,Phenobarbital
,3592381,troughs,"Seemingly, 6.65 mg of phenobarbital/kg as a 20-minute infusion given every 12 hours would provide approximate peaks of 29 micrograms/ml and troughs of 15 micrograms/ml.",Pharmacokinetics of phenobarbital in the horse. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592381/),[μg] / [ml],15,192283,DB01174,Phenobarbital
,2897213,volume of distribution,"When given alone, metronidazole had a mean volume of distribution of 0.667 +/- 0.15 lkg-1, a half-life of 9.7 +/- 3.1 h and an oral clearance of 0.852 +/- 0.23 (ml-1 min) kg-1.","Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897213/),1/[lkg],0.667,192515,DB01174,Phenobarbital
,2897213,half-life,"When given alone, metronidazole had a mean volume of distribution of 0.667 +/- 0.15 lkg-1, a half-life of 9.7 +/- 3.1 h and an oral clearance of 0.852 +/- 0.23 (ml-1 min) kg-1.","Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897213/),h,9.7,192516,DB01174,Phenobarbital
,2897213,oral clearance,"When given alone, metronidazole had a mean volume of distribution of 0.667 +/- 0.15 lkg-1, a half-life of 9.7 +/- 3.1 h and an oral clearance of 0.852 +/- 0.23 (ml-1 min) kg-1.","Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897213/),[min] / [kg·ml],0.852,192517,DB01174,Phenobarbital
,6430705,total radioactivity exhaled,"The total radioactivity exhaled remained constant at 56 +/- 4.5% (SD) of the applied dose throughout a tenfold dose range of methacetin (0.6, 4.0 and 6.0 mg/kg i.p.), administered to groups of three rats each and measured over a period of 4 hours.","A kinetic evaluation of 14CO2 in expired air after 14C-methacetin administration in rats, used for the in vivo study of the metabolism of drugs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6430705/),%,56,194116,DB01174,Phenobarbital
,426475,peak serum concentrations,"A metabolite, monomethoxymethyl phenobarbital (MMP), was detected in all patients, with peak serum concentrations averaging 1.96 nmol/ml at 1.3 hours.",Metabolism of dimethoxymethyl phenobarbital (eterobarb) in patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/426475/),[nM] / [ml],1.96,194646,DB01174,Phenobarbital
,239546,Total body clearance,Total body clearance of aminopyrine as obtained after an oral test dose increases more than twofold from 251 to 551 ml/min upon phenobarbital treatment.,Comparison of methods to study enzyme induction in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/239546/),[ml] / [min],251,195875,DB01174,Phenobarbital
,239546,Total body clearance,Total body clearance of aminopyrine as obtained after an oral test dose increases more than twofold from 251 to 551 ml/min upon phenobarbital treatment.,Comparison of methods to study enzyme induction in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/239546/),[ml] / [min],551,195876,DB01174,Phenobarbital
,3562386,recoveries,"After tinidazole, the recoveries of the intact drug in urine and bile were 48.1% and 1.7%, respectively.",Effect of enzyme induction and inhibition on the fate of metronidazole and tinidazole in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3562386/),%,48.1,196658,DB01174,Phenobarbital
,3562386,recoveries,"After tinidazole, the recoveries of the intact drug in urine and bile were 48.1% and 1.7%, respectively.",Effect of enzyme induction and inhibition on the fate of metronidazole and tinidazole in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3562386/),%,1.7,196659,DB01174,Phenobarbital
,10996503,plasma concentrations,LTG dose of 369+/-236 mg per day (8.1+/-5.9 mg/kg per day) achieved LTG plasma concentrations of 6.8+/-3.3 microg/ml.,Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[μg] / [ml],6.8,196945,DB01174,Phenobarbital
,10996503,oral clearance (Cl/F),"The observed LTG monotherapy, LTG+IND, and LTG+VPA oral clearance (Cl/F) were 0. 69+/-0.2, 1.60+/-0.65 and 0.2+/-0.05 ml/kg per min, respectively.",Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[ml] / [kg·min],0. 69,196946,DB01174,Phenobarbital
,10996503,oral clearance (Cl/F),"The observed LTG monotherapy, LTG+IND, and LTG+VPA oral clearance (Cl/F) were 0. 69+/-0.2, 1.60+/-0.65 and 0.2+/-0.05 ml/kg per min, respectively.",Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[ml] / [kg·min],1.60,196947,DB01174,Phenobarbital
,10996503,oral clearance (Cl/F),"The observed LTG monotherapy, LTG+IND, and LTG+VPA oral clearance (Cl/F) were 0. 69+/-0.2, 1.60+/-0.65 and 0.2+/-0.05 ml/kg per min, respectively.",Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[ml] / [kg·min],0.2,196948,DB01174,Phenobarbital
,9210976,nonrenal clearance,The nonrenal clearance (1.63 versus 3.30 mL min-1 kg-1) of azosemide increased significantly in 3-MC pretreated rats.,"Effect of phenobarbital, 3-methylcholanthrene, and chloramphenicol pretreatment on the pharmacokinetics and pharmacodynamics of azosemide in rats. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210976/),[ml] / [kg·min],1.63,197326,DB01174,Phenobarbital
,9210976,nonrenal clearance,The nonrenal clearance (1.63 versus 3.30 mL min-1 kg-1) of azosemide increased significantly in 3-MC pretreated rats.,"Effect of phenobarbital, 3-methylcholanthrene, and chloramphenicol pretreatment on the pharmacokinetics and pharmacodynamics of azosemide in rats. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210976/),[ml] / [kg·min],3.30,197327,DB01174,Phenobarbital
,9210976,urine output,The 8 h urine output (29.2 versus 18.1 mL) and 8 h urinary excretion of sodium (4.02 versus 2.39 mmol) and chloride (4.01 versus 2.73 mmol) per 100 g body weight decreased significantly in 3-MC pretreated rats.,"Effect of phenobarbital, 3-methylcholanthrene, and chloramphenicol pretreatment on the pharmacokinetics and pharmacodynamics of azosemide in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210976/),ml,29.2,197328,DB01174,Phenobarbital
,9210976,urine output,The 8 h urine output (29.2 versus 18.1 mL) and 8 h urinary excretion of sodium (4.02 versus 2.39 mmol) and chloride (4.01 versus 2.73 mmol) per 100 g body weight decreased significantly in 3-MC pretreated rats.,"Effect of phenobarbital, 3-methylcholanthrene, and chloramphenicol pretreatment on the pharmacokinetics and pharmacodynamics of azosemide in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210976/),ml,18.1,197329,DB01174,Phenobarbital
,9210976,urinary excretion,The 8 h urine output (29.2 versus 18.1 mL) and 8 h urinary excretion of sodium (4.02 versus 2.39 mmol) and chloride (4.01 versus 2.73 mmol) per 100 g body weight decreased significantly in 3-MC pretreated rats.,"Effect of phenobarbital, 3-methylcholanthrene, and chloramphenicol pretreatment on the pharmacokinetics and pharmacodynamics of azosemide in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210976/),mM,4.02,197330,DB01174,Phenobarbital
,9210976,urinary excretion,The 8 h urine output (29.2 versus 18.1 mL) and 8 h urinary excretion of sodium (4.02 versus 2.39 mmol) and chloride (4.01 versus 2.73 mmol) per 100 g body weight decreased significantly in 3-MC pretreated rats.,"Effect of phenobarbital, 3-methylcholanthrene, and chloramphenicol pretreatment on the pharmacokinetics and pharmacodynamics of azosemide in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210976/),mM,2.39,197331,DB01174,Phenobarbital
,9210976,urinary excretion,The 8 h urine output (29.2 versus 18.1 mL) and 8 h urinary excretion of sodium (4.02 versus 2.39 mmol) and chloride (4.01 versus 2.73 mmol) per 100 g body weight decreased significantly in 3-MC pretreated rats.,"Effect of phenobarbital, 3-methylcholanthrene, and chloramphenicol pretreatment on the pharmacokinetics and pharmacodynamics of azosemide in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210976/),mM,4.01,197332,DB01174,Phenobarbital
,9210976,urinary excretion,The 8 h urine output (29.2 versus 18.1 mL) and 8 h urinary excretion of sodium (4.02 versus 2.39 mmol) and chloride (4.01 versus 2.73 mmol) per 100 g body weight decreased significantly in 3-MC pretreated rats.,"Effect of phenobarbital, 3-methylcholanthrene, and chloramphenicol pretreatment on the pharmacokinetics and pharmacodynamics of azosemide in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210976/),mM,2.73,197333,DB01174,Phenobarbital
,6657737,half-life,Brodifacoum disappeared slowly from serum with a half-life of 156 h.,Dispositional and pharmacodynamic characteristics of brodifacoum in warfarin-sensitive rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6657737/),h,156,197523,DB01174,Phenobarbital
,17516704,apparent elimination half-life (t((1/2))),In plasma after a single oral administration of oxcarbazepine the mean apparent elimination half-life (t((1/2))) of MHD in adults was 8-9h.,Overview of the clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516704/),h,8-9,197924,DB01174,Phenobarbital
,17516704,ki [inhibition constant],"In vitro, MHD inhibits the cytochrome P450 (CYP) 2C19 (ki [inhibition constant] = 88 micromol/L).",Overview of the clinical pharmacokinetics of oxcarbazepine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516704/),[μM] / [l],88,197925,DB01174,Phenobarbital
,9687400,absorption rate constant,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),1/[h],0. 201,198972,DB01174,Phenobarbital
,9687400,clearance/bioavailability (CL/F,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),[l] / [h],60.9,198973,DB01174,Phenobarbital
,9687400,volume of the central compartment/bioavailability,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),l,231,198974,DB01174,Phenobarbital
,9687400,intercompartmental clearance,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),[l] / [h],60.3,198975,DB01174,Phenobarbital
,9687400,volume of the peripheral compartment/bioavailability (Vp/F,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),l,"1,050",198976,DB01174,Phenobarbital
,9687400,distribution,"The distribution and elimination half-lives were 1.24 and 25.4 h, respectively.",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),h,1.24,198977,DB01174,Phenobarbital
,9687400,elimination half-lives,"The distribution and elimination half-lives were 1.24 and 25.4 h, respectively.",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),h,25.4,198978,DB01174,Phenobarbital
,4075936,clearance,The mean (+/- CV) clearance of phenobarbital was 0.0047 liter/h/kg (+/- 19%) and the mean (+/- CV) volume of distribution (Vd) was 0.96 liter/kg (+/- 16%).,Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4075936/),[l] / [h·kg],0.0047,200487,DB01174,Phenobarbital
,4075936,volume of distribution (Vd),The mean (+/- CV) clearance of phenobarbital was 0.0047 liter/h/kg (+/- 19%) and the mean (+/- CV) volume of distribution (Vd) was 0.96 liter/kg (+/- 16%).,Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4075936/),[l] / [kg],0.96,200488,DB01174,Phenobarbital
,4075936,serum half-life,The calculated mean serum half-life was 141 h.,Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4075936/),h,141,200489,DB01174,Phenobarbital
,25711374,peak concentration (Cmax ),"Compared to the PB and PB-BR groups, the BR group had significantly higher peak concentration (Cmax ) (73.4 ± 24.0 versus 37.5 ± 13.7 and 26.5 ± 8.96 μg/mL, respectively, P < .001) and AUC (329 ± 114 versus 140 ± 64.7 and 98.7 ± 42.2 h*μg/mL, respectively, P < .001), and significantly lower clearance (CL/F) (71.8 ± 22.1 versus 187 ± 81.9 and 269 ± 127 mL/h/kg, respectively, P = .028).","Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25711374/),[μg] / [ml],73.4,201441,DB01174,Phenobarbital
,25711374,peak concentration (Cmax ),"Compared to the PB and PB-BR groups, the BR group had significantly higher peak concentration (Cmax ) (73.4 ± 24.0 versus 37.5 ± 13.7 and 26.5 ± 8.96 μg/mL, respectively, P < .001) and AUC (329 ± 114 versus 140 ± 64.7 and 98.7 ± 42.2 h*μg/mL, respectively, P < .001), and significantly lower clearance (CL/F) (71.8 ± 22.1 versus 187 ± 81.9 and 269 ± 127 mL/h/kg, respectively, P = .028).","Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25711374/),[μg] / [ml],37.5,201442,DB01174,Phenobarbital
,25711374,peak concentration (Cmax ),"Compared to the PB and PB-BR groups, the BR group had significantly higher peak concentration (Cmax ) (73.4 ± 24.0 versus 37.5 ± 13.7 and 26.5 ± 8.96 μg/mL, respectively, P < .001) and AUC (329 ± 114 versus 140 ± 64.7 and 98.7 ± 42.2 h*μg/mL, respectively, P < .001), and significantly lower clearance (CL/F) (71.8 ± 22.1 versus 187 ± 81.9 and 269 ± 127 mL/h/kg, respectively, P = .028).","Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25711374/),[μg] / [ml],26.5,201443,DB01174,Phenobarbital
,25711374,AUC,"Compared to the PB and PB-BR groups, the BR group had significantly higher peak concentration (Cmax ) (73.4 ± 24.0 versus 37.5 ± 13.7 and 26.5 ± 8.96 μg/mL, respectively, P < .001) and AUC (329 ± 114 versus 140 ± 64.7 and 98.7 ± 42.2 h*μg/mL, respectively, P < .001), and significantly lower clearance (CL/F) (71.8 ± 22.1 versus 187 ± 81.9 and 269 ± 127 mL/h/kg, respectively, P = .028).","Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25711374/),[h·μg] / [ml],329,201444,DB01174,Phenobarbital
,25711374,AUC,"Compared to the PB and PB-BR groups, the BR group had significantly higher peak concentration (Cmax ) (73.4 ± 24.0 versus 37.5 ± 13.7 and 26.5 ± 8.96 μg/mL, respectively, P < .001) and AUC (329 ± 114 versus 140 ± 64.7 and 98.7 ± 42.2 h*μg/mL, respectively, P < .001), and significantly lower clearance (CL/F) (71.8 ± 22.1 versus 187 ± 81.9 and 269 ± 127 mL/h/kg, respectively, P = .028).","Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25711374/),[h·μg] / [ml],140,201445,DB01174,Phenobarbital
,25711374,AUC,"Compared to the PB and PB-BR groups, the BR group had significantly higher peak concentration (Cmax ) (73.4 ± 24.0 versus 37.5 ± 13.7 and 26.5 ± 8.96 μg/mL, respectively, P < .001) and AUC (329 ± 114 versus 140 ± 64.7 and 98.7 ± 42.2 h*μg/mL, respectively, P < .001), and significantly lower clearance (CL/F) (71.8 ± 22.1 versus 187 ± 81.9 and 269 ± 127 mL/h/kg, respectively, P = .028).","Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25711374/),[h·μg] / [ml],98.7,201446,DB01174,Phenobarbital
,25711374,clearance (CL/F),"Compared to the PB and PB-BR groups, the BR group had significantly higher peak concentration (Cmax ) (73.4 ± 24.0 versus 37.5 ± 13.7 and 26.5 ± 8.96 μg/mL, respectively, P < .001) and AUC (329 ± 114 versus 140 ± 64.7 and 98.7 ± 42.2 h*μg/mL, respectively, P < .001), and significantly lower clearance (CL/F) (71.8 ± 22.1 versus 187 ± 81.9 and 269 ± 127 mL/h/kg, respectively, P = .028).","Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25711374/),[ml] / [h·kg],71.8,201447,DB01174,Phenobarbital
,25711374,clearance (CL/F),"Compared to the PB and PB-BR groups, the BR group had significantly higher peak concentration (Cmax ) (73.4 ± 24.0 versus 37.5 ± 13.7 and 26.5 ± 8.96 μg/mL, respectively, P < .001) and AUC (329 ± 114 versus 140 ± 64.7 and 98.7 ± 42.2 h*μg/mL, respectively, P < .001), and significantly lower clearance (CL/F) (71.8 ± 22.1 versus 187 ± 81.9 and 269 ± 127 mL/h/kg, respectively, P = .028).","Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25711374/),[ml] / [h·kg],187,201448,DB01174,Phenobarbital
,25711374,clearance (CL/F),"Compared to the PB and PB-BR groups, the BR group had significantly higher peak concentration (Cmax ) (73.4 ± 24.0 versus 37.5 ± 13.7 and 26.5 ± 8.96 μg/mL, respectively, P < .001) and AUC (329 ± 114 versus 140 ± 64.7 and 98.7 ± 42.2 h*μg/mL, respectively, P < .001), and significantly lower clearance (CL/F) (71.8 ± 22.1 versus 187 ± 81.9 and 269 ± 127 mL/h/kg, respectively, P = .028).","Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25711374/),[ml] / [h·kg],269,201449,DB01174,Phenobarbital
,8618250,elimination half-life,"The phenobarbital elimination half-life was 148 hours, 47 hours and 19 hours during the control, alkalinization and charcoal phases, respectively.",Multiple-dose activated charcoal compared to urinary alkalinization for the enhancement of phenobarbital elimination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618250/),h,148,201565,DB01174,Phenobarbital
,8618250,elimination half-life,"The phenobarbital elimination half-life was 148 hours, 47 hours and 19 hours during the control, alkalinization and charcoal phases, respectively.",Multiple-dose activated charcoal compared to urinary alkalinization for the enhancement of phenobarbital elimination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618250/),h,47,201566,DB01174,Phenobarbital
,8618250,elimination half-life,"The phenobarbital elimination half-life was 148 hours, 47 hours and 19 hours during the control, alkalinization and charcoal phases, respectively.",Multiple-dose activated charcoal compared to urinary alkalinization for the enhancement of phenobarbital elimination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618250/),h,19,201567,DB01174,Phenobarbital
,24107313,Elimination half-life,Elimination half-life was about 50 h (50.3 ± 3.1 vs. 52.9 ± 2.8 h) without differences between the formulations.,"Is switching from brand name to generic formulations of phenobarbital associated with loss of antiepileptic efficacy?: a pharmacokinetic study with two oral formulations (Luminal(®) vet, Phenoleptil(®)) in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24107313/),h,50,202076,DB01174,Phenobarbital
,24107313,Elimination half-life,Elimination half-life was about 50 h (50.3 ± 3.1 vs. 52.9 ± 2.8 h) without differences between the formulations.,"Is switching from brand name to generic formulations of phenobarbital associated with loss of antiepileptic efficacy?: a pharmacokinetic study with two oral formulations (Luminal(®) vet, Phenoleptil(®)) in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24107313/),h,50.3,202077,DB01174,Phenobarbital
,24107313,Elimination half-life,Elimination half-life was about 50 h (50.3 ± 3.1 vs. 52.9 ± 2.8 h) without differences between the formulations.,"Is switching from brand name to generic formulations of phenobarbital associated with loss of antiepileptic efficacy?: a pharmacokinetic study with two oral formulations (Luminal(®) vet, Phenoleptil(®)) in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24107313/),h,52.9,202078,DB01174,Phenobarbital
,24107313,relative bioavailability,"The relative bioavailability of the two products (Phenoleptil(®) vs. Luminal(®) vet.) was 0.98 ± 0.031, indicating that both formulations resulted in about the same bioavailability.","Is switching from brand name to generic formulations of phenobarbital associated with loss of antiepileptic efficacy?: a pharmacokinetic study with two oral formulations (Luminal(®) vet, Phenoleptil(®)) in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24107313/),,0.98,202079,DB01174,Phenobarbital
,1873508,nonrenal clearance,The nonrenal clearance (19.3 vs 29.6 ml min-1 per kg) of bumetanide increased significantly in PB treated rats.,Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and the pharmacodynamics of bumetanide in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1873508/),[ml] / [kg·min],19.3,204437,DB01174,Phenobarbital
,1873508,nonrenal clearance,The nonrenal clearance (19.3 vs 29.6 ml min-1 per kg) of bumetanide increased significantly in PB treated rats.,Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and the pharmacodynamics of bumetanide in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1873508/),[ml] / [kg·min],29.6,204438,DB01174,Phenobarbital
,2085904,serum half-life,"Peritoneal dialysis decreased the serum half-life and the area under the serum concentration-time curve (AUC) value of theophylline from 2.1 to 1.5 h and from 38 to 26 micrograms.h/ml, respectively and increased the total body clearance by 47% as compared with the control.",Pharmacokinetics of theophylline and phenobarbital during peritoneal dialysis compared with intestinal dialysis in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085904/),h,2,205329,DB01174,Phenobarbital
,2085904,area under the serum concentration-time curve (AUC),"Peritoneal dialysis decreased the serum half-life and the area under the serum concentration-time curve (AUC) value of theophylline from 2.1 to 1.5 h and from 38 to 26 micrograms.h/ml, respectively and increased the total body clearance by 47% as compared with the control.",Pharmacokinetics of theophylline and phenobarbital during peritoneal dialysis compared with intestinal dialysis in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085904/),[h·μg] / [ml],38 to 26,205330,DB01174,Phenobarbital
,2085904,serum half-life,"The dialysis also decreased the serum half-life and the AUC value of phenobarbital from 8.3 to 5.3 h and from 116 to 83 micrograms.h/ml, respectively and increased the total body clearance by 112% as compared with the control.",Pharmacokinetics of theophylline and phenobarbital during peritoneal dialysis compared with intestinal dialysis in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085904/),h,8.3 to 5.3,205331,DB01174,Phenobarbital
,2085904,AUC,"The dialysis also decreased the serum half-life and the AUC value of phenobarbital from 8.3 to 5.3 h and from 116 to 83 micrograms.h/ml, respectively and increased the total body clearance by 112% as compared with the control.",Pharmacokinetics of theophylline and phenobarbital during peritoneal dialysis compared with intestinal dialysis in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085904/),[h·μg] / [ml],116 to 83,205332,DB01174,Phenobarbital
,8363647,unbound fractions,"Acetaminophen, AG and acetaminophen sulfate (AS) were not bound extensively in hepatic cytosol (mean +/- SD unbound fractions were 0.90 +/- 0.08, 0.97 +/- 0.08, and 0.88 +/- 0.06, respectively).","Hepatic disposition of acetaminophen and metabolites. Pharmacokinetic modeling, protein binding and subcellular distribution. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363647/),,0.90,205804,DB01174,Phenobarbital
,8363647,unbound fractions,"Acetaminophen, AG and acetaminophen sulfate (AS) were not bound extensively in hepatic cytosol (mean +/- SD unbound fractions were 0.90 +/- 0.08, 0.97 +/- 0.08, and 0.88 +/- 0.06, respectively).","Hepatic disposition of acetaminophen and metabolites. Pharmacokinetic modeling, protein binding and subcellular distribution. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363647/),,0.97,205805,DB01174,Phenobarbital
,8363647,unbound fractions,"Acetaminophen, AG and acetaminophen sulfate (AS) were not bound extensively in hepatic cytosol (mean +/- SD unbound fractions were 0.90 +/- 0.08, 0.97 +/- 0.08, and 0.88 +/- 0.06, respectively).","Hepatic disposition of acetaminophen and metabolites. Pharmacokinetic modeling, protein binding and subcellular distribution. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363647/),,0.88,205806,DB01174,Phenobarbital
,21371018,Minimum,"Minimum and maximum concentration (24.7 ± 8.8 and 30.63 ± 10.3 mg/L), average plasma concentration (27.37 ± 9.4 mg/L), and half-life (173.9 ± 62.5 h) were considerably higher than reported in literature for normothermic newborns.",Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy: a pharmacokinetic study during whole body hypothermia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21371018/),[mg] / [l],24.7,207775,DB01174,Phenobarbital
,21371018,maximum concentration,"Minimum and maximum concentration (24.7 ± 8.8 and 30.63 ± 10.3 mg/L), average plasma concentration (27.37 ± 9.4 mg/L), and half-life (173.9 ± 62.5 h) were considerably higher than reported in literature for normothermic newborns.",Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy: a pharmacokinetic study during whole body hypothermia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21371018/),[mg] / [l],24.7,207776,DB01174,Phenobarbital
,21371018,maximum concentration,"Minimum and maximum concentration (24.7 ± 8.8 and 30.63 ± 10.3 mg/L), average plasma concentration (27.37 ± 9.4 mg/L), and half-life (173.9 ± 62.5 h) were considerably higher than reported in literature for normothermic newborns.",Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy: a pharmacokinetic study during whole body hypothermia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21371018/),[mg] / [l],30.63,207777,DB01174,Phenobarbital
,21371018,plasma concentration,"Minimum and maximum concentration (24.7 ± 8.8 and 30.63 ± 10.3 mg/L), average plasma concentration (27.37 ± 9.4 mg/L), and half-life (173.9 ± 62.5 h) were considerably higher than reported in literature for normothermic newborns.",Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy: a pharmacokinetic study during whole body hypothermia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21371018/),[mg] / [l],27.37,207778,DB01174,Phenobarbital
,21371018,half-life,"Minimum and maximum concentration (24.7 ± 8.8 and 30.63 ± 10.3 mg/L), average plasma concentration (27.37 ± 9.4 mg/L), and half-life (173.9 ± 62.5 h) were considerably higher than reported in literature for normothermic newborns.",Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy: a pharmacokinetic study during whole body hypothermia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21371018/),h,173.9,207779,DB01174,Phenobarbital
,7068937,distribution half-life,"After the intravenous dose, the mean distribution half-life was 0.18 hour and the mean elimination half-life was 5.8 days.",Phenobarbital pharmacokinetics and bioavailability in adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7068937/),h,0.18,209102,DB01174,Phenobarbital
,7068937,elimination half-life,"After the intravenous dose, the mean distribution half-life was 0.18 hour and the mean elimination half-life was 5.8 days.",Phenobarbital pharmacokinetics and bioavailability in adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7068937/),d,5.8,209103,DB01174,Phenobarbital
,7068937,total body clearance,"Mean total body clearance and mean renal clearance were 3.0 ml/hr/kg and 0.8 ml/hr/kg, respectively.",Phenobarbital pharmacokinetics and bioavailability in adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7068937/),[ml] / [h·kg],3.0,209104,DB01174,Phenobarbital
,7068937,renal clearance,"Mean total body clearance and mean renal clearance were 3.0 ml/hr/kg and 0.8 ml/hr/kg, respectively.",Phenobarbital pharmacokinetics and bioavailability in adults. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7068937/),[ml] / [h·kg],0.8,209105,DB01174,Phenobarbital
,7068937,apparent volume of distribution,The apparent volume of distribution was 0.60 liter/kg.,Phenobarbital pharmacokinetics and bioavailability in adults. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7068937/),[l] / [kg],0.60,209106,DB01174,Phenobarbital
,7068937,maximum phenobarbital serum concentration,"After administration of phenobarbital tablets, the maximum phenobarbital serum concentration was 5.5 mg/liter at 2.3 hours after the dose.",Phenobarbital pharmacokinetics and bioavailability in adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7068937/),[mg] / [l],5.5,209107,DB01174,Phenobarbital
,7068937,absolute availability,Adjusted absolute availability of phenobarbital from the tablets studied was 94.9 per cent (range 81-111.9 per cent).,Phenobarbital pharmacokinetics and bioavailability in adults. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7068937/),%,94.9,209108,DB01174,Phenobarbital
,7068937,elimination half-life,The elimination half-life averaged 5.1 days for the oral dose.,Phenobarbital pharmacokinetics and bioavailability in adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7068937/),d,5.1,209109,DB01174,Phenobarbital
,19429015,"maximal concentration, C(max)","In vehicle pre-treated rats, hippocampal phenobarbital concentrations were lower in MP (maximal concentration, C(max): 6.0+/-0.6 microg ml(-1), p<0.05) than in C animals (C(max): 9.4+/-0.9 microg ml(-1)).",Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429015/),[μg] / [ml],6.0,210613,DB01174,Phenobarbital
,19429015,C(max),"In vehicle pre-treated rats, hippocampal phenobarbital concentrations were lower in MP (maximal concentration, C(max): 6.0+/-0.6 microg ml(-1), p<0.05) than in C animals (C(max): 9.4+/-0.9 microg ml(-1)).",Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429015/),[μg] / [ml],9.4,210614,DB01174,Phenobarbital
,19429015,C(max),Control rats pre-treated with nimodipine showed similar results (C(max): 10.7+/-0.6 microg ml(-1)) than those pre-treated with vehicle.,Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429015/),[μg] / [ml],10.7,210615,DB01174,Phenobarbital
,19429015,C(max),"Nimodipine pre-treatment in MP rats enhanced hippocampal phenobarbital concentrations (C(max): 10.2+/-1.0 microg ml(-1), p<0.05) as compared with vehicle pre-treatment.",Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429015/),[μg] / [ml],10.2,210616,DB01174,Phenobarbital
,3348533,area under the curve of plasma concentration,"Phenobarbital (16 mg/kg of body weight, PO, q 24 h), administered for 14 days, reduced the area under the curve of plasma concentration of thiopental vs time from 10,688 micrograms.",Effects of phenobarbital on thiopental pharmacokinetics in greyhounds. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348533/),μg,"10,688",212047,DB01174,Phenobarbital
,3348533,time to recovery from anesthesia,"Furthermore, the time to recovery from anesthesia (ie, return to standing position) decreased from 103 minutes to 35.7 minutes after phenobarbital.",Effects of phenobarbital on thiopental pharmacokinetics in greyhounds. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348533/),min,103,212048,DB01174,Phenobarbital
,3348533,time to recovery from anesthesia,"Furthermore, the time to recovery from anesthesia (ie, return to standing position) decreased from 103 minutes to 35.7 minutes after phenobarbital.",Effects of phenobarbital on thiopental pharmacokinetics in greyhounds. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348533/),min,35.7,212049,DB01174,Phenobarbital
,2291873,half-lives,2. Primidone half-lives and clearance values (mean +/- s.d.) were similar in the elderly and in the young (12.1 +/- 4.6 vs 14.7 +/- 3.5 h and 34.8 +/- 9.0 vs 33.2 +/- 7.2 ml h-1 kg-1 respectively.,The disposition of primidone in elderly patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291873/),h,12.1,212076,DB01174,Phenobarbital
,2291873,clearance,2. Primidone half-lives and clearance values (mean +/- s.d.) were similar in the elderly and in the young (12.1 +/- 4.6 vs 14.7 +/- 3.5 h and 34.8 +/- 9.0 vs 33.2 +/- 7.2 ml h-1 kg-1 respectively.,The disposition of primidone in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291873/),h,14.7,212077,DB01174,Phenobarbital
,2291873,clearance,2. Primidone half-lives and clearance values (mean +/- s.d.) were similar in the elderly and in the young (12.1 +/- 4.6 vs 14.7 +/- 3.5 h and 34.8 +/- 9.0 vs 33.2 +/- 7.2 ml h-1 kg-1 respectively.,The disposition of primidone in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291873/),[ml] / [h·kg],34.8,212078,DB01174,Phenobarbital
,2291873,clearance,2. Primidone half-lives and clearance values (mean +/- s.d.) were similar in the elderly and in the young (12.1 +/- 4.6 vs 14.7 +/- 3.5 h and 34.8 +/- 9.0 vs 33.2 +/- 7.2 ml h-1 kg-1 respectively.,The disposition of primidone in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291873/),[ml] / [h·kg],33.2,212079,DB01174,Phenobarbital
,22281062,effective doses (ED(50),"Moreover, HMIPPS (50mg/kg) significantly enhanced the anticonvulsant activity of phenobarbital and valproate in the mouse maximal electroshock-induced seizure model by reducing their median effective doses (ED(50) values) from 23.25mg/kg to 16.82 mg/kg (P<0.01; for phenobarbital) and from 259.3mg/kg to 189.7 mg/kg (P<0.001; for valproate), respectively.",Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22281062/),[mg] / [kg],23.25,213580,DB01174,Phenobarbital
,22281062,effective doses (ED(50),"Moreover, HMIPPS (50mg/kg) significantly enhanced the anticonvulsant activity of phenobarbital and valproate in the mouse maximal electroshock-induced seizure model by reducing their median effective doses (ED(50) values) from 23.25mg/kg to 16.82 mg/kg (P<0.01; for phenobarbital) and from 259.3mg/kg to 189.7 mg/kg (P<0.001; for valproate), respectively.",Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22281062/),[mg] / [kg],16.82,213581,DB01174,Phenobarbital
,22281062,effective doses (ED(50),"Moreover, HMIPPS (50mg/kg) significantly enhanced the anticonvulsant activity of phenobarbital and valproate in the mouse maximal electroshock-induced seizure model by reducing their median effective doses (ED(50) values) from 23.25mg/kg to 16.82 mg/kg (P<0.01; for phenobarbital) and from 259.3mg/kg to 189.7 mg/kg (P<0.001; for valproate), respectively.",Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22281062/),[mg] / [kg],259.3,213582,DB01174,Phenobarbital
,22281062,effective doses (ED(50),"Moreover, HMIPPS (50mg/kg) significantly enhanced the anticonvulsant activity of phenobarbital and valproate in the mouse maximal electroshock-induced seizure model by reducing their median effective doses (ED(50) values) from 23.25mg/kg to 16.82 mg/kg (P<0.01; for phenobarbital) and from 259.3mg/kg to 189.7 mg/kg (P<0.001; for valproate), respectively.",Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22281062/),[mg] / [kg],189.7,213583,DB01174,Phenobarbital
,22281062,ED(50),"HMIPPS (25mg/kg) significantly potentiated the anticonvulsant action of valproate by reducing its ED(50) value from 259.3mg/kg to 210.6 mg/kg (P>0.05), but not that of phenobarbital, phenytoin and carbamazepine in the mouse maximal electroshock-induced seizure model.",Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22281062/),[mg] / [kg],259.3,213584,DB01174,Phenobarbital
,22281062,ED(50),"HMIPPS (25mg/kg) significantly potentiated the anticonvulsant action of valproate by reducing its ED(50) value from 259.3mg/kg to 210.6 mg/kg (P>0.05), but not that of phenobarbital, phenytoin and carbamazepine in the mouse maximal electroshock-induced seizure model.",Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22281062/),[mg] / [kg],210.6,213585,DB01174,Phenobarbital
,2724142,elimination half-life,The pharmacokinetics of phenobarbital were studied in a separate set of rats (elimination half-life 11 +/- 2 hr).,Pharmacokinetic modeling of the anticonvulsant action of phenobarbital in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724142/),h,11,214436,DB01174,Phenobarbital
,2724142,EC50,"The EC50 for total serum was 76 +/- 9 mg/l and for free serum, cerebrospinal fluid and brain 44 +/- 5, 43 +/- 7 and 50 +/- 8 mg/l and mg/kg, respectively (means +/- S.E.).",Pharmacokinetic modeling of the anticonvulsant action of phenobarbital in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724142/),[mg] / [l],76,214437,DB01174,Phenobarbital
,2724142,EC50,"The EC50 for total serum was 76 +/- 9 mg/l and for free serum, cerebrospinal fluid and brain 44 +/- 5, 43 +/- 7 and 50 +/- 8 mg/l and mg/kg, respectively (means +/- S.E.).",Pharmacokinetic modeling of the anticonvulsant action of phenobarbital in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724142/),[mg] / [l],44,214438,DB01174,Phenobarbital
,2724142,EC50,"The EC50 for total serum was 76 +/- 9 mg/l and for free serum, cerebrospinal fluid and brain 44 +/- 5, 43 +/- 7 and 50 +/- 8 mg/l and mg/kg, respectively (means +/- S.E.).",Pharmacokinetic modeling of the anticonvulsant action of phenobarbital in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724142/),[mg] / [l],43,214439,DB01174,Phenobarbital
,2724142,EC50,"The EC50 for total serum was 76 +/- 9 mg/l and for free serum, cerebrospinal fluid and brain 44 +/- 5, 43 +/- 7 and 50 +/- 8 mg/l and mg/kg, respectively (means +/- S.E.).",Pharmacokinetic modeling of the anticonvulsant action of phenobarbital in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724142/),[mg] / [l],50,214440,DB01174,Phenobarbital
,2724142,maximum effect,The maximum effect was about 120 mg/l of pentylenetrazol.,Pharmacokinetic modeling of the anticonvulsant action of phenobarbital in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724142/),[mg] / [l],120,214441,DB01174,Phenobarbital
,7153873,plasma clearance (CL),"The mean (+/- SD) of plasma clearance (CL), volume of distribution (V), and half-life (t 1/2) during the control period for EPO were 5.57 +/- 2.15 liters/hr, 7.48 +/- 2.50 liters and 0.95 +/- 0.16 hr, respectively.","Induction effect of phenobarbital on carbamazepine-10,11-epoxide kinetics in the rhesus monkey. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7153873/),[l] / [h],5.57,214654,DB01174,Phenobarbital
,7153873,volume of distribution (V),"The mean (+/- SD) of plasma clearance (CL), volume of distribution (V), and half-life (t 1/2) during the control period for EPO were 5.57 +/- 2.15 liters/hr, 7.48 +/- 2.50 liters and 0.95 +/- 0.16 hr, respectively.","Induction effect of phenobarbital on carbamazepine-10,11-epoxide kinetics in the rhesus monkey. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7153873/),l,7.48,214655,DB01174,Phenobarbital
,7153873,half-life (t 1/2),"The mean (+/- SD) of plasma clearance (CL), volume of distribution (V), and half-life (t 1/2) during the control period for EPO were 5.57 +/- 2.15 liters/hr, 7.48 +/- 2.50 liters and 0.95 +/- 0.16 hr, respectively.","Induction effect of phenobarbital on carbamazepine-10,11-epoxide kinetics in the rhesus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7153873/),h,0.95,214656,DB01174,Phenobarbital
,7153873,CL,"Subchronic administration of PB caused an increase in CL (8.23 +/- 2.03 liters/hr, p less than 0.05), a decrease in t 1/2 (0.67 +/- 0.09, p larger than 0.05 but less than 0.10), and no change in V.","Induction effect of phenobarbital on carbamazepine-10,11-epoxide kinetics in the rhesus monkey. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7153873/),[l] / [h],8.23,214657,DB01174,Phenobarbital
,7153873,t 1/2,"Subchronic administration of PB caused an increase in CL (8.23 +/- 2.03 liters/hr, p less than 0.05), a decrease in t 1/2 (0.67 +/- 0.09, p larger than 0.05 but less than 0.10), and no change in V.","Induction effect of phenobarbital on carbamazepine-10,11-epoxide kinetics in the rhesus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7153873/),,0.67,214658,DB01174,Phenobarbital
up to,1743171,bioavailability,"Storage of carbamazepine (CBZ) and phenytoin (PHT) formulations in hot, humid conditions alters the dosage form and reduces bioavailability up to 50%.",Pharmacokinetic pitfalls of present antiepileptic medications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743171/),%,50,215613,DB01174,Phenobarbital
,3392664,total apparent oral clearance,"Mean total apparent oral clearance after a single dose of verapamil was increased after phenobarbital treatment (75.1 +/- 49.2 vs. 376.2 +/- 221.8 ml/min/kg, P less than .05).",Effects of chronic phenobarbital on verapamil disposition in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392664/),[ml] / [kg·min],75.1,217679,DB01174,Phenobarbital
,3392664,total apparent oral clearance,"Mean total apparent oral clearance after a single dose of verapamil was increased after phenobarbital treatment (75.1 +/- 49.2 vs. 376.2 +/- 221.8 ml/min/kg, P less than .05).",Effects of chronic phenobarbital on verapamil disposition in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392664/),[ml] / [kg·min],376.2,217680,DB01174,Phenobarbital
,3392664,systemic clearance,"Mean total verapamil systemic clearance was increased (9.95 +/- 1.3 vs. 18.9 +/- 8.7 ml/min/kg, P less than .05); however free drug clearance was not altered.",Effects of chronic phenobarbital on verapamil disposition in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392664/),[ml] / [kg·min],9.95,217681,DB01174,Phenobarbital
,3392664,systemic clearance,"Mean total verapamil systemic clearance was increased (9.95 +/- 1.3 vs. 18.9 +/- 8.7 ml/min/kg, P less than .05); however free drug clearance was not altered.",Effects of chronic phenobarbital on verapamil disposition in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392664/),[ml] / [kg·min],18.9,217682,DB01174,Phenobarbital
,3392664,apparent oral clearance,"After multiple oral administration, total verapamil apparent oral clearance was increased after phenobarbital pretreatment (21.2 +/- 9.8 vs. 91.2 +/- 28.5 ml/min/kg, P less than .05).",Effects of chronic phenobarbital on verapamil disposition in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392664/),[ml] / [kg·min],21.2,217683,DB01174,Phenobarbital
,3392664,apparent oral clearance,"After multiple oral administration, total verapamil apparent oral clearance was increased after phenobarbital pretreatment (21.2 +/- 9.8 vs. 91.2 +/- 28.5 ml/min/kg, P less than .05).",Effects of chronic phenobarbital on verapamil disposition in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392664/),[ml] / [kg·min],91.2,217684,DB01174,Phenobarbital
,16525862,half-life of,"The half-life of the induction process was estimated to be 2 days for CYP1A2, CYP3A1/2, and CYP2B1/2, and 3 days for androstenedione producing enzymes.",A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16525862/),d,2,218374,DB01174,Phenobarbital
,16525862,half-life of,"The half-life of the induction process was estimated to be 2 days for CYP1A2, CYP3A1/2, and CYP2B1/2, and 3 days for androstenedione producing enzymes.",A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16525862/),d,3,218375,DB01174,Phenobarbital
,6502518,volume of distribution,The volume of distribution of phenobarbital in obese Zucker rats was larger (0.416 liter) than for lean Zucker (0.299 liter) or Sprague-Dawley rats (0.312 liter).,Phenobarbital in the genetically obese Zucker rat. I. Pharmacokinetics after acute and chronic administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502518/),l,0.416,218854,DB01174,Phenobarbital
,6502518,volume of distribution,The volume of distribution of phenobarbital in obese Zucker rats was larger (0.416 liter) than for lean Zucker (0.299 liter) or Sprague-Dawley rats (0.312 liter).,Phenobarbital in the genetically obese Zucker rat. I. Pharmacokinetics after acute and chronic administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502518/),l,0.299,218855,DB01174,Phenobarbital
,6502518,volume of distribution,The volume of distribution of phenobarbital in obese Zucker rats was larger (0.416 liter) than for lean Zucker (0.299 liter) or Sprague-Dawley rats (0.312 liter).,Phenobarbital in the genetically obese Zucker rat. I. Pharmacokinetics after acute and chronic administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502518/),l,0.312,218856,DB01174,Phenobarbital
,6502518,clearance,"Intra- and inter-strain differences in phenobarbital clearance were observed between the obese and lean Zucker (11.9 and 14.1 ml/hr, respectively) and lean Sprague-Dawley rats (23.0 ml/hr).",Phenobarbital in the genetically obese Zucker rat. I. Pharmacokinetics after acute and chronic administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502518/),[ml] / [h],11.9,218857,DB01174,Phenobarbital
,6502518,clearance,"Intra- and inter-strain differences in phenobarbital clearance were observed between the obese and lean Zucker (11.9 and 14.1 ml/hr, respectively) and lean Sprague-Dawley rats (23.0 ml/hr).",Phenobarbital in the genetically obese Zucker rat. I. Pharmacokinetics after acute and chronic administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502518/),[ml] / [h],14.1,218858,DB01174,Phenobarbital
,6502518,clearance,"Intra- and inter-strain differences in phenobarbital clearance were observed between the obese and lean Zucker (11.9 and 14.1 ml/hr, respectively) and lean Sprague-Dawley rats (23.0 ml/hr).",Phenobarbital in the genetically obese Zucker rat. I. Pharmacokinetics after acute and chronic administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502518/),[ml] / [h],23.0,218859,DB01174,Phenobarbital
,2053116,plasma clearance,"Patients had a significantly higher plasma clearance of CBZ-E than the control group (mean values +/- SD = 220.2 +/- 63.5 versus 112.5 +/- 46.0 ml/h/kg, p less than 0.007) and a significantly shorter plasma half-life (mean values +/- SD = 4.3 +/- 1.0 versus 6.7 +/- 0.8 h, p less than 0.0015).","Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053116/),[ml] / [h·kg],220.2,220515,DB01174,Phenobarbital
,2053116,plasma clearance,"Patients had a significantly higher plasma clearance of CBZ-E than the control group (mean values +/- SD = 220.2 +/- 63.5 versus 112.5 +/- 46.0 ml/h/kg, p less than 0.007) and a significantly shorter plasma half-life (mean values +/- SD = 4.3 +/- 1.0 versus 6.7 +/- 0.8 h, p less than 0.0015).","Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053116/),[ml] / [h·kg],112.5,220516,DB01174,Phenobarbital
,2053116,plasma half-life,"Patients had a significantly higher plasma clearance of CBZ-E than the control group (mean values +/- SD = 220.2 +/- 63.5 versus 112.5 +/- 46.0 ml/h/kg, p less than 0.007) and a significantly shorter plasma half-life (mean values +/- SD = 4.3 +/- 1.0 versus 6.7 +/- 0.8 h, p less than 0.0015).","Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053116/),h,4.3,220517,DB01174,Phenobarbital
,2053116,plasma half-life,"Patients had a significantly higher plasma clearance of CBZ-E than the control group (mean values +/- SD = 220.2 +/- 63.5 versus 112.5 +/- 46.0 ml/h/kg, p less than 0.007) and a significantly shorter plasma half-life (mean values +/- SD = 4.3 +/- 1.0 versus 6.7 +/- 0.8 h, p less than 0.0015).","Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053116/),h,6.7,220518,DB01174,Phenobarbital
,9140764,limit of detection (LOD),"The accuracy and precision of the assay were within +/- 15% and the limit of detection (LOD) was 1 microM, suitable for pharmacokinetic studies.",High-performance liquid chromatographic analysis of phenobarbital and phenobarbital metabolites in human urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9140764/),μM,1,220608,DB01174,Phenobarbital
,12692732,partition coefficient PB,"We applied these techniques to study the in vivo metabolism of hexamethyldisiloxane (HMDS), a volatile siloxane with low blood/air (partition coefficient PB approximately 1.00) and high fat/blood partitioning (partition coefficient PF approximately 300).",Closed-chamber inhalation pharmacokinetic studies with hexamethyldisiloxane in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12692732/),,1.00,220780,DB01174,Phenobarbital
,12692732,partition coefficient,"We applied these techniques to study the in vivo metabolism of hexamethyldisiloxane (HMDS), a volatile siloxane with low blood/air (partition coefficient PB approximately 1.00) and high fat/blood partitioning (partition coefficient PF approximately 300).",Closed-chamber inhalation pharmacokinetic studies with hexamethyldisiloxane in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12692732/),,300,220781,DB01174,Phenobarbital
,12692732,PF,"We applied these techniques to study the in vivo metabolism of hexamethyldisiloxane (HMDS), a volatile siloxane with low blood/air (partition coefficient PB approximately 1.00) and high fat/blood partitioning (partition coefficient PF approximately 300).",Closed-chamber inhalation pharmacokinetic studies with hexamethyldisiloxane in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12692732/),,300,220782,DB01174,Phenobarbital
,12692732,V(max),"Metabolism, restricted to the liver, was described as a single saturable process (V(max) = 113.6 micro mol/h/kg; K(m) = 42.6 micro mol/L) and was affected by inhibitors (diethyldithiocarbamate) or inducers (phenobarbital) of cytochrome P-450s.",Closed-chamber inhalation pharmacokinetic studies with hexamethyldisiloxane in the rat. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12692732/),[μmol] / [h·kg],113.6,220783,DB01174,Phenobarbital
,12692732,K(m),"Metabolism, restricted to the liver, was described as a single saturable process (V(max) = 113.6 micro mol/h/kg; K(m) = 42.6 micro mol/L) and was affected by inhibitors (diethyldithiocarbamate) or inducers (phenobarbital) of cytochrome P-450s.",Closed-chamber inhalation pharmacokinetic studies with hexamethyldisiloxane in the rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12692732/),[μmol] / [l],42.6,220784,DB01174,Phenobarbital
,6845397,clearance,"Prior to barbiturate treatment, theophylline clearance was 4.78 ml/kg/min.",Effect of secobarbital on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6845397/),[ml] / [kg·min],4.78,221737,DB01174,Phenobarbital
,6845397,peak value,"After 29 days of barbiturate administration, theophylline clearance attained a peak value of 16.1 ml/kg/min, an increase of 337% from the prebarbiturate rate.",Effect of secobarbital on theophylline clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6845397/),[ml] / [kg·min],16.1,221738,DB01174,Phenobarbital
,6845397,clearance,"After secobarbital was discontinued, theophylline clearance returned to 4.53 ml/kg/min.",Effect of secobarbital on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6845397/),[ml] / [kg·min],4.53,221739,DB01174,Phenobarbital
,25098448,concentrations,Group 2 median concentrations were 26.0 μg/ml (observed range 18.0-37.0 μg/ml).,Therapeutic serum phenobarbital concentrations obtained using chronic transdermal administration of phenobarbital in healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25098448/),[μg] / [ml],26.0,222771,DB01174,Phenobarbital
,9040097,Concentrations,Concentrations of codeine and phenobarbital in SD hair samples were 0.98 +/- 0.10 and 17.01 +/- 1.40 ng/mg hair.,A comparison of phenobarbital and codeine incorporation into pigmented and nonpigmented rat hair. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040097/),ng,0.98,223112,DB01174,Phenobarbital
,9040097,Concentrations,Concentrations of codeine and phenobarbital in SD hair samples were 0.98 +/- 0.10 and 17.01 +/- 1.40 ng/mg hair.,A comparison of phenobarbital and codeine incorporation into pigmented and nonpigmented rat hair. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040097/),ng,17.01,223113,DB01174,Phenobarbital
,9040097,areas under the curve (AUC),"The areas under the curve (AUC) of plasma concentration versus time for codeine and phenobarbital were 1.58 and 414.50 micrograms h/microL, respectively.",A comparison of phenobarbital and codeine incorporation into pigmented and nonpigmented rat hair. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040097/),[h·μg] / [μl],1.58,223114,DB01174,Phenobarbital
,9040097,areas under the curve (AUC),"The areas under the curve (AUC) of plasma concentration versus time for codeine and phenobarbital were 1.58 and 414.50 micrograms h/microL, respectively.",A comparison of phenobarbital and codeine incorporation into pigmented and nonpigmented rat hair. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040097/),[h·μg] / [μl],414.50,223115,DB01174,Phenobarbital
,15890479,total area under the plasma concentration-time curve from time zero to time infinity (AUC),The total area under the plasma concentration-time curve from time zero to time infinity (AUC) of torasemide was significantly greater in rats pretreated with SKF 525-A (a non-specific CYP isozyme inhibitor in rats) than that in control rats (3570 versus 1350 microg min/ml).,Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15890479/),[min·μg] / [ml],3570,223408,DB01174,Phenobarbital
,15890479,total area under the plasma concentration-time curve from time zero to time infinity (AUC),The total area under the plasma concentration-time curve from time zero to time infinity (AUC) of torasemide was significantly greater in rats pretreated with SKF 525-A (a non-specific CYP isozyme inhibitor in rats) than that in control rats (3570 versus 1350 microg min/ml).,Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15890479/),[min·μg] / [ml],1350,223409,DB01174,Phenobarbital
,15890479,AUC,"However, in rats pretreated with dexamethasone (a main inducer of CYP3A1/2 in rats), the AUC was significantly smaller than that in control rats (1290 versus 1590 microg min/ml).",Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15890479/),[min·μg] / [ml],1290,223410,DB01174,Phenobarbital
,15890479,AUC,"However, in rats pretreated with dexamethasone (a main inducer of CYP3A1/2 in rats), the AUC was significantly smaller than that in control rats (1290 versus 1590 microg min/ml).",Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15890479/),[min·μg] / [ml],1590,223411,DB01174,Phenobarbital
,15890479,AUC,It has been reported from our laboratories that in rats pretreated with sulfaphenazole (a main inhibitor of CYP2C11 in rats) the AUC was significantly greater than that in control rats (2970 versus 1610 microg min/ml).,Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15890479/),[min·μg] / [ml],2970,223412,DB01174,Phenobarbital
,15890479,AUC,It has been reported from our laboratories that in rats pretreated with sulfaphenazole (a main inhibitor of CYP2C11 in rats) the AUC was significantly greater than that in control rats (2970 versus 1610 microg min/ml).,Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15890479/),[min·μg] / [ml],1610,223413,DB01174,Phenobarbital
,29897629,serum concentration,"Median phenobarbital dose was enteral = 2.6 (IQR 1.9, 3.9) mg kg-1 dose-1 ; intravenous = 2.6 (IQR 2.2, 4.9) mg kg-1 dose-1 ) and mean serum concentration was 41.1 ± 23.9 mg/L at median 6.5 (IQR 2.9, 11.1) hours after a dose.",Phenobarbital population pharmacokinetics across the pediatric age spectrum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29897629/),[mg] / [l],41.1,223760,DB01174,Phenobarbital
,2338627,concentrations,"With a phenobarbital dose of 100 mg/kg daily, CSF concentrations at the onset of LRR significantly increased from 136 +/- 12 to 176 +/- 21 mg/L (p less than 0.001), indicating that functional tolerance developed for the anesthetic effect.",Pharmacodynamics of tolerance development to the anesthetic and anticonvulsant effects of phenobarbital in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338627/),mg,136,225170,DB01174,Phenobarbital
,2338627,concentrations,"With a phenobarbital dose of 100 mg/kg daily, CSF concentrations at the onset of LRR significantly increased from 136 +/- 12 to 176 +/- 21 mg/L (p less than 0.001), indicating that functional tolerance developed for the anesthetic effect.",Pharmacodynamics of tolerance development to the anesthetic and anticonvulsant effects of phenobarbital in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338627/),mg,176,225171,DB01174,Phenobarbital
,34255318,total clearance,The population mean value of lamotrigine total clearance generated in the final model (with covariates) was 2.12 L/hr.,Population Pharmacokinetics Modeling of Lamotrigine in Jordanian Epileptic Patients Using Dried Blood Spot Sampling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34255318/),[l] / [h],2.12,226356,DB01174,Phenobarbital
,26496779,half-life,"In adults, the half-life of phenobarbital is 100 hours and in term and preterm infants is 103 and 141 hours, respectively.","Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26496779/),h,100,226362,DB01174,Phenobarbital
,26496779,half-life,"In adults, the half-life of phenobarbital is 100 hours and in term and preterm infants is 103 and 141 hours, respectively.","Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26496779/),h,103,226363,DB01174,Phenobarbital
,26496779,half-life,"In adults, the half-life of phenobarbital is 100 hours and in term and preterm infants is 103 and 141 hours, respectively.","Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26496779/),h,141,226364,DB01174,Phenobarbital
,26496779,half-life,The half-life of phenobarbital decreases 4.6 hours per day and it is 67 hours in infants 4 week old.,"Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26496779/),[h] / [d],4.6,226365,DB01174,Phenobarbital
,26496779,half-life,The half-life of phenobarbital decreases 4.6 hours per day and it is 67 hours in infants 4 week old.,"Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26496779/),h,67,226366,DB01174,Phenobarbital
,6726633,time to peak concentration,"One of the tablets exhibited a time to peak concentration of 8.6 h, which was significantly longer than any of the other dosage forms.",Absorption of phenobarbital from tablets and elixir. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726633/),h,8.6,227621,DB01174,Phenobarbital
greater,1550696,Peak blood PB concentrations,"3. Peak blood PB concentrations were equal to or greater than 15 mg l-1 in 27% of the patients on quinine and 23% of those not on quinine; a concentration of 10 mg l-1 was achieved or exceeded by 100% and 92% of each group, respectively, and was maintained for 39 +/- 24 h (mean +/- s.d.), and 33 +/- 21 h, respectively.",Prophylactic phenobarbitone in young children with severe falciparum malaria: pharmacokinetics and clinical effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1550696/),[mg] / [l],15,227841,DB01174,Phenobarbital
,32224827,peak,Optimal phenobarbital loading doses were determined based on attainment of peak and maintenance concentrations between 20 and 40 mg/L.,Population Pharmacokinetics of IV Phenobarbital in Neonates After Congenital Heart Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32224827/),[mg] / [l],20 and 40,227934,DB01174,Phenobarbital
,32224827,maintenance concentrations,Optimal phenobarbital loading doses were determined based on attainment of peak and maintenance concentrations between 20 and 40 mg/L.,Population Pharmacokinetics of IV Phenobarbital in Neonates After Congenital Heart Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32224827/),[mg] / [l],20 and 40,227935,DB01174,Phenobarbital
,7094973,apparent plasma half-lives,"In the first group, the apparent plasma half-lives ranged from 96 to 6.8 h with a significant inverse relationship (p less than 0.01) between the gestational age and the elimination rate.",Pharmacokinetics of furosemide in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094973/),h,96 to 6.8,228897,DB01174,Phenobarbital
,7094973,plasma half-life,"In the neonates receiving the drug i.v. for therapeutic reasons, the elimination kinetics appeared to follow a two-compartment open model, with a significant difference in the therminal plasma half-life between premature (26.8 +/- 12.2 h) and full-term newborns (13.4 +/- 8.6 h).",Pharmacokinetics of furosemide in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094973/),h,26.8,228898,DB01174,Phenobarbital
,7094973,plasma half-life,"In the neonates receiving the drug i.v. for therapeutic reasons, the elimination kinetics appeared to follow a two-compartment open model, with a significant difference in the therminal plasma half-life between premature (26.8 +/- 12.2 h) and full-term newborns (13.4 +/- 8.6 h).",Pharmacokinetics of furosemide in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094973/),h,13.4,228899,DB01174,Phenobarbital
,210001,Biological half-life,"Biological half-life in environmentally contaminated cows, studied for 6 months about a year after contamination, was 60 days.",Distribution and kinetics of PBB residues in cattle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/210001/),d,60,229002,DB01174,Phenobarbital
,7002338,t1/2,No cases of peripheral neuropathy were seen and the plasma misonidazole t1/2 of 8.6 +/- 0.62 (S.D.) hours were low.,The Cambridge glioma trial of misonidazole and radiation therapy with associated pharmacokinetic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7002338/),h,8.6,229875,DB01174,Phenobarbital
,15811169,CL/F,"The final pharmacokinetic parameters were CL/F (mL/h) = 3.41.TBW (kg) + 1.64. PNA (weeks), Vd/F(L) = 1.09.TBW.(kg) [corrected] and F = 0.406 for oral administration and F = 1 for suppository.",Population pharmacokinetic investigation of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811169/),[ml] / [h],3.41,231144,DB01174,Phenobarbital
,15811169,Vd/F,"The final pharmacokinetic parameters were CL/F (mL/h) = 3.41.TBW (kg) + 1.64. PNA (weeks), Vd/F(L) = 1.09.TBW.(kg) [corrected] and F = 0.406 for oral administration and F = 1 for suppository.",Population pharmacokinetic investigation of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811169/),l,1.09,231145,DB01174,Phenobarbital
,15811169,F,"The final pharmacokinetic parameters were CL/F (mL/h) = 3.41.TBW (kg) + 1.64. PNA (weeks), Vd/F(L) = 1.09.TBW.(kg) [corrected] and F = 0.406 for oral administration and F = 1 for suppository.",Population pharmacokinetic investigation of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811169/),,0.406,231146,DB01174,Phenobarbital
,15811169,F,"The final pharmacokinetic parameters were CL/F (mL/h) = 3.41.TBW (kg) + 1.64. PNA (weeks), Vd/F(L) = 1.09.TBW.(kg) [corrected] and F = 0.406 for oral administration and F = 1 for suppository.",Population pharmacokinetic investigation of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811169/),,1,231147,DB01174,Phenobarbital
>,33107271,time to normalization,"Severe asphyxia was defined as pH of arterial umbilical cord blood ≤7.1 and Apgar 5 ≤5, and severe HIE was defined as time to normalization of amplitude-integrated electroencephalography (aEEG) >24 h.",Severity parameters for asphyxia or hypoxic-ischemic encephalopathy do not explain interindividual variability in the pharmacokinetics of phenobarbital in newborns treated with therapeutic hypothermia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107271/),h,24,231777,DB01174,Phenobarbital
,33107271,volume of distribution,At weight of 1 kg volume of distribution was 0.91 L and for every additional kg it increased in 0.91 L.,Severity parameters for asphyxia or hypoxic-ischemic encephalopathy do not explain interindividual variability in the pharmacokinetics of phenobarbital in newborns treated with therapeutic hypothermia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107271/),l,0.91,231778,DB01174,Phenobarbital
,33107271,Clearance,Clearance was 0.00563 L/h.,Severity parameters for asphyxia or hypoxic-ischemic encephalopathy do not explain interindividual variability in the pharmacokinetics of phenobarbital in newborns treated with therapeutic hypothermia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107271/),[l] / [h],0.00563,231779,DB01174,Phenobarbital
,11298071,Apparent remacemide clearance (CL/F),"Apparent remacemide clearance (CL/F) and elimination half-life values were unchanged after 7 days intake of the drug in the absence of phenobarbitone (1.25 +/- 0.32 vs 1.18 +/- 0.22 l kg(-1) h(-1) and 3.29 +/- 0.68 vs 3.62 +/- 0.85 h, respectively).",Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298071/),[l] / [h·kg],1.25,232781,DB01174,Phenobarbital
,11298071,Apparent remacemide clearance (CL/F),"Apparent remacemide clearance (CL/F) and elimination half-life values were unchanged after 7 days intake of the drug in the absence of phenobarbitone (1.25 +/- 0.32 vs 1.18 +/- 0.22 l kg(-1) h(-1) and 3.29 +/- 0.68 vs 3.62 +/- 0.85 h, respectively).",Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298071/),[l] / [h·kg],1.18,232782,DB01174,Phenobarbital
,11298071,elimination half-life,"Apparent remacemide clearance (CL/F) and elimination half-life values were unchanged after 7 days intake of the drug in the absence of phenobarbitone (1.25 +/- 0.32 vs 1.18 +/- 0.22 l kg(-1) h(-1) and 3.29 +/- 0.68 vs 3.62 +/- 0.85 h, respectively).",Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298071/),[l] / [h·kg],1.18,232783,DB01174,Phenobarbital
,11298071,elimination half-life,"Apparent remacemide clearance (CL/F) and elimination half-life values were unchanged after 7 days intake of the drug in the absence of phenobarbitone (1.25 +/- 0.32 vs 1.18 +/- 0.22 l kg(-1) h(-1) and 3.29 +/- 0.68 vs 3.62 +/- 0.85 h, respectively).",Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298071/),h,3.29,232784,DB01174,Phenobarbital
,11298071,elimination half-life,"Apparent remacemide clearance (CL/F) and elimination half-life values were unchanged after 7 days intake of the drug in the absence of phenobarbitone (1.25 +/- 0.32 vs 1.18 +/- 0.22 l kg(-1) h(-1) and 3.29 +/- 0.68 vs 3.62 +/- 0.85 h, respectively).",Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298071/),h,3.62,232785,DB01174,Phenobarbital
,11298071,CL/F,"Concomitant administration of remacemide with phenobarbitone resulted in an increase in the estimated CL/F of remacemide (1.25 +/- 0.32 vs 2.09 +/-0.53 l kg-1 h-1), and a decreased remacemide half-life (3.29 +/- 0.68 vs 2.69 +/- 0.33 h).",Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298071/),[l] / [h·kg],1.25,232786,DB01174,Phenobarbital
,11298071,CL/F,"Concomitant administration of remacemide with phenobarbitone resulted in an increase in the estimated CL/F of remacemide (1.25 +/- 0.32 vs 2.09 +/-0.53 l kg-1 h-1), and a decreased remacemide half-life (3.29 +/- 0.68 vs 2.69 +/- 0.33 h).",Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298071/),[l] / [h·kg],2.09,232787,DB01174,Phenobarbital
,11298071,half-life,"Concomitant administration of remacemide with phenobarbitone resulted in an increase in the estimated CL/F of remacemide (1.25 +/- 0.32 vs 2.09 +/-0.53 l kg-1 h-1), and a decreased remacemide half-life (3.29 +/- 0.68 vs 2.69 +/- 0.33 h).",Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298071/),h,3.29,232788,DB01174,Phenobarbital
,11298071,half-life,"Concomitant administration of remacemide with phenobarbitone resulted in an increase in the estimated CL/F of remacemide (1.25 +/- 0.32 vs 2.09 +/-0.53 l kg-1 h-1), and a decreased remacemide half-life (3.29 +/- 0.68 vs 2.69 +/- 0.33 h).",Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298071/),h,2.69,232789,DB01174,Phenobarbital
,11298071,half-life,"The elimination of the desglycinyl metabolite of remacemide also appeared to be increased after the phenobarbitone intake (half-life 14.72 +/- 2.82 vs 9.61 +/- 5.51 h, AUC 1532 +/- 258 vs 533 +/- 281 ng ml(-1) h).",Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298071/),h,14.72,232790,DB01174,Phenobarbital
,11298071,half-life,"The elimination of the desglycinyl metabolite of remacemide also appeared to be increased after the phenobarbitone intake (half-life 14.72 +/- 2.82 vs 9.61 +/- 5.51 h, AUC 1532 +/- 258 vs 533 +/- 281 ng ml(-1) h).",Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298071/),h,9.61,232791,DB01174,Phenobarbital
,11298071,AUC,"The elimination of the desglycinyl metabolite of remacemide also appeared to be increased after the phenobarbitone intake (half-life 14.72 +/- 2.82 vs 9.61 +/- 5.51 h, AUC 1532 +/- 258 vs 533 +/- 281 ng ml(-1) h).",Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298071/),[h·ng] / [ml],1532,232792,DB01174,Phenobarbital
,11298071,AUC,"The elimination of the desglycinyl metabolite of remacemide also appeared to be increased after the phenobarbitone intake (half-life 14.72 +/- 2.82 vs 9.61 +/- 5.51 h, AUC 1532 +/- 258 vs 533 +/- 281 ng ml(-1) h).",Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11298071/),[h·ng] / [ml],533,232793,DB01174,Phenobarbital
,16600575,50% effective dose,"For example, in the proportion of 1:1 the theoretically calculated 50% effective dose for additivity (ED(50add)) was 138 mg/kg, while the experimentally derived ED(50) for the mixture (ED(50mix)) was 85.2 mg/kg.",Isobolographic analysis of interactions between losigamone and conventional antiepileptic drugs in the mouse maximal electroshock model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16600575/),,138,234359,DB01174,Phenobarbital
,16600575,ED(50),"For example, in the proportion of 1:1 the theoretically calculated 50% effective dose for additivity (ED(50add)) was 138 mg/kg, while the experimentally derived ED(50) for the mixture (ED(50mix)) was 85.2 mg/kg.",Isobolographic analysis of interactions between losigamone and conventional antiepileptic drugs in the mouse maximal electroshock model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16600575/),[mg] / [kg],85.2,234360,DB01174,Phenobarbital
,22246398,serum concentration,The mean ± SD serum concentration of OHC was 14.47 ± 8.28 μg/mL at a mean daily dose of 16.22 ± 7.99 mg/kg.,Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22246398/),[μg] / [ml],14.47,235025,DB01174,Phenobarbital
,9571229,AUC ratio,"For the control rats, the mean AUC for (S)-IF in plasma was greater than that for (R)-IF (R/S AUC ratio, 0.78) and the mean half-life of 41.8 min for (S)-IF was slightly longer than that of 34.3 min for (R)-IF.",Effects of phenobarbital on stereoselective metabolism of ifosfamide in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571229/),,0.78,235252,DB01174,Phenobarbital
,9571229,half-life,"For the control rats, the mean AUC for (S)-IF in plasma was greater than that for (R)-IF (R/S AUC ratio, 0.78) and the mean half-life of 41.8 min for (S)-IF was slightly longer than that of 34.3 min for (R)-IF.",Effects of phenobarbital on stereoselective metabolism of ifosfamide in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571229/),min,41.8,235253,DB01174,Phenobarbital
,9571229,half-life,"For the control rats, the mean AUC for (S)-IF in plasma was greater than that for (R)-IF (R/S AUC ratio, 0.78) and the mean half-life of 41.8 min for (S)-IF was slightly longer than that of 34.3 min for (R)-IF.",Effects of phenobarbital on stereoselective metabolism of ifosfamide in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571229/),min,34.3,235254,DB01174,Phenobarbital
,9571229,half-life,"Phenobarbital pretreatment significantly decreased the AUC values for (R)-IF and (S)-IF, to 21 and 30% of the control values, respectively, and shortened plasma half-lives for both enantiomers [half-life for (R)-IF, 19.8 min; half-life for (S)-IF, 19.4 min].",Effects of phenobarbital on stereoselective metabolism of ifosfamide in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571229/),min,19.8,235255,DB01174,Phenobarbital
,9571229,half-life,"Phenobarbital pretreatment significantly decreased the AUC values for (R)-IF and (S)-IF, to 21 and 30% of the control values, respectively, and shortened plasma half-lives for both enantiomers [half-life for (R)-IF, 19.8 min; half-life for (S)-IF, 19.4 min].",Effects of phenobarbital on stereoselective metabolism of ifosfamide in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571229/),min,19.4,235256,DB01174,Phenobarbital
,21219341,peak concentration (C(max) ),"Compared with values determined when LEV was administered alone, concurrent administration of PB resulted in a decrease in LEV peak concentration (C(max) ) from 32.39 ± 6.76 to 18.22 ± 8.97 (P = 0.0071), a decrease in elimination half-life (T(1/2) ) from 3.43 ± 0.47 to 1.73 ± 0.22 (P = 0.0005), and an increase in oral clearance from 124.93 ± 26.93 to 252.99 ± 135.43 ml/h/kg (P < 0.0001).",The pharmacokinetics of levetiracetam in healthy dogs concurrently receiving phenobarbital. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219341/),,32.39,236411,DB01174,Phenobarbital
,21219341,peak concentration (C(max) ),"Compared with values determined when LEV was administered alone, concurrent administration of PB resulted in a decrease in LEV peak concentration (C(max) ) from 32.39 ± 6.76 to 18.22 ± 8.97 (P = 0.0071), a decrease in elimination half-life (T(1/2) ) from 3.43 ± 0.47 to 1.73 ± 0.22 (P = 0.0005), and an increase in oral clearance from 124.93 ± 26.93 to 252.99 ± 135.43 ml/h/kg (P < 0.0001).",The pharmacokinetics of levetiracetam in healthy dogs concurrently receiving phenobarbital. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219341/),,18.22,236412,DB01174,Phenobarbital
,21219341,elimination half-life (T(1/2) ),"Compared with values determined when LEV was administered alone, concurrent administration of PB resulted in a decrease in LEV peak concentration (C(max) ) from 32.39 ± 6.76 to 18.22 ± 8.97 (P = 0.0071), a decrease in elimination half-life (T(1/2) ) from 3.43 ± 0.47 to 1.73 ± 0.22 (P = 0.0005), and an increase in oral clearance from 124.93 ± 26.93 to 252.99 ± 135.43 ml/h/kg (P < 0.0001).",The pharmacokinetics of levetiracetam in healthy dogs concurrently receiving phenobarbital. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219341/),,3.43,236413,DB01174,Phenobarbital
,21219341,elimination half-life (T(1/2) ),"Compared with values determined when LEV was administered alone, concurrent administration of PB resulted in a decrease in LEV peak concentration (C(max) ) from 32.39 ± 6.76 to 18.22 ± 8.97 (P = 0.0071), a decrease in elimination half-life (T(1/2) ) from 3.43 ± 0.47 to 1.73 ± 0.22 (P = 0.0005), and an increase in oral clearance from 124.93 ± 26.93 to 252.99 ± 135.43 ml/h/kg (P < 0.0001).",The pharmacokinetics of levetiracetam in healthy dogs concurrently receiving phenobarbital. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219341/),,1.73,236414,DB01174,Phenobarbital
,21219341,oral clearance,"Compared with values determined when LEV was administered alone, concurrent administration of PB resulted in a decrease in LEV peak concentration (C(max) ) from 32.39 ± 6.76 to 18.22 ± 8.97 (P = 0.0071), a decrease in elimination half-life (T(1/2) ) from 3.43 ± 0.47 to 1.73 ± 0.22 (P = 0.0005), and an increase in oral clearance from 124.93 ± 26.93 to 252.99 ± 135.43 ml/h/kg (P < 0.0001).",The pharmacokinetics of levetiracetam in healthy dogs concurrently receiving phenobarbital. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219341/),[ml] / [h·kg],124.93,236415,DB01174,Phenobarbital
,21219341,oral clearance,"Compared with values determined when LEV was administered alone, concurrent administration of PB resulted in a decrease in LEV peak concentration (C(max) ) from 32.39 ± 6.76 to 18.22 ± 8.97 (P = 0.0071), a decrease in elimination half-life (T(1/2) ) from 3.43 ± 0.47 to 1.73 ± 0.22 (P = 0.0005), and an increase in oral clearance from 124.93 ± 26.93 to 252.99 ± 135.43 ml/h/kg (P < 0.0001).",The pharmacokinetics of levetiracetam in healthy dogs concurrently receiving phenobarbital. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219341/),[ml] / [h·kg],252.99,236416,DB01174,Phenobarbital
,2143097,elimination half-life (t1/2 b),The elimination half-life (t1/2 b) after the final day of treatment was 43.3 +/- 2.92 h.,Pharmacokinetics of phenobarbital in the cat following multiple oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2143097/),h,43.3,240538,DB01174,Phenobarbital
,2143097,apparent volume of distribution,The large apparent volume of distribution of 695.0 +/- 43.9 mL/kg suggests that the drug was widely distributed within the body.,Pharmacokinetics of phenobarbital in the cat following multiple oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2143097/),[ml] / [kg],695.0,240539,DB01174,Phenobarbital
,10197296,apparent oral clearance,The population mean apparent oral clearance of lamotrigine in adult patients receiving one concomitant enzyme-inducing antiepileptic drug and not valproic acid was estimated to be 1 mL/min/kg.,Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10197296/),[ml] / [kg·min],1,241375,DB01174,Phenobarbital
,17375984,elimination half-lives,The mean elimination half-lives of the highest doses of recombinant human porphobilinogen deaminase ranged between 1.7 and 2.5 hours for both healthy men and asymptomatic porphobilinogen deaminase-deficient subjects.,"Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17375984/),h,1.7 and 2.5,242099,DB01174,Phenobarbital
,17375984,elimination half-life,"The pharmacokinetic profile of recombinant human porphobilinogen deaminase showed dose proportionality, and the elimination half-life was about 2.0 hours for the two highest doses.","Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17375984/),h,2.0,242100,DB01174,Phenobarbital
,26172282,CL,"A typical neonate with NAS (body weight, 2.9 kg; postnatal age; 5.4 days) had a CL of 3.5 L/kg/hour and elimination half-life of 11 hours.",Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26172282/),[l] / [h·kg],3.5,243066,DB01174,Phenobarbital
,26172282,elimination half-life,"A typical neonate with NAS (body weight, 2.9 kg; postnatal age; 5.4 days) had a CL of 3.5 L/kg/hour and elimination half-life of 11 hours.",Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26172282/),h,11,243067,DB01174,Phenobarbital
,16403497,effective dose (ED50),"Moreover, 2-PMPA administered i.p. at a constant dose of 150 mg/kg (the dose increasing the threshold for electroconvulsions) enhanced significantly the anticonvulsant action of valproate, by reducing its median effective dose (ED50) from 281.4 to 230.1 mg/kg (P<0.05).",2-phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16403497/),[mg] / [kg],281.4,243510,DB01174,Phenobarbital
,16403497,effective dose (ED50),"Moreover, 2-PMPA administered i.p. at a constant dose of 150 mg/kg (the dose increasing the threshold for electroconvulsions) enhanced significantly the anticonvulsant action of valproate, by reducing its median effective dose (ED50) from 281.4 to 230.1 mg/kg (P<0.05).",2-phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16403497/),[mg] / [kg],230.1,243511,DB01174,Phenobarbital
,31168770,clearance,"The typical fentanyl clearance for 70 kg (reference weight) and 20.1 kg (median weight) patients were 34.6 and 13.6 L/h, respectively.",Factors Contributing to Fentanyl Pharmacokinetic Variability Among Diagnostically Diverse Critically Ill Children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31168770/),[l] / [h],34.6,247080,DB01174,Phenobarbital
,31168770,clearance,"The typical fentanyl clearance for 70 kg (reference weight) and 20.1 kg (median weight) patients were 34.6 and 13.6 L/h, respectively.",Factors Contributing to Fentanyl Pharmacokinetic Variability Among Diagnostically Diverse Critically Ill Children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31168770/),[l] / [h],13.6,247081,DB01174,Phenobarbital
,25380628,CL/F,Typical value of PB CL/F for final model was estimated at 0.314 l/h.,Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25380628/),[l] / [h],0.314,249519,DB01174,Phenobarbital
,9578000,Css,Twenty-five patients taking phenytoin (PHT) and/ or phenobarbital (PB) and/or primidone (PRM) underwent a rapid switchover to CBZ following a 10 mg/kg single-dose kinetic study (day 1) which allowed calculation of a maintenance dose necessary to yield a mean Css of 10.2 (+/-2.2) mg/l.,Rapid switchover to carbamazepine using pharmacokinetic parameters. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578000/),[mg] / [l],10.2,249787,DB01174,Phenobarbital
,9578000,Css,"All patients completed the switchover to CBZ within a mean time period of 6 days (+/-2), reaching a mean maintenance dose of 1,639 mg/day (+/-370) which yielded a mean Css of 11.3 (+/-3.2) mg/l.",Rapid switchover to carbamazepine using pharmacokinetic parameters. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578000/),[mg] / [l],11.3,249788,DB01174,Phenobarbital
,22612290,"half-life (t(1/2,eff) )","After ESL oral administration, the effective half-life (t(1/2,eff) ) of eslicarbazepine was 20-24 h, which is approximately two times longer than its terminal half-life (t(1/2)).",Pharmacokinetics and drug interactions of eslicarbazepine acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612290/),h,20-24,249977,DB01174,Phenobarbital
,7363932,half-life of,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),min,323,250135,DB01174,Phenobarbital
,7363932,half-life of,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),min,357,250136,DB01174,Phenobarbital
,7363932,half-life of,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),min,344,250137,DB01174,Phenobarbital
,7363932,clearances,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),[ml] / [kg·min],3.41,250138,DB01174,Phenobarbital
,7363932,clearances,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),[ml] / [kg·min],4.08,250139,DB01174,Phenobarbital
,7363932,clearances,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),[ml] / [kg·min],3.81,250140,DB01174,Phenobarbital
,1560386,threshold cerebrospinal fluid concentration,"With respect to the pharmacodynamics, however, evidence for an increase in brain sensitivity was observed, as reflected in a decrease in the threshold cerebrospinal fluid concentration from 181 +/- 4 mg/l (mean +/- S.E.M.) at 4 months to 134 +/- 4 mg/l at 31 months.",Increased sensitivity to the anesthetic effect of phenobarbital in aging BN/BiRij rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1560386/),[mg] / [l],181,250827,DB01174,Phenobarbital
,1560386,threshold cerebrospinal fluid concentration,"With respect to the pharmacodynamics, however, evidence for an increase in brain sensitivity was observed, as reflected in a decrease in the threshold cerebrospinal fluid concentration from 181 +/- 4 mg/l (mean +/- S.E.M.) at 4 months to 134 +/- 4 mg/l at 31 months.",Increased sensitivity to the anesthetic effect of phenobarbital in aging BN/BiRij rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1560386/),[mg] / [l],134,250828,DB01174,Phenobarbital
,9120767,pulmonary extraction ratio,The mean pulmonary extraction ratio was estimated to be 0.06.,In-vivo assessment of extrahepatic metabolism of paeoniflorin in rats: relevance to intestinal floral metabolism. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120767/),,0.06,250869,DB01174,Phenobarbital
,9120767,intestinal permeability,The low intestinal permeability (19.4% at 60 min) was demonstrated by the comparison with phenobarbital (63.1% at 60 min).,In-vivo assessment of extrahepatic metabolism of paeoniflorin in rats: relevance to intestinal floral metabolism. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120767/),%,19.4,250870,DB01174,Phenobarbital
,9120767,intestinal permeability,The low intestinal permeability (19.4% at 60 min) was demonstrated by the comparison with phenobarbital (63.1% at 60 min).,In-vivo assessment of extrahepatic metabolism of paeoniflorin in rats: relevance to intestinal floral metabolism. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120767/),%,63.1,250871,DB01174,Phenobarbital
,10366993,Cl,"The results showed that phenobarbital increased the Cl and Vdss of DTZ from 24 +/- 14 to 51 +/- 4.9 ml/min/kg and from 1.9 +/- 1.2 to 3.8 +/- 0.7 l/kg, respectively (p < 0.05).",Pharmacokinetics and hypotensive effect of diltiazem in rabbits after a single intravenous administration: effect of phenobarbital. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366993/),[ml] / [kg·min],24,252776,DB01174,Phenobarbital
,10366993,Vdss,"The results showed that phenobarbital increased the Cl and Vdss of DTZ from 24 +/- 14 to 51 +/- 4.9 ml/min/kg and from 1.9 +/- 1.2 to 3.8 +/- 0.7 l/kg, respectively (p < 0.05).",Pharmacokinetics and hypotensive effect of diltiazem in rabbits after a single intravenous administration: effect of phenobarbital. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366993/),[ml] / [kg·min],51,252777,DB01174,Phenobarbital
,10366993,Vdss,"The results showed that phenobarbital increased the Cl and Vdss of DTZ from 24 +/- 14 to 51 +/- 4.9 ml/min/kg and from 1.9 +/- 1.2 to 3.8 +/- 0.7 l/kg, respectively (p < 0.05).",Pharmacokinetics and hypotensive effect of diltiazem in rabbits after a single intravenous administration: effect of phenobarbital. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366993/),[l] / [kg],1.9,252778,DB01174,Phenobarbital
,10366993,Vdss,"The results showed that phenobarbital increased the Cl and Vdss of DTZ from 24 +/- 14 to 51 +/- 4.9 ml/min/kg and from 1.9 +/- 1.2 to 3.8 +/- 0.7 l/kg, respectively (p < 0.05).",Pharmacokinetics and hypotensive effect of diltiazem in rabbits after a single intravenous administration: effect of phenobarbital. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366993/),[l] / [kg],3.8,252779,DB01174,Phenobarbital
,3592366,half-life,"The IV treatment mean half-life of phenobarbital sodium was 92.6 +/- 23.7 and 72.3 +/- 15.5 hours, whereas mean total clearance was 5.60 +/- 2.31 and 6.66 +/- 0.78 ml/hr/kg for doses of 5 and 15 mg/kg, respectively.",Pharmacokinetics of single doses of phenobarbital given intravenously and orally to dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592366/),h,92.6,252975,DB01174,Phenobarbital
,3592366,half-life,"The IV treatment mean half-life of phenobarbital sodium was 92.6 +/- 23.7 and 72.3 +/- 15.5 hours, whereas mean total clearance was 5.60 +/- 2.31 and 6.66 +/- 0.78 ml/hr/kg for doses of 5 and 15 mg/kg, respectively.",Pharmacokinetics of single doses of phenobarbital given intravenously and orally to dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592366/),h,72.3,252976,DB01174,Phenobarbital
,3592366,total clearance,"The IV treatment mean half-life of phenobarbital sodium was 92.6 +/- 23.7 and 72.3 +/- 15.5 hours, whereas mean total clearance was 5.60 +/- 2.31 and 6.66 +/- 0.78 ml/hr/kg for doses of 5 and 15 mg/kg, respectively.",Pharmacokinetics of single doses of phenobarbital given intravenously and orally to dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592366/),[ml] / [h·kg],5.60,252977,DB01174,Phenobarbital
,3592366,total clearance,"The IV treatment mean half-life of phenobarbital sodium was 92.6 +/- 23.7 and 72.3 +/- 15.5 hours, whereas mean total clearance was 5.60 +/- 2.31 and 6.66 +/- 0.78 ml/hr/kg for doses of 5 and 15 mg/kg, respectively.",Pharmacokinetics of single doses of phenobarbital given intravenously and orally to dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592366/),[ml] / [h·kg],6.66,252978,DB01174,Phenobarbital
,3592366,mean residence time,"The mean residence time was 124 +/- 34 hours and 106 +/- 23 hours for the 5.5 and 15 mg/kg, IV doses, respectively.",Pharmacokinetics of single doses of phenobarbital given intravenously and orally to dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592366/),h,124,252979,DB01174,Phenobarbital
,3592366,mean residence time,"The mean residence time was 124 +/- 34 hours and 106 +/- 23 hours for the 5.5 and 15 mg/kg, IV doses, respectively.",Pharmacokinetics of single doses of phenobarbital given intravenously and orally to dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592366/),h,106,252980,DB01174,Phenobarbital
,3592366,bioavailability,"Mean bioavailability was 88.1 +/- 12.4% and 96.8 +/- 9.0%, half life of absorption was 0.263 +/- 0.185 and 0.353 +/- 0.443 hour, and lag time was 0.611 +/- 0.683 and 0.741 +/- 0.554 hour for groups A and B, respectively.",Pharmacokinetics of single doses of phenobarbital given intravenously and orally to dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592366/),%,88.1,252981,DB01174,Phenobarbital
,3592366,bioavailability,"Mean bioavailability was 88.1 +/- 12.4% and 96.8 +/- 9.0%, half life of absorption was 0.263 +/- 0.185 and 0.353 +/- 0.443 hour, and lag time was 0.611 +/- 0.683 and 0.741 +/- 0.554 hour for groups A and B, respectively.",Pharmacokinetics of single doses of phenobarbital given intravenously and orally to dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592366/),%,96.8,252982,DB01174,Phenobarbital
,3592366,half life of absorption,"Mean bioavailability was 88.1 +/- 12.4% and 96.8 +/- 9.0%, half life of absorption was 0.263 +/- 0.185 and 0.353 +/- 0.443 hour, and lag time was 0.611 +/- 0.683 and 0.741 +/- 0.554 hour for groups A and B, respectively.",Pharmacokinetics of single doses of phenobarbital given intravenously and orally to dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592366/),h,0.263,252983,DB01174,Phenobarbital
,3592366,half life of absorption,"Mean bioavailability was 88.1 +/- 12.4% and 96.8 +/- 9.0%, half life of absorption was 0.263 +/- 0.185 and 0.353 +/- 0.443 hour, and lag time was 0.611 +/- 0.683 and 0.741 +/- 0.554 hour for groups A and B, respectively.",Pharmacokinetics of single doses of phenobarbital given intravenously and orally to dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592366/),h,0.353,252984,DB01174,Phenobarbital
,3592366,lag time,"Mean bioavailability was 88.1 +/- 12.4% and 96.8 +/- 9.0%, half life of absorption was 0.263 +/- 0.185 and 0.353 +/- 0.443 hour, and lag time was 0.611 +/- 0.683 and 0.741 +/- 0.554 hour for groups A and B, respectively.",Pharmacokinetics of single doses of phenobarbital given intravenously and orally to dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592366/),h,0.611,252985,DB01174,Phenobarbital
,3592366,lag time,"Mean bioavailability was 88.1 +/- 12.4% and 96.8 +/- 9.0%, half life of absorption was 0.263 +/- 0.185 and 0.353 +/- 0.443 hour, and lag time was 0.611 +/- 0.683 and 0.741 +/- 0.554 hour for groups A and B, respectively.",Pharmacokinetics of single doses of phenobarbital given intravenously and orally to dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592366/),h,0.741,252986,DB01174,Phenobarbital
,11180198,AUC,"In rats pretreated with dexamethasone (CYP3A23 inducer), the AUC was significantly smaller (41.5 compared with 52.5 microg min/mL), Cl was significantly faster (72.2 compared with 57.1 mL/min/kg), and the amounts and/or tissue-to-plasma ratios of parathion was significantly (or tended to be) smaller than those in control rats.",Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180198/),[min·μg] / [ml],41.5,253908,DB01174,Phenobarbital
,11180198,AUC,"In rats pretreated with dexamethasone (CYP3A23 inducer), the AUC was significantly smaller (41.5 compared with 52.5 microg min/mL), Cl was significantly faster (72.2 compared with 57.1 mL/min/kg), and the amounts and/or tissue-to-plasma ratios of parathion was significantly (or tended to be) smaller than those in control rats.",Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180198/),[min·μg] / [ml],52.5,253909,DB01174,Phenobarbital
,11180198,Cl,"In rats pretreated with dexamethasone (CYP3A23 inducer), the AUC was significantly smaller (41.5 compared with 52.5 microg min/mL), Cl was significantly faster (72.2 compared with 57.1 mL/min/kg), and the amounts and/or tissue-to-plasma ratios of parathion was significantly (or tended to be) smaller than those in control rats.",Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180198/),[ml] / [kg·min],72.2,253910,DB01174,Phenobarbital
,11180198,Cl,"In rats pretreated with dexamethasone (CYP3A23 inducer), the AUC was significantly smaller (41.5 compared with 52.5 microg min/mL), Cl was significantly faster (72.2 compared with 57.1 mL/min/kg), and the amounts and/or tissue-to-plasma ratios of parathion was significantly (or tended to be) smaller than those in control rats.",Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180198/),[ml] / [kg·min],57.1,253911,DB01174,Phenobarbital
,11180198,Cl(int),This was supported by in vitro intrinsic clearance (Cl(int)) of parathion to form paraoxon in hepatic microsomal fraction; the Cl(int) in rats pretreated with dexamethasone was significantly faster (0.0900 compared with 0.0290 mL/min/mg protein) than that in control rats.,Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180198/),[ml] / [mg·min],0.0900,253912,DB01174,Phenobarbital
,11180198,Cl(int),This was supported by in vitro intrinsic clearance (Cl(int)) of parathion to form paraoxon in hepatic microsomal fraction; the Cl(int) in rats pretreated with dexamethasone was significantly faster (0.0900 compared with 0.0290 mL/min/mg protein) than that in control rats.,Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180198/),[ml] / [mg·min],0.0290,253913,DB01174,Phenobarbital
,5389794,half-life,The mean half-life of antipyrine in the plasma of four sets of identical and four sets of fraternal twins after a single oral dose of 16 mg/kg of antipyrine was 12.7 +/-(SD) 3.3 hr.,Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5389794/),h,12.7,255207,DB01174,Phenobarbital
,5389794,half-life,After 2 wk on sodium phenobarbital (2 mg/kg daily) the half-life of antipyrine in the plasma of these twins was reduced to 8.0 +/-(SD) 1.5 hr.,Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5389794/),h,8.0,255208,DB01174,Phenobarbital
,6815599,clearance,"The antipyrine clearance at term (0.53 +/- 0.11 ml/min/kg, mean +/- SD) was lower than it was early during puerperium (0.70 +/- 0.14 ml/min/kg, P less than .05) and approximately 3 months after delivery (1.14 +/- 0.26 ml/min/kg, P less than .01).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],0.53,256724,DB01174,Phenobarbital
,6815599,clearance,"The antipyrine clearance at term (0.53 +/- 0.11 ml/min/kg, mean +/- SD) was lower than it was early during puerperium (0.70 +/- 0.14 ml/min/kg, P less than .05) and approximately 3 months after delivery (1.14 +/- 0.26 ml/min/kg, P less than .01).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],0.70,256725,DB01174,Phenobarbital
,6815599,clearance,"The antipyrine clearance at term (0.53 +/- 0.11 ml/min/kg, mean +/- SD) was lower than it was early during puerperium (0.70 +/- 0.14 ml/min/kg, P less than .05) and approximately 3 months after delivery (1.14 +/- 0.26 ml/min/kg, P less than .01).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],1.14,256726,DB01174,Phenobarbital
,6815599,clearance,"The antipyrine clearance in nonpregnant epileptics (1.17 +/- 0.44 ml/min/kg) was comparable to that found 3 months after delivery, whereas it was significantly (P less than .01) higher than that found in healthy women (0.47 +/- 0.02 ml/min/kg).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],1.17,256727,DB01174,Phenobarbital
,6815599,clearance,"The antipyrine clearance in nonpregnant epileptics (1.17 +/- 0.44 ml/min/kg) was comparable to that found 3 months after delivery, whereas it was significantly (P less than .01) higher than that found in healthy women (0.47 +/- 0.02 ml/min/kg).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],0.47,256728,DB01174,Phenobarbital
,2591421,distribution half-life,A distribution half-life of 6 +/- 1 min and an elimination half-life of 95 +/- 6 min was determined in Group 1.,Pharmacokinetics and antiarrhythmic efficacy of intravenous ajmaline in ventricular arrhythmia of acute onset. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591421/),min,6,256955,DB01174,Phenobarbital
,2591421,elimination half-life,A distribution half-life of 6 +/- 1 min and an elimination half-life of 95 +/- 6 min was determined in Group 1.,Pharmacokinetics and antiarrhythmic efficacy of intravenous ajmaline in ventricular arrhythmia of acute onset. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591421/),min,95,256956,DB01174,Phenobarbital
,2591421,plasma protein binding,The ajmaline plasma protein binding was 76 +/- 9%.,Pharmacokinetics and antiarrhythmic efficacy of intravenous ajmaline in ventricular arrhythmia of acute onset. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591421/),%,76,256957,DB01174,Phenobarbital
<,9619751,AUC,Five patients demonstrated extremely low AUC and Cmax (< 10 ng/ml) values on day 1.,Pharmacokinetic study of low- versus high-dose medroxyprogesterone acetate (MPA) in women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9619751/),[ng] / [ml],10,257240,DB01174,Phenobarbital
<,9619751,Cmax,Five patients demonstrated extremely low AUC and Cmax (< 10 ng/ml) values on day 1.,Pharmacokinetic study of low- versus high-dose medroxyprogesterone acetate (MPA) in women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9619751/),[ng] / [ml],10,257241,DB01174,Phenobarbital
,2900742,terminal half-life,It has a terminal half-life of 9 hr.,Pharmacokinetics of cannabidiol in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900742/),h,9,257531,DB01174,Phenobarbital
,2900742,total body clearance,The total body clearance of CBD was 17 liters/hr (after the 45-mg dose) and 16 liters/hr (after the 90-mg dose).,Pharmacokinetics of cannabidiol in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900742/),[l] / [h],17,257532,DB01174,Phenobarbital
,2900742,total body clearance,The total body clearance of CBD was 17 liters/hr (after the 45-mg dose) and 16 liters/hr (after the 90-mg dose).,Pharmacokinetics of cannabidiol in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900742/),[l] / [h],16,257533,DB01174,Phenobarbital
,2900742,extraction ratio,"This clearance value, after its normalization to blood clearance using mathematical equations, approaches the value of the hepatic blood flow; the extraction ratio in the liver is 0.74.",Pharmacokinetics of cannabidiol in dogs. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900742/),,0.74,257534,DB01174,Phenobarbital
,2900742,volume of distribution,"CBD was observed to have a large volume of distribution, approximately 100 liters.",Pharmacokinetics of cannabidiol in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900742/),l,100,257535,DB01174,Phenobarbital
,2900742,oral bioavailability,"In the other three, the oral bioavailability ranged from 13 to 19%.",Pharmacokinetics of cannabidiol in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900742/),%,13 to 19,257536,DB01174,Phenobarbital
,2886306,Total body clearance,"Total body clearance of 8-MOP increased from 0.55 +/- 0.06 liter/kg/hr in control rats to 5.6 +/- 0.4, 2.7 +/- 0.4, and 1.2 +/- 0.0 liters/kg/hr in rats pretreated with BNF, PB, and 8-MOP, respectively, indicating that all three compounds are inducers of 8-MOP metabolism.",Disposition of 8-methoxypsoralen in the rat. Induction of metabolism in vivo and in vitro and identification of urinary metabolites by thermospray mass spectrometry. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886306/),[l] / [h·kg],0.55,259009,DB01174,Phenobarbital
,2886306,Total body clearance,"Total body clearance of 8-MOP increased from 0.55 +/- 0.06 liter/kg/hr in control rats to 5.6 +/- 0.4, 2.7 +/- 0.4, and 1.2 +/- 0.0 liters/kg/hr in rats pretreated with BNF, PB, and 8-MOP, respectively, indicating that all three compounds are inducers of 8-MOP metabolism.",Disposition of 8-methoxypsoralen in the rat. Induction of metabolism in vivo and in vitro and identification of urinary metabolites by thermospray mass spectrometry. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886306/),[l] / [h·kg],5.6,259010,DB01174,Phenobarbital
,2886306,Total body clearance,"Total body clearance of 8-MOP increased from 0.55 +/- 0.06 liter/kg/hr in control rats to 5.6 +/- 0.4, 2.7 +/- 0.4, and 1.2 +/- 0.0 liters/kg/hr in rats pretreated with BNF, PB, and 8-MOP, respectively, indicating that all three compounds are inducers of 8-MOP metabolism.",Disposition of 8-methoxypsoralen in the rat. Induction of metabolism in vivo and in vitro and identification of urinary metabolites by thermospray mass spectrometry. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886306/),[l] / [h·kg],2.7,259011,DB01174,Phenobarbital
,2886306,Total body clearance,"Total body clearance of 8-MOP increased from 0.55 +/- 0.06 liter/kg/hr in control rats to 5.6 +/- 0.4, 2.7 +/- 0.4, and 1.2 +/- 0.0 liters/kg/hr in rats pretreated with BNF, PB, and 8-MOP, respectively, indicating that all three compounds are inducers of 8-MOP metabolism.",Disposition of 8-methoxypsoralen in the rat. Induction of metabolism in vivo and in vitro and identification of urinary metabolites by thermospray mass spectrometry. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886306/),[l] / [h·kg],1.2,259012,DB01174,Phenobarbital
,2886306,rates,"8-MOP was metabolized in incubations with liver microsomes at rates of 0.22 +/- 0.06, 0.38 +/- 0.06, 0.78 +/- 0.07, and 0.91 +/- 0.03 nmol/min/mg of protein for vehicle, 8-MOP-, PB-, and BNF-pretreated rats, respectively.",Disposition of 8-methoxypsoralen in the rat. Induction of metabolism in vivo and in vitro and identification of urinary metabolites by thermospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886306/),[nM] / [mg·min],0.22,259013,DB01174,Phenobarbital
,2886306,rates,"8-MOP was metabolized in incubations with liver microsomes at rates of 0.22 +/- 0.06, 0.38 +/- 0.06, 0.78 +/- 0.07, and 0.91 +/- 0.03 nmol/min/mg of protein for vehicle, 8-MOP-, PB-, and BNF-pretreated rats, respectively.",Disposition of 8-methoxypsoralen in the rat. Induction of metabolism in vivo and in vitro and identification of urinary metabolites by thermospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886306/),[nM] / [mg·min],0.38,259014,DB01174,Phenobarbital
,2886306,rates,"8-MOP was metabolized in incubations with liver microsomes at rates of 0.22 +/- 0.06, 0.38 +/- 0.06, 0.78 +/- 0.07, and 0.91 +/- 0.03 nmol/min/mg of protein for vehicle, 8-MOP-, PB-, and BNF-pretreated rats, respectively.",Disposition of 8-methoxypsoralen in the rat. Induction of metabolism in vivo and in vitro and identification of urinary metabolites by thermospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886306/),[nM] / [mg·min],0.78,259015,DB01174,Phenobarbital
,2886306,rates,"8-MOP was metabolized in incubations with liver microsomes at rates of 0.22 +/- 0.06, 0.38 +/- 0.06, 0.78 +/- 0.07, and 0.91 +/- 0.03 nmol/min/mg of protein for vehicle, 8-MOP-, PB-, and BNF-pretreated rats, respectively.",Disposition of 8-methoxypsoralen in the rat. Induction of metabolism in vivo and in vitro and identification of urinary metabolites by thermospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886306/),[nM] / [mg·min],0.91,259016,DB01174,Phenobarbital
,26681081,Volume of distribution,"Volume of distribution, clearance, and half-life median values (95 % CI) for phenobarbital in the whole study population (n=37) were 0.48 (0.41-0.56) l/kg, 0.0034 (0.0028-0.0040) l/h/kg, and 93.7 (88.1-99.2) h, respectively.",Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681081/),[l] / [kg],0.48,261685,DB01174,Phenobarbital
,26681081,clearance,"Volume of distribution, clearance, and half-life median values (95 % CI) for phenobarbital in the whole study population (n=37) were 0.48 (0.41-0.56) l/kg, 0.0034 (0.0028-0.0040) l/h/kg, and 93.7 (88.1-99.2) h, respectively.",Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681081/),[l] / [h·kg],0.0034,261686,DB01174,Phenobarbital
,26681081,half-life,"Volume of distribution, clearance, and half-life median values (95 % CI) for phenobarbital in the whole study population (n=37) were 0.48 (0.41-0.56) l/kg, 0.0034 (0.0028-0.0040) l/h/kg, and 93.7 (88.1-99.2) h, respectively.",Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681081/),h,93.7,261687,DB01174,Phenobarbital
,3096674,Elimination half-life,"Elimination half-life was 58.9 +/- 9.5 h and 30.15 +/- 6.1 h for malnourished and healthy children, respectively.",Pharmacokinetics of phenobarbitone in protein energy malnutrition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3096674/),h,58.9,261880,DB01174,Phenobarbital
,3096674,Elimination half-life,"Elimination half-life was 58.9 +/- 9.5 h and 30.15 +/- 6.1 h for malnourished and healthy children, respectively.",Pharmacokinetics of phenobarbitone in protein energy malnutrition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3096674/),h,30.15,261881,DB01174,Phenobarbital
,11294510,Urinary excretion,"Urinary excretion (12.5% versus 7.7%) and formation clearance (29.8 versus 21.1 mL/h) of p-OHPB, one of the main metabolites of PB, were significantly lower (p < .05) in PMs than in EMs.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),%,12.5,262384,DB01174,Phenobarbital
,11294510,Urinary excretion,"Urinary excretion (12.5% versus 7.7%) and formation clearance (29.8 versus 21.1 mL/h) of p-OHPB, one of the main metabolites of PB, were significantly lower (p < .05) in PMs than in EMs.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),%,7.7,262385,DB01174,Phenobarbital
,11294510,formation clearance,"Urinary excretion (12.5% versus 7.7%) and formation clearance (29.8 versus 21.1 mL/h) of p-OHPB, one of the main metabolites of PB, were significantly lower (p < .05) in PMs than in EMs.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),[ml] / [h],29.8,262386,DB01174,Phenobarbital
,11294510,formation clearance,"Urinary excretion (12.5% versus 7.7%) and formation clearance (29.8 versus 21.1 mL/h) of p-OHPB, one of the main metabolites of PB, were significantly lower (p < .05) in PMs than in EMs.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),[ml] / [h],21.1,262387,DB01174,Phenobarbital
,11294510,area under the serum concentration-time curve,"However, area under the serum concentration-time curve (153.3 in the EMs versus 122.9 microg x h/mL in the PMs), total (210.8 versus 254.9 mL/h) and renal clearance (53.1 versus 66.1 mL/h) of PB were identical between the two groups.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),[h·μg] / [ml],153.3,262388,DB01174,Phenobarbital
,11294510,area under the serum concentration-time curve,"However, area under the serum concentration-time curve (153.3 in the EMs versus 122.9 microg x h/mL in the PMs), total (210.8 versus 254.9 mL/h) and renal clearance (53.1 versus 66.1 mL/h) of PB were identical between the two groups.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),[h·μg] / [ml],122.9,262389,DB01174,Phenobarbital
,11294510,total,"However, area under the serum concentration-time curve (153.3 in the EMs versus 122.9 microg x h/mL in the PMs), total (210.8 versus 254.9 mL/h) and renal clearance (53.1 versus 66.1 mL/h) of PB were identical between the two groups.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),[ml] / [h],210.8,262390,DB01174,Phenobarbital
,11294510,total,"However, area under the serum concentration-time curve (153.3 in the EMs versus 122.9 microg x h/mL in the PMs), total (210.8 versus 254.9 mL/h) and renal clearance (53.1 versus 66.1 mL/h) of PB were identical between the two groups.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),[ml] / [h],254.9,262391,DB01174,Phenobarbital
,11294510,renal clearance,"However, area under the serum concentration-time curve (153.3 in the EMs versus 122.9 microg x h/mL in the PMs), total (210.8 versus 254.9 mL/h) and renal clearance (53.1 versus 66.1 mL/h) of PB were identical between the two groups.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),[ml] / [h],53.1,262392,DB01174,Phenobarbital
,11294510,renal clearance,"However, area under the serum concentration-time curve (153.3 in the EMs versus 122.9 microg x h/mL in the PMs), total (210.8 versus 254.9 mL/h) and renal clearance (53.1 versus 66.1 mL/h) of PB were identical between the two groups.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),[ml] / [h],66.1,262393,DB01174,Phenobarbital
,11294510,hydroxylation index,"The mephenytoin hydroxylation index did not change in either EMs (1.42 versus 1.42) or PMs (341.4 versus 403.5), showing that CYP2C19 was not induced by treatment with PB.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),,1.42,262394,DB01174,Phenobarbital
,11294510,hydroxylation index,"The mephenytoin hydroxylation index did not change in either EMs (1.42 versus 1.42) or PMs (341.4 versus 403.5), showing that CYP2C19 was not induced by treatment with PB.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),,341.4,262395,DB01174,Phenobarbital
,11294510,hydroxylation index,"The mephenytoin hydroxylation index did not change in either EMs (1.42 versus 1.42) or PMs (341.4 versus 403.5), showing that CYP2C19 was not induced by treatment with PB.",P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294510/),,403.5,262396,DB01174,Phenobarbital
,6694030,rate constant,"The mean +/- SEM values for the observed parameters were as follows: rate constant for the disposition of paraldehyde 0.0680 +/- 0.0071 hr,-1 half-life 10.2 +/- 1.0 hr; volume of distribution 1.73 +/- 0.20 L/kg; clearance 0.121 +/- 0.023 L/hr/kg.",Pharmacokinetics of paraldehyde disposition in the neonate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6694030/),h,0.0680,262549,DB01174,Phenobarbital
,6694030,-1 half-life,"The mean +/- SEM values for the observed parameters were as follows: rate constant for the disposition of paraldehyde 0.0680 +/- 0.0071 hr,-1 half-life 10.2 +/- 1.0 hr; volume of distribution 1.73 +/- 0.20 L/kg; clearance 0.121 +/- 0.023 L/hr/kg.",Pharmacokinetics of paraldehyde disposition in the neonate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6694030/),h,10.2,262550,DB01174,Phenobarbital
,6694030,volume of distribution,"The mean +/- SEM values for the observed parameters were as follows: rate constant for the disposition of paraldehyde 0.0680 +/- 0.0071 hr,-1 half-life 10.2 +/- 1.0 hr; volume of distribution 1.73 +/- 0.20 L/kg; clearance 0.121 +/- 0.023 L/hr/kg.",Pharmacokinetics of paraldehyde disposition in the neonate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6694030/),[l] / [kg],1.73,262551,DB01174,Phenobarbital
,6694030,clearance,"The mean +/- SEM values for the observed parameters were as follows: rate constant for the disposition of paraldehyde 0.0680 +/- 0.0071 hr,-1 half-life 10.2 +/- 1.0 hr; volume of distribution 1.73 +/- 0.20 L/kg; clearance 0.121 +/- 0.023 L/hr/kg.",Pharmacokinetics of paraldehyde disposition in the neonate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6694030/),[l] / [h·kg],0.121,262552,DB01174,Phenobarbital
,4004495,apparent half life,"The disappearance curve was biphasic; it varied the first 7 days, then remained constant for the following week (apparent half life 106 hours).",[Pharmacokinetics of injectable phenobarbital in the premature infant. Study of a new lyophilized form]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4004495/),h,106,263902,DB01174,Phenobarbital
,508562,acute LD50,The acute LD50 for MIS was increased from 1.54 to 1.90 g/kg after phenobarbitone pretreatment and 1.78 g/kg after phenytoin pretreatment.,Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/508562/),[g] / [kg],1.54,264004,DB01174,Phenobarbital
,508562,acute LD50,The acute LD50 for MIS was increased from 1.54 to 1.90 g/kg after phenobarbitone pretreatment and 1.78 g/kg after phenytoin pretreatment.,Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/508562/),[g] / [kg],1.90,264005,DB01174,Phenobarbital
,508562,acute LD50,The acute LD50 for MIS was increased from 1.54 to 1.90 g/kg after phenobarbitone pretreatment and 1.78 g/kg after phenytoin pretreatment.,Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/508562/),[g] / [kg],1.78,264006,DB01174,Phenobarbital
,1263279,half-life,The half-life of DES in adult rats (14 min) was reached between the 15th and 25th day after birth.,Studies on the biological disposition of diethylstilbestrol in rats and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1263279/),min,14,265513,DB01174,Phenobarbital
,6520745,half-life,After PB pretreatment plasma quinidine concentrations at the end of a 10 hr infusion increased about twofold while the half-life decreased from a control value of about 16 hr to 6 hr.,Induction of quinidine metabolism and plasma protein binding by phenobarbital in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6520745/),h,16,269134,DB01174,Phenobarbital
,6520745,half-life,After PB pretreatment plasma quinidine concentrations at the end of a 10 hr infusion increased about twofold while the half-life decreased from a control value of about 16 hr to 6 hr.,Induction of quinidine metabolism and plasma protein binding by phenobarbital in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6520745/),h,6,269135,DB01174,Phenobarbital
,6520745,steady-state volume of distribution (Vdss),"Pharmacokinetic analysis of the data showed a decrease in steady-state volume of distribution (Vdss) of quinidine from an average value of 153 L to 54 L after PB treatment, while the total clearance did not change (6.6 vs. 5.6 L/hr).",Induction of quinidine metabolism and plasma protein binding by phenobarbital in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6520745/),l,153,269136,DB01174,Phenobarbital
,6520745,steady-state volume of distribution (Vdss),"Pharmacokinetic analysis of the data showed a decrease in steady-state volume of distribution (Vdss) of quinidine from an average value of 153 L to 54 L after PB treatment, while the total clearance did not change (6.6 vs. 5.6 L/hr).",Induction of quinidine metabolism and plasma protein binding by phenobarbital in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6520745/),l,54,269137,DB01174,Phenobarbital
,6520745,total clearance,"Pharmacokinetic analysis of the data showed a decrease in steady-state volume of distribution (Vdss) of quinidine from an average value of 153 L to 54 L after PB treatment, while the total clearance did not change (6.6 vs. 5.6 L/hr).",Induction of quinidine metabolism and plasma protein binding by phenobarbital in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6520745/),[l] / [h],6.6,269138,DB01174,Phenobarbital
,6520745,total clearance,"Pharmacokinetic analysis of the data showed a decrease in steady-state volume of distribution (Vdss) of quinidine from an average value of 153 L to 54 L after PB treatment, while the total clearance did not change (6.6 vs. 5.6 L/hr).",Induction of quinidine metabolism and plasma protein binding by phenobarbital in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6520745/),[l] / [h],5.6,269139,DB01174,Phenobarbital
,1587059,Peak serum concentrations,Peak serum concentrations of 19.8 and 17.8 mg/L were measured.,Phenobarbital pharmacokinetics in obesity. A case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587059/),[mg] / [l],19.8,269640,DB01174,Phenobarbital
,1587059,Peak serum concentrations,Peak serum concentrations of 19.8 and 17.8 mg/L were measured.,Phenobarbital pharmacokinetics in obesity. A case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587059/),[mg] / [l],17.8,269641,DB01174,Phenobarbital
,1587059,apparent volume of distribution (Vd),"An apparent volume of distribution (Vd) of 154.9L (0.82 L/kg TBW), total body clearance (CL) of 29 ml/min (1.74 L/h) and elimination half-life of 61h were determined.",Phenobarbital pharmacokinetics in obesity. A case report. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587059/),l,154.9,269642,DB01174,Phenobarbital
,1587059,total body clearance (CL),"An apparent volume of distribution (Vd) of 154.9L (0.82 L/kg TBW), total body clearance (CL) of 29 ml/min (1.74 L/h) and elimination half-life of 61h were determined.",Phenobarbital pharmacokinetics in obesity. A case report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587059/),[ml] / [min],29,269643,DB01174,Phenobarbital
,1587059,elimination half-life,"An apparent volume of distribution (Vd) of 154.9L (0.82 L/kg TBW), total body clearance (CL) of 29 ml/min (1.74 L/h) and elimination half-life of 61h were determined.",Phenobarbital pharmacokinetics in obesity. A case report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587059/),h,61,269644,DB01174,Phenobarbital
,119355,half-life,"2. Treatment with phenobarbital decreased the antipyrine half-life from 65 to 30 min, but did not significantly change the urinary metabolite profile.",Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/119355/),min,65,270570,DB01174,Phenobarbital
,119355,half-life,"2. Treatment with phenobarbital decreased the antipyrine half-life from 65 to 30 min, but did not significantly change the urinary metabolite profile.",Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/119355/),min,30,270571,DB01174,Phenobarbital
,119355,half-life,3. 3-Methylcholanthrene treatment resulted in a decrease of antipyrine half-life from 72 to 37 min.,Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/119355/),min,72,270572,DB01174,Phenobarbital
,119355,half-life,3. 3-Methylcholanthrene treatment resulted in a decrease of antipyrine half-life from 72 to 37 min.,Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/119355/),min,37,270573,DB01174,Phenobarbital
,9616196,maximal velocity Vmax,"Estimated primidone metabolism, as expressed by the maximal velocity Vmax, ranged from 0 to 0.24 mg.","Physiologically based pharmacokinetics model of primidone and its metabolites phenobarbital and phenylethylmalonamide in humans, rats, and mice. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9616196/),mg,0 to 0.24,270948,DB01174,Phenobarbital
,12915337,half-life,"Although its half-life is relatively short (6 to 8 hours), its duration of action is longer than anticipated from its pharmacokinetics in plasma, and a twice-daily dosing regimen is adequate to produce the desired response.",The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915337/),h,6 to 8,271378,DB01174,Phenobarbital
,10217336,concentration/dose (C/D) ratio,"In 20 patients in monotherapy, the concentration/dose (C/D) ratio was 65 (range: 50-84) nmol/L/mg (mean and 95% confidence interval, antilog from lognormal distribution).",Lamotrigine drug interactions in a TDM material. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],65,272553,DB01174,Phenobarbital
less,10217336,C/D ratio,"In 37 patients with concomitant carbamazepine treatment, the C/D ratio was less than half that of the patients in monotherapy; 31 (2146) nmol/L/mg, and in 14 patients with phenytoin, it was even lower; 17 (13-23) nmol/L/mg.",Lamotrigine drug interactions in a TDM material. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],31,272554,DB01174,Phenobarbital
,10217336,C/D ratio,"In 37 patients with concomitant carbamazepine treatment, the C/D ratio was less than half that of the patients in monotherapy; 31 (2146) nmol/L/mg, and in 14 patients with phenytoin, it was even lower; 17 (13-23) nmol/L/mg.",Lamotrigine drug interactions in a TDM material. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],17,272555,DB01174,Phenobarbital
,10217336,C/D,Valproic acid significantly increased the C/D to 251 (200-320) nmol/L/mg in 13 patients.,Lamotrigine drug interactions in a TDM material. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],251,272556,DB01174,Phenobarbital
,8923333,total,"For the phenobarbital group, a significant increase for antipyrine total (36 versus 45 mL/h/kg) and nonrenal (35 versus 44 mL/h/kg) clearances and 6 beta-hydroxycortisol excretion (338 versus 529 micrograms) and a significant decrease in the terminal exponential half-life (11 versus 9 h) of antipyrine were observed.",Assessment of doxylamine influence on mixed function oxidase activity upon multiple dose oral administration to normal volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8923333/),[ml] / [h·kg],36,273424,DB01174,Phenobarbital
,8923333,total,"For the phenobarbital group, a significant increase for antipyrine total (36 versus 45 mL/h/kg) and nonrenal (35 versus 44 mL/h/kg) clearances and 6 beta-hydroxycortisol excretion (338 versus 529 micrograms) and a significant decrease in the terminal exponential half-life (11 versus 9 h) of antipyrine were observed.",Assessment of doxylamine influence on mixed function oxidase activity upon multiple dose oral administration to normal volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8923333/),[ml] / [h·kg],45,273425,DB01174,Phenobarbital
,8923333,excretion,"For the phenobarbital group, a significant increase for antipyrine total (36 versus 45 mL/h/kg) and nonrenal (35 versus 44 mL/h/kg) clearances and 6 beta-hydroxycortisol excretion (338 versus 529 micrograms) and a significant decrease in the terminal exponential half-life (11 versus 9 h) of antipyrine were observed.",Assessment of doxylamine influence on mixed function oxidase activity upon multiple dose oral administration to normal volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8923333/),μg,338,273426,DB01174,Phenobarbital
,8923333,excretion,"For the phenobarbital group, a significant increase for antipyrine total (36 versus 45 mL/h/kg) and nonrenal (35 versus 44 mL/h/kg) clearances and 6 beta-hydroxycortisol excretion (338 versus 529 micrograms) and a significant decrease in the terminal exponential half-life (11 versus 9 h) of antipyrine were observed.",Assessment of doxylamine influence on mixed function oxidase activity upon multiple dose oral administration to normal volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8923333/),μg,529,273427,DB01174,Phenobarbital
,8923333,terminal exponential half-life,"For the phenobarbital group, a significant increase for antipyrine total (36 versus 45 mL/h/kg) and nonrenal (35 versus 44 mL/h/kg) clearances and 6 beta-hydroxycortisol excretion (338 versus 529 micrograms) and a significant decrease in the terminal exponential half-life (11 versus 9 h) of antipyrine were observed.",Assessment of doxylamine influence on mixed function oxidase activity upon multiple dose oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8923333/),h,11,273428,DB01174,Phenobarbital
,8923333,terminal exponential half-life,"For the phenobarbital group, a significant increase for antipyrine total (36 versus 45 mL/h/kg) and nonrenal (35 versus 44 mL/h/kg) clearances and 6 beta-hydroxycortisol excretion (338 versus 529 micrograms) and a significant decrease in the terminal exponential half-life (11 versus 9 h) of antipyrine were observed.",Assessment of doxylamine influence on mixed function oxidase activity upon multiple dose oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8923333/),h,9,273429,DB01174,Phenobarbital
